[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDAfLNFz45BPrSL--0p0LEDgmk7iJKdswzZ0bZO3_tyU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"Alliance for Clinical Trials in Oncology",[4],508,false,70,160,177735,111,108,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Lung Cancer",78,{"name":18,"count":19},"Breast Cancer",72,{"name":21,"count":22},"Lymphoma",45,{"name":24,"count":25},"Colorectal Cancer",41,{"name":27,"count":28},"Leukemia",40,{"name":30,"count":31},"Unspecified Adult Solid Tumor, Protocol Specific",34,{"name":33,"count":34},"Prostate Cancer",29,{"name":36,"count":37},"Esophageal Cancer",19,[39,44,49,54,59,64,69,73,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT00430183","Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer","2018-10-02","docetaxel",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT02749903","Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers","2019-02-21","enzalutamide",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT01511562","Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma","2020-12-10","carmustine",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT02143726","Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","2021-01-28","sorafenib",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04533451","Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer","2023-10-31","Pembrolizumab",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT01905046","Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer","2023-11-10","metformin hydrochloride",{"nctId":70,"briefTitle":71,"date":72,"intervention":63},"NCT04637594","Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy","2024-06-01",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04094688","Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","2024-07-15","Bevacizumab",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT03944941","Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer","2025-02-26","Avelumab",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT03927027","Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection","2025-11-26","Isosulfan Blue",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,429,523,952,1190,1354,1391,1508,1684,1903,2041,2128,2220,2263,2319,2359,2511,2625,2714,2744,2790,2828,2858,2884,2906,2928,2956,2978,3009,3149,3219,3365,3435,3484,3545,3579,3609,3664,3694,3728,3754,3783,3830,3856,3883,3905,3934,3961,3979,4009,4027,4045,4063,4081,4099,4117,4135,4153,4171,4189,4207,4225,4243,4261,4306,4324,4342,4360,4378,4396,4420,4438,4456,4482,4500,4518,4691,4818,4868,5062,5156,5223,5276,5310,5340,5382,5415,5433,5451,5469,5487,5505,5523,5541,5559,5577,5595,5622,5640,5658,5676,5694,5712,5730,5748,5766,5850,5909,5967,5992,6014,6032,6126,6194,6259,6308,6345,6383,6427,6479,6505,6545,6576,6614,6644,6677,6699,6723,6745,6767,6789,6824,6846,6873,6895,6917,6946,6964,6988,7011,7032,7050,7068,7086,7104,7128,7146,7168,7186,7212,7230,7252,7270,7296,7314,7336,7354,7379,7401,7424,7442,7460,7478,7505,7523,7544,7566,7584,7602,7627,7650,7668,7686,7704,7722,7740,7758,7780,7802,7826,7848,7871,7893,7911,7936,7958,7976,7994,8012,8036,8054,8076,8094,8112,8166,8208,8242,8280,8320,8350,8380,8406,8434,8460,8493,8519,8547,8569,8594,8616,8640,8662,8687,8713,8735,8762,8784,8806,8828,8846,8864,8886,8904,8922,8940,8958,8979,8997,9018,9039,9057,9078,9096,9114,9132,9150,9168,9186,9204,9222,9240,9261,9286,9307,9329,9347,9365,9386,9413,9431,9453,9471,9489,9507,9525,9547,9565,9589,9607,9625,9643,9661,9679,9697,9722,9744,9762,9780,9802,9820,9842,9860,9882,9907,9925,9943,9961,9983,10001,10023,10041,10059,10077,10098,10116,10134,10156,10174,10192,10214,10238,10256,10274,10292,10310,10331,10410,10480,10547,10600,10638,10681,10719,10745,10782,10808,10833,10855,10877,10899,10921,10939,10957,10978,11001,11019,11041,11059,11077,11095],{"intervention":97,"totalTrials":98,"cells":99},"oxaliplatin",25,{"EARLY_PHASE1":100,"PHASE1":124,"PHASE2":126,"PHASE3":273,"PHASE4":404,"NA":406},{"trials":101,"activeCount":123},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":117},"NCT01821612","Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer","COMPLETED",[89],"2014-11-01","2018-06-15","2013-05-29",23,[112,113,114,115,116],"Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer","Stage II Pancreatic Cancer","Stage III Pancreatic Cancer",[97,118,119,120,121,122],"irinotecan","leucovorin","5-fluorouracil","capecitabine","gemcitabine",0,{"trials":125,"activeCount":123},[],{"trials":127,"activeCount":272,"soonestReadout":260},[128,141,153,164,174,186,195,206,215,231,239,249,255],{"nctId":129,"briefTitle":130,"status":105,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT00080951","Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",[91],"2005-04","2008-02","2004-03",14,[24],[138,139,140,97],"fluorouracil","irinotecan hydrochloride","leucovorin calcium",{"nctId":142,"briefTitle":143,"status":105,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":152},"NCT00433550","Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer",[91],"2014-12","2016-05","2007-05",33,[150,151],"Small Intestine Adenocarcinoma","Recurrent Small Intestine Cancer",[121,139,97],{"nctId":154,"briefTitle":155,"status":105,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT00040859","Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer",[91],"2005-01","2008-04","2002-09",48,[36,162],"Gastric Cancer",[121,97],{"nctId":165,"briefTitle":166,"status":167,"phases":168,"primaryCompletion":169,"start":169,"enrollment":123,"conditions":170,"interventions":172},"NCT01473303","Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer","WITHDRAWN",[90,91],"2012-08",[171],"Pancreatic Cancer",[173,138,139,140,97],"ganitumab",{"nctId":175,"briefTitle":176,"status":105,"phases":177,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":183},"NCT00112528","Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer",[91],"2006-08","2010-11","2005-06",53,[171],[184,185,97],"bevacizumab","gemcitabine hydrochloride",{"nctId":187,"briefTitle":188,"status":105,"phases":189,"primaryCompletion":190,"completion":145,"start":191,"enrollment":192,"conditions":193,"interventions":194},"NCT00114231","Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer",[91],"2013-12","2006-05",90,[24],[121,97],{"nctId":196,"briefTitle":197,"status":105,"phases":198,"primaryCompletion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT00056030","Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer",[91],"2007-10","2004-12",73,[24,203],"Metastatic Cancer",[205,138,140,97],"cetuximab",{"nctId":207,"briefTitle":208,"status":105,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":214},"NCT00003834","Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer",[91],"2005-12","1999-03",44,[24,203],[138,140,97],{"nctId":216,"briefTitle":217,"status":105,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT01333033","PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy",[91],"2015-11","2023-04-01","2011-07",257,[224,36],"Adenocarcinoma of the Gastroesophageal Junction",[226,227,228,229,230],"Oxaliplatin","Leucovorin Calcium","Fluorouracil","Carboplatin","Paclitaxel",{"nctId":232,"briefTitle":233,"status":105,"phases":234,"primaryCompletion":190,"completion":235,"start":236,"enrollment":201,"conditions":237,"interventions":238},"NCT00938470","Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction",[91],"2018-03","2010-01",[224,36,162],[121,43,138,97],{"nctId":240,"briefTitle":241,"status":105,"phases":242,"primaryCompletion":243,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":248},"NCT00004190","Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer",[91],"2003-04","2003-06","1999-10",59,[171],[185,97],{"nctId":250,"briefTitle":251,"status":167,"phases":252,"enrollment":123,"conditions":253,"interventions":254},"NCT00571740","Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer",[91],[24],[184,205,138,140,97],{"nctId":256,"briefTitle":257,"status":258,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":268},"NCT05610163","Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation","ACTIVE_NOT_RECRUITING",[91],"2026-09-30","2033-09-30","2022-12-08",783,[265,266,267],"Locally Advanced Rectal Carcinoma","Stage II Rectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8",[269,120,270,271,226],"Capecitabine","Leucovorin calcium","Irinotecan",1,{"trials":274,"activeCount":403,"soonestReadout":76},[275,286,295,309,320,334,347,355,367,377],{"nctId":276,"briefTitle":277,"status":105,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":284},"NCT01150045","Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",[92],"2020-02-28","2022-08-11","2010-06",2527,[24],[285,120,97,119],"celecoxib",{"nctId":287,"briefTitle":288,"status":105,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":294},"NCT00003594","Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer",[92],"2004-10","1998-10",1691,[24],[118,138,140,97],{"nctId":296,"briefTitle":297,"status":105,"phases":298,"primaryCompletion":299,"completion":300,"start":281,"enrollment":301,"conditions":302,"interventions":306},"NCT01099449","Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy",[92],"2012-12","2013-03",362,[303,24,304,305],"Chemotherapeutic Agent Toxicity","Neuropathy","Neurotoxicity",[307,308,97],"calcium gluconate","magnesium sulfate",{"nctId":310,"briefTitle":311,"status":312,"phases":313,"primaryCompletion":314,"completion":107,"start":315,"enrollment":316,"conditions":317,"interventions":319},"NCT01279681","Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer","TERMINATED",[92],"2014-11","2011-01",32,[318,24,305],"Cognitive\u002FFunctional Effects",[184,121,138,140,97],{"nctId":321,"briefTitle":322,"status":258,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":331},"NCT04137107","Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer",[91,92],"2026-02-28","2026-12-31","2020-06-17",220,[329,330],"Stage II Colorectal Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8",[226,332,333],"Duloxetine Hydrochloride","Duloxetine",{"nctId":335,"briefTitle":336,"status":258,"phases":337,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":345},"NCT04340141","Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer",[92],"2028-12-31","2030-11-01","2020-10-13",358,[343,344,171],"Pancreatic Adenosquamous Carcinoma","Resectable Pancreatic Adenocarcinoma",[226,346,227,228],"Irinotecan Hydrochloride",{"nctId":74,"briefTitle":75,"status":258,"phases":348,"primaryCompletion":76,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":354},[92],"2026-07-01","2019-10-29",455,[353],"Colorectal Adenocarcinoma",[77,226,227,228,346,271],{"nctId":356,"briefTitle":357,"status":312,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":363},"NCT01167725","Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer",[92],"2012-01","2010-08",340,[24],[184,205,364,365,121,138,139,140,366,97],"FOLFIRI regimen","FOLFOX regimen","mitomycin C",{"nctId":368,"briefTitle":369,"status":312,"phases":370,"primaryCompletion":371,"completion":281,"start":372,"enrollment":373,"conditions":374,"interventions":375},"NCT00077233","FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum",[92],"2006-12","2003-12",238,[24],[205,376,118,119,97],"5-FU",{"nctId":378,"briefTitle":379,"status":380,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":401},"NCT05677490","mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","RECRUITING",[92],"2028-11-08","2023-01-31",382,[386,387,388,389,390,391,392,393,394,395,396,397,398,399,400],"Advanced Esophageal Adenocarcinoma","Advanced Gastric Adenocarcinoma","Advanced Gastroesophageal Junction Adenocarcinoma","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Unresectable Esophageal Adenocarcinoma","Unresectable Gastric Adenocarcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma",[228,227,226,271,402],"Nivolumab",4,{"trials":405,"activeCount":123},[],{"trials":407,"activeCount":272,"soonestReadout":412},[408],{"nctId":409,"briefTitle":410,"status":380,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":427},"NCT07283939","Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays",[94],"2030-05-01","2030-05-02","2026-02-13",420,[417,418,419,420,421,422,423,424,425,426],"Ampulla of Vater Carcinoma","Appendix Carcinoma","Carcinoma of Unknown Primary With Gastrointestinal Profile","Colon Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Gastroesophageal Junction Carcinoma","Malignant Digestive System Neoplasm","Rectal Carcinoma","Small Intestinal Carcinoma",[226,428,228],"Folinic Acid",{"intervention":63,"totalTrials":430,"cells":431},5,{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":453,"PHASE4":519,"NA":521},{"trials":433,"activeCount":123},[],{"trials":435,"activeCount":123},[],{"trials":437,"activeCount":272,"soonestReadout":62},[438],{"nctId":60,"briefTitle":61,"status":258,"phases":439,"primaryCompletion":62,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":451},[91],"2027-05-31","2020-11-16",101,[444,445,446,447,448,449,450],"Metastatic Lung Adenocarcinoma","Metastatic Lung Non-Small Cell Carcinoma","Recurrent Lung Adenocarcinoma","Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[63,452,229],"Pemetrexed",{"trials":454,"activeCount":403,"soonestReadout":72},[455,474,492,506],{"nctId":70,"briefTitle":71,"status":258,"phases":456,"primaryCompletion":72,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":471},[92],"2030-09","2022-05-27",3,[461,462,463,464,465,466,467,468,469,470],"Locally Advanced Bladder Urothelial Carcinoma","Locally Advanced Renal Pelvis Urothelial Carcinoma","Locally Advanced Ureter Urothelial Carcinoma","Locally Advanced Urethral Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma","Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis Urothelial Carcinoma","Metastatic Ureter Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Metastatic Urothelial Carcinoma",[63,402,472,473,82],"Atezolizumab","Durvalumab",{"nctId":475,"briefTitle":476,"status":380,"phases":477,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":487},"NCT06632327","Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer",[92],"2029-04-30","2030-04-30","2024-12-11",1100,[483,484,485,486],"Resectable Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8",[488,229,452,489,490,491,402,63,472],"Cisplatin","Gemcitabine","Docetaxel","Vinorelbine",{"nctId":493,"briefTitle":494,"status":380,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":504},"NCT06661720","Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer",[92],"2037-11","2025-03-14",1040,[500,501,502,503],"Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma (RCC)","Stage II Renal Pelvis Cancer AJCC v8","Stage III Renal Pelvis Cancer AJCC v8",[63,505],"Tivozanib",{"nctId":507,"briefTitle":508,"status":380,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":518},"NCT05812807","Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab",[92],"2033-05-31","2023-06-14",1295,[514,515,516,517],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Early Stage Triple-Negative Breast Carcinoma",[63],{"trials":520,"activeCount":123},[],{"trials":522,"activeCount":123},[],{"intervention":524,"totalTrials":525,"cells":526},"carboplatin",42,{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":551,"PHASE3":853,"PHASE4":948,"NA":950},{"trials":528,"activeCount":123},[],{"trials":530,"activeCount":123},[531,541],{"nctId":532,"briefTitle":533,"status":105,"phases":534,"primaryCompletion":535,"completion":236,"start":536,"enrollment":537,"conditions":538,"interventions":539},"NCT00032032","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer",[90],"2008-01","2002-05",69,[15],[524,540],"paclitaxel",{"nctId":542,"briefTitle":543,"status":105,"phases":544,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":550},"NCT01486602","Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",[90],"2017-01","2018-01-16","2012-03",22,[15],[524,540],{"trials":552,"activeCount":852,"soonestReadout":62},[553,562,572,584,596,604,614,625,634,644,653,660,670,681,691,700,711,728,737,746,750,760,768,772,783,792,801,809,819,829,836,844],{"nctId":554,"briefTitle":555,"status":105,"phases":556,"primaryCompletion":371,"completion":557,"start":372,"enrollment":558,"conditions":559,"interventions":560},"NCT00070486","Carboplatin and Gemcitabine Combined With Celecoxib and\u002For Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer",[91],"2011-05",140,[15],[524,285,185,561],"zileuton",{"nctId":563,"briefTitle":564,"status":105,"phases":565,"primaryCompletion":566,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":571},"NCT00005059","Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer",[91],"2003-07","2006-04","2000-01",51,[15],[524,540],{"nctId":573,"briefTitle":574,"status":105,"phases":575,"primaryCompletion":576,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":582},"NCT00404235","Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery",[91],"2008-12","2010-03","2006-10",76,[581],"Melanoma (Skin)",[524,583],"paclitaxel albumin-stabilized nanoparticle formulation",{"nctId":585,"briefTitle":586,"status":105,"phases":587,"primaryCompletion":588,"completion":589,"start":211,"enrollment":590,"conditions":591,"interventions":592},"NCT00003812","Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer",[91],"2004-06","2006-03",75,[15],[593,524,594,540,595],"filgrastim","etoposide","topotecan hydrochloride",{"nctId":597,"briefTitle":598,"status":105,"phases":599,"primaryCompletion":178,"completion":179,"start":290,"enrollment":600,"conditions":601,"interventions":602},"NCT00062062","Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer",[91],65,[15],[524,603,540],"gefitinib",{"nctId":605,"briefTitle":606,"status":105,"phases":607,"primaryCompletion":608,"completion":609,"start":610,"enrollment":16,"conditions":611,"interventions":612},"NCT00553462","Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery",[91],"2014-01","2017-06-15","2008-03",[15],[524,613,583],"erlotinib hydrochloride",{"nctId":615,"briefTitle":616,"status":105,"phases":617,"primaryCompletion":299,"completion":618,"start":619,"enrollment":620,"conditions":621,"interventions":623},"NCT00936702","Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary",[91],"2013-08","2009-09",46,[622],"Carcinoma of Unknown Primary Origin",[524,624,540],"everolimus",{"nctId":626,"briefTitle":627,"status":105,"phases":628,"primaryCompletion":629,"completion":630,"start":631,"enrollment":181,"conditions":632,"interventions":633},"NCT00005963","Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer",[91],"2002-10","2009-01","2000-11",[18],[524,43],{"nctId":635,"briefTitle":636,"status":105,"phases":637,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":643},"NCT00028925","Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer",[91],"2005-11","2008-08","2001-11",27,[15],[593,524,595],{"nctId":645,"briefTitle":646,"status":105,"phases":647,"primaryCompletion":372,"completion":648,"start":649,"enrollment":28,"conditions":650,"interventions":651},"NCT00005810","Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy",[91],"2006-06","2000-03",[33],[593,524,43,652],"estramustine phosphate sodium",{"nctId":654,"briefTitle":655,"status":167,"phases":656,"enrollment":123,"conditions":657,"interventions":658},"NCT00951444","Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],[15],[659,524,185],"dalotuzumab",{"nctId":661,"briefTitle":662,"status":105,"phases":663,"primaryCompletion":210,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT00003612","Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer",[91],"2019-03-15","1999-04",92,[18],[669,524,540],"trastuzumab",{"nctId":671,"briefTitle":672,"status":105,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT00107341","Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction",[91],"2007-02","2008-05","2005-08",37,[36],[680,524,540],"bortezomib",{"nctId":682,"briefTitle":683,"status":105,"phases":684,"primaryCompletion":685,"completion":675,"start":686,"enrollment":31,"conditions":687,"interventions":688},"NCT00016913","Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer",[91],"2007-07","2001-05",[33],[524,689,540,690],"estramustine","leuprolide or goserelin acetate",{"nctId":692,"briefTitle":693,"status":105,"phases":694,"primaryCompletion":145,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":699},"NCT00976573","Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",[91],"2015-09","2010-04",149,[581],[184,524,624,540],{"nctId":701,"briefTitle":702,"status":105,"phases":703,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":709},"NCT00227565","Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[91],"2007-12","2009-10","2006-02",50,[15],[524,710],"pemetrexed disodium",{"nctId":712,"briefTitle":713,"status":380,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":722},"NCT06632977","Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial",[91],"2030-04-11","2034-10-11","2025-02-06",474,[720,721],"Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8",[723,229,724,725,726,727],"Valemetostat Tosylate","Cabazitaxel","Abiraterone Acetate","Enzalutamide","Lutetium Lu 177 Vipivotide Tetraxetan",{"nctId":729,"briefTitle":730,"status":105,"phases":731,"primaryCompletion":732,"completion":133,"start":733,"enrollment":25,"conditions":734,"interventions":735},"NCT00041054","Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[91],"2004-08","2002-06",[15],[524,594,736],"exisulind",{"nctId":738,"briefTitle":739,"status":105,"phases":740,"primaryCompletion":741,"start":676,"enrollment":742,"conditions":743,"interventions":744},"NCT00107510","Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer",[91],"2007-09",58,[18],[745,524,43],"pegfilgrastim",{"nctId":216,"briefTitle":217,"status":105,"phases":747,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":748,"interventions":749},[91],[224,36],[226,227,228,229,230],{"nctId":751,"briefTitle":752,"status":105,"phases":753,"primaryCompletion":754,"completion":755,"start":756,"enrollment":442,"conditions":757,"interventions":758},"NCT00326599","Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],"2009-04","2010-02","2007-06",[15],[524,759,185],"cediranib maleate",{"nctId":761,"briefTitle":762,"status":105,"phases":763,"primaryCompletion":764,"completion":754,"start":765,"enrollment":600,"conditions":766,"interventions":767},"NCT00033696","Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer",[91],"2007-01","2001-09",[15],[593,524,594,540,595],{"nctId":60,"briefTitle":61,"status":258,"phases":769,"primaryCompletion":62,"completion":440,"start":441,"enrollment":442,"conditions":770,"interventions":771},[91],[444,445,446,447,448,449,450],[63,452,229],{"nctId":773,"briefTitle":774,"status":105,"phases":775,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":781},"NCT00820872","Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer",[91],"2010-12","2019-08-15","2009-02",30,[18],[669,524,43,782],"lapatinib ditosylate",{"nctId":784,"briefTitle":785,"status":105,"phases":786,"primaryCompletion":756,"completion":787,"start":788,"enrollment":16,"conditions":789,"interventions":790},"NCT00072527","Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer",[91],"2013-01","2003-11",[15],[524,791,594,139],"cisplatin",{"nctId":793,"briefTitle":794,"status":105,"phases":795,"primaryCompletion":796,"completion":630,"start":797,"enrollment":798,"conditions":799,"interventions":800},"NCT00022139","Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction",[91],"2005-07","2002-01",56,[36,162],[524,138,540],{"nctId":802,"briefTitle":803,"status":105,"phases":804,"primaryCompletion":805,"completion":806,"start":576,"enrollment":600,"conditions":807,"interventions":808},"NCT00798603","Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],"2011-03","2013-05",[15],[184,524,710],{"nctId":810,"briefTitle":811,"status":105,"phases":812,"primaryCompletion":813,"completion":814,"start":815,"enrollment":816,"conditions":817,"interventions":818},"NCT00117962","Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer",[91],"2009-03","2012-09","2005-09",109,[15],[205,524,710],{"nctId":820,"briefTitle":821,"status":105,"phases":822,"primaryCompletion":823,"completion":824,"start":639,"enrollment":825,"conditions":826,"interventions":827},"NCT00626405","Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery",[91],"2010-07","2012-11",95,[581],[184,524,583,828],"temozolomide",{"nctId":830,"briefTitle":831,"status":312,"phases":832,"primaryCompletion":535,"completion":833,"start":567,"enrollment":641,"conditions":834,"interventions":835},"NCT00268437","Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery",[91],"2015-03",[36],[524,452],{"nctId":837,"briefTitle":838,"status":105,"phases":839,"primaryCompletion":371,"completion":371,"start":840,"enrollment":841,"conditions":842,"interventions":843},"NCT00003255","Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia",[91],"1999-11",38,[27],[524,595],{"nctId":845,"briefTitle":846,"status":105,"phases":847,"primaryCompletion":848,"completion":281,"start":849,"enrollment":537,"conditions":850,"interventions":851},"NCT00033553","Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer",[91],"2006-09","2002-03",[15],[524,185,540],2,{"trials":854,"activeCount":852,"soonestReadout":478},[855,864,887,895,899,922,931,939],{"nctId":856,"briefTitle":857,"status":105,"phases":858,"primaryCompletion":200,"completion":859,"start":860,"enrollment":861,"conditions":862,"interventions":863},"NCT00003117","Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer",[92],"2006-01","1997-10",584,[15],[524,540],{"nctId":865,"briefTitle":866,"status":258,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":415,"conditions":870,"interventions":882},"NCT02375204","Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors",[92],"2031-06-01","2015-08-06",[871,872,873,874,875,876,877,878,879,880,881],"Germ Cell Tumor","Teratoma","Choriocarcinoma","Germinoma","Mixed Germ Cell Tumor","Yolk Sac Tumor","Childhood Teratoma","Malignant Germ Cell Neoplasm","Extragonadal Seminoma","Non-seminomatous Germ Cell Tumor","Seminoma",[540,883,791,884,885,524,886],"ifosfamide","pegylated G-CSF","G-CSF","etoposide phosphate",{"nctId":888,"briefTitle":889,"status":105,"phases":890,"primaryCompletion":180,"completion":676,"start":891,"enrollment":892,"conditions":893,"interventions":894},"NCT00003317","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer",[92],"1998-05",480,[15],[524,540],{"nctId":475,"briefTitle":476,"status":380,"phases":896,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":897,"interventions":898},[92],[483,484,485,486],[488,229,452,489,490,491,402,63,472],{"nctId":900,"briefTitle":901,"status":105,"phases":902,"primaryCompletion":169,"completion":169,"start":903,"enrollment":904,"conditions":905,"interventions":920},"NCT02311907","Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and\u002For Primary Peritoneal Cancer",[92],"2009-12",195,[303,304,906,907,908,909,910,911,912,913,914,915,916,917,918,919],"Neurotoxicity Syndrome","Pain","Stage IIIA Fallopian Tube Cancer","Stage IIIA Ovarian Cancer","Stage IIIA Primary Peritoneal Cancer","Stage IIIB Fallopian Tube Cancer","Stage IIIB Ovarian Cancer","Stage IIIB Primary Peritoneal Cancer","Stage IIIC Fallopian Tube Cancer","Stage IIIC Ovarian Cancer","Stage IIIC Primary Peritoneal Cancer","Stage IV Fallopian Tube Cancer","Stage IV Ovarian Cancer","Stage IV Primary Peritoneal Cancer",[229,921,230],"Glutathione",{"nctId":923,"briefTitle":924,"status":925,"phases":926,"primaryCompletion":927,"start":610,"enrollment":928,"conditions":929,"interventions":930},"NCT00632853","Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide","UNKNOWN",[92],"2022-03-02",731,[15],[791,594,524],{"nctId":932,"briefTitle":933,"status":312,"phases":934,"primaryCompletion":935,"completion":235,"start":755,"enrollment":936,"conditions":937,"interventions":938},"NCT01041781","Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer",[92],"2017-01-17",313,[15],[524,285,185,710],{"nctId":940,"briefTitle":941,"status":105,"phases":942,"primaryCompletion":147,"completion":754,"start":943,"enrollment":944,"conditions":945,"interventions":946},"NCT00003387","Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery",[92],"1998-07",366,[15],[524,947,540],"chemotherapy",{"trials":949,"activeCount":123},[],{"trials":951,"activeCount":123},[],{"intervention":791,"totalTrials":953,"cells":954},26,{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":967,"PHASE3":1106,"PHASE4":1186,"NA":1188},{"trials":956,"activeCount":123},[],{"trials":958,"activeCount":123},[959],{"nctId":960,"briefTitle":961,"status":105,"phases":962,"primaryCompletion":963,"completion":963,"start":964,"enrollment":953,"conditions":965,"interventions":966},"NCT00003157","Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas or Stomach",[90],"2003-05","1998-02",[162,171],[791,185],{"trials":968,"activeCount":272,"soonestReadout":1084},[969,977,985,995,1003,1014,1024,1036,1044,1052,1059,1068,1080,1095,1099],{"nctId":970,"briefTitle":971,"status":105,"phases":972,"primaryCompletion":299,"completion":973,"start":706,"enrollment":974,"conditions":975,"interventions":976},"NCT00316862","Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery",[91],"2014-10-15",82,[36],[791,139],{"nctId":978,"briefTitle":979,"status":105,"phases":980,"primaryCompletion":588,"completion":754,"start":981,"enrollment":982,"conditions":983,"interventions":984},"NCT00012220","Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas",[91],"2001-01",259,[171],[791,43,185,139],{"nctId":986,"briefTitle":987,"status":105,"phases":988,"primaryCompletion":685,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":993},"NCT00059826","Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer",[91],"2011-02","2003-03",89,[171],[994,791,120],"interferon-alfa-2b",{"nctId":996,"briefTitle":997,"status":105,"phases":998,"primaryCompletion":999,"completion":145,"start":630,"enrollment":8,"conditions":1000,"interventions":1001},"NCT00757172","Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction",[91],"2011-11",[224,36],[1002,791,43],"panitumumab",{"nctId":1004,"briefTitle":1005,"status":105,"phases":1006,"primaryCompletion":566,"completion":133,"start":1007,"enrollment":742,"conditions":1008,"interventions":1009},"NCT00005601","Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",[91],"2000-10",[21],[1010,791,1011,1012,1013],"rituximab","cytarabine","dexamethasone","sargramostim",{"nctId":1015,"briefTitle":1016,"status":105,"phases":1017,"primaryCompletion":1018,"completion":675,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT00003996","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[91],"2001-08","1999-05",93,[1022],"Brain and Central Nervous System Tumors",[53,947,791,594],{"nctId":1025,"briefTitle":1026,"status":105,"phases":1027,"primaryCompletion":1028,"completion":754,"start":732,"enrollment":9,"conditions":1029,"interventions":1033},"NCT00077311","Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],"2006-07",[1030,1031,15,1032],"Anemia","Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Neutropenia",[1034,745,791,43,1035],"darbepoetin alfa","BNP7787",{"nctId":1037,"briefTitle":1038,"status":105,"phases":1039,"primaryCompletion":1040,"completion":796,"start":1041,"enrollment":34,"conditions":1042,"interventions":1043},"NCT00003621","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma",[91],"2005-02","1999-02",[1022],[53,791,594],{"nctId":1045,"briefTitle":762,"status":105,"phases":1046,"primaryCompletion":191,"completion":191,"start":1047,"enrollment":201,"conditions":1048,"interventions":1050},"NCT00006012",[90,91],"2001-02",[1031,15,1049],"Radiation Toxicity",[593,1051,791,594,540,595],"amifostine trihydrate",{"nctId":1053,"briefTitle":1054,"status":105,"phases":1055,"primaryCompletion":132,"completion":191,"start":1056,"enrollment":246,"conditions":1057,"interventions":1058},"NCT00002998","Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer",[91],"1997-08",[18],[791,185],{"nctId":1060,"briefTitle":1061,"status":105,"phases":1062,"primaryCompletion":1063,"completion":107,"start":281,"enrollment":160,"conditions":1064,"interventions":1066},"NCT01091454","Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer",[91],"2012-06",[1065],"Triple-negative Breast Cancer",[1067,791],"brostallicin",{"nctId":1069,"briefTitle":1070,"status":105,"phases":1071,"primaryCompletion":1072,"completion":1072,"start":1018,"enrollment":1073,"conditions":1074,"interventions":1078},"NCT00005850","Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer",[91],"2003-09",21,[1075,1076,1077,15],"Anxiety Disorder","Depression","Fatigue",[791,1079,185],"fluoxetine",{"nctId":1081,"briefTitle":1082,"status":258,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1092},"NCT03609216","Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations",[91],"2027-02-01","2029-02-01","2018-12-10",237,[1089,1090,1091],"Infiltrating Bladder Urothelial Carcinoma","Stage II Bladder Urothelial Carcinoma","Stage III Bladder Urothelial Carcinoma",[1093,488,1094],"Gemcitabine Hydrochloride","Pegfilgrastim",{"nctId":784,"briefTitle":785,"status":105,"phases":1096,"primaryCompletion":756,"completion":787,"start":788,"enrollment":16,"conditions":1097,"interventions":1098},[91],[15],[524,791,594,139],{"nctId":1100,"briefTitle":1101,"status":105,"phases":1102,"primaryCompletion":756,"completion":1103,"start":765,"enrollment":160,"conditions":1104,"interventions":1105},"NCT00026403","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer",[91],"2009-07",[171],[791,185],{"trials":1107,"activeCount":459,"soonestReadout":1112},[1108,1125,1131,1135,1145,1155,1163,1167,1171,1178],{"nctId":1109,"briefTitle":1110,"status":258,"phases":1111,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1123},"NCT06115499","The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1\u002F2 or PALB2-Associated Metastatic Pancreatic Cancer",[91,92],"2029-01-15","2029-12-09","2024-08-13",10,[1117,1118,343,1119,1120,1121,1122],"Pancreatic Acinar Cell Carcinoma","Pancreatic Adenocarcinoma","Pancreatic Carcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Squamous Cell Carcinoma","Stage IV Pancreatic Cancer AJCC v8",[1124,489,488],"Nab paclitaxel",{"nctId":1126,"briefTitle":1127,"status":105,"phases":1128,"primaryCompletion":649,"completion":649,"start":860,"enrollment":798,"conditions":1129,"interventions":1130},"NCT00003118","Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus",[92],[36],[791,138],{"nctId":865,"briefTitle":866,"status":258,"phases":1132,"primaryCompletion":868,"completion":868,"start":869,"enrollment":415,"conditions":1133,"interventions":1134},[92],[871,872,873,874,875,876,877,878,879,880,881],[540,883,791,884,885,524,886],{"nctId":1136,"briefTitle":1137,"status":105,"phases":1138,"primaryCompletion":1063,"completion":1139,"start":1140,"enrollment":1141,"conditions":1142,"interventions":1143},"NCT00052910","Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer",[92],"2016-12","2002-12",546,[36,162],[791,1144,138,140],"epirubicin hydrochloride",{"nctId":1146,"briefTitle":1147,"status":312,"phases":1148,"primaryCompletion":132,"completion":132,"start":1149,"enrollment":272,"conditions":1150,"interventions":1153},"NCT00072215","Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors",[92],"2004-04",[1151,1152],"Extragonadal Germ Cell Tumor","Testicular Germ Cell Tumor",[791,883,540,1154],"vinblastine",{"nctId":1156,"briefTitle":1157,"status":105,"phases":1158,"primaryCompletion":796,"completion":754,"start":134,"enrollment":525,"conditions":1159,"interventions":1161},"NCT00014534","Combination Chemotherapy in Treating Patients With Bladder Cancer",[92],[1160],"Bladder Cancer",[593,791,1162,185],"doxorubicin hydrochloride",{"nctId":475,"briefTitle":476,"status":380,"phases":1164,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":1165,"interventions":1166},[92],[483,484,485,486],[488,229,452,489,490,491,402,63,472],{"nctId":923,"briefTitle":924,"status":925,"phases":1168,"primaryCompletion":927,"start":610,"enrollment":928,"conditions":1169,"interventions":1170},[92],[15],[791,594,524],{"nctId":1172,"briefTitle":1173,"status":312,"phases":1174,"primaryCompletion":999,"completion":824,"start":813,"enrollment":31,"conditions":1175,"interventions":1176},"NCT00863512","Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer",[92],[15],[791,43,185,710,1177],"vinorelbine tartrate",{"nctId":1179,"briefTitle":1180,"status":105,"phases":1181,"primaryCompletion":180,"completion":859,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1185},"NCT00003299","Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[92],"1998-04",587,[15],[791,594,540],{"trials":1187,"activeCount":123},[],{"trials":1189,"activeCount":123},[],{"intervention":140,"totalTrials":1191,"cells":1192},24,{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1303,"PHASE4":1350,"NA":1352},{"trials":1194,"activeCount":123},[],{"trials":1196,"activeCount":123},[],{"trials":1198,"activeCount":272,"soonestReadout":260},[1199,1203,1211,1223,1227,1235,1245,1249,1262,1266,1270,1279,1286,1290,1294],{"nctId":129,"briefTitle":130,"status":105,"phases":1200,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":1201,"interventions":1202},[91],[24],[138,139,140,97],{"nctId":1204,"briefTitle":1205,"status":105,"phases":1206,"primaryCompletion":1149,"completion":1149,"start":1207,"enrollment":1208,"conditions":1209,"interventions":1210},"NCT00023751","Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer",[91],"2001-07",320,[24],[138,140],{"nctId":1212,"briefTitle":1213,"status":105,"phases":1214,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":1217,"interventions":1218},"NCT00020943","Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma",[91],"2001-06",79,[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],"cyclophosphamide","methotrexate","prednisone","vincristine sulfate",{"nctId":165,"briefTitle":166,"status":167,"phases":1224,"primaryCompletion":169,"start":169,"enrollment":123,"conditions":1225,"interventions":1226},[90,91],[171],[173,138,139,140,97],{"nctId":1228,"briefTitle":1229,"status":105,"phases":1230,"primaryCompletion":236,"completion":1231,"start":290,"enrollment":1232,"conditions":1233,"interventions":1234},"NCT00098774","Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma",[91],"2014-09",47,[21],[593,1010,1011,594,140,1220,828],{"nctId":1236,"briefTitle":1237,"status":105,"phases":1238,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1242},"NCT00002494","Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia",[91],"1992-05",134,[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],"mesna","therapeutic hydrocortisone",{"nctId":196,"briefTitle":197,"status":105,"phases":1246,"primaryCompletion":199,"start":200,"enrollment":201,"conditions":1247,"interventions":1248},[91],[24,203],[205,138,140,97],{"nctId":1250,"briefTitle":1251,"status":105,"phases":1252,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":1256,"interventions":1257},"NCT00003700","Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia",[91],"2004-02","1999-01",163,[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],"asparaginase","daunorubicin hydrochloride","mercaptopurine","Allopurinol",{"nctId":207,"briefTitle":208,"status":105,"phases":1263,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":1264,"interventions":1265},[91],[24,203],[138,140,97],{"nctId":216,"briefTitle":217,"status":105,"phases":1267,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":1268,"interventions":1269},[91],[224,36],[226,227,228,229,230],{"nctId":1271,"briefTitle":1272,"status":105,"phases":1273,"primaryCompletion":157,"completion":705,"start":686,"enrollment":525,"conditions":1274,"interventions":1278},"NCT00009893","Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer",[91],[1275,1276,1277],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Liver Cancer",[138,185,140],{"nctId":1280,"briefTitle":1281,"status":105,"phases":1282,"primaryCompletion":1149,"completion":705,"start":1283,"enrollment":37,"conditions":1284,"interventions":1285},"NCT00016952","Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer",[91],"2001-04",[24],[138,139,140],{"nctId":250,"briefTitle":251,"status":167,"phases":1287,"enrollment":123,"conditions":1288,"interventions":1289},[91],[24],[184,205,138,140,97],{"nctId":256,"briefTitle":257,"status":258,"phases":1291,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":1292,"interventions":1293},[91],[265,266,267],[269,120,270,271,226],{"nctId":1295,"briefTitle":1296,"status":105,"phases":1297,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":1301,"interventions":1302},"NCT00039130","Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia",[91],"2010-09","2014-10",105,[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"trials":1304,"activeCount":459,"soonestReadout":76},[1305,1309,1313,1317,1321,1325,1329,1337,1341],{"nctId":1136,"briefTitle":1137,"status":105,"phases":1306,"primaryCompletion":1063,"completion":1139,"start":1140,"enrollment":1141,"conditions":1307,"interventions":1308},[92],[36,162],[791,1144,138,140],{"nctId":287,"briefTitle":288,"status":105,"phases":1310,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":1311,"interventions":1312},[92],[24],[118,138,140,97],{"nctId":310,"briefTitle":311,"status":312,"phases":1314,"primaryCompletion":314,"completion":107,"start":315,"enrollment":316,"conditions":1315,"interventions":1316},[92],[318,24,305],[184,121,138,140,97],{"nctId":335,"briefTitle":336,"status":258,"phases":1318,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":1319,"interventions":1320},[92],[343,344,171],[226,346,227,228],{"nctId":74,"briefTitle":75,"status":258,"phases":1322,"primaryCompletion":76,"completion":349,"start":350,"enrollment":351,"conditions":1323,"interventions":1324},[92],[353],[77,226,227,228,346,271],{"nctId":356,"briefTitle":357,"status":312,"phases":1326,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":1327,"interventions":1328},[92],[24],[184,205,364,365,121,138,139,140,366,97],{"nctId":1330,"briefTitle":208,"status":105,"phases":1331,"primaryCompletion":589,"completion":178,"start":1332,"enrollment":1333,"conditions":1334,"interventions":1335},"NCT00002716",[92],"1996-01",135,[24,203],[1012,1336,138,140],"floxuridine",{"nctId":378,"briefTitle":379,"status":380,"phases":1338,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":1339,"interventions":1340},[92],[386,387,388,389,390,391,392,393,394,395,396,397,398,399,400],[228,227,226,271,402],{"nctId":1342,"briefTitle":1343,"status":105,"phases":1344,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":1347,"conditions":1348,"interventions":1349},"NCT00006103","Combination Chemotherapy in Treating Patients With Colorectal Cancer",[92],"2002-04","2000-07",400,[24],[138,139,140],{"trials":1351,"activeCount":123},[],{"trials":1353,"activeCount":123},[],{"intervention":402,"totalTrials":403,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1373,"PHASE4":1387,"NA":1389},{"trials":1357,"activeCount":123},[],{"trials":1359,"activeCount":123},[],{"trials":1361,"activeCount":272,"soonestReadout":1366},[1362],{"nctId":1363,"briefTitle":1364,"status":380,"phases":1365,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":953,"conditions":1368,"interventions":1371},"NCT05647265","Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma",[91],"2026-12-15","2024-11-27",[1369,1370],"Pleural Biphasic Mesothelioma","Pleural Sarcomatoid Mesothelioma",[402,1372],"Ipilimumab",{"trials":1374,"activeCount":459,"soonestReadout":72},[1375,1379,1383],{"nctId":70,"briefTitle":71,"status":258,"phases":1376,"primaryCompletion":72,"completion":457,"start":458,"enrollment":459,"conditions":1377,"interventions":1378},[92],[461,462,463,464,465,466,467,468,469,470],[63,402,472,473,82],{"nctId":475,"briefTitle":476,"status":380,"phases":1380,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":1381,"interventions":1382},[92],[483,484,485,486],[488,229,452,489,490,491,402,63,472],{"nctId":378,"briefTitle":379,"status":380,"phases":1384,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":1385,"interventions":1386},[92],[386,387,388,389,390,391,392,393,394,395,396,397,398,399,400],[228,227,226,271,402],{"trials":1388,"activeCount":123},[],{"trials":1390,"activeCount":123},[],{"intervention":138,"totalTrials":1191,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1458,"PHASE4":1500,"NA":1502},{"trials":1394,"activeCount":123},[],{"trials":1396,"activeCount":123},[],{"trials":1398,"activeCount":123},[1399,1403,1407,1414,1418,1422,1426,1430,1434,1438,1442,1450,1454],{"nctId":129,"briefTitle":130,"status":105,"phases":1400,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":1401,"interventions":1402},[91],[24],[138,139,140,97],{"nctId":1204,"briefTitle":1205,"status":105,"phases":1404,"primaryCompletion":1149,"completion":1149,"start":1207,"enrollment":1208,"conditions":1405,"interventions":1406},[91],[24],[138,140],{"nctId":1408,"briefTitle":1409,"status":105,"phases":1410,"primaryCompletion":210,"completion":281,"start":765,"enrollment":1411,"conditions":1412,"interventions":1413},"NCT00026130","Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer",[91],81,[171],[138,185],{"nctId":165,"briefTitle":166,"status":167,"phases":1415,"primaryCompletion":169,"start":169,"enrollment":123,"conditions":1416,"interventions":1417},[90,91],[171],[173,138,139,140,97],{"nctId":196,"briefTitle":197,"status":105,"phases":1419,"primaryCompletion":199,"start":200,"enrollment":201,"conditions":1420,"interventions":1421},[91],[24,203],[205,138,140,97],{"nctId":207,"briefTitle":208,"status":105,"phases":1423,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":1424,"interventions":1425},[91],[24,203],[138,140,97],{"nctId":216,"briefTitle":217,"status":105,"phases":1427,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":1428,"interventions":1429},[91],[224,36],[226,227,228,229,230],{"nctId":1271,"briefTitle":1272,"status":105,"phases":1431,"primaryCompletion":157,"completion":705,"start":686,"enrollment":525,"conditions":1432,"interventions":1433},[91],[1275,1276,1277],[138,185,140],{"nctId":232,"briefTitle":233,"status":105,"phases":1435,"primaryCompletion":190,"completion":235,"start":236,"enrollment":201,"conditions":1436,"interventions":1437},[91],[224,36,162],[121,43,138,97],{"nctId":793,"briefTitle":794,"status":105,"phases":1439,"primaryCompletion":796,"completion":630,"start":797,"enrollment":798,"conditions":1440,"interventions":1441},[91],[36,162],[524,138,540],{"nctId":1443,"briefTitle":1444,"status":105,"phases":1445,"primaryCompletion":221,"completion":806,"start":1446,"enrollment":1447,"conditions":1448,"interventions":1449},"NCT00601627","Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery",[91],"2009-06",52,[171],[1002,121,138,185],{"nctId":1280,"briefTitle":1281,"status":105,"phases":1451,"primaryCompletion":1149,"completion":705,"start":1283,"enrollment":37,"conditions":1452,"interventions":1453},[91],[24],[138,139,140],{"nctId":250,"briefTitle":251,"status":167,"phases":1455,"enrollment":123,"conditions":1456,"interventions":1457},[91],[24],[184,205,138,140,97],{"trials":1459,"activeCount":459,"soonestReadout":76},[1460,1464,1468,1472,1476,1480,1484,1488,1492,1496],{"nctId":1126,"briefTitle":1127,"status":105,"phases":1461,"primaryCompletion":649,"completion":649,"start":860,"enrollment":798,"conditions":1462,"interventions":1463},[92],[36],[791,138],{"nctId":1136,"briefTitle":1137,"status":105,"phases":1465,"primaryCompletion":1063,"completion":1139,"start":1140,"enrollment":1141,"conditions":1466,"interventions":1467},[92],[36,162],[791,1144,138,140],{"nctId":287,"briefTitle":288,"status":105,"phases":1469,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":1470,"interventions":1471},[92],[24],[118,138,140,97],{"nctId":310,"briefTitle":311,"status":312,"phases":1473,"primaryCompletion":314,"completion":107,"start":315,"enrollment":316,"conditions":1474,"interventions":1475},[92],[318,24,305],[184,121,138,140,97],{"nctId":335,"briefTitle":336,"status":258,"phases":1477,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":1478,"interventions":1479},[92],[343,344,171],[226,346,227,228],{"nctId":74,"briefTitle":75,"status":258,"phases":1481,"primaryCompletion":76,"completion":349,"start":350,"enrollment":351,"conditions":1482,"interventions":1483},[92],[353],[77,226,227,228,346,271],{"nctId":356,"briefTitle":357,"status":312,"phases":1485,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":1486,"interventions":1487},[92],[24],[184,205,364,365,121,138,139,140,366,97],{"nctId":1330,"briefTitle":208,"status":105,"phases":1489,"primaryCompletion":589,"completion":178,"start":1332,"enrollment":1333,"conditions":1490,"interventions":1491},[92],[24,203],[1012,1336,138,140],{"nctId":378,"briefTitle":379,"status":380,"phases":1493,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":1494,"interventions":1495},[92],[386,387,388,389,390,391,392,393,394,395,396,397,398,399,400],[228,227,226,271,402],{"nctId":1342,"briefTitle":1343,"status":105,"phases":1497,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":1347,"conditions":1498,"interventions":1499},[92],[24],[138,139,140],{"trials":1501,"activeCount":123},[],{"trials":1503,"activeCount":272,"soonestReadout":412},[1504],{"nctId":409,"briefTitle":410,"status":380,"phases":1505,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":1506,"interventions":1507},[94],[417,418,419,420,421,422,423,424,425,426],[226,428,228],{"intervention":43,"totalTrials":98,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1626,"PHASE4":1680,"NA":1682},{"trials":1511,"activeCount":123},[],{"trials":1513,"activeCount":123},[],{"trials":1515,"activeCount":123},[1516,1522,1531,1539,1543,1547,1553,1557,1561,1565,1571,1577,1584,1593,1597,1605,1609,1613,1620],{"nctId":1517,"briefTitle":1518,"status":105,"phases":1519,"primaryCompletion":674,"completion":133,"start":1072,"enrollment":620,"conditions":1520,"interventions":1521},"NCT00054457","Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction",[91],[36,162],[121,43],{"nctId":1523,"briefTitle":1524,"status":105,"phases":1525,"primaryCompletion":1526,"completion":859,"start":1527,"enrollment":1528,"conditions":1529,"interventions":1530},"NCT00004139","Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",[91],"2004-07","1999-09",80,[15],[43,185,139],{"nctId":1532,"briefTitle":1533,"status":105,"phases":1534,"primaryCompletion":859,"completion":535,"start":1535,"enrollment":816,"conditions":1536,"interventions":1538},"NCT00003565","Docetaxel in Treating Patients With Solid Tumors",[91],"1998-09",[1160,18,1537,15,30],"Head and Neck Cancer",[43],{"nctId":978,"briefTitle":979,"status":105,"phases":1540,"primaryCompletion":588,"completion":754,"start":981,"enrollment":982,"conditions":1541,"interventions":1542},[91],[171],[791,43,185,139],{"nctId":996,"briefTitle":997,"status":105,"phases":1544,"primaryCompletion":999,"completion":145,"start":630,"enrollment":8,"conditions":1545,"interventions":1546},[91],[224,36],[1002,791,43],{"nctId":1548,"briefTitle":1549,"status":105,"phases":1550,"primaryCompletion":589,"completion":589,"start":245,"enrollment":160,"conditions":1551,"interventions":1552},"NCT00003900","Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer",[91],[15],[43,139],{"nctId":626,"briefTitle":627,"status":105,"phases":1554,"primaryCompletion":629,"completion":630,"start":631,"enrollment":181,"conditions":1555,"interventions":1556},[91],[18],[524,43],{"nctId":1025,"briefTitle":1026,"status":105,"phases":1558,"primaryCompletion":1028,"completion":754,"start":732,"enrollment":9,"conditions":1559,"interventions":1560},[91],[1030,1031,15,1032],[1034,745,791,43,1035],{"nctId":645,"briefTitle":646,"status":105,"phases":1562,"primaryCompletion":372,"completion":648,"start":649,"enrollment":28,"conditions":1563,"interventions":1564},[91],[33],[593,524,43,652],{"nctId":1566,"briefTitle":1567,"status":105,"phases":1568,"primaryCompletion":732,"completion":732,"start":568,"enrollment":1232,"conditions":1569,"interventions":1570},"NCT00004235","Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach",[91],[36,162],[43,139],{"nctId":1572,"briefTitle":1573,"status":105,"phases":1574,"primaryCompletion":178,"completion":776,"start":200,"enrollment":620,"conditions":1575,"interventions":1576},"NCT00088998","Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer",[91],[18],[184,121,43],{"nctId":1578,"briefTitle":1579,"status":105,"phases":1580,"primaryCompletion":859,"completion":754,"start":1581,"enrollment":1528,"conditions":1582,"interventions":1583},"NCT00052845","Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",[91],"2002-11",[33],[43,652,736],{"nctId":1585,"briefTitle":1586,"status":312,"phases":1587,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":430,"conditions":1590,"interventions":1592},"NCT02485834","FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer",[91],"2018-08-01","2015-11-12",[224,1591,162],"Gastric Adenocarcinoma",[376,121,43,271],{"nctId":738,"briefTitle":739,"status":105,"phases":1594,"primaryCompletion":741,"start":676,"enrollment":742,"conditions":1595,"interventions":1596},[91],[18],[745,524,43],{"nctId":1598,"briefTitle":1599,"status":105,"phases":1600,"primaryCompletion":1601,"completion":675,"start":1041,"enrollment":1602,"conditions":1603,"interventions":1604},"NCT00003762","Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",[91],"2003-02",106,[15],[43,185],{"nctId":773,"briefTitle":774,"status":105,"phases":1606,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":1607,"interventions":1608},[91],[18],[669,524,43,782],{"nctId":232,"briefTitle":233,"status":105,"phases":1610,"primaryCompletion":190,"completion":235,"start":236,"enrollment":201,"conditions":1611,"interventions":1612},[91],[224,36,162],[121,43,138,97],{"nctId":1614,"briefTitle":1615,"status":105,"phases":1616,"primaryCompletion":1617,"completion":158,"start":765,"enrollment":98,"conditions":1618,"interventions":1619},"NCT00006010","Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer",[91],"2004-05",[1277],[43,185],{"nctId":1621,"briefTitle":1622,"status":105,"phases":1623,"primaryCompletion":674,"completion":776,"start":1149,"enrollment":8,"conditions":1624,"interventions":1625},"NCT00079118","Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer",[91],[18],[43,139],{"trials":1627,"activeCount":459,"soonestReadout":42},[1628,1639,1653,1661,1672,1676],{"nctId":1629,"briefTitle":1630,"status":167,"phases":1631,"enrollment":123,"conditions":1632,"interventions":1637},"NCT00041171","Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery",[92],[1633,18,1537,1634,1635,1636],"Adult Solid Tumor","Kidney and Urinary Cancer","Male Reproductive Cancer","Thorax and Respiratory Cancer",[1638,43],"Hypericum perforatum",{"nctId":1640,"briefTitle":1641,"status":380,"phases":1642,"primaryCompletion":1643,"completion":1644,"start":1645,"enrollment":1646,"conditions":1647,"interventions":1650},"NCT06931340","Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial",[92],"2031-11-11","2039-05-08","2025-12-01",1260,[1648,1649,721],"Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Adenocarcinoma",[1651,1652,490],"Androgen Therapy","Apalutamide",{"nctId":40,"briefTitle":41,"status":258,"phases":1654,"primaryCompletion":42,"completion":1655,"start":1656,"enrollment":1657,"conditions":1658,"interventions":1659},[92],"2030-10","2007-05-08",788,[33],[43,1660],"LHRH agonist",{"nctId":1662,"briefTitle":1663,"status":105,"phases":1664,"primaryCompletion":706,"completion":1665,"start":629,"enrollment":1666,"conditions":1667,"interventions":1670},"NCT00040885","Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10\u002F05\u002F05)",[92],"2008-10",67,[1668,1669,1077,15],"Anorexia","Cachexia",[1671,43],"infliximab",{"nctId":475,"briefTitle":476,"status":380,"phases":1673,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":1674,"interventions":1675},[92],[483,484,485,486],[488,229,452,489,490,491,402,63,472],{"nctId":1172,"briefTitle":1173,"status":312,"phases":1677,"primaryCompletion":999,"completion":824,"start":813,"enrollment":31,"conditions":1678,"interventions":1679},[92],[15],[791,43,185,710,1177],{"trials":1681,"activeCount":123},[],{"trials":1683,"activeCount":123},[],{"intervention":1010,"totalTrials":110,"cells":1685},{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1720,"PHASE3":1852,"PHASE4":1899,"NA":1901},{"trials":1687,"activeCount":123},[],{"trials":1689,"activeCount":123},[1690,1698,1709],{"nctId":1691,"briefTitle":1692,"status":105,"phases":1693,"primaryCompletion":1694,"completion":1695,"start":547,"enrollment":953,"conditions":1696,"interventions":1697},"NCT01334502","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",[90],"2015-02","2017-08",[21],[1010,1219,1162,624,1221,1222],{"nctId":1699,"briefTitle":1700,"status":105,"phases":1701,"primaryCompletion":314,"completion":1702,"start":1703,"enrollment":953,"conditions":1704,"interventions":1706},"NCT01429025","Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",[90],"2019-07-01","2012-05",[1705],"Refractory\u002FRelapsed Indolent Non-Hodgkin Lymphoma",[1010,1707,1708],"bendamustine","lenalidomide",{"nctId":1710,"briefTitle":1711,"status":105,"phases":1712,"primaryCompletion":1713,"completion":609,"start":754,"enrollment":1714,"conditions":1715,"interventions":1716},"NCT00787969","Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",[90],"2012-04",74,[21],[1010,1717,1718,1719,1094],"cladribine","temsirolimus","Filgrastim",{"trials":1721,"activeCount":272,"soonestReadout":1802},[1722,1730,1737,1745,1754,1758,1766,1770,1778,1786,1794,1798,1821,1833,1841,1845],{"nctId":1723,"briefTitle":1724,"status":105,"phases":1725,"primaryCompletion":1040,"completion":133,"start":1726,"enrollment":1727,"conditions":1728,"interventions":1729},"NCT00003849","Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease",[91],"1999-07",39,[21],[1010],{"nctId":1731,"briefTitle":1732,"status":105,"phases":1733,"primaryCompletion":859,"completion":1734,"start":1601,"enrollment":779,"conditions":1735,"interventions":1736},"NCT00053027","Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",[91],"2009-11",[21],[1010,1717],{"nctId":1738,"briefTitle":1739,"status":105,"phases":1740,"primaryCompletion":1741,"completion":805,"start":158,"enrollment":1191,"conditions":1742,"interventions":1743},"NCT00460109","Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma",[91],"2010-10",[21],[1744,1010],"denileukin diftitox",{"nctId":1746,"briefTitle":1747,"status":105,"phases":1748,"primaryCompletion":1665,"completion":1749,"start":859,"enrollment":1750,"conditions":1751,"interventions":1752},"NCT00301821","Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",[91],"2015-04",107,[21],[1753,1010,1219,1162,1221,1222],"epratuzumab",{"nctId":1004,"briefTitle":1005,"status":105,"phases":1755,"primaryCompletion":566,"completion":133,"start":1007,"enrollment":742,"conditions":1756,"interventions":1757},[91],[21],[1010,791,1011,1012,1013],{"nctId":1759,"briefTitle":1760,"status":105,"phases":1761,"primaryCompletion":1762,"completion":1762,"start":1149,"enrollment":1763,"conditions":1764,"interventions":1765},"NCT00062114","Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",[91],"2007-04",84,[21],[1010],{"nctId":1212,"briefTitle":1213,"status":105,"phases":1767,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":1768,"interventions":1769},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":1771,"briefTitle":1772,"status":105,"phases":1773,"primaryCompletion":1063,"completion":1774,"start":589,"enrollment":1775,"conditions":1776,"interventions":1777},"NCT00238238","Rituximab and\u002For Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab",[91],"2015-08",97,[21],[1010,1708],{"nctId":1779,"briefTitle":1780,"status":105,"phases":1781,"primaryCompletion":823,"completion":1782,"start":610,"enrollment":1783,"conditions":1784,"interventions":1785},"NCT00553501","Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma",[91],"2014-07",60,[21],[1753,1010],{"nctId":1787,"briefTitle":1788,"status":105,"phases":1789,"primaryCompletion":756,"completion":618,"start":180,"enrollment":1790,"conditions":1791,"interventions":1792},"NCT00117975","Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",[91],62,[21],[1793,1010],"galiximab",{"nctId":1228,"briefTitle":1229,"status":105,"phases":1795,"primaryCompletion":236,"completion":1231,"start":290,"enrollment":1232,"conditions":1796,"interventions":1797},[91],[21],[593,1010,1011,594,140,1220,828],{"nctId":1799,"briefTitle":1800,"status":258,"phases":1801,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":1806,"interventions":1809},"NCT05303792","Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma",[91],"2027-04-01","2029-05","2023-06-09",68,[1807,1808],"B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma",[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],"Cyclophosphamide","Vincristine","Dexamethasone","Inotuzumab Ozogamicin","Methotrexate","Cytarabine","Methylprednisolone","Rituximab","Prednisone","Mercaptopurine","Doxorubicin",{"nctId":1822,"briefTitle":1823,"status":105,"phases":1824,"primaryCompletion":1825,"completion":1826,"start":755,"enrollment":1805,"conditions":1827,"interventions":1828},"NCT01027000","Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2016-01","2023-04",[27,21],[1010,1829,1219,1830,1220,1831,1832],"busulfan","fludarabine phosphate","sirolimus","tacrolimus",{"nctId":1834,"briefTitle":1835,"status":105,"phases":1836,"primaryCompletion":243,"completion":281,"start":1837,"enrollment":1838,"conditions":1839,"interventions":1840},"NCT00003248","Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia",[91],"1998-03",104,[27],[1010,1830],{"nctId":1295,"briefTitle":1296,"status":105,"phases":1842,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":1843,"interventions":1844},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"nctId":1846,"briefTitle":1847,"status":105,"phases":1848,"primaryCompletion":200,"completion":754,"start":1849,"enrollment":16,"conditions":1850,"interventions":1851},"NCT00032019","Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",[91],"2002-02",[21],[593,1010,1219,1162,594,1221,1222],{"trials":1853,"activeCount":852,"soonestReadout":1871},[1854,1867,1881,1888],{"nctId":1855,"briefTitle":1856,"status":105,"phases":1857,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":1861,"conditions":1862,"interventions":1864},"NCT00118209","Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma",[92],"2017-10","2021-11-15","2005-05",524,[1863],"Large B Cell Lymphoma",[1010,1219,1865,1866,1221,594,593,745],"doxorubicin","vincristine",{"nctId":1868,"briefTitle":1869,"status":380,"phases":1870,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":1875,"interventions":1876},"NCT03150693","Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",[92],"2027-03-01","2027-08","2017-09-20",310,[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],"Daunorubicin Hydrochloride","Vincristine Sulfate","Pegylated L-Asparaginase","Thioguanine",{"nctId":1882,"briefTitle":1883,"status":312,"phases":1884,"primaryCompletion":1885,"completion":1885,"start":535,"enrollment":1763,"conditions":1886,"interventions":1887},"NCT00513747","Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia",[92],"2016-06",[27],[1010,1830],{"nctId":1889,"briefTitle":1890,"status":380,"phases":1891,"primaryCompletion":1892,"completion":1892,"start":1893,"enrollment":1894,"conditions":1895,"interventions":1897},"NCT05976763","Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma",[92],"2038-08-31","2023-10-20",421,[1896],"Mantle Cell Lymphoma",[1898,1817],"Zanubrutinib",{"trials":1900,"activeCount":123},[],{"trials":1902,"activeCount":123},[],{"intervention":1012,"totalTrials":1904,"cells":1905},15,{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1981,"PHASE4":2037,"NA":2039},{"trials":1907,"activeCount":123},[],{"trials":1909,"activeCount":123},[],{"trials":1911,"activeCount":852,"soonestReadout":1802},[1912,1920,1924,1938,1950,1954,1958,1970,1977],{"nctId":1913,"briefTitle":1914,"status":105,"phases":1915,"primaryCompletion":578,"completion":578,"start":1916,"enrollment":1917,"conditions":1918,"interventions":1919},"NCT00002676","Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma",[91],"1995-07",36,[21],[53,1219,1011,1012,1162,1220,1222],{"nctId":1004,"briefTitle":1005,"status":105,"phases":1921,"primaryCompletion":566,"completion":133,"start":1007,"enrollment":742,"conditions":1922,"interventions":1923},[91],[21],[1010,791,1011,1012,1013],{"nctId":1925,"briefTitle":1926,"status":380,"phases":1927,"primaryCompletion":1928,"completion":1929,"start":1930,"enrollment":1931,"conditions":1932,"interventions":1935},"NCT06232044","Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma",[90,91],"2028-05-01","2030-08-01","2025-04-23",88,[1933,1934],"Recurrent Multiple Myeloma","Refractory Multiple Myeloma",[1936,1937,1812],"Iberdomide","Belantamab Mafodotin",{"nctId":1939,"briefTitle":1940,"status":925,"phases":1941,"primaryCompletion":1942,"start":1943,"enrollment":1944,"conditions":1945,"interventions":1947},"NCT02004275","Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma",[90,91],"2021-12-01","2014-02",118,[1946],"Multiple Myeloma in Relapse",[1948,1949,1012],"pomalidomide","ixazomib",{"nctId":1236,"briefTitle":1237,"status":105,"phases":1951,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":1952,"interventions":1953},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"nctId":1799,"briefTitle":1800,"status":258,"phases":1955,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":1956,"interventions":1957},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"nctId":1959,"briefTitle":1960,"status":105,"phases":1961,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":1966,"interventions":1967},"NCT00558519","Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",[91],"2016-09","2024-06-24","2008-03-12",318,[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],"pegaspargase","thioguanine",{"nctId":1971,"briefTitle":1972,"status":105,"phases":1973,"primaryCompletion":244,"completion":244,"start":1837,"enrollment":1974,"conditions":1975,"interventions":1976},"NCT00003278","Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma",[91],28,[21],[1012],{"nctId":1295,"briefTitle":1296,"status":105,"phases":1978,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":1979,"interventions":1980},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"trials":1982,"activeCount":272,"soonestReadout":1871},[1983,1987,1997,2008,2012,2023],{"nctId":1868,"briefTitle":1869,"status":380,"phases":1984,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":1985,"interventions":1986},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"nctId":1988,"briefTitle":1989,"status":105,"phases":1990,"primaryCompletion":805,"completion":1991,"start":754,"enrollment":1992,"conditions":1993,"interventions":1995},"NCT00880191","Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy",[92],"2015-05",430,[1994,30],"Nausea and Vomiting",[1012,1996],"gabapentin",{"nctId":1998,"briefTitle":1999,"status":925,"phases":2000,"primaryCompletion":2001,"start":2002,"enrollment":2003,"conditions":2004,"interventions":2006},"NCT02516423","Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone",[92],"2024-09","2015-12",11,[2005],"Solitary Osseous Plasmacytoma",[1949,1708,1012,2007],"zoledronic acid",{"nctId":1330,"briefTitle":208,"status":105,"phases":2009,"primaryCompletion":589,"completion":178,"start":1332,"enrollment":1333,"conditions":2010,"interventions":2011},[92],[24,203],[1012,1336,138,140],{"nctId":2013,"briefTitle":2014,"status":312,"phases":2015,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":1727,"conditions":2019,"interventions":2021},"NCT03839940","Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer",[92],"2021-01-08","2022-08-03","2019-06-03",[2020],"Malignant Neoplasm",[1812,2022],"Everolimus",{"nctId":2024,"briefTitle":2025,"status":105,"phases":2026,"primaryCompletion":2027,"completion":2028,"start":2029,"enrollment":2030,"conditions":2031,"interventions":2032},"NCT03578081","Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy",[92],"2021-11-08","2023-05-01","2018-11-20",690,[2020],[2033,2034,1812,2035,2036],"Palonosetron Hydrochloride","Ondansetron Hydrochloride","Fosaprepitant Dimeglumine","Olanzapine",{"trials":2038,"activeCount":123},[],{"trials":2040,"activeCount":123},[],{"intervention":1011,"totalTrials":135,"cells":2042},{"EARLY_PHASE1":2043,"PHASE1":2045,"PHASE2":2047,"PHASE3":2107,"PHASE4":2124,"NA":2126},{"trials":2044,"activeCount":123},[],{"trials":2046,"activeCount":123},[],{"trials":2048,"activeCount":852,"soonestReadout":52},[2049,2056,2060,2068,2072,2076,2083,2087,2091,2095,2099,2103],{"nctId":2050,"briefTitle":2051,"status":105,"phases":2052,"primaryCompletion":1601,"completion":813,"start":2053,"enrollment":569,"conditions":2054,"interventions":2055},"NCT00002768","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission",[91],"1996-06",[27],[593,1829,1011,594,1220],{"nctId":1913,"briefTitle":1914,"status":105,"phases":2057,"primaryCompletion":578,"completion":578,"start":1916,"enrollment":1917,"conditions":2058,"interventions":2059},[91],[21],[53,1219,1011,1012,1162,1220,1222],{"nctId":2061,"briefTitle":2062,"status":105,"phases":2063,"primaryCompletion":1601,"completion":1601,"start":631,"enrollment":403,"conditions":2064,"interventions":2066},"NCT00006747","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma",[91],[2065,21],"Graft Versus Host Disease",[53,2067,594,1011,1832,1220,1013],"melphalan",{"nctId":1004,"briefTitle":1005,"status":105,"phases":2069,"primaryCompletion":566,"completion":133,"start":1007,"enrollment":742,"conditions":2070,"interventions":2071},[91],[21],[1010,791,1011,1012,1013],{"nctId":1212,"briefTitle":1213,"status":105,"phases":2073,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":2074,"interventions":2075},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":50,"briefTitle":51,"status":258,"phases":2077,"primaryCompletion":52,"completion":2078,"start":814,"enrollment":2079,"conditions":2080,"interventions":2081},[91],"2027-05-02",113,[21],[53,1011,594,2082,885],"thiotepa",{"nctId":1228,"briefTitle":1229,"status":105,"phases":2084,"primaryCompletion":236,"completion":1231,"start":290,"enrollment":1232,"conditions":2085,"interventions":2086},[91],[21],[593,1010,1011,594,140,1220,828],{"nctId":1236,"briefTitle":1237,"status":105,"phases":2088,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":2089,"interventions":2090},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"nctId":1250,"briefTitle":1251,"status":105,"phases":2092,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":2093,"interventions":2094},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"nctId":1799,"briefTitle":1800,"status":258,"phases":2096,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":2097,"interventions":2098},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"nctId":1959,"briefTitle":1960,"status":105,"phases":2100,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":2101,"interventions":2102},[91],[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],{"nctId":1295,"briefTitle":1296,"status":105,"phases":2104,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":2105,"interventions":2106},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"trials":2108,"activeCount":272,"soonestReadout":1871},[2109,2113],{"nctId":1868,"briefTitle":1869,"status":380,"phases":2110,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":2111,"interventions":2112},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"nctId":2114,"briefTitle":2115,"status":925,"phases":2116,"primaryCompletion":2117,"start":158,"enrollment":2118,"conditions":2119,"interventions":2120},"NCT00651261","Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[92],"2016-07",717,[27],[1011,2121,2122,2123],"daunorubicin","midostaurin","dexamethasone acetate",{"trials":2125,"activeCount":123},[],{"trials":2127,"activeCount":123},[],{"intervention":828,"totalTrials":2129,"cells":2130},9,{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2190,"PHASE4":2216,"NA":2218},{"trials":2132,"activeCount":123},[],{"trials":2134,"activeCount":123},[],{"trials":2136,"activeCount":272,"soonestReadout":2141},[2137,2151,2159,2163,2170,2178,2186],{"nctId":2138,"briefTitle":2139,"status":258,"phases":2140,"primaryCompletion":2141,"completion":2142,"start":2143,"enrollment":2144,"conditions":2145,"interventions":2148},"NCT05247905","Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors",[91],"2028-03-31","2033-10-01","2023-02-16",31,[2146,2147],"Metastatic Pancreatic Neuroendocrine Tumor","Unresectable Pancreatic Neuroendocrine Carcinoma",[2149,269,2150],"Lutetium Lu 177 Dotatate","Temozolomide",{"nctId":2152,"briefTitle":2153,"status":105,"phases":2154,"primaryCompletion":359,"completion":2155,"start":813,"enrollment":2156,"conditions":2157,"interventions":2158},"NCT00553150","Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma",[90,91],"2019-11-15",122,[1022],[624,828],{"nctId":1228,"briefTitle":1229,"status":105,"phases":2160,"primaryCompletion":236,"completion":1231,"start":290,"enrollment":1232,"conditions":2161,"interventions":2162},[91],[21],[593,1010,1011,594,140,1220,828],{"nctId":2164,"briefTitle":2165,"status":105,"phases":2166,"primaryCompletion":903,"completion":776,"start":535,"enrollment":2167,"conditions":2168,"interventions":2169},"NCT00521001","Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery",[91],49,[581],[624,828],{"nctId":2171,"briefTitle":2172,"status":312,"phases":2173,"primaryCompletion":2174,"completion":577,"start":2175,"enrollment":25,"conditions":2176,"interventions":2177},"NCT00068666","Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System",[91],"2005-03","2004-01",[581,203],[828],{"nctId":2179,"briefTitle":2180,"status":105,"phases":2181,"primaryCompletion":1299,"completion":2155,"start":1446,"enrollment":2182,"conditions":2183,"interventions":2184},"NCT00869401","Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[90,91],217,[1022],[2185,828],"dasatinib",{"nctId":820,"briefTitle":821,"status":105,"phases":2187,"primaryCompletion":823,"completion":824,"start":639,"enrollment":825,"conditions":2188,"interventions":2189},[91],[581],[184,524,583,828],{"trials":2191,"activeCount":852,"soonestReadout":2197},[2192,2205],{"nctId":2193,"briefTitle":2194,"status":2195,"phases":2196,"primaryCompletion":2197,"completion":2198,"start":2199,"enrollment":2200,"conditions":2201,"interventions":2203},"NCT07605364","Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer","NOT_YET_RECRUITING",[91,92],"2029-09-30","2031-01-05","2026-06-10",422,[2202],"Advanced Glioblastoma",[2150,2204],"Mycophenolate Mofetil",{"nctId":2206,"briefTitle":2207,"status":2195,"phases":2208,"primaryCompletion":510,"completion":2209,"start":2210,"enrollment":2211,"conditions":2212,"interventions":2214},"NCT07215910","Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer",[92],"2040-01","2025-10-20",408,[2213],"Astrocytoma, IDH-Mutant, Grade 3",[2150,2215],"Vorasidenib",{"trials":2217,"activeCount":123},[],{"trials":2219,"activeCount":123},[],{"intervention":271,"totalTrials":2221,"cells":2222},7,{"EARLY_PHASE1":2223,"PHASE1":2229,"PHASE2":2231,"PHASE3":2241,"PHASE4":2259,"NA":2261},{"trials":2224,"activeCount":123},[2225],{"nctId":103,"briefTitle":104,"status":105,"phases":2226,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":2227,"interventions":2228},[89],[112,113,114,115,116],[97,118,119,120,121,122],{"trials":2230,"activeCount":123},[],{"trials":2232,"activeCount":272,"soonestReadout":260},[2233,2237],{"nctId":1585,"briefTitle":1586,"status":312,"phases":2234,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":430,"conditions":2235,"interventions":2236},[91],[224,1591,162],[376,121,43,271],{"nctId":256,"briefTitle":257,"status":258,"phases":2238,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":2239,"interventions":2240},[91],[265,266,267],[269,120,270,271,226],{"trials":2242,"activeCount":852,"soonestReadout":76},[2243,2247,2251,2255],{"nctId":287,"briefTitle":288,"status":105,"phases":2244,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":2245,"interventions":2246},[92],[24],[118,138,140,97],{"nctId":74,"briefTitle":75,"status":258,"phases":2248,"primaryCompletion":76,"completion":349,"start":350,"enrollment":351,"conditions":2249,"interventions":2250},[92],[353],[77,226,227,228,346,271],{"nctId":368,"briefTitle":369,"status":312,"phases":2252,"primaryCompletion":371,"completion":281,"start":372,"enrollment":373,"conditions":2253,"interventions":2254},[92],[24],[205,376,118,119,97],{"nctId":378,"briefTitle":379,"status":380,"phases":2256,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":2257,"interventions":2258},[92],[386,387,388,389,390,391,392,393,394,395,396,397,398,399,400],[228,227,226,271,402],{"trials":2260,"activeCount":123},[],{"trials":2262,"activeCount":123},[],{"intervention":48,"totalTrials":403,"cells":2264},{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2282,"PHASE4":2315,"NA":2317},{"trials":2266,"activeCount":123},[],{"trials":2268,"activeCount":123},[],{"trials":2270,"activeCount":852,"soonestReadout":47},[2271,2278],{"nctId":45,"briefTitle":46,"status":258,"phases":2272,"primaryCompletion":47,"completion":2273,"start":2274,"enrollment":620,"conditions":2275,"interventions":2277},[91],"2028-07-05","2016-09-14",[2276],"Salivary Cancer",[48],{"nctId":712,"briefTitle":713,"status":380,"phases":2279,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":2280,"interventions":2281},[91],[720,721],[723,229,724,725,726,727],{"trials":2283,"activeCount":272,"soonestReadout":2303},[2284,2299],{"nctId":2285,"briefTitle":2286,"status":925,"phases":2287,"primaryCompletion":2288,"completion":2289,"start":2290,"enrollment":2291,"conditions":2292,"interventions":2297},"NCT01949337","Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer",[92],"2018-11-02","2024-08-31","2014-01-22",1311,[2293,2294,2295,2296],"Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer","Stage IV Prostate Cancer",[48,2298,1221],"abiraterone",{"nctId":2300,"briefTitle":2301,"status":258,"phases":2302,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":2307,"interventions":2310},"NCT04455750","A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy",[92],"2027-03-15","2027-09","2021-10-14",61,[720,1649,2308,2309,721],"Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8",[726,2311,2312,2313,2314],"Rucaparib camsylate","Leuprolide Acetate","Goserelin Acetate","Degarelix",{"trials":2316,"activeCount":123},[],{"trials":2318,"activeCount":123},[],{"intervention":489,"totalTrials":403,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2327,"PHASE2":2329,"PHASE3":2331,"PHASE4":2355,"NA":2357},{"trials":2322,"activeCount":123},[2323],{"nctId":103,"briefTitle":104,"status":105,"phases":2324,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":2325,"interventions":2326},[89],[112,113,114,115,116],[97,118,119,120,121,122],{"trials":2328,"activeCount":123},[],{"trials":2330,"activeCount":123},[],{"trials":2332,"activeCount":459,"soonestReadout":2345},[2333,2337,2341],{"nctId":1109,"briefTitle":1110,"status":258,"phases":2334,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":2335,"interventions":2336},[91,92],[1117,1118,343,1119,1120,1121,1122],[1124,489,488],{"nctId":475,"briefTitle":476,"status":380,"phases":2338,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":2339,"interventions":2340},[92],[483,484,485,486],[488,229,452,489,490,491,402,63,472],{"nctId":2342,"briefTitle":2343,"status":380,"phases":2344,"primaryCompletion":2345,"completion":2346,"start":2347,"enrollment":2348,"conditions":2349,"interventions":2353},"NCT07000084","Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy",[92],"2028-06-05","2028-12-05","2025-07-17",330,[2350,2351,2352],"Recurrent Non-Muscle Invasive Bladder Carcinoma","Stage 0a Bladder Cancer AJCC v8","Stage I Bladder Cancer AJCC v8",[2354,489],"BCG Solution",{"trials":2356,"activeCount":123},[],{"trials":2358,"activeCount":123},[],{"intervention":139,"totalTrials":953,"cells":2360},{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2371,"PHASE3":2489,"PHASE4":2507,"NA":2509},{"trials":2362,"activeCount":123},[],{"trials":2364,"activeCount":123},[2365],{"nctId":2366,"briefTitle":2367,"status":105,"phases":2368,"primaryCompletion":648,"completion":648,"start":765,"enrollment":558,"conditions":2369,"interventions":2370},"NCT00026195","Irinotecan in Treating Aging Patients With Solid Tumors",[90],[30],[139],{"trials":2372,"activeCount":123},[2373,2380,2384,2391,2395,2399,2406,2410,2414,2418,2424,2428,2432,2439,2446,2455,2462,2466,2473,2481,2485],{"nctId":2374,"briefTitle":2375,"status":105,"phases":2376,"primaryCompletion":158,"completion":813,"start":1253,"enrollment":2144,"conditions":2377,"interventions":2379},"NCT00066781","Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary",[91],[2378],"Carcinoma of Unknown Primary",[185,139],{"nctId":129,"briefTitle":130,"status":105,"phases":2381,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":2382,"interventions":2383},[91],[24],[138,139,140,97],{"nctId":2385,"briefTitle":2386,"status":312,"phases":2387,"primaryCompletion":2388,"completion":999,"start":610,"enrollment":430,"conditions":2389,"interventions":2390},"NCT00588900","Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab",[91],"2010-05",[24],[759,139],{"nctId":142,"briefTitle":143,"status":105,"phases":2392,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":2393,"interventions":2394},[91],[150,151],[121,139,97],{"nctId":1523,"briefTitle":1524,"status":105,"phases":2396,"primaryCompletion":1526,"completion":859,"start":1527,"enrollment":1528,"conditions":2397,"interventions":2398},[91],[15],[43,185,139],{"nctId":2400,"briefTitle":2401,"status":105,"phases":2402,"primaryCompletion":578,"completion":133,"start":2403,"enrollment":201,"conditions":2404,"interventions":2405},"NCT00005972","Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer",[91],"2000-05",[15],[185,139],{"nctId":970,"briefTitle":971,"status":105,"phases":2407,"primaryCompletion":299,"completion":973,"start":706,"enrollment":974,"conditions":2408,"interventions":2409},[91],[36],[791,139],{"nctId":978,"briefTitle":979,"status":105,"phases":2411,"primaryCompletion":588,"completion":754,"start":981,"enrollment":982,"conditions":2412,"interventions":2413},[91],[171],[791,43,185,139],{"nctId":1548,"briefTitle":1549,"status":105,"phases":2415,"primaryCompletion":589,"completion":589,"start":245,"enrollment":160,"conditions":2416,"interventions":2417},[91],[15],[43,139],{"nctId":2419,"briefTitle":2420,"status":105,"phases":2421,"primaryCompletion":674,"completion":778,"start":706,"enrollment":1073,"conditions":2422,"interventions":2423},"NCT00275041","Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer",[91],[18],[205,139],{"nctId":165,"briefTitle":166,"status":167,"phases":2425,"primaryCompletion":169,"start":169,"enrollment":123,"conditions":2426,"interventions":2427},[90,91],[171],[173,138,139,140,97],{"nctId":1566,"briefTitle":1567,"status":105,"phases":2429,"primaryCompletion":732,"completion":732,"start":568,"enrollment":1232,"conditions":2430,"interventions":2431},[91],[36,162],[43,139],{"nctId":2433,"briefTitle":2434,"status":105,"phases":2435,"primaryCompletion":578,"completion":578,"start":2436,"enrollment":1838,"conditions":2437,"interventions":2438},"NCT00003351","Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer",[91],"1998-08",[18],[139],{"nctId":2440,"briefTitle":2441,"status":105,"phases":2442,"primaryCompletion":1526,"completion":1526,"start":2443,"enrollment":8,"conditions":2444,"interventions":2445},"NCT00003137","Irinotecan in Treating Patients With Advanced Cancer of the Stomach",[91],"1997-12",[36,162],[139],{"nctId":2447,"briefTitle":2448,"status":105,"phases":2449,"primaryCompletion":2450,"completion":630,"start":2451,"enrollment":2452,"conditions":2453,"interventions":2454},"NCT00003134","Irinotecan in Treating Patients With Recurrent Glioma",[91],"2001-10","1998-01",64,[1022],[139],{"nctId":2456,"briefTitle":2457,"status":105,"phases":2458,"primaryCompletion":2459,"completion":2459,"start":1837,"enrollment":28,"conditions":2460,"interventions":2461},"NCT00003276","Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer",[91],"2001-03",[1276],[139],{"nctId":784,"briefTitle":785,"status":105,"phases":2463,"primaryCompletion":756,"completion":787,"start":788,"enrollment":16,"conditions":2464,"interventions":2465},[91],[15],[524,791,594,139],{"nctId":2467,"briefTitle":2468,"status":105,"phases":2469,"primaryCompletion":578,"completion":1103,"start":2470,"enrollment":742,"conditions":2471,"interventions":2472},"NCT00027612","Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme",[90,91],"2002-07",[1022],[53,139],{"nctId":2474,"briefTitle":2475,"status":105,"phases":2476,"primaryCompletion":200,"completion":200,"start":2477,"enrollment":2478,"conditions":2479,"interventions":2480},"NCT00063960","Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer",[91],"2003-08",94,[24,203],[1336,139],{"nctId":1280,"briefTitle":1281,"status":105,"phases":2482,"primaryCompletion":1149,"completion":705,"start":1283,"enrollment":37,"conditions":2483,"interventions":2484},[91],[24],[138,139,140],{"nctId":1621,"briefTitle":1622,"status":105,"phases":2486,"primaryCompletion":674,"completion":776,"start":1149,"enrollment":8,"conditions":2487,"interventions":2488},[91],[18],[43,139],{"trials":2490,"activeCount":852,"soonestReadout":76},[2491,2495,2499,2503],{"nctId":335,"briefTitle":336,"status":258,"phases":2492,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":2493,"interventions":2494},[92],[343,344,171],[226,346,227,228],{"nctId":74,"briefTitle":75,"status":258,"phases":2496,"primaryCompletion":76,"completion":349,"start":350,"enrollment":351,"conditions":2497,"interventions":2498},[92],[353],[77,226,227,228,346,271],{"nctId":356,"briefTitle":357,"status":312,"phases":2500,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":2501,"interventions":2502},[92],[24],[184,205,364,365,121,138,139,140,366,97],{"nctId":1342,"briefTitle":1343,"status":105,"phases":2504,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":1347,"conditions":2505,"interventions":2506},[92],[24],[138,139,140],{"trials":2508,"activeCount":123},[],{"trials":2510,"activeCount":123},[],{"intervention":1220,"totalTrials":2512,"cells":2513},17,{"EARLY_PHASE1":2514,"PHASE1":2516,"PHASE2":2518,"PHASE3":2615,"PHASE4":2621,"NA":2623},{"trials":2515,"activeCount":123},[],{"trials":2517,"activeCount":123},[],{"trials":2519,"activeCount":272,"soonestReadout":1802},[2520,2529,2541,2545,2553,2557,2561,2565,2569,2573,2577,2588,2592,2596,2600,2611],{"nctId":2521,"briefTitle":2522,"status":105,"phases":2523,"primaryCompletion":648,"completion":755,"start":640,"enrollment":1783,"conditions":2524,"interventions":2527},"NCT00028600","Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma",[91],[2525,2526],"Multiple Myeloma","Plasma Cell Neoplasm",[593,2528,1219,1830,2067,1220,1832],"CD34+ cells",{"nctId":2530,"briefTitle":2531,"status":105,"phases":2532,"primaryCompletion":2533,"completion":360,"start":1140,"enrollment":974,"conditions":2534,"interventions":2537},"NCT00053196","Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer",[91],"2006-11",[27,21,2525,2526,2535,2536],"Myelodysplastic Syndromes","Myeloproliferative Neoplasms",[2538,885,1829,1830,1220,2539,1832,2540],"anti-thymocyte globulin","mycophenolate mofetil","allopurinol",{"nctId":2050,"briefTitle":2051,"status":105,"phases":2542,"primaryCompletion":1601,"completion":813,"start":2053,"enrollment":569,"conditions":2543,"interventions":2544},[91],[27],[593,1829,1011,594,1220],{"nctId":2546,"briefTitle":2547,"status":105,"phases":2548,"primaryCompletion":648,"completion":648,"start":2450,"enrollment":1917,"conditions":2549,"interventions":2551},"NCT00027573","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer",[91],[2550],"Kidney Cancer",[593,2552,1219,1830,1220,1832],"therapeutic allogeneic lymphocytes",{"nctId":1913,"briefTitle":1914,"status":105,"phases":2554,"primaryCompletion":578,"completion":578,"start":1916,"enrollment":1917,"conditions":2555,"interventions":2556},[91],[21],[53,1219,1011,1012,1162,1220,1222],{"nctId":2061,"briefTitle":2062,"status":105,"phases":2558,"primaryCompletion":1601,"completion":1601,"start":631,"enrollment":403,"conditions":2559,"interventions":2560},[91],[2065,21],[53,2067,594,1011,1832,1220,1013],{"nctId":1212,"briefTitle":1213,"status":105,"phases":2562,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":2563,"interventions":2564},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":1228,"briefTitle":1229,"status":105,"phases":2566,"primaryCompletion":236,"completion":1231,"start":290,"enrollment":1232,"conditions":2567,"interventions":2568},[91],[21],[593,1010,1011,594,140,1220,828],{"nctId":1236,"briefTitle":1237,"status":105,"phases":2570,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":2571,"interventions":2572},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"nctId":1250,"briefTitle":1251,"status":105,"phases":2574,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":2575,"interventions":2576},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"nctId":2578,"briefTitle":2579,"status":312,"phases":2580,"primaryCompletion":547,"completion":618,"start":776,"enrollment":2581,"conditions":2582,"interventions":2586},"NCT01118013","Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant",[91],6,[27,21,2583,2584,2535,2585],"Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Neoplasms",[2538,2587,593,2552,1829,1830,1220,2539,1832],"donor lymphocytes",{"nctId":1799,"briefTitle":1800,"status":258,"phases":2589,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":2590,"interventions":2591},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"nctId":1822,"briefTitle":1823,"status":105,"phases":2593,"primaryCompletion":1825,"completion":1826,"start":755,"enrollment":1805,"conditions":2594,"interventions":2595},[91],[27,21],[1010,1829,1219,1830,1220,1831,1832],{"nctId":1959,"briefTitle":1960,"status":105,"phases":2597,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":2598,"interventions":2599},[91],[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],{"nctId":2601,"briefTitle":2602,"status":105,"phases":2603,"primaryCompletion":190,"completion":2604,"start":2175,"enrollment":2605,"conditions":2606,"interventions":2609},"NCT00070135","Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission",[91],"2016-06-15",121,[2607,2608],"Adult Acute Myeloid Leukemia in Remission","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",[593,2610,1829,1830,1220,1832],"Anti-Thymocyte Globulin",{"nctId":1295,"briefTitle":1296,"status":105,"phases":2612,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":2613,"interventions":2614},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"trials":2616,"activeCount":272,"soonestReadout":1871},[2617],{"nctId":1868,"briefTitle":1869,"status":380,"phases":2618,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":2619,"interventions":2620},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"trials":2622,"activeCount":123},[],{"trials":2624,"activeCount":123},[],{"intervention":205,"totalTrials":2003,"cells":2626},{"EARLY_PHASE1":2627,"PHASE1":2629,"PHASE2":2631,"PHASE3":2676,"PHASE4":2710,"NA":2712},{"trials":2628,"activeCount":123},[],{"trials":2630,"activeCount":123},[],{"trials":2632,"activeCount":272,"soonestReadout":81},[2633,2639,2643,2655,2659,2668,2672],{"nctId":2634,"briefTitle":2635,"status":105,"phases":2636,"primaryCompletion":133,"completion":833,"start":859,"enrollment":742,"conditions":2637,"interventions":2638},"NCT00124618","Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer",[91],[15],[205],{"nctId":2419,"briefTitle":2420,"status":105,"phases":2640,"primaryCompletion":674,"completion":778,"start":706,"enrollment":1073,"conditions":2641,"interventions":2642},[91],[18],[205,139],{"nctId":2644,"briefTitle":2645,"status":105,"phases":2646,"primaryCompletion":2647,"completion":973,"start":2648,"enrollment":2649,"conditions":2650,"interventions":2651},"NCT00381706","Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer",[91],"2011-04","2006-09-15",245,[36],[205,2652,2653,2654],"ECF","IC","FOLFOX",{"nctId":196,"briefTitle":197,"status":105,"phases":2656,"primaryCompletion":199,"start":200,"enrollment":201,"conditions":2657,"interventions":2658},[91],[24,203],[205,138,140,97],{"nctId":79,"briefTitle":80,"status":258,"phases":2660,"primaryCompletion":81,"completion":2661,"start":2662,"enrollment":1783,"conditions":2663,"interventions":2666},[91],"2028-12-01","2019-06-17",[2664,2665],"Skin Squamous Cell Carcinoma","Metastatic Skin Cancer",[82,2667],"Cetuximab",{"nctId":810,"briefTitle":811,"status":105,"phases":2669,"primaryCompletion":813,"completion":814,"start":815,"enrollment":816,"conditions":2670,"interventions":2671},[91],[15],[205,524,710],{"nctId":250,"briefTitle":251,"status":167,"phases":2673,"enrollment":123,"conditions":2674,"interventions":2675},[91],[24],[184,205,138,140,97],{"trials":2677,"activeCount":272,"soonestReadout":2692},[2678,2688,2702,2706],{"nctId":2679,"briefTitle":2680,"status":105,"phases":2681,"primaryCompletion":1694,"completion":2682,"start":638,"enrollment":2683,"conditions":2684,"interventions":2685},"NCT00265850","Cetuximab and\u002For Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer",[92],"2018-01",2334,[24],[184,205,2686,2687],"FOLFOX or","FOLFIRI",{"nctId":2689,"briefTitle":2690,"status":258,"phases":2691,"primaryCompletion":2692,"completion":2692,"start":2693,"enrollment":272,"conditions":2694,"interventions":2700},"NCT05710406","Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer",[91,92],"2034-06-01","2023-08-16",[2695,2696,2697,2698,2699],"Colon Adenocarcinoma","Microsatellite Stable Colon Carcinoma","Stage IIB Colon Cancer AJCC v8","Stage IIC Colon Cancer AJCC v8","Stage III Colon Cancer AJCC v8",[2701,2667],"Encorafenib",{"nctId":356,"briefTitle":357,"status":312,"phases":2703,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":2704,"interventions":2705},[92],[24],[184,205,364,365,121,138,139,140,366,97],{"nctId":368,"briefTitle":369,"status":312,"phases":2707,"primaryCompletion":371,"completion":281,"start":372,"enrollment":373,"conditions":2708,"interventions":2709},[92],[24],[205,376,118,119,97],{"trials":2711,"activeCount":123},[],{"trials":2713,"activeCount":123},[],{"intervention":885,"totalTrials":403,"cells":2715},{"EARLY_PHASE1":2716,"PHASE1":2718,"PHASE2":2720,"PHASE3":2734,"PHASE4":2740,"NA":2742},{"trials":2717,"activeCount":123},[],{"trials":2719,"activeCount":123},[],{"trials":2721,"activeCount":272,"soonestReadout":52},[2722,2726,2730],{"nctId":2530,"briefTitle":2531,"status":105,"phases":2723,"primaryCompletion":2533,"completion":360,"start":1140,"enrollment":974,"conditions":2724,"interventions":2725},[91],[27,21,2525,2526,2535,2536],[2538,885,1829,1830,1220,2539,1832,2540],{"nctId":50,"briefTitle":51,"status":258,"phases":2727,"primaryCompletion":52,"completion":2078,"start":814,"enrollment":2079,"conditions":2728,"interventions":2729},[91],[21],[53,1011,594,2082,885],{"nctId":1250,"briefTitle":1251,"status":105,"phases":2731,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":2732,"interventions":2733},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"trials":2735,"activeCount":272,"soonestReadout":868},[2736],{"nctId":865,"briefTitle":866,"status":258,"phases":2737,"primaryCompletion":868,"completion":868,"start":869,"enrollment":415,"conditions":2738,"interventions":2739},[92],[871,872,873,874,875,876,877,878,879,880,881],[540,883,791,884,885,524,886],{"trials":2741,"activeCount":123},[],{"trials":2743,"activeCount":123},[],{"intervention":1820,"totalTrials":403,"cells":2745},{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2776,"PHASE4":2786,"NA":2788},{"trials":2747,"activeCount":123},[],{"trials":2749,"activeCount":123},[],{"trials":2751,"activeCount":272,"soonestReadout":1802},[2752,2772],{"nctId":2753,"briefTitle":2754,"status":2755,"phases":2756,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":2760,"interventions":2768},"NCT04803201","Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","SUSPENDED",[91],"2027-05-19","2021-10-08",170,[2761,2762,2763,2764,2765,2766,2767],"Angioimmunoblastic T-cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma","Follicular T-Cell Lymphoma","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Peripheral T-Cell Lymphoma, Not Otherwise Specified",[1810,1820,1811,1818,2769,2770,2771],"Etoposide","Duvelisib","Oral azacitidine",{"nctId":1799,"briefTitle":1800,"status":258,"phases":2773,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":2774,"interventions":2775},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"trials":2777,"activeCount":272,"soonestReadout":1871},[2778,2782],{"nctId":1855,"briefTitle":1856,"status":105,"phases":2779,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":1861,"conditions":2780,"interventions":2781},[92],[1863],[1010,1219,1865,1866,1221,594,593,745],{"nctId":1868,"briefTitle":1869,"status":380,"phases":2783,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":2784,"interventions":2785},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"trials":2787,"activeCount":123},[],{"trials":2789,"activeCount":123},[],{"intervention":1866,"totalTrials":403,"cells":2791},{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2796,"PHASE3":2806,"PHASE4":2824,"NA":2826},{"trials":2793,"activeCount":123},[],{"trials":2795,"activeCount":123},[],{"trials":2797,"activeCount":272,"soonestReadout":1802},[2798,2802],{"nctId":2753,"briefTitle":2754,"status":2755,"phases":2799,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":2800,"interventions":2801},[91],[2761,2762,2763,2764,2765,2766,2767],[1810,1820,1811,1818,2769,2770,2771],{"nctId":1799,"briefTitle":1800,"status":258,"phases":2803,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":2804,"interventions":2805},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"trials":2807,"activeCount":272,"soonestReadout":2816},[2808,2812],{"nctId":1855,"briefTitle":1856,"status":105,"phases":2809,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":1861,"conditions":2810,"interventions":2811},[92],[1863],[1010,1219,1865,1866,1221,594,593,745],{"nctId":2813,"briefTitle":2814,"status":258,"phases":2815,"primaryCompletion":2816,"completion":2816,"start":619,"enrollment":2817,"conditions":2818,"interventions":2819},"NCT00887146","Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma",[92],"2029-10-31",305,[1022],[2820,2821,2822,2823,1866],"concomitant temozolomide","procarbazine","adjuvant temozolomide","CCNU",{"trials":2825,"activeCount":123},[],{"trials":2827,"activeCount":123},[],{"intervention":1819,"totalTrials":403,"cells":2829},{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2834,"PHASE3":2848,"PHASE4":2854,"NA":2856},{"trials":2831,"activeCount":123},[],{"trials":2833,"activeCount":123},[],{"trials":2835,"activeCount":272,"soonestReadout":1802},[2836,2840,2844],{"nctId":1250,"briefTitle":1251,"status":105,"phases":2837,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":2838,"interventions":2839},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"nctId":1799,"briefTitle":1800,"status":258,"phases":2841,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":2842,"interventions":2843},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"nctId":1959,"briefTitle":1960,"status":105,"phases":2845,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":2846,"interventions":2847},[91],[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],{"trials":2849,"activeCount":272,"soonestReadout":1871},[2850],{"nctId":1868,"briefTitle":1869,"status":380,"phases":2851,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":2852,"interventions":2853},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"trials":2855,"activeCount":123},[],{"trials":2857,"activeCount":123},[],{"intervention":452,"totalTrials":459,"cells":2859},{"EARLY_PHASE1":2860,"PHASE1":2862,"PHASE2":2864,"PHASE3":2874,"PHASE4":2880,"NA":2882},{"trials":2861,"activeCount":123},[],{"trials":2863,"activeCount":123},[],{"trials":2865,"activeCount":272,"soonestReadout":62},[2866,2870],{"nctId":60,"briefTitle":61,"status":258,"phases":2867,"primaryCompletion":62,"completion":440,"start":441,"enrollment":442,"conditions":2868,"interventions":2869},[91],[444,445,446,447,448,449,450],[63,452,229],{"nctId":830,"briefTitle":831,"status":312,"phases":2871,"primaryCompletion":535,"completion":833,"start":567,"enrollment":641,"conditions":2872,"interventions":2873},[91],[36],[524,452],{"trials":2875,"activeCount":272,"soonestReadout":478},[2876],{"nctId":475,"briefTitle":476,"status":380,"phases":2877,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":2878,"interventions":2879},[92],[483,484,485,486],[488,229,452,489,490,491,402,63,472],{"trials":2881,"activeCount":123},[],{"trials":2883,"activeCount":123},[],{"intervention":472,"totalTrials":852,"cells":2885},{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2890,"PHASE3":2892,"PHASE4":2902,"NA":2904},{"trials":2887,"activeCount":123},[],{"trials":2889,"activeCount":123},[],{"trials":2891,"activeCount":123},[],{"trials":2893,"activeCount":852,"soonestReadout":72},[2894,2898],{"nctId":70,"briefTitle":71,"status":258,"phases":2895,"primaryCompletion":72,"completion":457,"start":458,"enrollment":459,"conditions":2896,"interventions":2897},[92],[461,462,463,464,465,466,467,468,469,470],[63,402,472,473,82],{"nctId":475,"briefTitle":476,"status":380,"phases":2899,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":2900,"interventions":2901},[92],[483,484,485,486],[488,229,452,489,490,491,402,63,472],{"trials":2903,"activeCount":123},[],{"trials":2905,"activeCount":123},[],{"intervention":82,"totalTrials":852,"cells":2907},{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2912,"PHASE3":2918,"PHASE4":2924,"NA":2926},{"trials":2909,"activeCount":123},[],{"trials":2911,"activeCount":123},[],{"trials":2913,"activeCount":272,"soonestReadout":81},[2914],{"nctId":79,"briefTitle":80,"status":258,"phases":2915,"primaryCompletion":81,"completion":2661,"start":2662,"enrollment":1783,"conditions":2916,"interventions":2917},[91],[2664,2665],[82,2667],{"trials":2919,"activeCount":272,"soonestReadout":72},[2920],{"nctId":70,"briefTitle":71,"status":258,"phases":2921,"primaryCompletion":72,"completion":457,"start":458,"enrollment":459,"conditions":2922,"interventions":2923},[92],[461,462,463,464,465,466,467,468,469,470],[63,402,472,473,82],{"trials":2925,"activeCount":123},[],{"trials":2927,"activeCount":123},[],{"intervention":727,"totalTrials":852,"cells":2929},{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2934,"PHASE3":2940,"PHASE4":2952,"NA":2954},{"trials":2931,"activeCount":123},[],{"trials":2933,"activeCount":123},[],{"trials":2935,"activeCount":272,"soonestReadout":715},[2936],{"nctId":712,"briefTitle":713,"status":380,"phases":2937,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":2938,"interventions":2939},[91],[720,721],[723,229,724,725,726,727],{"trials":2941,"activeCount":272,"soonestReadout":2946},[2942],{"nctId":2943,"briefTitle":2944,"status":2195,"phases":2945,"primaryCompletion":2946,"completion":2946,"start":2947,"enrollment":2948,"conditions":2949,"interventions":2951},"NCT07200830","Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial",[92],"2034-09-09","2025-10-08",1524,[2950,1649,721],"Metastatic Castration-Resistant Prostate Carcinoma",[727],{"trials":2953,"activeCount":123},[],{"trials":2955,"activeCount":123},[],{"intervention":1813,"totalTrials":852,"cells":2957},{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2968,"PHASE4":2974,"NA":2976},{"trials":2959,"activeCount":123},[],{"trials":2961,"activeCount":123},[],{"trials":2963,"activeCount":272,"soonestReadout":1802},[2964],{"nctId":1799,"briefTitle":1800,"status":258,"phases":2965,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":2966,"interventions":2967},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"trials":2969,"activeCount":272,"soonestReadout":1871},[2970],{"nctId":1868,"briefTitle":1869,"status":380,"phases":2971,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":2972,"interventions":2973},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"trials":2975,"activeCount":123},[],{"trials":2977,"activeCount":123},[],{"intervention":1898,"totalTrials":852,"cells":2979},{"EARLY_PHASE1":2980,"PHASE1":2982,"PHASE2":2984,"PHASE3":2986,"PHASE4":3005,"NA":3007},{"trials":2981,"activeCount":123},[],{"trials":2983,"activeCount":123},[],{"trials":2985,"activeCount":123},[],{"trials":2987,"activeCount":852,"soonestReadout":2992},[2988,3001],{"nctId":2989,"briefTitle":2990,"status":2195,"phases":2991,"primaryCompletion":2992,"completion":2993,"start":2994,"enrollment":2995,"conditions":2996,"interventions":2999},"NCT07321652","Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL\u002FSLL",[92],"2028-09-30","2038-09-30","2026-01-15",466,[2997,2998],"Chronic Lymphocytic Leukemia","Small Lymphocytic Leukemia",[1898,3000],"Sonrotoclax",{"nctId":1889,"briefTitle":1890,"status":380,"phases":3002,"primaryCompletion":1892,"completion":1892,"start":1893,"enrollment":1894,"conditions":3003,"interventions":3004},[92],[1896],[1898,1817],{"trials":3006,"activeCount":123},[],{"trials":3008,"activeCount":123},[],{"intervention":1219,"totalTrials":110,"cells":3010},{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3019,"PHASE3":3108,"PHASE4":3135,"NA":3137},{"trials":3012,"activeCount":123},[],{"trials":3014,"activeCount":123},[3015],{"nctId":1691,"briefTitle":1692,"status":105,"phases":3016,"primaryCompletion":1694,"completion":1695,"start":547,"enrollment":953,"conditions":3017,"interventions":3018},[90],[21],[1010,1219,1162,624,1221,1222],{"trials":3020,"activeCount":272,"soonestReadout":1802},[3021,3027,3031,3035,3039,3046,3050,3054,3058,3065,3069,3073,3088,3092,3096,3100,3104],{"nctId":3022,"briefTitle":3023,"status":105,"phases":3024,"primaryCompletion":589,"completion":589,"start":2403,"enrollment":246,"conditions":3025,"interventions":3026},"NCT00005964","Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",[91],[21],[593,1219,1162,594,1221,1222],{"nctId":2521,"briefTitle":2522,"status":105,"phases":3028,"primaryCompletion":648,"completion":755,"start":640,"enrollment":1783,"conditions":3029,"interventions":3030},[91],[2525,2526],[593,2528,1219,1830,2067,1220,1832],{"nctId":2753,"briefTitle":2754,"status":2755,"phases":3032,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":3033,"interventions":3034},[91],[2761,2762,2763,2764,2765,2766,2767],[1810,1820,1811,1818,2769,2770,2771],{"nctId":2546,"briefTitle":2547,"status":105,"phases":3036,"primaryCompletion":648,"completion":648,"start":2450,"enrollment":1917,"conditions":3037,"interventions":3038},[91],[2550],[593,2552,1219,1830,1220,1832],{"nctId":3040,"briefTitle":3041,"status":105,"phases":3042,"primaryCompletion":1207,"completion":859,"start":3043,"enrollment":34,"conditions":3044,"interventions":3045},"NCT00002501","Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma",[91],"1992-10",[21],[593,1219],{"nctId":1913,"briefTitle":1914,"status":105,"phases":3047,"primaryCompletion":578,"completion":578,"start":1916,"enrollment":1917,"conditions":3048,"interventions":3049},[91],[21],[53,1219,1011,1012,1162,1220,1222],{"nctId":1746,"briefTitle":1747,"status":105,"phases":3051,"primaryCompletion":1665,"completion":1749,"start":859,"enrollment":1750,"conditions":3052,"interventions":3053},[91],[21],[1753,1010,1219,1162,1221,1222],{"nctId":1212,"briefTitle":1213,"status":105,"phases":3055,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":3056,"interventions":3057},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":3059,"briefTitle":3060,"status":105,"phases":3061,"primaryCompletion":686,"completion":1665,"start":3062,"enrollment":31,"conditions":3063,"interventions":3064},"NCT00003829","Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia",[91],"1999-08",[27],[1219,1830],{"nctId":1236,"briefTitle":1237,"status":105,"phases":3066,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":3067,"interventions":3068},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"nctId":1250,"briefTitle":1251,"status":105,"phases":3070,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":3071,"interventions":3072},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"nctId":3074,"briefTitle":3075,"status":105,"phases":3076,"primaryCompletion":3077,"completion":2682,"start":2388,"enrollment":3078,"conditions":3079,"interventions":3080},"NCT01132807","Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma",[91],"2016-02",164,[21],[3081,3082,3083,3084,3085,1810,3086,1221,3087],"Bleomycin Sulfate","Doxorubicin Hydrochloride","Procarbazine Hydrochloride","Vinblastine Sulfate","Dacarbazine","Etoposide phosphate","Radiation Therapy",{"nctId":1799,"briefTitle":1800,"status":258,"phases":3089,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":3090,"interventions":3091},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"nctId":1822,"briefTitle":1823,"status":105,"phases":3093,"primaryCompletion":1825,"completion":1826,"start":755,"enrollment":1805,"conditions":3094,"interventions":3095},[91],[27,21],[1010,1829,1219,1830,1220,1831,1832],{"nctId":1959,"briefTitle":1960,"status":105,"phases":3097,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":3098,"interventions":3099},[91],[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],{"nctId":1295,"briefTitle":1296,"status":105,"phases":3101,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":3102,"interventions":3103},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"nctId":1846,"briefTitle":1847,"status":105,"phases":3105,"primaryCompletion":200,"completion":754,"start":1849,"enrollment":16,"conditions":3106,"interventions":3107},[91],[21],[593,1010,1219,1162,594,1221,1222],{"trials":3109,"activeCount":272,"soonestReadout":1871},[3110,3114,3123,3127],{"nctId":1855,"briefTitle":1856,"status":105,"phases":3111,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":1861,"conditions":3112,"interventions":3113},[92],[1863],[1010,1219,1865,1866,1221,594,593,745],{"nctId":3115,"briefTitle":3116,"status":105,"phases":3117,"primaryCompletion":1713,"completion":3118,"start":536,"enrollment":3119,"conditions":3120,"interventions":3121},"NCT00041119","Four Versus Six Cycles of Cyclophosphamide\u002FDoxorubicin or Paclitaxel in Adjuvant Breast Cancer",[92],"2014-06",3871,[18],[3122,1219,1162,540],"AC regimen",{"nctId":1868,"briefTitle":1869,"status":380,"phases":3124,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":3125,"interventions":3126},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"nctId":3128,"briefTitle":3129,"status":105,"phases":3130,"primaryCompletion":243,"completion":244,"start":3131,"enrollment":3132,"conditions":3133,"interventions":3134},"NCT00003088","Combination Chemotherapy in Treating Patients With Breast Cancer",[92],"1997-09",2005,[18],[1219,1162,540],{"trials":3136,"activeCount":123},[],{"trials":3138,"activeCount":123},[3139],{"nctId":3140,"briefTitle":3141,"status":105,"phases":3142,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":3145,"conditions":3146,"interventions":3147},"NCT00897026","Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344",[],"2012-04-27","2008-07",1195,[18],[1219,1162,540,3148],"fluorescence in situ hybridization",{"intervention":947,"totalTrials":2221,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3171,"PHASE4":3200,"NA":3202},{"trials":3152,"activeCount":123},[],{"trials":3154,"activeCount":123},[],{"trials":3156,"activeCount":272,"soonestReadout":338},[3157,3161],{"nctId":1015,"briefTitle":1016,"status":105,"phases":3158,"primaryCompletion":1018,"completion":675,"start":1019,"enrollment":1020,"conditions":3159,"interventions":3160},[91],[1022],[53,947,791,594],{"nctId":3162,"briefTitle":3163,"status":2195,"phases":3164,"primaryCompletion":338,"completion":3165,"start":3166,"enrollment":3078,"conditions":3167,"interventions":3169},"NCT07293247","A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment",[91],"2032-03-01","2026-03-14",[3168],"Lung Non-Small Cell Carcinoma",[3170],"Chemotherapy",{"trials":3172,"activeCount":272,"soonestReadout":3177},[3173,3185,3196],{"nctId":3174,"briefTitle":3175,"status":380,"phases":3176,"primaryCompletion":3177,"completion":3178,"start":3179,"enrollment":3180,"conditions":3181,"interventions":3184},"NCT05673148","Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study",[92],"2028-07-03","2032-08-12","2023-10-09",364,[3182,3183],"Metastatic Colorectal Adenocarcinoma","Stage IV Colorectal Cancer AJCC v8",[3170],{"nctId":3186,"briefTitle":3187,"status":105,"phases":3188,"primaryCompletion":3189,"completion":609,"start":3190,"enrollment":3191,"conditions":3192,"interventions":3194},"NCT02116530","Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy",[92],"2015-04-04","2014-08-20",401,[3193,1994,30],"Hematopoietic\u002FLymphoid Cancer",[2036,3170,3195],"Antiemetic treatment",{"nctId":940,"briefTitle":941,"status":105,"phases":3197,"primaryCompletion":147,"completion":754,"start":943,"enrollment":944,"conditions":3198,"interventions":3199},[92],[15],[524,947,540],{"trials":3201,"activeCount":123},[],{"trials":3203,"activeCount":123},[3204,3212],{"nctId":3205,"briefTitle":3206,"status":105,"phases":3207,"primaryCompletion":1703,"completion":3208,"start":1849,"enrollment":3209,"conditions":3210,"interventions":3211},"NCT00033397","Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery",[],"2012-05-01",360,[18],[947],{"nctId":3213,"briefTitle":3214,"status":105,"phases":3215,"primaryCompletion":796,"completion":630,"start":840,"enrollment":3216,"conditions":3217,"interventions":3218},"NCT00004867","Positron Emission Tomography in Determining Stage of Esophageal Cancer",[94],235,[36],[947],{"intervention":184,"totalTrials":3220,"cells":3221},20,{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3334,"PHASE4":3361,"NA":3363},{"trials":3223,"activeCount":123},[],{"trials":3225,"activeCount":123},[],{"trials":3227,"activeCount":123},[3228,3235,3244,3248,3252,3263,3269,3277,3281,3290,3297,3301,3305,3309,3322],{"nctId":3229,"briefTitle":3230,"status":105,"phases":3231,"primaryCompletion":1713,"completion":806,"start":754,"enrollment":1191,"conditions":3232,"interventions":3233},"NCT00867321","Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer",[90,91],[1277],[184,3234],"sorafenib tosylate",{"nctId":3236,"briefTitle":3237,"status":105,"phases":3238,"primaryCompletion":778,"completion":3239,"start":3240,"enrollment":1917,"conditions":3241,"interventions":3242},"NCT00423917","Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer",[91],"2017-01-15","2007-08",[18],[184,3243],"fulvestrant",{"nctId":1572,"briefTitle":1573,"status":105,"phases":3245,"primaryCompletion":178,"completion":776,"start":200,"enrollment":620,"conditions":3246,"interventions":3247},[91],[18],[184,121,43],{"nctId":175,"briefTitle":176,"status":105,"phases":3249,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":3250,"interventions":3251},[91],[171],[184,185,97],{"nctId":3253,"briefTitle":3254,"status":105,"phases":3255,"primaryCompletion":236,"completion":1943,"start":619,"enrollment":3256,"conditions":3257,"interventions":3262},"NCT00826540","Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",[91],83,[3258,3259,3260,3261],"Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer",[3234,184],{"nctId":3264,"briefTitle":3265,"status":105,"phases":3266,"primaryCompletion":147,"completion":696,"start":191,"enrollment":160,"conditions":3267,"interventions":3268},"NCT00268489","Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[91],[15],[184,710],{"nctId":3270,"briefTitle":3271,"status":105,"phases":3272,"primaryCompletion":314,"completion":1702,"start":705,"enrollment":3273,"conditions":3274,"interventions":3276},"NCT00892177","Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme",[91],144,[3275],"Glioblastoma Multiforme",[184,2185],{"nctId":692,"briefTitle":693,"status":105,"phases":3278,"primaryCompletion":145,"completion":695,"start":696,"enrollment":697,"conditions":3279,"interventions":3280},[91],[581],[184,524,624,540],{"nctId":3282,"briefTitle":3283,"status":105,"phases":3284,"primaryCompletion":1741,"completion":3285,"start":3286,"enrollment":3287,"conditions":3288,"interventions":3289},"NCT00621686","Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme",[91],"2014-02-19","2008-09",54,[1022],[184,3234],{"nctId":3291,"briefTitle":3292,"status":105,"phases":3293,"primaryCompletion":360,"completion":618,"start":3294,"enrollment":707,"conditions":3295,"interventions":3296},"NCT00662129","Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer",[91],"2008-11",[18],[184,185,583],{"nctId":802,"briefTitle":803,"status":105,"phases":3298,"primaryCompletion":805,"completion":806,"start":576,"enrollment":600,"conditions":3299,"interventions":3300},[91],[15],[184,524,710],{"nctId":820,"briefTitle":821,"status":105,"phases":3302,"primaryCompletion":823,"completion":824,"start":639,"enrollment":825,"conditions":3303,"interventions":3304},[91],[581],[184,524,583,828],{"nctId":250,"briefTitle":251,"status":167,"phases":3306,"enrollment":123,"conditions":3307,"interventions":3308},[91],[24],[184,205,138,140,97],{"nctId":3310,"briefTitle":3311,"status":312,"phases":3312,"primaryCompletion":3313,"completion":3314,"start":3315,"enrollment":192,"conditions":3316,"interventions":3320},"NCT01814813","Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery",[91],"2017-04-03","2023-05-22","2013-06-19",[3317,3318,3319],"Recurrent Glioblastoma","Recurrent Adult Brain Tumor","Gliosarcoma",[3321,184],"HSPPC-96",{"nctId":3323,"briefTitle":3324,"status":312,"phases":3325,"primaryCompletion":3326,"completion":3327,"start":3328,"enrollment":37,"conditions":3329,"interventions":3332},"NCT02490878","Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases",[91],"2019-02-01","2022-12-15","2016-04",[3330,3331],"Radionecrosis","Brain Metastases",[184,3333],"corticosteroids",{"trials":3335,"activeCount":272,"soonestReadout":76},[3336,3340,3344,3348,3352],{"nctId":2679,"briefTitle":2680,"status":105,"phases":3337,"primaryCompletion":1694,"completion":2682,"start":638,"enrollment":2683,"conditions":3338,"interventions":3339},[92],[24],[184,205,2686,2687],{"nctId":310,"briefTitle":311,"status":312,"phases":3341,"primaryCompletion":314,"completion":107,"start":315,"enrollment":316,"conditions":3342,"interventions":3343},[92],[318,24,305],[184,121,138,140,97],{"nctId":74,"briefTitle":75,"status":258,"phases":3345,"primaryCompletion":76,"completion":349,"start":350,"enrollment":351,"conditions":3346,"interventions":3347},[92],[353],[77,226,227,228,346,271],{"nctId":356,"briefTitle":357,"status":312,"phases":3349,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":3350,"interventions":3351},[92],[24],[184,205,364,365,121,138,139,140,366,97],{"nctId":3353,"briefTitle":3354,"status":105,"phases":3355,"primaryCompletion":2175,"completion":824,"start":3356,"enrollment":3357,"conditions":3358,"interventions":3359},"NCT00072046","Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)",[92],"2003-10",732,[2550],[184,3360],"recombinant interferon alfa",{"trials":3362,"activeCount":123},[],{"trials":3364,"activeCount":123},[],{"intervention":1222,"totalTrials":3366,"cells":3367},12,{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3376,"PHASE3":3425,"PHASE4":3431,"NA":3433},{"trials":3369,"activeCount":123},[],{"trials":3371,"activeCount":123},[3372],{"nctId":1691,"briefTitle":1692,"status":105,"phases":3373,"primaryCompletion":1694,"completion":1695,"start":547,"enrollment":953,"conditions":3374,"interventions":3375},[90],[21],[1010,1219,1162,624,1221,1222],{"trials":3377,"activeCount":123},[3378,3382,3393,3397,3401,3405,3409,3413,3417,3421],{"nctId":3022,"briefTitle":3023,"status":105,"phases":3379,"primaryCompletion":589,"completion":589,"start":2403,"enrollment":246,"conditions":3380,"interventions":3381},[91],[21],[593,1219,1162,594,1221,1222],{"nctId":3383,"briefTitle":3384,"status":105,"phases":3385,"primaryCompletion":3386,"completion":1526,"start":3387,"enrollment":3388,"conditions":3389,"interventions":3390},"NCT00002806","Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma",[91],"2003-01","1996-07",43,[1022],[3391,3392,1222],"lomustine","procarbazine hydrochloride",{"nctId":1913,"briefTitle":1914,"status":105,"phases":3394,"primaryCompletion":578,"completion":578,"start":1916,"enrollment":1917,"conditions":3395,"interventions":3396},[91],[21],[53,1219,1011,1012,1162,1220,1222],{"nctId":1746,"briefTitle":1747,"status":105,"phases":3398,"primaryCompletion":1665,"completion":1749,"start":859,"enrollment":1750,"conditions":3399,"interventions":3400},[91],[21],[1753,1010,1219,1162,1221,1222],{"nctId":1212,"briefTitle":1213,"status":105,"phases":3402,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":3403,"interventions":3404},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":1236,"briefTitle":1237,"status":105,"phases":3406,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":3407,"interventions":3408},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"nctId":1250,"briefTitle":1251,"status":105,"phases":3410,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":3411,"interventions":3412},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"nctId":1959,"briefTitle":1960,"status":105,"phases":3414,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":3415,"interventions":3416},[91],[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],{"nctId":1295,"briefTitle":1296,"status":105,"phases":3418,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":3419,"interventions":3420},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"nctId":1846,"briefTitle":1847,"status":105,"phases":3422,"primaryCompletion":200,"completion":754,"start":1849,"enrollment":16,"conditions":3423,"interventions":3424},[91],[21],[593,1010,1219,1162,594,1221,1222],{"trials":3426,"activeCount":272,"soonestReadout":1871},[3427],{"nctId":1868,"briefTitle":1869,"status":380,"phases":3428,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":3429,"interventions":3430},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"trials":3432,"activeCount":123},[],{"trials":3434,"activeCount":123},[],{"intervention":669,"totalTrials":430,"cells":3436},{"EARLY_PHASE1":3437,"PHASE1":3439,"PHASE2":3441,"PHASE3":3457,"PHASE4":3480,"NA":3482},{"trials":3438,"activeCount":123},[],{"trials":3440,"activeCount":123},[],{"trials":3442,"activeCount":123},[3443,3449,3453],{"nctId":3444,"briefTitle":3445,"status":105,"phases":3446,"primaryCompletion":576,"completion":806,"start":732,"enrollment":1232,"conditions":3447,"interventions":3448},"NCT00093808","Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer",[91],[18],[669,121,1177],{"nctId":661,"briefTitle":662,"status":105,"phases":3450,"primaryCompletion":210,"completion":664,"start":665,"enrollment":666,"conditions":3451,"interventions":3452},[91],[18],[669,524,540],{"nctId":773,"briefTitle":774,"status":105,"phases":3454,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":3455,"interventions":3456},[91],[18],[669,524,43,782],{"trials":3458,"activeCount":272,"soonestReadout":3463},[3459,3471],{"nctId":3460,"briefTitle":3461,"status":380,"phases":3462,"primaryCompletion":3463,"completion":3464,"start":3465,"enrollment":2948,"conditions":3466,"interventions":3468},"NCT06876714","ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab",[92],"2028-03-13","2037-03-13","2025-09-17",[514,515,3467],"Early Stage Breast Carcinoma",[3469,3470],"Trastuzumab","Pertuzumab",{"nctId":3472,"briefTitle":3473,"status":167,"phases":3474,"enrollment":123,"conditions":3475,"interventions":3478},"NCT00053339","Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer",[92],[3476,3477],"Stage IV Breast Cancer","Recurrent Breast Cancer",[3479,669],"tamoxifen",{"trials":3481,"activeCount":123},[],{"trials":3483,"activeCount":123},[],{"intervention":1996,"totalTrials":430,"cells":3485},{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3492,"PHASE4":3541,"NA":3543},{"trials":3487,"activeCount":123},[],{"trials":3489,"activeCount":123},[],{"trials":3491,"activeCount":123},[],{"trials":3493,"activeCount":272,"soonestReadout":3519},[3494,3503,3507,3515,3533],{"nctId":3495,"briefTitle":3496,"status":105,"phases":3497,"primaryCompletion":1762,"completion":1762,"start":3498,"enrollment":1944,"conditions":3499,"interventions":3501},"NCT00087399","Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy",[92],"2004-11",[18,3500],"Hot Flashes",[1996,3502],"antidepressant",{"nctId":1988,"briefTitle":1989,"status":105,"phases":3504,"primaryCompletion":805,"completion":1991,"start":754,"enrollment":1992,"conditions":3505,"interventions":3506},[92],[1994,30],[1012,1996],{"nctId":3508,"briefTitle":3509,"status":105,"phases":3510,"primaryCompletion":371,"completion":1762,"start":3511,"enrollment":3512,"conditions":3513,"interventions":3514},"NCT00028574","Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer",[92],"2001-12",223,[3500,33],[1996],{"nctId":3516,"briefTitle":3517,"status":380,"phases":3518,"primaryCompletion":3519,"completion":3520,"start":3521,"enrollment":3522,"conditions":3523,"interventions":3529},"NCT06992427","High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer",[92],"2029-08-15","2031-04-15","2025-06-05",228,[3524,3525,3526,3527,3528],"Head and Neck Squamous Cell Carcinoma","Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",[3530,3531,3532],"Gabapentin","Chemotheraphy","Analgesic Agent",{"nctId":3534,"briefTitle":3535,"status":105,"phases":3536,"primaryCompletion":3537,"completion":3537,"start":1849,"enrollment":3538,"conditions":3539,"interventions":3540},"NCT00027963","Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy",[92],"2007-11",100,[305,907],[1996],{"trials":3542,"activeCount":123},[],{"trials":3544,"activeCount":123},[],{"intervention":2539,"totalTrials":403,"cells":3546},{"EARLY_PHASE1":3547,"PHASE1":3549,"PHASE2":3551,"PHASE3":3569,"PHASE4":3575,"NA":3577},{"trials":3548,"activeCount":123},[],{"trials":3550,"activeCount":123},[],{"trials":3552,"activeCount":123},[3553,3557,3561],{"nctId":2530,"briefTitle":2531,"status":105,"phases":3554,"primaryCompletion":2533,"completion":360,"start":1140,"enrollment":974,"conditions":3555,"interventions":3556},[91],[27,21,2525,2526,2535,2536],[2538,885,1829,1830,1220,2539,1832,2540],{"nctId":2578,"briefTitle":2579,"status":312,"phases":3558,"primaryCompletion":547,"completion":618,"start":776,"enrollment":2581,"conditions":3559,"interventions":3560},[91],[27,21,2583,2584,2535,2585],[2538,2587,593,2552,1829,1830,1220,2539,1832],{"nctId":3562,"briefTitle":3563,"status":167,"phases":3564,"primaryCompletion":764,"completion":764,"start":191,"enrollment":123,"conditions":3565,"interventions":3566},"NCT00085449","Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",[90,91],[27,21,2584,2535,2585],[3567,3568,1830,2067,2539],"alemtuzumab","cyclosporine",{"trials":3570,"activeCount":272,"soonestReadout":2197},[3571],{"nctId":2193,"briefTitle":2194,"status":2195,"phases":3572,"primaryCompletion":2197,"completion":2198,"start":2199,"enrollment":2200,"conditions":3573,"interventions":3574},[91,92],[2202],[2150,2204],{"trials":3576,"activeCount":123},[],{"trials":3578,"activeCount":123},[],{"intervention":1261,"totalTrials":403,"cells":3580},{"EARLY_PHASE1":3581,"PHASE1":3583,"PHASE2":3585,"PHASE3":3599,"PHASE4":3605,"NA":3607},{"trials":3582,"activeCount":123},[],{"trials":3584,"activeCount":123},[],{"trials":3586,"activeCount":123},[3587,3591,3595],{"nctId":2530,"briefTitle":2531,"status":105,"phases":3588,"primaryCompletion":2533,"completion":360,"start":1140,"enrollment":974,"conditions":3589,"interventions":3590},[91],[27,21,2525,2526,2535,2536],[2538,885,1829,1830,1220,2539,1832,2540],{"nctId":1250,"briefTitle":1251,"status":105,"phases":3592,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":3593,"interventions":3594},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"nctId":1295,"briefTitle":1296,"status":105,"phases":3596,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":3597,"interventions":3598},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"trials":3600,"activeCount":272,"soonestReadout":1871},[3601],{"nctId":1868,"briefTitle":1869,"status":380,"phases":3602,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":3603,"interventions":3604},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"trials":3606,"activeCount":123},[],{"trials":3608,"activeCount":123},[],{"intervention":3243,"totalTrials":403,"cells":3610},{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3615,"PHASE3":3642,"PHASE4":3660,"NA":3662},{"trials":3612,"activeCount":123},[],{"trials":3614,"activeCount":123},[],{"trials":3616,"activeCount":123},[3617,3621,3636],{"nctId":3236,"briefTitle":3237,"status":105,"phases":3618,"primaryCompletion":778,"completion":3239,"start":3240,"enrollment":1917,"conditions":3619,"interventions":3620},[91],[18],[184,3243],{"nctId":3622,"briefTitle":3623,"status":105,"phases":3624,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":1020,"conditions":3628,"interventions":3632},"NCT03633331","Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer",[91],"2020-09-08","2026-02-27","2018-08-15",[3629,3630,3631],"Estrogen Receptor-positive Breast Cancer","HER2\u002FNeu Negative","Stage IV Breast Cancer AJCC v6 and v7",[3633,3634,3635],"Palbociclib","Letrozole","Fulvestrant",{"nctId":3637,"briefTitle":3638,"status":105,"phases":3639,"primaryCompletion":589,"completion":639,"start":686,"enrollment":1528,"conditions":3640,"interventions":3641},"NCT00012025","ICI 182780 in Treating Women With Metastatic Breast Cancer",[91],[18],[3243],{"trials":3643,"activeCount":272,"soonestReadout":1802},[3644],{"nctId":3645,"briefTitle":3646,"status":258,"phases":3647,"primaryCompletion":1802,"completion":1802,"start":3648,"enrollment":3649,"conditions":3650,"interventions":3658},"NCT01953588","Fulvestrant and\u002For Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery",[92],"2014-02-27",1473,[3629,3651,3652,3653,3477,3654,3655,3656,3657],"HER2-negative Breast Cancer","Invasive Ductal Breast Carcinoma","Invasive Lobular Breast Carcinoma","Stage II Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[3243,3659],"anastrozole",{"trials":3661,"activeCount":123},[],{"trials":3663,"activeCount":123},[],{"intervention":883,"totalTrials":403,"cells":3665},{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3670,"PHASE3":3680,"PHASE4":3690,"NA":3692},{"trials":3667,"activeCount":123},[],{"trials":3669,"activeCount":123},[],{"trials":3671,"activeCount":123},[3672,3676],{"nctId":1236,"briefTitle":1237,"status":105,"phases":3673,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":3674,"interventions":3675},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"nctId":1295,"briefTitle":1296,"status":105,"phases":3677,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":3678,"interventions":3679},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"trials":3681,"activeCount":272,"soonestReadout":868},[3682,3686],{"nctId":865,"briefTitle":866,"status":258,"phases":3683,"primaryCompletion":868,"completion":868,"start":869,"enrollment":415,"conditions":3684,"interventions":3685},[92],[871,872,873,874,875,876,877,878,879,880,881],[540,883,791,884,885,524,886],{"nctId":1146,"briefTitle":1147,"status":312,"phases":3687,"primaryCompletion":132,"completion":132,"start":1149,"enrollment":272,"conditions":3688,"interventions":3689},[92],[1151,1152],[791,883,540,1154],{"trials":3691,"activeCount":123},[],{"trials":3693,"activeCount":123},[],{"intervention":2036,"totalTrials":459,"cells":3695},{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3702,"PHASE4":3724,"NA":3726},{"trials":3697,"activeCount":123},[],{"trials":3699,"activeCount":123},[],{"trials":3701,"activeCount":123},[],{"trials":3703,"activeCount":272,"soonestReadout":1802},[3704,3716,3720],{"nctId":3705,"briefTitle":3706,"status":258,"phases":3707,"primaryCompletion":1802,"completion":3708,"start":3709,"enrollment":3710,"conditions":3711,"interventions":3714},"NCT04939090","Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients",[92],"2027-12-31","2022-01-03",227,[3712,1668,3713],"Advanced Malignant Solid Neoplasm","Hematopoietic and Lymphoid Cell Neoplasm",[2036,3715],"Megestrol Acetate",{"nctId":3186,"briefTitle":3187,"status":105,"phases":3717,"primaryCompletion":3189,"completion":609,"start":3190,"enrollment":3191,"conditions":3718,"interventions":3719},[92],[3193,1994,30],[2036,3170,3195],{"nctId":2024,"briefTitle":2025,"status":105,"phases":3721,"primaryCompletion":2027,"completion":2028,"start":2029,"enrollment":2030,"conditions":3722,"interventions":3723},[92],[2020],[2033,2034,1812,2035,2036],{"trials":3725,"activeCount":123},[],{"trials":3727,"activeCount":123},[],{"intervention":1259,"totalTrials":459,"cells":3729},{"EARLY_PHASE1":3730,"PHASE1":3732,"PHASE2":3734,"PHASE3":3744,"PHASE4":3750,"NA":3752},{"trials":3731,"activeCount":123},[],{"trials":3733,"activeCount":123},[],{"trials":3735,"activeCount":123},[3736,3740],{"nctId":1250,"briefTitle":1251,"status":105,"phases":3737,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":3738,"interventions":3739},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"nctId":1959,"briefTitle":1960,"status":105,"phases":3741,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":3742,"interventions":3743},[91],[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],{"trials":3745,"activeCount":272,"soonestReadout":1871},[3746],{"nctId":1868,"briefTitle":1869,"status":380,"phases":3747,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":3748,"interventions":3749},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"trials":3751,"activeCount":123},[],{"trials":3753,"activeCount":123},[],{"intervention":3086,"totalTrials":459,"cells":3755},{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3773,"PHASE4":3779,"NA":3781},{"trials":3757,"activeCount":123},[],{"trials":3759,"activeCount":123},[],{"trials":3761,"activeCount":123},[3762,3766],{"nctId":3074,"briefTitle":3075,"status":105,"phases":3763,"primaryCompletion":3077,"completion":2682,"start":2388,"enrollment":3078,"conditions":3764,"interventions":3765},[91],[21],[3081,3082,3083,3084,3085,1810,3086,1221,3087],{"nctId":3767,"briefTitle":3768,"status":105,"phases":3769,"primaryCompletion":981,"completion":535,"start":3770,"enrollment":181,"conditions":3771,"interventions":3772},"NCT00002880","Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",[91],"1996-11",[21],[3086],{"trials":3774,"activeCount":272,"soonestReadout":868},[3775],{"nctId":865,"briefTitle":866,"status":258,"phases":3776,"primaryCompletion":868,"completion":868,"start":869,"enrollment":415,"conditions":3777,"interventions":3778},[92],[871,872,873,874,875,876,877,878,879,880,881],[540,883,791,884,885,524,886],{"trials":3780,"activeCount":123},[],{"trials":3782,"activeCount":123},[],{"intervention":3659,"totalTrials":459,"cells":3784},{"EARLY_PHASE1":3785,"PHASE1":3787,"PHASE2":3789,"PHASE3":3791,"PHASE4":3826,"NA":3828},{"trials":3786,"activeCount":123},[],{"trials":3788,"activeCount":123},[],{"trials":3790,"activeCount":123},[],{"trials":3792,"activeCount":272,"soonestReadout":1802},[3793,3812,3816],{"nctId":3794,"briefTitle":3795,"status":2755,"phases":3796,"primaryCompletion":3797,"completion":3798,"start":3799,"enrollment":3800,"conditions":3801,"interventions":3807},"NCT06671912","Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial",[92],"2030-11-30","2031-11-30","2025-02-19",1156,[3802,3803,3804,3805,3806],"Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage 1 Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Estrogen Receptor-Positive Breast Carcinoma","HER2-Negative Breast Carcinoma",[3808,3634,3809,3810,3811],"Anastrozole","Exemestane","Tamoxifen","Dual X-ray Absorptiometry",{"nctId":3645,"briefTitle":3646,"status":258,"phases":3813,"primaryCompletion":1802,"completion":1802,"start":3648,"enrollment":3649,"conditions":3814,"interventions":3815},[92],[3629,3651,3652,3653,3477,3654,3655,3656,3657],[3243,3659],{"nctId":3817,"briefTitle":3818,"status":105,"phases":3819,"primaryCompletion":169,"completion":3820,"start":859,"enrollment":3821,"conditions":3822,"interventions":3823},"NCT00265759","Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer",[92],"2019-11-27",622,[18],[3659,3824,3825],"exemestane","letrozole",{"trials":3827,"activeCount":123},[],{"trials":3829,"activeCount":123},[],{"intervention":3715,"totalTrials":852,"cells":3831},{"EARLY_PHASE1":3832,"PHASE1":3834,"PHASE2":3836,"PHASE3":3838,"PHASE4":3852,"NA":3854},{"trials":3833,"activeCount":123},[],{"trials":3835,"activeCount":123},[],{"trials":3837,"activeCount":123},[],{"trials":3839,"activeCount":272,"soonestReadout":1802},[3840,3844],{"nctId":3705,"briefTitle":3706,"status":258,"phases":3841,"primaryCompletion":1802,"completion":3708,"start":3709,"enrollment":3710,"conditions":3842,"interventions":3843},[92],[3712,1668,3713],[2036,3715],{"nctId":3845,"briefTitle":3846,"status":105,"phases":3847,"primaryCompletion":2175,"completion":2175,"start":649,"enrollment":3848,"conditions":3849,"interventions":3850},"NCT00031707","Comparison of Megestrol and\u002For Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite",[92],429,[1668,1669],[3851],"megestrol acetate",{"trials":3853,"activeCount":123},[],{"trials":3855,"activeCount":123},[],{"intervention":1660,"totalTrials":852,"cells":3857},{"EARLY_PHASE1":3858,"PHASE1":3860,"PHASE2":3862,"PHASE3":3873,"PHASE4":3879,"NA":3881},{"trials":3859,"activeCount":123},[],{"trials":3861,"activeCount":123},[],{"trials":3863,"activeCount":123},[3864],{"nctId":3865,"briefTitle":3866,"status":105,"phases":3867,"primaryCompletion":199,"completion":547,"start":3868,"enrollment":3869,"conditions":3870,"interventions":3871},"NCT00006359","Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer",[91],"2000-09",63,[33],[1660,3872],"antiandrogen",{"trials":3874,"activeCount":272,"soonestReadout":42},[3875],{"nctId":40,"briefTitle":41,"status":258,"phases":3876,"primaryCompletion":42,"completion":1655,"start":1656,"enrollment":1657,"conditions":3877,"interventions":3878},[92],[33],[43,1660],{"trials":3880,"activeCount":123},[],{"trials":3882,"activeCount":123},[],{"intervention":1880,"totalTrials":852,"cells":3884},{"EARLY_PHASE1":3885,"PHASE1":3887,"PHASE2":3889,"PHASE3":3895,"PHASE4":3901,"NA":3903},{"trials":3886,"activeCount":123},[],{"trials":3888,"activeCount":123},[],{"trials":3890,"activeCount":123},[3891],{"nctId":1959,"briefTitle":1960,"status":105,"phases":3892,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":3893,"interventions":3894},[91],[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],{"trials":3896,"activeCount":272,"soonestReadout":1871},[3897],{"nctId":1868,"briefTitle":1869,"status":380,"phases":3898,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":3899,"interventions":3900},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"trials":3902,"activeCount":123},[],{"trials":3904,"activeCount":123},[],{"intervention":2312,"totalTrials":852,"cells":3906},{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3911,"PHASE3":3924,"PHASE4":3930,"NA":3932},{"trials":3908,"activeCount":123},[],{"trials":3910,"activeCount":123},[],{"trials":3912,"activeCount":123},[3913],{"nctId":3914,"briefTitle":3915,"status":105,"phases":3916,"primaryCompletion":2175,"completion":1446,"start":3917,"enrollment":3918,"conditions":3919,"interventions":3920},"NCT00002889","Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer",[91],"1997-05",180,[33],[3921,3922,3923],"flutamide","goserelin","leuprolide acetate",{"trials":3925,"activeCount":272,"soonestReadout":2303},[3926],{"nctId":2300,"briefTitle":2301,"status":258,"phases":3927,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":3928,"interventions":3929},[92],[720,1649,2308,2309,721],[726,2311,2312,2313,2314],{"trials":3931,"activeCount":123},[],{"trials":3933,"activeCount":123},[],{"intervention":332,"totalTrials":852,"cells":3935},{"EARLY_PHASE1":3936,"PHASE1":3938,"PHASE2":3940,"PHASE3":3942,"PHASE4":3957,"NA":3959},{"trials":3937,"activeCount":123},[],{"trials":3939,"activeCount":123},[],{"trials":3941,"activeCount":123},[],{"trials":3943,"activeCount":272,"soonestReadout":324},[3944,3948],{"nctId":321,"briefTitle":322,"status":258,"phases":3945,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":3946,"interventions":3947},[91,92],[329,330],[226,332,333],{"nctId":3949,"briefTitle":3950,"status":105,"phases":3951,"primaryCompletion":359,"completion":300,"start":158,"enrollment":3952,"conditions":3953,"interventions":3955},"NCT00489411","Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer",[92],231,[305,907,3954,30],"Peripheral Neuropathy",[3956],"duloxetine hydrochloride",{"trials":3958,"activeCount":123},[],{"trials":3960,"activeCount":123},[],{"intervention":3470,"totalTrials":272,"cells":3962},{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3967,"PHASE3":3969,"PHASE4":3975,"NA":3977},{"trials":3964,"activeCount":123},[],{"trials":3966,"activeCount":123},[],{"trials":3968,"activeCount":123},[],{"trials":3970,"activeCount":272,"soonestReadout":3463},[3971],{"nctId":3460,"briefTitle":3461,"status":380,"phases":3972,"primaryCompletion":3463,"completion":3464,"start":3465,"enrollment":2948,"conditions":3973,"interventions":3974},[92],[514,515,3467],[3469,3470],{"trials":3976,"activeCount":123},[],{"trials":3978,"activeCount":123},[],{"intervention":3980,"totalTrials":272,"cells":3981},"Denosumab",{"EARLY_PHASE1":3982,"PHASE1":3984,"PHASE2":3986,"PHASE3":3988,"PHASE4":4005,"NA":4007},{"trials":3983,"activeCount":123},[],{"trials":3985,"activeCount":123},[],{"trials":3987,"activeCount":123},[],{"trials":3989,"activeCount":272,"soonestReadout":3994},[3990],{"nctId":3991,"briefTitle":3992,"status":258,"phases":3993,"primaryCompletion":3994,"completion":3995,"start":3996,"enrollment":3997,"conditions":3998,"interventions":4004},"NCT04711109","Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation",[92],"2027-07","2033-12","2023-02-14",300,[3999,18,4000,4001,4002,4003],"BRCA1 Mutation","Breast Diseases","Breast Neoplasms","Breast Carcinoma","Neoplasms",[3980],{"trials":4006,"activeCount":123},[],{"trials":4008,"activeCount":123},[],{"intervention":473,"totalTrials":272,"cells":4010},{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4017,"PHASE4":4023,"NA":4025},{"trials":4012,"activeCount":123},[],{"trials":4014,"activeCount":123},[],{"trials":4016,"activeCount":123},[],{"trials":4018,"activeCount":272,"soonestReadout":72},[4019],{"nctId":70,"briefTitle":71,"status":258,"phases":4020,"primaryCompletion":72,"completion":457,"start":458,"enrollment":459,"conditions":4021,"interventions":4022},[92],[461,462,463,464,465,466,467,468,469,470],[63,402,472,473,82],{"trials":4024,"activeCount":123},[],{"trials":4026,"activeCount":123},[],{"intervention":1651,"totalTrials":272,"cells":4028},{"EARLY_PHASE1":4029,"PHASE1":4031,"PHASE2":4033,"PHASE3":4035,"PHASE4":4041,"NA":4043},{"trials":4030,"activeCount":123},[],{"trials":4032,"activeCount":123},[],{"trials":4034,"activeCount":123},[],{"trials":4036,"activeCount":272,"soonestReadout":1643},[4037],{"nctId":1640,"briefTitle":1641,"status":380,"phases":4038,"primaryCompletion":1643,"completion":1644,"start":1645,"enrollment":1646,"conditions":4039,"interventions":4040},[92],[1648,1649,721],[1651,1652,490],{"trials":4042,"activeCount":123},[],{"trials":4044,"activeCount":123},[],{"intervention":1652,"totalTrials":272,"cells":4046},{"EARLY_PHASE1":4047,"PHASE1":4049,"PHASE2":4051,"PHASE3":4053,"PHASE4":4059,"NA":4061},{"trials":4048,"activeCount":123},[],{"trials":4050,"activeCount":123},[],{"trials":4052,"activeCount":123},[],{"trials":4054,"activeCount":272,"soonestReadout":1643},[4055],{"nctId":1640,"briefTitle":1641,"status":380,"phases":4056,"primaryCompletion":1643,"completion":1644,"start":1645,"enrollment":1646,"conditions":4057,"interventions":4058},[92],[1648,1649,721],[1651,1652,490],{"trials":4060,"activeCount":123},[],{"trials":4062,"activeCount":123},[],{"intervention":1124,"totalTrials":272,"cells":4064},{"EARLY_PHASE1":4065,"PHASE1":4067,"PHASE2":4069,"PHASE3":4071,"PHASE4":4077,"NA":4079},{"trials":4066,"activeCount":123},[],{"trials":4068,"activeCount":123},[],{"trials":4070,"activeCount":123},[],{"trials":4072,"activeCount":272,"soonestReadout":1112},[4073],{"nctId":1109,"briefTitle":1110,"status":258,"phases":4074,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":4075,"interventions":4076},[91,92],[1117,1118,343,1119,1120,1121,1122],[1124,489,488],{"trials":4078,"activeCount":123},[],{"trials":4080,"activeCount":123},[],{"intervention":2820,"totalTrials":272,"cells":4082},{"EARLY_PHASE1":4083,"PHASE1":4085,"PHASE2":4087,"PHASE3":4089,"PHASE4":4095,"NA":4097},{"trials":4084,"activeCount":123},[],{"trials":4086,"activeCount":123},[],{"trials":4088,"activeCount":123},[],{"trials":4090,"activeCount":272,"soonestReadout":2816},[4091],{"nctId":2813,"briefTitle":2814,"status":258,"phases":4092,"primaryCompletion":2816,"completion":2816,"start":619,"enrollment":2817,"conditions":4093,"interventions":4094},[92],[1022],[2820,2821,2822,2823,1866],{"trials":4096,"activeCount":123},[],{"trials":4098,"activeCount":123},[],{"intervention":2821,"totalTrials":272,"cells":4100},{"EARLY_PHASE1":4101,"PHASE1":4103,"PHASE2":4105,"PHASE3":4107,"PHASE4":4113,"NA":4115},{"trials":4102,"activeCount":123},[],{"trials":4104,"activeCount":123},[],{"trials":4106,"activeCount":123},[],{"trials":4108,"activeCount":272,"soonestReadout":2816},[4109],{"nctId":2813,"briefTitle":2814,"status":258,"phases":4110,"primaryCompletion":2816,"completion":2816,"start":619,"enrollment":2817,"conditions":4111,"interventions":4112},[92],[1022],[2820,2821,2822,2823,1866],{"trials":4114,"activeCount":123},[],{"trials":4116,"activeCount":123},[],{"intervention":2822,"totalTrials":272,"cells":4118},{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4125,"PHASE4":4131,"NA":4133},{"trials":4120,"activeCount":123},[],{"trials":4122,"activeCount":123},[],{"trials":4124,"activeCount":123},[],{"trials":4126,"activeCount":272,"soonestReadout":2816},[4127],{"nctId":2813,"briefTitle":2814,"status":258,"phases":4128,"primaryCompletion":2816,"completion":2816,"start":619,"enrollment":2817,"conditions":4129,"interventions":4130},[92],[1022],[2820,2821,2822,2823,1866],{"trials":4132,"activeCount":123},[],{"trials":4134,"activeCount":123},[],{"intervention":2823,"totalTrials":272,"cells":4136},{"EARLY_PHASE1":4137,"PHASE1":4139,"PHASE2":4141,"PHASE3":4143,"PHASE4":4149,"NA":4151},{"trials":4138,"activeCount":123},[],{"trials":4140,"activeCount":123},[],{"trials":4142,"activeCount":123},[],{"trials":4144,"activeCount":272,"soonestReadout":2816},[4145],{"nctId":2813,"briefTitle":2814,"status":258,"phases":4146,"primaryCompletion":2816,"completion":2816,"start":619,"enrollment":2817,"conditions":4147,"interventions":4148},[92],[1022],[2820,2821,2822,2823,1866],{"trials":4150,"activeCount":123},[],{"trials":4152,"activeCount":123},[],{"intervention":1879,"totalTrials":272,"cells":4154},{"EARLY_PHASE1":4155,"PHASE1":4157,"PHASE2":4159,"PHASE3":4161,"PHASE4":4167,"NA":4169},{"trials":4156,"activeCount":123},[],{"trials":4158,"activeCount":123},[],{"trials":4160,"activeCount":123},[],{"trials":4162,"activeCount":272,"soonestReadout":1871},[4163],{"nctId":1868,"briefTitle":1869,"status":380,"phases":4164,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":4165,"interventions":4166},[92],[1807],[1261,1815,1877,1878,1812,1879,1814,1810,1819,1817,1820,1880,1813],{"trials":4168,"activeCount":123},[],{"trials":4170,"activeCount":123},[],{"intervention":884,"totalTrials":272,"cells":4172},{"EARLY_PHASE1":4173,"PHASE1":4175,"PHASE2":4177,"PHASE3":4179,"PHASE4":4185,"NA":4187},{"trials":4174,"activeCount":123},[],{"trials":4176,"activeCount":123},[],{"trials":4178,"activeCount":123},[],{"trials":4180,"activeCount":272,"soonestReadout":868},[4181],{"nctId":865,"briefTitle":866,"status":258,"phases":4182,"primaryCompletion":868,"completion":868,"start":869,"enrollment":415,"conditions":4183,"interventions":4184},[92],[871,872,873,874,875,876,877,878,879,880,881],[540,883,791,884,885,524,886],{"trials":4186,"activeCount":123},[],{"trials":4188,"activeCount":123},[],{"intervention":2311,"totalTrials":272,"cells":4190},{"EARLY_PHASE1":4191,"PHASE1":4193,"PHASE2":4195,"PHASE3":4197,"PHASE4":4203,"NA":4205},{"trials":4192,"activeCount":123},[],{"trials":4194,"activeCount":123},[],{"trials":4196,"activeCount":123},[],{"trials":4198,"activeCount":272,"soonestReadout":2303},[4199],{"nctId":2300,"briefTitle":2301,"status":258,"phases":4200,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":4201,"interventions":4202},[92],[720,1649,2308,2309,721],[726,2311,2312,2313,2314],{"trials":4204,"activeCount":123},[],{"trials":4206,"activeCount":123},[],{"intervention":2313,"totalTrials":272,"cells":4208},{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4215,"PHASE4":4221,"NA":4223},{"trials":4210,"activeCount":123},[],{"trials":4212,"activeCount":123},[],{"trials":4214,"activeCount":123},[],{"trials":4216,"activeCount":272,"soonestReadout":2303},[4217],{"nctId":2300,"briefTitle":2301,"status":258,"phases":4218,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":4219,"interventions":4220},[92],[720,1649,2308,2309,721],[726,2311,2312,2313,2314],{"trials":4222,"activeCount":123},[],{"trials":4224,"activeCount":123},[],{"intervention":2314,"totalTrials":272,"cells":4226},{"EARLY_PHASE1":4227,"PHASE1":4229,"PHASE2":4231,"PHASE3":4233,"PHASE4":4239,"NA":4241},{"trials":4228,"activeCount":123},[],{"trials":4230,"activeCount":123},[],{"trials":4232,"activeCount":123},[],{"trials":4234,"activeCount":272,"soonestReadout":2303},[4235],{"nctId":2300,"briefTitle":2301,"status":258,"phases":4236,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":4237,"interventions":4238},[92],[720,1649,2308,2309,721],[726,2311,2312,2313,2314],{"trials":4240,"activeCount":123},[],{"trials":4242,"activeCount":123},[],{"intervention":491,"totalTrials":272,"cells":4244},{"EARLY_PHASE1":4245,"PHASE1":4247,"PHASE2":4249,"PHASE3":4251,"PHASE4":4257,"NA":4259},{"trials":4246,"activeCount":123},[],{"trials":4248,"activeCount":123},[],{"trials":4250,"activeCount":123},[],{"trials":4252,"activeCount":272,"soonestReadout":478},[4253],{"nctId":475,"briefTitle":476,"status":380,"phases":4254,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":4255,"interventions":4256},[92],[483,484,485,486],[488,229,452,489,490,491,402,63,472],{"trials":4258,"activeCount":123},[],{"trials":4260,"activeCount":123},[],{"intervention":4262,"totalTrials":272,"cells":4263},"Trastuzumab Emtansine",{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4268,"PHASE3":4270,"PHASE4":4302,"NA":4304},{"trials":4265,"activeCount":123},[],{"trials":4267,"activeCount":123},[],{"trials":4269,"activeCount":123},[],{"trials":4271,"activeCount":272,"soonestReadout":4276},[4272],{"nctId":4273,"briefTitle":4274,"status":258,"phases":4275,"primaryCompletion":4276,"completion":4277,"start":4278,"enrollment":4279,"conditions":4280,"interventions":4300},"NCT04457596","T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial",[92],"2028-01-31","2035-05-31","2021-03-02",1056,[4281,515,3804,4282,516,4283,4284,4285,4286,4287,4288,4289,4290,4291,4292,4293,4294,4295,4296,4297,4298,4299],"Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","HER2 Positive Breast Carcinoma","Invasive Breast Carcinoma","Multifocal Breast Carcinoma","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Synchronous Bilateral Breast Carcinoma",[4262,4301],"Tucatinib",{"trials":4303,"activeCount":123},[],{"trials":4305,"activeCount":123},[],{"intervention":4301,"totalTrials":272,"cells":4307},{"EARLY_PHASE1":4308,"PHASE1":4310,"PHASE2":4312,"PHASE3":4314,"PHASE4":4320,"NA":4322},{"trials":4309,"activeCount":123},[],{"trials":4311,"activeCount":123},[],{"trials":4313,"activeCount":123},[],{"trials":4315,"activeCount":272,"soonestReadout":4276},[4316],{"nctId":4273,"briefTitle":4274,"status":258,"phases":4317,"primaryCompletion":4276,"completion":4277,"start":4278,"enrollment":4279,"conditions":4318,"interventions":4319},[92],[4281,515,3804,4282,516,4283,4284,4285,4286,4287,4288,4289,4290,4291,4292,4293,4294,4295,4296,4297,4298,4299],[4262,4301],{"trials":4321,"activeCount":123},[],{"trials":4323,"activeCount":123},[],{"intervention":2701,"totalTrials":272,"cells":4325},{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4330,"PHASE3":4332,"PHASE4":4338,"NA":4340},{"trials":4327,"activeCount":123},[],{"trials":4329,"activeCount":123},[],{"trials":4331,"activeCount":123},[],{"trials":4333,"activeCount":272,"soonestReadout":2692},[4334],{"nctId":2689,"briefTitle":2690,"status":258,"phases":4335,"primaryCompletion":2692,"completion":2692,"start":2693,"enrollment":272,"conditions":4336,"interventions":4337},[91,92],[2695,2696,2697,2698,2699],[2701,2667],{"trials":4339,"activeCount":123},[],{"trials":4341,"activeCount":123},[],{"intervention":3000,"totalTrials":272,"cells":4343},{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4348,"PHASE3":4350,"PHASE4":4356,"NA":4358},{"trials":4345,"activeCount":123},[],{"trials":4347,"activeCount":123},[],{"trials":4349,"activeCount":123},[],{"trials":4351,"activeCount":272,"soonestReadout":2992},[4352],{"nctId":2989,"briefTitle":2990,"status":2195,"phases":4353,"primaryCompletion":2992,"completion":2993,"start":2994,"enrollment":2995,"conditions":4354,"interventions":4355},[92],[2997,2998],[1898,3000],{"trials":4357,"activeCount":123},[],{"trials":4359,"activeCount":123},[],{"intervention":3531,"totalTrials":272,"cells":4361},{"EARLY_PHASE1":4362,"PHASE1":4364,"PHASE2":4366,"PHASE3":4368,"PHASE4":4374,"NA":4376},{"trials":4363,"activeCount":123},[],{"trials":4365,"activeCount":123},[],{"trials":4367,"activeCount":123},[],{"trials":4369,"activeCount":272,"soonestReadout":3519},[4370],{"nctId":3516,"briefTitle":3517,"status":380,"phases":4371,"primaryCompletion":3519,"completion":3520,"start":3521,"enrollment":3522,"conditions":4372,"interventions":4373},[92],[3524,3525,3526,3527,3528],[3530,3531,3532],{"trials":4375,"activeCount":123},[],{"trials":4377,"activeCount":123},[],{"intervention":3532,"totalTrials":272,"cells":4379},{"EARLY_PHASE1":4380,"PHASE1":4382,"PHASE2":4384,"PHASE3":4386,"PHASE4":4392,"NA":4394},{"trials":4381,"activeCount":123},[],{"trials":4383,"activeCount":123},[],{"trials":4385,"activeCount":123},[],{"trials":4387,"activeCount":272,"soonestReadout":3519},[4388],{"nctId":3516,"briefTitle":3517,"status":380,"phases":4389,"primaryCompletion":3519,"completion":3520,"start":3521,"enrollment":3522,"conditions":4390,"interventions":4391},[92],[3524,3525,3526,3527,3528],[3530,3531,3532],{"trials":4393,"activeCount":123},[],{"trials":4395,"activeCount":123},[],{"intervention":87,"totalTrials":272,"cells":4397},{"EARLY_PHASE1":4398,"PHASE1":4400,"PHASE2":4402,"PHASE3":4404,"PHASE4":4416,"NA":4418},{"trials":4399,"activeCount":123},[],{"trials":4401,"activeCount":123},[],{"trials":4403,"activeCount":123},[],{"trials":4405,"activeCount":272,"soonestReadout":86},[4406],{"nctId":84,"briefTitle":85,"status":258,"phases":4407,"primaryCompletion":86,"completion":4408,"start":4409,"enrollment":4410,"conditions":4411,"interventions":4415},[92],"2027-01","2019-07-29",534,[4412,4413,4414],"Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III",[87],{"trials":4417,"activeCount":123},[],{"trials":4419,"activeCount":123},[],{"intervention":333,"totalTrials":272,"cells":4421},{"EARLY_PHASE1":4422,"PHASE1":4424,"PHASE2":4426,"PHASE3":4428,"PHASE4":4434,"NA":4436},{"trials":4423,"activeCount":123},[],{"trials":4425,"activeCount":123},[],{"trials":4427,"activeCount":123},[],{"trials":4429,"activeCount":272,"soonestReadout":324},[4430],{"nctId":321,"briefTitle":322,"status":258,"phases":4431,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":4432,"interventions":4433},[91,92],[329,330],[226,332,333],{"trials":4435,"activeCount":123},[],{"trials":4437,"activeCount":123},[],{"intervention":2215,"totalTrials":272,"cells":4439},{"EARLY_PHASE1":4440,"PHASE1":4442,"PHASE2":4444,"PHASE3":4446,"PHASE4":4452,"NA":4454},{"trials":4441,"activeCount":123},[],{"trials":4443,"activeCount":123},[],{"trials":4445,"activeCount":123},[],{"trials":4447,"activeCount":272,"soonestReadout":510},[4448],{"nctId":2206,"briefTitle":2207,"status":2195,"phases":4449,"primaryCompletion":510,"completion":2209,"start":2210,"enrollment":2211,"conditions":4450,"interventions":4451},[92],[2213],[2150,2215],{"trials":4453,"activeCount":123},[],{"trials":4455,"activeCount":123},[],{"intervention":68,"totalTrials":272,"cells":4457},{"EARLY_PHASE1":4458,"PHASE1":4460,"PHASE2":4462,"PHASE3":4464,"PHASE4":4478,"NA":4480},{"trials":4459,"activeCount":123},[],{"trials":4461,"activeCount":123},[],{"trials":4463,"activeCount":123},[],{"trials":4465,"activeCount":272,"soonestReadout":67},[4466],{"nctId":65,"briefTitle":66,"status":258,"phases":4467,"primaryCompletion":67,"completion":4468,"start":4469,"enrollment":4470,"conditions":4471,"interventions":4477},[92],"2026-11","2015-11-23",86,[4472,4473,4474,4475,4476],"Atypical Ductal Breast Hyperplasia","BRCA1 Mutation Carrier","BRCA2 Mutation Carrier","Ductal Breast Carcinoma in Situ","Lobular Breast Carcinoma in Situ",[68],{"trials":4479,"activeCount":123},[],{"trials":4481,"activeCount":123},[],{"intervention":505,"totalTrials":272,"cells":4483},{"EARLY_PHASE1":4484,"PHASE1":4486,"PHASE2":4488,"PHASE3":4490,"PHASE4":4496,"NA":4498},{"trials":4485,"activeCount":123},[],{"trials":4487,"activeCount":123},[],{"trials":4489,"activeCount":123},[],{"trials":4491,"activeCount":272,"soonestReadout":496},[4492],{"nctId":493,"briefTitle":494,"status":380,"phases":4493,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":4494,"interventions":4495},[92],[500,501,502,503],[63,505],{"trials":4497,"activeCount":123},[],{"trials":4499,"activeCount":123},[],{"intervention":2354,"totalTrials":272,"cells":4501},{"EARLY_PHASE1":4502,"PHASE1":4504,"PHASE2":4506,"PHASE3":4508,"PHASE4":4514,"NA":4516},{"trials":4503,"activeCount":123},[],{"trials":4505,"activeCount":123},[],{"trials":4507,"activeCount":123},[],{"trials":4509,"activeCount":272,"soonestReadout":2345},[4510],{"nctId":2342,"briefTitle":2343,"status":380,"phases":4511,"primaryCompletion":2345,"completion":2346,"start":2347,"enrollment":2348,"conditions":4512,"interventions":4513},[92],[2350,2351,2352],[2354,489],{"trials":4515,"activeCount":123},[],{"trials":4517,"activeCount":123},[],{"intervention":540,"totalTrials":316,"cells":4519},{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4532,"PHASE3":4638,"PHASE4":4683,"NA":4685},{"trials":4521,"activeCount":123},[],{"trials":4523,"activeCount":123},[4524,4528],{"nctId":532,"briefTitle":533,"status":105,"phases":4525,"primaryCompletion":535,"completion":236,"start":536,"enrollment":537,"conditions":4526,"interventions":4527},[90],[15],[524,540],{"nctId":542,"briefTitle":543,"status":105,"phases":4529,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":4530,"interventions":4531},[90],[15],[524,540],{"trials":4533,"activeCount":123},[4534,4538,4542,4546,4550,4557,4561,4565,4569,4581,4585,4591,4598,4602,4608,4612,4626,4630,4634],{"nctId":563,"briefTitle":564,"status":105,"phases":4535,"primaryCompletion":566,"completion":567,"start":568,"enrollment":569,"conditions":4536,"interventions":4537},[91],[15],[524,540],{"nctId":585,"briefTitle":586,"status":105,"phases":4539,"primaryCompletion":588,"completion":589,"start":211,"enrollment":590,"conditions":4540,"interventions":4541},[91],[15],[593,524,594,540,595],{"nctId":597,"briefTitle":598,"status":105,"phases":4543,"primaryCompletion":178,"completion":179,"start":290,"enrollment":600,"conditions":4544,"interventions":4545},[91],[15],[524,603,540],{"nctId":615,"briefTitle":616,"status":105,"phases":4547,"primaryCompletion":299,"completion":618,"start":619,"enrollment":620,"conditions":4548,"interventions":4549},[91],[622],[524,624,540],{"nctId":4551,"briefTitle":4552,"status":105,"phases":4553,"primaryCompletion":797,"completion":859,"start":4554,"enrollment":316,"conditions":4555,"interventions":4556},"NCT00003130","Paclitaxel in Treating Women With Recurrent Solid Tumors",[91],"1997-11",[30],[540],{"nctId":661,"briefTitle":662,"status":105,"phases":4558,"primaryCompletion":210,"completion":664,"start":665,"enrollment":666,"conditions":4559,"interventions":4560},[91],[18],[669,524,540],{"nctId":671,"briefTitle":672,"status":105,"phases":4562,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":4563,"interventions":4564},[91],[36],[680,524,540],{"nctId":682,"briefTitle":683,"status":105,"phases":4566,"primaryCompletion":685,"completion":675,"start":686,"enrollment":31,"conditions":4567,"interventions":4568},[91],[33],[524,689,540,690],{"nctId":4570,"briefTitle":4571,"status":105,"phases":4572,"primaryCompletion":4573,"completion":4574,"start":4575,"enrollment":37,"conditions":4576,"interventions":4579},"NCT02152137","Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer",[91],"2019-02-27","2023-04-15","2014-12-30",[4577,4578],"Anaplastic Thyroid Cancer","Recurrent Thyroid Cancer",[4580,540],"efatutazone",{"nctId":692,"briefTitle":693,"status":105,"phases":4582,"primaryCompletion":145,"completion":695,"start":696,"enrollment":697,"conditions":4583,"interventions":4584},[91],[581],[184,524,624,540],{"nctId":4586,"briefTitle":4587,"status":105,"phases":4588,"primaryCompletion":1526,"completion":1526,"start":840,"enrollment":841,"conditions":4589,"interventions":4590},"NCT00004055","Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer",[91],[15],[593,540,595],{"nctId":4592,"briefTitle":4593,"status":105,"phases":4594,"primaryCompletion":2175,"completion":133,"start":4595,"enrollment":1917,"conditions":4596,"interventions":4597},"NCT00005646","Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[91],"2000-04",[15],[540],{"nctId":216,"briefTitle":217,"status":105,"phases":4599,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":4600,"interventions":4601},[91],[224,36],[226,227,228,229,230],{"nctId":4603,"briefTitle":4604,"status":105,"phases":4605,"primaryCompletion":589,"completion":589,"start":1182,"enrollment":1763,"conditions":4606,"interventions":4607},"NCT00003281","Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer",[91],[15],[540,595],{"nctId":1045,"briefTitle":762,"status":105,"phases":4609,"primaryCompletion":191,"completion":191,"start":1047,"enrollment":201,"conditions":4610,"interventions":4611},[90,91],[1031,15,1049],[593,1051,791,594,540,595],{"nctId":4613,"briefTitle":4614,"status":2755,"phases":4615,"primaryCompletion":4616,"completion":4617,"start":4618,"enrollment":4619,"conditions":4620,"interventions":4624},"NCT05751668","Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)",[91],"2028-03-15","2032-03-15","2023-11-02",98,[4621,4622,4623],"Anatomic Stage IV Breast Cancer AJCC v8","Chemotherapy-Induced Peripheral Neuropathy","Metastatic Breast Carcinoma",[230,4625],"Monosialotetrahexosylganglioside",{"nctId":761,"briefTitle":762,"status":105,"phases":4627,"primaryCompletion":764,"completion":754,"start":765,"enrollment":600,"conditions":4628,"interventions":4629},[91],[15],[593,524,594,540,595],{"nctId":793,"briefTitle":794,"status":105,"phases":4631,"primaryCompletion":796,"completion":630,"start":797,"enrollment":798,"conditions":4632,"interventions":4633},[91],[36,162],[524,138,540],{"nctId":845,"briefTitle":846,"status":105,"phases":4635,"primaryCompletion":848,"completion":281,"start":849,"enrollment":537,"conditions":4636,"interventions":4637},[91],[15],[524,185,540],{"trials":4639,"activeCount":272,"soonestReadout":868},[4640,4644,4648,4652,4656,4660,4664,4668,4675,4679],{"nctId":856,"briefTitle":857,"status":105,"phases":4641,"primaryCompletion":200,"completion":859,"start":860,"enrollment":861,"conditions":4642,"interventions":4643},[92],[15],[524,540],{"nctId":3115,"briefTitle":3116,"status":105,"phases":4645,"primaryCompletion":1713,"completion":3118,"start":536,"enrollment":3119,"conditions":4646,"interventions":4647},[92],[18],[3122,1219,1162,540],{"nctId":865,"briefTitle":866,"status":258,"phases":4649,"primaryCompletion":868,"completion":868,"start":869,"enrollment":415,"conditions":4650,"interventions":4651},[92],[871,872,873,874,875,876,877,878,879,880,881],[540,883,791,884,885,524,886],{"nctId":1146,"briefTitle":1147,"status":312,"phases":4653,"primaryCompletion":132,"completion":132,"start":1149,"enrollment":272,"conditions":4654,"interventions":4655},[92],[1151,1152],[791,883,540,1154],{"nctId":888,"briefTitle":889,"status":105,"phases":4657,"primaryCompletion":180,"completion":676,"start":891,"enrollment":892,"conditions":4658,"interventions":4659},[92],[15],[524,540],{"nctId":3128,"briefTitle":3129,"status":105,"phases":4661,"primaryCompletion":243,"completion":244,"start":3131,"enrollment":3132,"conditions":4662,"interventions":4663},[92],[18],[1219,1162,540],{"nctId":900,"briefTitle":901,"status":105,"phases":4665,"primaryCompletion":169,"completion":169,"start":903,"enrollment":904,"conditions":4666,"interventions":4667},[92],[303,304,906,907,908,909,910,911,912,913,914,915,916,917,918,919],[229,921,230],{"nctId":4669,"briefTitle":4670,"status":105,"phases":4671,"primaryCompletion":589,"completion":648,"start":3131,"enrollment":4672,"conditions":4673,"interventions":4674},"NCT00003092","Paclitaxel in Treating Older Patients With Solid Tumors",[92],120,[30],[540],{"nctId":1179,"briefTitle":1180,"status":105,"phases":4676,"primaryCompletion":180,"completion":859,"start":1182,"enrollment":1183,"conditions":4677,"interventions":4678},[92],[15],[791,594,540],{"nctId":940,"briefTitle":941,"status":105,"phases":4680,"primaryCompletion":147,"completion":754,"start":943,"enrollment":944,"conditions":4681,"interventions":4682},[92],[15],[524,947,540],{"trials":4684,"activeCount":123},[],{"trials":4686,"activeCount":123},[4687],{"nctId":3140,"briefTitle":3141,"status":105,"phases":4688,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":3145,"conditions":4689,"interventions":4690},[],[18],[1219,1162,540,3148],{"intervention":121,"totalTrials":548,"cells":4692},{"EARLY_PHASE1":4693,"PHASE1":4699,"PHASE2":4708,"PHASE3":4796,"PHASE4":4814,"NA":4816},{"trials":4694,"activeCount":123},[4695],{"nctId":103,"briefTitle":104,"status":105,"phases":4696,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":4697,"interventions":4698},[89],[112,113,114,115,116],[97,118,119,120,121,122],{"trials":4700,"activeCount":123},[4701],{"nctId":4702,"briefTitle":4703,"status":105,"phases":4704,"primaryCompletion":566,"completion":566,"start":665,"enrollment":569,"conditions":4705,"interventions":4707},"NCT00003704","Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer",[90],[4706],"Cancer",[121],{"trials":4709,"activeCount":852,"soonestReadout":260},[4710,4714,4718,4724,4731,4735,4741,4745,4753,4761,4765,4769,4773,4777,4784,4788,4792],{"nctId":1517,"briefTitle":1518,"status":105,"phases":4711,"primaryCompletion":674,"completion":133,"start":1072,"enrollment":620,"conditions":4712,"interventions":4713},[91],[36,162],[121,43],{"nctId":142,"briefTitle":143,"status":105,"phases":4715,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":4716,"interventions":4717},[91],[150,151],[121,139,97],{"nctId":4719,"briefTitle":4720,"status":105,"phases":4721,"primaryCompletion":848,"completion":848,"start":629,"enrollment":1783,"conditions":4722,"interventions":4723},"NCT00042965","Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer",[91],[2550],[121,185],{"nctId":4725,"briefTitle":4726,"status":105,"phases":4727,"primaryCompletion":372,"completion":859,"start":631,"enrollment":641,"conditions":4728,"interventions":4730},"NCT00004183","Capecitabine in Treating Patients With Malignant Mesothelioma",[91],[4729],"Malignant Mesothelioma",[121],{"nctId":2138,"briefTitle":2139,"status":258,"phases":4732,"primaryCompletion":2141,"completion":2142,"start":2143,"enrollment":2144,"conditions":4733,"interventions":4734},[91],[2146,2147],[2149,269,2150],{"nctId":4736,"briefTitle":4737,"status":312,"phases":4738,"primaryCompletion":706,"completion":179,"start":200,"enrollment":459,"conditions":4739,"interventions":4740},"NCT00081224","Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum",[91],[24],[121,285],{"nctId":154,"briefTitle":155,"status":105,"phases":4742,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":4743,"interventions":4744},[91],[36,162],[121,97],{"nctId":4746,"briefTitle":4747,"status":167,"phases":4748,"primaryCompletion":630,"completion":630,"start":4749,"enrollment":123,"conditions":4750,"interventions":4751},"NCT00450515","Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer",[91],"2007-03",[18],[121,4752],"vinflunine",{"nctId":4754,"briefTitle":4755,"status":105,"phases":4756,"primaryCompletion":787,"completion":787,"start":4757,"enrollment":3366,"conditions":4758,"interventions":4759},"NCT00891878","Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction",[91],"2009-08",[224,36],[121,4760],"sunitinib malate",{"nctId":3444,"briefTitle":3445,"status":105,"phases":4762,"primaryCompletion":576,"completion":806,"start":732,"enrollment":1232,"conditions":4763,"interventions":4764},[91],[18],[669,121,1177],{"nctId":1572,"briefTitle":1573,"status":105,"phases":4766,"primaryCompletion":178,"completion":776,"start":200,"enrollment":620,"conditions":4767,"interventions":4768},[91],[18],[184,121,43],{"nctId":187,"briefTitle":188,"status":105,"phases":4770,"primaryCompletion":190,"completion":145,"start":191,"enrollment":192,"conditions":4771,"interventions":4772},[91],[24],[121,97],{"nctId":1585,"briefTitle":1586,"status":312,"phases":4774,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":430,"conditions":4775,"interventions":4776},[91],[224,1591,162],[376,121,43,271],{"nctId":4778,"briefTitle":4779,"status":105,"phases":4780,"primaryCompletion":3240,"completion":806,"start":706,"enrollment":160,"conditions":4781,"interventions":4782},"NCT00265733","Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer",[91],[18],[121,4783],"paclitaxel poliglumex",{"nctId":232,"briefTitle":233,"status":105,"phases":4785,"primaryCompletion":190,"completion":235,"start":236,"enrollment":201,"conditions":4786,"interventions":4787},[91],[224,36,162],[121,43,138,97],{"nctId":1443,"briefTitle":1444,"status":105,"phases":4789,"primaryCompletion":221,"completion":806,"start":1446,"enrollment":1447,"conditions":4790,"interventions":4791},[91],[171],[1002,121,138,185],{"nctId":256,"briefTitle":257,"status":258,"phases":4793,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":4794,"interventions":4795},[91],[265,266,267],[269,120,270,271,226],{"trials":4797,"activeCount":123},[4798,4802,4806],{"nctId":310,"briefTitle":311,"status":312,"phases":4799,"primaryCompletion":314,"completion":107,"start":315,"enrollment":316,"conditions":4800,"interventions":4801},[92],[318,24,305],[184,121,138,140,97],{"nctId":356,"briefTitle":357,"status":312,"phases":4803,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":4804,"interventions":4805},[92],[24],[184,205,364,365,121,138,139,140,366,97],{"nctId":4807,"briefTitle":4808,"status":105,"phases":4809,"primaryCompletion":675,"completion":824,"start":765,"enrollment":4810,"conditions":4811,"interventions":4812},"NCT00024102","Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer",[92],633,[18],[4813,121],"Standard Treatment",{"trials":4815,"activeCount":123},[],{"trials":4817,"activeCount":123},[],{"intervention":4819,"totalTrials":852,"cells":4820},"Abemaciclib",{"EARLY_PHASE1":4821,"PHASE1":4823,"PHASE2":4825,"PHASE3":4862,"PHASE4":4864,"NA":4866},{"trials":4822,"activeCount":123},[],{"trials":4824,"activeCount":123},[],{"trials":4826,"activeCount":852,"soonestReadout":4847},[4827,4843],{"nctId":4828,"briefTitle":4829,"status":380,"phases":4830,"primaryCompletion":4831,"completion":4832,"start":4833,"enrollment":4834,"conditions":4835,"interventions":4839},"NCT02523014","Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",[91],"2027-01-01","2028-01","2015-09-28",124,[4836,4837,4838],"Intracranial Meningioma","Recurrent Meningioma","NF2 Gene Mutation",[4840,4841,4842,4819],"Vismodegib","FAK Inhibitor GSK2256098","Capivasertib",{"nctId":4844,"briefTitle":4845,"status":258,"phases":4846,"primaryCompletion":4847,"completion":4848,"start":4849,"enrollment":707,"conditions":4850,"interventions":4858},"NCT03994796","Genetic Testing in Guiding Treatment for Patients With Brain Metastases",[91],"2026-10","2028-06","2019-10-17",[4851,4852,4853,4854,4855,4856,4857],"CDK Gene Mutation","Metastatic Malignant Neoplasm in the Brain","Metastatic Malignant Solid Neoplasm","NTRK Family Gene Mutation","PI3K Gene Mutation","ROS1 Gene Mutation","KRAS G12C Mutation",[4819,4859,4860,4861],"PI3K Inhibitor paxalisib","Entrectinib","Adagrasib",{"trials":4863,"activeCount":123},[],{"trials":4865,"activeCount":123},[],{"trials":4867,"activeCount":123},[],{"intervention":185,"totalTrials":677,"cells":4869},{"EARLY_PHASE1":4870,"PHASE1":4872,"PHASE2":4878,"PHASE3":5044,"PHASE4":5058,"NA":5060},{"trials":4871,"activeCount":123},[],{"trials":4873,"activeCount":123},[4874],{"nctId":960,"briefTitle":961,"status":105,"phases":4875,"primaryCompletion":963,"completion":963,"start":964,"enrollment":953,"conditions":4876,"interventions":4877},[90],[162,171],[791,185],{"trials":4879,"activeCount":272,"soonestReadout":1084},[4880,4884,4888,4892,4896,4902,4906,4913,4917,4923,4927,4933,4941,4945,4952,4956,4963,4969,4976,4980,4984,4990,4994,4998,5002,5006,5010,5016,5020,5024,5028,5032,5036],{"nctId":554,"briefTitle":555,"status":105,"phases":4881,"primaryCompletion":371,"completion":557,"start":372,"enrollment":558,"conditions":4882,"interventions":4883},[91],[15],[524,285,185,561],{"nctId":2374,"briefTitle":2375,"status":105,"phases":4885,"primaryCompletion":158,"completion":813,"start":1253,"enrollment":2144,"conditions":4886,"interventions":4887},[91],[2378],[185,139],{"nctId":4719,"briefTitle":4720,"status":105,"phases":4889,"primaryCompletion":848,"completion":848,"start":629,"enrollment":1783,"conditions":4890,"interventions":4891},[91],[2550],[121,185],{"nctId":1523,"briefTitle":1524,"status":105,"phases":4893,"primaryCompletion":1526,"completion":859,"start":1527,"enrollment":1528,"conditions":4894,"interventions":4895},[91],[15],[43,185,139],{"nctId":4897,"briefTitle":4898,"status":105,"phases":4899,"primaryCompletion":732,"completion":675,"start":1207,"enrollment":537,"conditions":4900,"interventions":4901},"NCT00017186","Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma",[91],[4729],[1144,185],{"nctId":2400,"briefTitle":2401,"status":105,"phases":4903,"primaryCompletion":578,"completion":133,"start":2403,"enrollment":201,"conditions":4904,"interventions":4905},[91],[15],[185,139],{"nctId":4907,"briefTitle":4908,"status":105,"phases":4909,"primaryCompletion":788,"completion":1665,"start":1018,"enrollment":4910,"conditions":4911,"interventions":4912},"NCT00022646","Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[91],157,[15],[185,710],{"nctId":978,"briefTitle":979,"status":105,"phases":4914,"primaryCompletion":588,"completion":754,"start":981,"enrollment":982,"conditions":4915,"interventions":4916},[91],[171],[791,43,185,139],{"nctId":4918,"briefTitle":4919,"status":105,"phases":4920,"primaryCompletion":178,"completion":630,"start":244,"enrollment":2306,"conditions":4921,"interventions":4922},"NCT00059852","Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and\u002For a Taxane",[91],[18],[613,185],{"nctId":1408,"briefTitle":1409,"status":105,"phases":4924,"primaryCompletion":210,"completion":281,"start":765,"enrollment":1411,"conditions":4925,"interventions":4926},[91],[171],[138,185],{"nctId":4928,"briefTitle":4929,"status":105,"phases":4930,"primaryCompletion":179,"completion":806,"start":813,"enrollment":1838,"conditions":4931,"interventions":4932},"NCT00550836","Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer",[91],[171],[1002,613,185],{"nctId":4934,"briefTitle":4935,"status":105,"phases":4936,"primaryCompletion":219,"completion":4937,"start":754,"enrollment":4938,"conditions":4939,"interventions":4940},"NCT00733746","Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery",[91],"2019-06-15",123,[171],[613,185],{"nctId":175,"briefTitle":176,"status":105,"phases":4942,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":4943,"interventions":4944},[91],[171],[184,185,97],{"nctId":4946,"briefTitle":4947,"status":105,"phases":4948,"primaryCompletion":629,"completion":158,"start":4949,"enrollment":548,"conditions":4950,"interventions":4951},"NCT00005829","Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia",[91],"2000-02",[27],[185],{"nctId":654,"briefTitle":655,"status":167,"phases":4953,"enrollment":123,"conditions":4954,"interventions":4955},[91],[15],[659,524,185],{"nctId":4957,"briefTitle":4958,"status":105,"phases":4959,"primaryCompletion":134,"completion":675,"start":4960,"enrollment":246,"conditions":4961,"interventions":4962},"NCT00006007","LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer",[91],"2000-12",[18],[185,710],{"nctId":4964,"briefTitle":4965,"status":105,"phases":4966,"primaryCompletion":4749,"completion":557,"start":1617,"enrollment":1838,"conditions":4967,"interventions":4968},"NCT00086801","Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma",[91],[21],[1162,185,1154],{"nctId":4970,"briefTitle":4971,"status":105,"phases":4972,"primaryCompletion":2175,"completion":2175,"start":1047,"enrollment":160,"conditions":4973,"interventions":4974},"NCT00006467","Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas",[91],[171],[4975,185],"ISIS 2503",{"nctId":1598,"briefTitle":1599,"status":105,"phases":4977,"primaryCompletion":1601,"completion":675,"start":1041,"enrollment":1602,"conditions":4978,"interventions":4979},[91],[15],[43,185],{"nctId":1053,"briefTitle":1054,"status":105,"phases":4981,"primaryCompletion":132,"completion":191,"start":1056,"enrollment":246,"conditions":4982,"interventions":4983},[91],[18],[791,185],{"nctId":4985,"briefTitle":4986,"status":105,"phases":4987,"primaryCompletion":674,"completion":133,"start":2175,"enrollment":1805,"conditions":4988,"interventions":4989},"NCT00059865","Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer",[90,91],[1275,1276,1277],[185,710],{"nctId":751,"briefTitle":752,"status":105,"phases":4991,"primaryCompletion":754,"completion":755,"start":756,"enrollment":442,"conditions":4992,"interventions":4993},[91],[15],[524,759,185],{"nctId":1069,"briefTitle":1070,"status":105,"phases":4995,"primaryCompletion":1072,"completion":1072,"start":1018,"enrollment":1073,"conditions":4996,"interventions":4997},[91],[1075,1076,1077,15],[791,1079,185],{"nctId":3291,"briefTitle":3292,"status":105,"phases":4999,"primaryCompletion":360,"completion":618,"start":3294,"enrollment":707,"conditions":5000,"interventions":5001},[91],[18],[184,185,583],{"nctId":1271,"briefTitle":1272,"status":105,"phases":5003,"primaryCompletion":157,"completion":705,"start":686,"enrollment":525,"conditions":5004,"interventions":5005},[91],[1275,1276,1277],[138,185,140],{"nctId":1081,"briefTitle":1082,"status":258,"phases":5007,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":5008,"interventions":5009},[91],[1089,1090,1091],[1093,488,1094],{"nctId":5011,"briefTitle":5012,"status":105,"phases":5013,"primaryCompletion":372,"completion":859,"start":1535,"enrollment":3388,"conditions":5014,"interventions":5015},"NCT00003546","Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer",[91],[171],[185],{"nctId":1443,"briefTitle":1444,"status":105,"phases":5017,"primaryCompletion":221,"completion":806,"start":1446,"enrollment":1447,"conditions":5018,"interventions":5019},[91],[171],[1002,121,138,185],{"nctId":240,"briefTitle":241,"status":105,"phases":5021,"primaryCompletion":243,"completion":244,"start":245,"enrollment":246,"conditions":5022,"interventions":5023},[91],[171],[185,97],{"nctId":1614,"briefTitle":1615,"status":105,"phases":5025,"primaryCompletion":1617,"completion":158,"start":765,"enrollment":98,"conditions":5026,"interventions":5027},[91],[1277],[43,185],{"nctId":1100,"briefTitle":1101,"status":105,"phases":5029,"primaryCompletion":756,"completion":1103,"start":765,"enrollment":160,"conditions":5030,"interventions":5031},[91],[171],[791,185],{"nctId":845,"briefTitle":846,"status":105,"phases":5033,"primaryCompletion":848,"completion":281,"start":849,"enrollment":537,"conditions":5034,"interventions":5035},[91],[15],[524,185,540],{"nctId":5037,"briefTitle":5038,"status":105,"phases":5039,"primaryCompletion":674,"completion":674,"start":1346,"enrollment":5040,"conditions":5041,"interventions":5042},"NCT00006029","Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma",[90,91],91,[21],[185,5043,1177],"pegylated liposomal doxorubicin hydrochloride",{"trials":5045,"activeCount":123},[5046,5050,5054],{"nctId":1156,"briefTitle":1157,"status":105,"phases":5047,"primaryCompletion":796,"completion":754,"start":134,"enrollment":525,"conditions":5048,"interventions":5049},[92],[1160],[593,791,1162,185],{"nctId":1172,"briefTitle":1173,"status":312,"phases":5051,"primaryCompletion":999,"completion":824,"start":813,"enrollment":31,"conditions":5052,"interventions":5053},[92],[15],[791,43,185,710,1177],{"nctId":932,"briefTitle":933,"status":312,"phases":5055,"primaryCompletion":935,"completion":235,"start":755,"enrollment":936,"conditions":5056,"interventions":5057},[92],[15],[524,285,185,710],{"trials":5059,"activeCount":123},[],{"trials":5061,"activeCount":123},[],{"intervention":594,"totalTrials":3220,"cells":5063},{"EARLY_PHASE1":5064,"PHASE1":5066,"PHASE2":5068,"PHASE3":5138,"PHASE4":5152,"NA":5154},{"trials":5065,"activeCount":123},[],{"trials":5067,"activeCount":123},[],{"trials":5069,"activeCount":272,"soonestReadout":52},[5070,5074,5078,5082,5086,5090,5094,5098,5102,5106,5110,5114,5118,5122,5126,5130,5134],{"nctId":3022,"briefTitle":3023,"status":105,"phases":5071,"primaryCompletion":589,"completion":589,"start":2403,"enrollment":246,"conditions":5072,"interventions":5073},[91],[21],[593,1219,1162,594,1221,1222],{"nctId":585,"briefTitle":586,"status":105,"phases":5075,"primaryCompletion":588,"completion":589,"start":211,"enrollment":590,"conditions":5076,"interventions":5077},[91],[15],[593,524,594,540,595],{"nctId":2050,"briefTitle":2051,"status":105,"phases":5079,"primaryCompletion":1601,"completion":813,"start":2053,"enrollment":569,"conditions":5080,"interventions":5081},[91],[27],[593,1829,1011,594,1220],{"nctId":2753,"briefTitle":2754,"status":2755,"phases":5083,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":5084,"interventions":5085},[91],[2761,2762,2763,2764,2765,2766,2767],[1810,1820,1811,1818,2769,2770,2771],{"nctId":2061,"briefTitle":2062,"status":105,"phases":5087,"primaryCompletion":1601,"completion":1601,"start":631,"enrollment":403,"conditions":5088,"interventions":5089},[91],[2065,21],[53,2067,594,1011,1832,1220,1013],{"nctId":1015,"briefTitle":1016,"status":105,"phases":5091,"primaryCompletion":1018,"completion":675,"start":1019,"enrollment":1020,"conditions":5092,"interventions":5093},[91],[1022],[53,947,791,594],{"nctId":1212,"briefTitle":1213,"status":105,"phases":5095,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":5096,"interventions":5097},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":50,"briefTitle":51,"status":258,"phases":5099,"primaryCompletion":52,"completion":2078,"start":814,"enrollment":2079,"conditions":5100,"interventions":5101},[91],[21],[53,1011,594,2082,885],{"nctId":1228,"briefTitle":1229,"status":105,"phases":5103,"primaryCompletion":236,"completion":1231,"start":290,"enrollment":1232,"conditions":5104,"interventions":5105},[91],[21],[593,1010,1011,594,140,1220,828],{"nctId":1236,"briefTitle":1237,"status":105,"phases":5107,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":5108,"interventions":5109},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"nctId":729,"briefTitle":730,"status":105,"phases":5111,"primaryCompletion":732,"completion":133,"start":733,"enrollment":25,"conditions":5112,"interventions":5113},[91],[15],[524,594,736],{"nctId":1037,"briefTitle":1038,"status":105,"phases":5115,"primaryCompletion":1040,"completion":796,"start":1041,"enrollment":34,"conditions":5116,"interventions":5117},[91],[1022],[53,791,594],{"nctId":1045,"briefTitle":762,"status":105,"phases":5119,"primaryCompletion":191,"completion":191,"start":1047,"enrollment":201,"conditions":5120,"interventions":5121},[90,91],[1031,15,1049],[593,1051,791,594,540,595],{"nctId":761,"briefTitle":762,"status":105,"phases":5123,"primaryCompletion":764,"completion":754,"start":765,"enrollment":600,"conditions":5124,"interventions":5125},[91],[15],[593,524,594,540,595],{"nctId":784,"briefTitle":785,"status":105,"phases":5127,"primaryCompletion":756,"completion":787,"start":788,"enrollment":16,"conditions":5128,"interventions":5129},[91],[15],[524,791,594,139],{"nctId":1295,"briefTitle":1296,"status":105,"phases":5131,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":5132,"interventions":5133},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"nctId":1846,"briefTitle":1847,"status":105,"phases":5135,"primaryCompletion":200,"completion":754,"start":1849,"enrollment":16,"conditions":5136,"interventions":5137},[91],[21],[593,1010,1219,1162,594,1221,1222],{"trials":5139,"activeCount":123},[5140,5144,5148],{"nctId":1855,"briefTitle":1856,"status":105,"phases":5141,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":1861,"conditions":5142,"interventions":5143},[92],[1863],[1010,1219,1865,1866,1221,594,593,745],{"nctId":923,"briefTitle":924,"status":925,"phases":5145,"primaryCompletion":927,"start":610,"enrollment":928,"conditions":5146,"interventions":5147},[92],[15],[791,594,524],{"nctId":1179,"briefTitle":1180,"status":105,"phases":5149,"primaryCompletion":180,"completion":859,"start":1182,"enrollment":1183,"conditions":5150,"interventions":5151},[92],[15],[791,594,540],{"trials":5153,"activeCount":123},[],{"trials":5155,"activeCount":123},[],{"intervention":1221,"totalTrials":5157,"cells":5158},13,{"EARLY_PHASE1":5159,"PHASE1":5161,"PHASE2":5167,"PHASE3":5209,"PHASE4":5219,"NA":5221},{"trials":5160,"activeCount":123},[],{"trials":5162,"activeCount":123},[5163],{"nctId":1691,"briefTitle":1692,"status":105,"phases":5164,"primaryCompletion":1694,"completion":1695,"start":547,"enrollment":953,"conditions":5165,"interventions":5166},[90],[21],[1010,1219,1162,624,1221,1222],{"trials":5168,"activeCount":272,"soonestReadout":1802},[5169,5173,5177,5181,5185,5189,5193,5197,5201,5205],{"nctId":3022,"briefTitle":3023,"status":105,"phases":5170,"primaryCompletion":589,"completion":589,"start":2403,"enrollment":246,"conditions":5171,"interventions":5172},[91],[21],[593,1219,1162,594,1221,1222],{"nctId":2753,"briefTitle":2754,"status":2755,"phases":5174,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":5175,"interventions":5176},[91],[2761,2762,2763,2764,2765,2766,2767],[1810,1820,1811,1818,2769,2770,2771],{"nctId":1746,"briefTitle":1747,"status":105,"phases":5178,"primaryCompletion":1665,"completion":1749,"start":859,"enrollment":1750,"conditions":5179,"interventions":5180},[91],[21],[1753,1010,1219,1162,1221,1222],{"nctId":1212,"briefTitle":1213,"status":105,"phases":5182,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":5183,"interventions":5184},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":1236,"briefTitle":1237,"status":105,"phases":5186,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":5187,"interventions":5188},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"nctId":1250,"briefTitle":1251,"status":105,"phases":5190,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":5191,"interventions":5192},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"nctId":3074,"briefTitle":3075,"status":105,"phases":5194,"primaryCompletion":3077,"completion":2682,"start":2388,"enrollment":3078,"conditions":5195,"interventions":5196},[91],[21],[3081,3082,3083,3084,3085,1810,3086,1221,3087],{"nctId":1799,"briefTitle":1800,"status":258,"phases":5198,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":5199,"interventions":5200},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"nctId":1295,"briefTitle":1296,"status":105,"phases":5202,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":5203,"interventions":5204},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"nctId":1846,"briefTitle":1847,"status":105,"phases":5206,"primaryCompletion":200,"completion":754,"start":1849,"enrollment":16,"conditions":5207,"interventions":5208},[91],[21],[593,1010,1219,1162,594,1221,1222],{"trials":5210,"activeCount":123},[5211,5215],{"nctId":2285,"briefTitle":2286,"status":925,"phases":5212,"primaryCompletion":2288,"completion":2289,"start":2290,"enrollment":2291,"conditions":5213,"interventions":5214},[92],[2293,2294,2295,2296],[48,2298,1221],{"nctId":1855,"briefTitle":1856,"status":105,"phases":5216,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":1861,"conditions":5217,"interventions":5218},[92],[1863],[1010,1219,1865,1866,1221,594,593,745],{"trials":5220,"activeCount":123},[],{"trials":5222,"activeCount":123},[],{"intervention":624,"totalTrials":5224,"cells":5225},8,{"EARLY_PHASE1":5226,"PHASE1":5228,"PHASE2":5234,"PHASE3":5266,"PHASE4":5272,"NA":5274},{"trials":5227,"activeCount":123},[],{"trials":5229,"activeCount":123},[5230],{"nctId":1691,"briefTitle":1692,"status":105,"phases":5231,"primaryCompletion":1694,"completion":1695,"start":547,"enrollment":953,"conditions":5232,"interventions":5233},[90],[21],[1010,1219,1162,624,1221,1222],{"trials":5235,"activeCount":272,"soonestReadout":57},[5236,5244,5248,5252,5256,5260],{"nctId":55,"briefTitle":56,"status":258,"phases":5237,"primaryCompletion":57,"completion":5238,"start":5239,"enrollment":5240,"conditions":5241,"interventions":5243},[91],"2028-08-06","2014-10-09",35,[5242],"Refractory Hurthle Cell Thyroid Cancer",[58,624],{"nctId":615,"briefTitle":616,"status":105,"phases":5245,"primaryCompletion":299,"completion":618,"start":619,"enrollment":620,"conditions":5246,"interventions":5247},[91],[622],[524,624,540],{"nctId":2152,"briefTitle":2153,"status":105,"phases":5249,"primaryCompletion":359,"completion":2155,"start":813,"enrollment":2156,"conditions":5250,"interventions":5251},[90,91],[1022],[624,828],{"nctId":692,"briefTitle":693,"status":105,"phases":5253,"primaryCompletion":145,"completion":695,"start":696,"enrollment":697,"conditions":5254,"interventions":5255},[91],[581],[184,524,624,540],{"nctId":2164,"briefTitle":2165,"status":105,"phases":5257,"primaryCompletion":903,"completion":776,"start":535,"enrollment":2167,"conditions":5258,"interventions":5259},[91],[581],[624,828],{"nctId":5261,"briefTitle":5262,"status":105,"phases":5263,"primaryCompletion":685,"completion":755,"start":132,"enrollment":181,"conditions":5264,"interventions":5265},"NCT00098553","Everolimus in Treating Patients With Stage IV Melanoma",[91],[581],[624],{"trials":5267,"activeCount":123},[5268],{"nctId":2013,"briefTitle":2014,"status":312,"phases":5269,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":1727,"conditions":5270,"interventions":5271},[92],[2020],[1812,2022],{"trials":5273,"activeCount":123},[],{"trials":5275,"activeCount":123},[],{"intervention":745,"totalTrials":430,"cells":5277},{"EARLY_PHASE1":5278,"PHASE1":5280,"PHASE2":5286,"PHASE3":5300,"PHASE4":5306,"NA":5308},{"trials":5279,"activeCount":123},[],{"trials":5281,"activeCount":123},[5282],{"nctId":1710,"briefTitle":1711,"status":105,"phases":5283,"primaryCompletion":1713,"completion":609,"start":754,"enrollment":1714,"conditions":5284,"interventions":5285},[90],[21],[1010,1717,1718,1719,1094],{"trials":5287,"activeCount":272,"soonestReadout":1084},[5288,5292,5296],{"nctId":1025,"briefTitle":1026,"status":105,"phases":5289,"primaryCompletion":1028,"completion":754,"start":732,"enrollment":9,"conditions":5290,"interventions":5291},[91],[1030,1031,15,1032],[1034,745,791,43,1035],{"nctId":738,"briefTitle":739,"status":105,"phases":5293,"primaryCompletion":741,"start":676,"enrollment":742,"conditions":5294,"interventions":5295},[91],[18],[745,524,43],{"nctId":1081,"briefTitle":1082,"status":258,"phases":5297,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":5298,"interventions":5299},[91],[1089,1090,1091],[1093,488,1094],{"trials":5301,"activeCount":123},[5302],{"nctId":1855,"briefTitle":1856,"status":105,"phases":5303,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":1861,"conditions":5304,"interventions":5305},[92],[1863],[1010,1219,1865,1866,1221,594,593,745],{"trials":5307,"activeCount":123},[],{"trials":5309,"activeCount":123},[],{"intervention":120,"totalTrials":403,"cells":5311},{"EARLY_PHASE1":5312,"PHASE1":5318,"PHASE2":5320,"PHASE3":5330,"PHASE4":5336,"NA":5338},{"trials":5313,"activeCount":123},[5314],{"nctId":103,"briefTitle":104,"status":105,"phases":5315,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":5316,"interventions":5317},[89],[112,113,114,115,116],[97,118,119,120,121,122],{"trials":5319,"activeCount":123},[],{"trials":5321,"activeCount":272,"soonestReadout":260},[5322,5326],{"nctId":986,"briefTitle":987,"status":105,"phases":5323,"primaryCompletion":685,"completion":989,"start":990,"enrollment":991,"conditions":5324,"interventions":5325},[91],[171],[994,791,120],{"nctId":256,"briefTitle":257,"status":258,"phases":5327,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":5328,"interventions":5329},[91],[265,266,267],[269,120,270,271,226],{"trials":5331,"activeCount":123},[5332],{"nctId":276,"briefTitle":277,"status":105,"phases":5333,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":5334,"interventions":5335},[92],[24],[285,120,97,119],{"trials":5337,"activeCount":123},[],{"trials":5339,"activeCount":123},[],{"intervention":53,"totalTrials":2221,"cells":5341},{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5376,"PHASE4":5378,"NA":5380},{"trials":5343,"activeCount":123},[],{"trials":5345,"activeCount":123},[],{"trials":5347,"activeCount":272,"soonestReadout":52},[5348,5352,5356,5360,5364,5368,5372],{"nctId":1913,"briefTitle":1914,"status":105,"phases":5349,"primaryCompletion":578,"completion":578,"start":1916,"enrollment":1917,"conditions":5350,"interventions":5351},[91],[21],[53,1219,1011,1012,1162,1220,1222],{"nctId":2061,"briefTitle":2062,"status":105,"phases":5353,"primaryCompletion":1601,"completion":1601,"start":631,"enrollment":403,"conditions":5354,"interventions":5355},[91],[2065,21],[53,2067,594,1011,1832,1220,1013],{"nctId":1015,"briefTitle":1016,"status":105,"phases":5357,"primaryCompletion":1018,"completion":675,"start":1019,"enrollment":1020,"conditions":5358,"interventions":5359},[91],[1022],[53,947,791,594],{"nctId":1212,"briefTitle":1213,"status":105,"phases":5361,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":5362,"interventions":5363},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":50,"briefTitle":51,"status":258,"phases":5365,"primaryCompletion":52,"completion":2078,"start":814,"enrollment":2079,"conditions":5366,"interventions":5367},[91],[21],[53,1011,594,2082,885],{"nctId":1037,"briefTitle":1038,"status":105,"phases":5369,"primaryCompletion":1040,"completion":796,"start":1041,"enrollment":34,"conditions":5370,"interventions":5371},[91],[1022],[53,791,594],{"nctId":2467,"briefTitle":2468,"status":105,"phases":5373,"primaryCompletion":578,"completion":1103,"start":2470,"enrollment":742,"conditions":5374,"interventions":5375},[90,91],[1022],[53,139],{"trials":5377,"activeCount":123},[],{"trials":5379,"activeCount":123},[],{"trials":5381,"activeCount":123},[],{"intervention":3633,"totalTrials":852,"cells":5383},{"EARLY_PHASE1":5384,"PHASE1":5386,"PHASE2":5388,"PHASE3":5409,"PHASE4":5411,"NA":5413},{"trials":5385,"activeCount":123},[],{"trials":5387,"activeCount":123},[],{"trials":5389,"activeCount":272,"soonestReadout":440},[5390,5405],{"nctId":5391,"briefTitle":5392,"status":258,"phases":5393,"primaryCompletion":440,"completion":440,"start":5394,"enrollment":5395,"conditions":5396,"interventions":5403},"NCT05694871","Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma",[91],"2023-06-07",77,[5397,5398,5399,5400,5401,5402],"Advanced Dedifferentiated Liposarcoma","Locally Advanced Dedifferentiated Liposarcoma","Metastatic Dedifferentiated Liposarcoma","Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Unresectable Dedifferentiated Liposarcoma",[3633,5404],"Cemiplimab",{"nctId":3622,"briefTitle":3623,"status":105,"phases":5406,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":1020,"conditions":5407,"interventions":5408},[91],[3629,3630,3631],[3633,3634,3635],{"trials":5410,"activeCount":123},[],{"trials":5412,"activeCount":123},[],{"trials":5414,"activeCount":123},[],{"intervention":5404,"totalTrials":272,"cells":5416},{"EARLY_PHASE1":5417,"PHASE1":5419,"PHASE2":5421,"PHASE3":5427,"PHASE4":5429,"NA":5431},{"trials":5418,"activeCount":123},[],{"trials":5420,"activeCount":123},[],{"trials":5422,"activeCount":272,"soonestReadout":440},[5423],{"nctId":5391,"briefTitle":5392,"status":258,"phases":5424,"primaryCompletion":440,"completion":440,"start":5394,"enrollment":5395,"conditions":5425,"interventions":5426},[91],[5397,5398,5399,5400,5401,5402],[3633,5404],{"trials":5428,"activeCount":123},[],{"trials":5430,"activeCount":123},[],{"trials":5432,"activeCount":123},[],{"intervention":58,"totalTrials":272,"cells":5434},{"EARLY_PHASE1":5435,"PHASE1":5437,"PHASE2":5439,"PHASE3":5445,"PHASE4":5447,"NA":5449},{"trials":5436,"activeCount":123},[],{"trials":5438,"activeCount":123},[],{"trials":5440,"activeCount":272,"soonestReadout":57},[5441],{"nctId":55,"briefTitle":56,"status":258,"phases":5442,"primaryCompletion":57,"completion":5238,"start":5239,"enrollment":5240,"conditions":5443,"interventions":5444},[91],[5242],[58,624],{"trials":5446,"activeCount":123},[],{"trials":5448,"activeCount":123},[],{"trials":5450,"activeCount":123},[],{"intervention":2149,"totalTrials":272,"cells":5452},{"EARLY_PHASE1":5453,"PHASE1":5455,"PHASE2":5457,"PHASE3":5463,"PHASE4":5465,"NA":5467},{"trials":5454,"activeCount":123},[],{"trials":5456,"activeCount":123},[],{"trials":5458,"activeCount":272,"soonestReadout":2141},[5459],{"nctId":2138,"briefTitle":2139,"status":258,"phases":5460,"primaryCompletion":2141,"completion":2142,"start":2143,"enrollment":2144,"conditions":5461,"interventions":5462},[91],[2146,2147],[2149,269,2150],{"trials":5464,"activeCount":123},[],{"trials":5466,"activeCount":123},[],{"trials":5468,"activeCount":123},[],{"intervention":1936,"totalTrials":272,"cells":5470},{"EARLY_PHASE1":5471,"PHASE1":5473,"PHASE2":5475,"PHASE3":5481,"PHASE4":5483,"NA":5485},{"trials":5472,"activeCount":123},[],{"trials":5474,"activeCount":123},[],{"trials":5476,"activeCount":272,"soonestReadout":1928},[5477],{"nctId":1925,"briefTitle":1926,"status":380,"phases":5478,"primaryCompletion":1928,"completion":1929,"start":1930,"enrollment":1931,"conditions":5479,"interventions":5480},[90,91],[1933,1934],[1936,1937,1812],{"trials":5482,"activeCount":123},[],{"trials":5484,"activeCount":123},[],{"trials":5486,"activeCount":123},[],{"intervention":1937,"totalTrials":272,"cells":5488},{"EARLY_PHASE1":5489,"PHASE1":5491,"PHASE2":5493,"PHASE3":5499,"PHASE4":5501,"NA":5503},{"trials":5490,"activeCount":123},[],{"trials":5492,"activeCount":123},[],{"trials":5494,"activeCount":272,"soonestReadout":1928},[5495],{"nctId":1925,"briefTitle":1926,"status":380,"phases":5496,"primaryCompletion":1928,"completion":1929,"start":1930,"enrollment":1931,"conditions":5497,"interventions":5498},[90,91],[1933,1934],[1936,1937,1812],{"trials":5500,"activeCount":123},[],{"trials":5502,"activeCount":123},[],{"trials":5504,"activeCount":123},[],{"intervention":4840,"totalTrials":272,"cells":5506},{"EARLY_PHASE1":5507,"PHASE1":5509,"PHASE2":5511,"PHASE3":5517,"PHASE4":5519,"NA":5521},{"trials":5508,"activeCount":123},[],{"trials":5510,"activeCount":123},[],{"trials":5512,"activeCount":272,"soonestReadout":4831},[5513],{"nctId":4828,"briefTitle":4829,"status":380,"phases":5514,"primaryCompletion":4831,"completion":4832,"start":4833,"enrollment":4834,"conditions":5515,"interventions":5516},[91],[4836,4837,4838],[4840,4841,4842,4819],{"trials":5518,"activeCount":123},[],{"trials":5520,"activeCount":123},[],{"trials":5522,"activeCount":123},[],{"intervention":4841,"totalTrials":272,"cells":5524},{"EARLY_PHASE1":5525,"PHASE1":5527,"PHASE2":5529,"PHASE3":5535,"PHASE4":5537,"NA":5539},{"trials":5526,"activeCount":123},[],{"trials":5528,"activeCount":123},[],{"trials":5530,"activeCount":272,"soonestReadout":4831},[5531],{"nctId":4828,"briefTitle":4829,"status":380,"phases":5532,"primaryCompletion":4831,"completion":4832,"start":4833,"enrollment":4834,"conditions":5533,"interventions":5534},[91],[4836,4837,4838],[4840,4841,4842,4819],{"trials":5536,"activeCount":123},[],{"trials":5538,"activeCount":123},[],{"trials":5540,"activeCount":123},[],{"intervention":4842,"totalTrials":272,"cells":5542},{"EARLY_PHASE1":5543,"PHASE1":5545,"PHASE2":5547,"PHASE3":5553,"PHASE4":5555,"NA":5557},{"trials":5544,"activeCount":123},[],{"trials":5546,"activeCount":123},[],{"trials":5548,"activeCount":272,"soonestReadout":4831},[5549],{"nctId":4828,"briefTitle":4829,"status":380,"phases":5550,"primaryCompletion":4831,"completion":4832,"start":4833,"enrollment":4834,"conditions":5551,"interventions":5552},[91],[4836,4837,4838],[4840,4841,4842,4819],{"trials":5554,"activeCount":123},[],{"trials":5556,"activeCount":123},[],{"trials":5558,"activeCount":123},[],{"intervention":1372,"totalTrials":272,"cells":5560},{"EARLY_PHASE1":5561,"PHASE1":5563,"PHASE2":5565,"PHASE3":5571,"PHASE4":5573,"NA":5575},{"trials":5562,"activeCount":123},[],{"trials":5564,"activeCount":123},[],{"trials":5566,"activeCount":272,"soonestReadout":1366},[5567],{"nctId":1363,"briefTitle":1364,"status":380,"phases":5568,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":953,"conditions":5569,"interventions":5570},[91],[1369,1370],[402,1372],{"trials":5572,"activeCount":123},[],{"trials":5574,"activeCount":123},[],{"trials":5576,"activeCount":123},[],{"intervention":2082,"totalTrials":272,"cells":5578},{"EARLY_PHASE1":5579,"PHASE1":5581,"PHASE2":5583,"PHASE3":5589,"PHASE4":5591,"NA":5593},{"trials":5580,"activeCount":123},[],{"trials":5582,"activeCount":123},[],{"trials":5584,"activeCount":272,"soonestReadout":52},[5585],{"nctId":50,"briefTitle":51,"status":258,"phases":5586,"primaryCompletion":52,"completion":2078,"start":814,"enrollment":2079,"conditions":5587,"interventions":5588},[91],[21],[53,1011,594,2082,885],{"trials":5590,"activeCount":123},[],{"trials":5592,"activeCount":123},[],{"trials":5594,"activeCount":123},[],{"intervention":5596,"totalTrials":272,"cells":5597},"Vemurafenib",{"EARLY_PHASE1":5598,"PHASE1":5600,"PHASE2":5602,"PHASE3":5616,"PHASE4":5618,"NA":5620},{"trials":5599,"activeCount":123},[],{"trials":5601,"activeCount":123},[],{"trials":5603,"activeCount":272,"soonestReadout":5608},[5604],{"nctId":5605,"briefTitle":5606,"status":258,"phases":5607,"primaryCompletion":5608,"completion":5609,"start":5610,"enrollment":1191,"conditions":5611,"interventions":5614},"NCT03224767","Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma",[91],"2026-10-01","2028-08-01","2018-01-05",[5612,5613],"BRAF V600E Mutation Present","Papillary Craniopharyngioma",[5596,5615],"Cobimetinib",{"trials":5617,"activeCount":123},[],{"trials":5619,"activeCount":123},[],{"trials":5621,"activeCount":123},[],{"intervention":5615,"totalTrials":272,"cells":5623},{"EARLY_PHASE1":5624,"PHASE1":5626,"PHASE2":5628,"PHASE3":5634,"PHASE4":5636,"NA":5638},{"trials":5625,"activeCount":123},[],{"trials":5627,"activeCount":123},[],{"trials":5629,"activeCount":272,"soonestReadout":5608},[5630],{"nctId":5605,"briefTitle":5606,"status":258,"phases":5631,"primaryCompletion":5608,"completion":5609,"start":5610,"enrollment":1191,"conditions":5632,"interventions":5633},[91],[5612,5613],[5596,5615],{"trials":5635,"activeCount":123},[],{"trials":5637,"activeCount":123},[],{"trials":5639,"activeCount":123},[],{"intervention":4859,"totalTrials":272,"cells":5641},{"EARLY_PHASE1":5642,"PHASE1":5644,"PHASE2":5646,"PHASE3":5652,"PHASE4":5654,"NA":5656},{"trials":5643,"activeCount":123},[],{"trials":5645,"activeCount":123},[],{"trials":5647,"activeCount":272,"soonestReadout":4847},[5648],{"nctId":4844,"briefTitle":4845,"status":258,"phases":5649,"primaryCompletion":4847,"completion":4848,"start":4849,"enrollment":707,"conditions":5650,"interventions":5651},[91],[4851,4852,4853,4854,4855,4856,4857],[4819,4859,4860,4861],{"trials":5653,"activeCount":123},[],{"trials":5655,"activeCount":123},[],{"trials":5657,"activeCount":123},[],{"intervention":4860,"totalTrials":272,"cells":5659},{"EARLY_PHASE1":5660,"PHASE1":5662,"PHASE2":5664,"PHASE3":5670,"PHASE4":5672,"NA":5674},{"trials":5661,"activeCount":123},[],{"trials":5663,"activeCount":123},[],{"trials":5665,"activeCount":272,"soonestReadout":4847},[5666],{"nctId":4844,"briefTitle":4845,"status":258,"phases":5667,"primaryCompletion":4847,"completion":4848,"start":4849,"enrollment":707,"conditions":5668,"interventions":5669},[91],[4851,4852,4853,4854,4855,4856,4857],[4819,4859,4860,4861],{"trials":5671,"activeCount":123},[],{"trials":5673,"activeCount":123},[],{"trials":5675,"activeCount":123},[],{"intervention":4861,"totalTrials":272,"cells":5677},{"EARLY_PHASE1":5678,"PHASE1":5680,"PHASE2":5682,"PHASE3":5688,"PHASE4":5690,"NA":5692},{"trials":5679,"activeCount":123},[],{"trials":5681,"activeCount":123},[],{"trials":5683,"activeCount":272,"soonestReadout":4847},[5684],{"nctId":4844,"briefTitle":4845,"status":258,"phases":5685,"primaryCompletion":4847,"completion":4848,"start":4849,"enrollment":707,"conditions":5686,"interventions":5687},[91],[4851,4852,4853,4854,4855,4856,4857],[4819,4859,4860,4861],{"trials":5689,"activeCount":123},[],{"trials":5691,"activeCount":123},[],{"trials":5693,"activeCount":123},[],{"intervention":723,"totalTrials":272,"cells":5695},{"EARLY_PHASE1":5696,"PHASE1":5698,"PHASE2":5700,"PHASE3":5706,"PHASE4":5708,"NA":5710},{"trials":5697,"activeCount":123},[],{"trials":5699,"activeCount":123},[],{"trials":5701,"activeCount":272,"soonestReadout":715},[5702],{"nctId":712,"briefTitle":713,"status":380,"phases":5703,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":5704,"interventions":5705},[91],[720,721],[723,229,724,725,726,727],{"trials":5707,"activeCount":123},[],{"trials":5709,"activeCount":123},[],{"trials":5711,"activeCount":123},[],{"intervention":724,"totalTrials":272,"cells":5713},{"EARLY_PHASE1":5714,"PHASE1":5716,"PHASE2":5718,"PHASE3":5724,"PHASE4":5726,"NA":5728},{"trials":5715,"activeCount":123},[],{"trials":5717,"activeCount":123},[],{"trials":5719,"activeCount":272,"soonestReadout":715},[5720],{"nctId":712,"briefTitle":713,"status":380,"phases":5721,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":5722,"interventions":5723},[91],[720,721],[723,229,724,725,726,727],{"trials":5725,"activeCount":123},[],{"trials":5727,"activeCount":123},[],{"trials":5729,"activeCount":123},[],{"intervention":725,"totalTrials":272,"cells":5731},{"EARLY_PHASE1":5732,"PHASE1":5734,"PHASE2":5736,"PHASE3":5742,"PHASE4":5744,"NA":5746},{"trials":5733,"activeCount":123},[],{"trials":5735,"activeCount":123},[],{"trials":5737,"activeCount":272,"soonestReadout":715},[5738],{"nctId":712,"briefTitle":713,"status":380,"phases":5739,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":5740,"interventions":5741},[91],[720,721],[723,229,724,725,726,727],{"trials":5743,"activeCount":123},[],{"trials":5745,"activeCount":123},[],{"trials":5747,"activeCount":123},[],{"intervention":1816,"totalTrials":272,"cells":5749},{"EARLY_PHASE1":5750,"PHASE1":5752,"PHASE2":5754,"PHASE3":5760,"PHASE4":5762,"NA":5764},{"trials":5751,"activeCount":123},[],{"trials":5753,"activeCount":123},[],{"trials":5755,"activeCount":272,"soonestReadout":1802},[5756],{"nctId":1799,"briefTitle":1800,"status":258,"phases":5757,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":5758,"interventions":5759},[91],[1807,1808],[1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],{"trials":5761,"activeCount":123},[],{"trials":5763,"activeCount":123},[],{"trials":5765,"activeCount":123},[],{"intervention":5767,"totalTrials":5224,"cells":5768},"gene expression analysis",{"EARLY_PHASE1":5769,"PHASE1":5771,"PHASE2":5773,"PHASE3":5775,"PHASE4":5777,"NA":5779},{"trials":5770,"activeCount":123},[],{"trials":5772,"activeCount":123},[],{"trials":5774,"activeCount":123},[],{"trials":5776,"activeCount":123},[],{"trials":5778,"activeCount":123},[],{"trials":5780,"activeCount":272,"soonestReadout":5796},[5781,5792,5803,5810,5821,5828,5834,5843],{"nctId":5782,"briefTitle":5783,"status":105,"phases":5784,"primaryCompletion":5785,"completion":5785,"start":5786,"enrollment":5787,"conditions":5788,"interventions":5789},"NCT01562288","Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab",[],"2019-04","2012-02",1576,[18],[5790,5767,5791],"DNA analysis","polymerase chain reaction",{"nctId":5793,"briefTitle":5794,"status":258,"phases":5795,"primaryCompletion":5796,"start":578,"enrollment":5797,"conditions":5798,"interventions":5799},"NCT00898456","Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia",[],"2100-01",600,[27],[5767,5800,5801,5802],"molecular genetic technique","polymorphism analysis","protein expression analysis",{"nctId":5804,"briefTitle":5805,"status":105,"phases":5806,"primaryCompletion":2682,"completion":2682,"start":2533,"enrollment":798,"conditions":5807,"interventions":5808},"NCT00897663","Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies",[],[1022],[5767,5809,5802],"microarray analysis",{"nctId":5811,"briefTitle":5812,"status":925,"phases":5813,"primaryCompletion":2002,"start":5814,"enrollment":5815,"conditions":5816,"interventions":5817},"NCT00900224","Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia",[],"2008-06",529,[27],[5790,5818,5767,5819,5791,5820],"DNA methylation analysis","mutation analysis","reverse transcriptase-polymerase chain reaction",{"nctId":5822,"briefTitle":5823,"status":105,"phases":5824,"primaryCompletion":2388,"completion":5786,"start":754,"enrollment":5825,"conditions":5826,"interventions":5827},"NCT00991263","Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741",[],3677,[18],[5767,5791],{"nctId":5829,"briefTitle":5830,"status":105,"phases":5831,"primaryCompletion":314,"completion":314,"start":1103,"enrollment":3538,"conditions":5832,"interventions":5833},"NCT00990873","Study of Tissue Samples From Patients With Stage I Non-Small Cell Lung Cancer Enrolled on Research Study CALGB-140202",[],[15],[5767,5809,5820],{"nctId":5835,"briefTitle":5836,"status":105,"phases":5837,"primaryCompletion":5838,"start":547,"enrollment":5839,"conditions":5840,"interventions":5841},"NCT01414595","Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer",[],"2017-02",248,[15],[5790,5818,5842,5767,5801],"RNA analysis",{"nctId":5844,"briefTitle":5845,"status":105,"phases":5846,"primaryCompletion":1231,"completion":1231,"start":989,"enrollment":5847,"conditions":5848,"interventions":5849},"NCT01284010","Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia",[],200,[27],[5790,3148,5767,5809,5819,5791],{"intervention":5801,"totalTrials":2221,"cells":5851},{"EARLY_PHASE1":5852,"PHASE1":5854,"PHASE2":5856,"PHASE3":5858,"PHASE4":5860,"NA":5862},{"trials":5853,"activeCount":123},[],{"trials":5855,"activeCount":123},[],{"trials":5857,"activeCount":123},[],{"trials":5859,"activeCount":123},[],{"trials":5861,"activeCount":123},[],{"trials":5863,"activeCount":272,"soonestReadout":5796},[5864,5868,5875,5881,5889,5896,5900],{"nctId":5793,"briefTitle":5794,"status":258,"phases":5865,"primaryCompletion":5796,"start":578,"enrollment":5797,"conditions":5866,"interventions":5867},[],[27],[5767,5800,5801,5802],{"nctId":5869,"briefTitle":5870,"status":105,"phases":5871,"primaryCompletion":1741,"completion":5872,"start":1665,"enrollment":8,"conditions":5873,"interventions":5874},"NCT00899535","Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030",[],"2013-02",[15],[5790,5842,5809,5819,5801],{"nctId":5876,"briefTitle":5877,"status":105,"phases":5878,"primaryCompletion":903,"completion":903,"start":741,"enrollment":558,"conditions":5879,"interventions":5880},"NCT00516698","Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer",[],[18],[5801],{"nctId":5882,"briefTitle":5883,"status":105,"phases":5884,"primaryCompletion":5885,"completion":5885,"start":576,"enrollment":272,"conditions":5886,"interventions":5888},"NCT00954655","Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001",[],"2013-04",[5887],"Gastrointestinal Stromal Tumor",[5819,5801],{"nctId":5890,"briefTitle":5891,"status":105,"phases":5892,"primaryCompletion":5893,"completion":5893,"start":3286,"enrollment":3180,"conditions":5894,"interventions":5895},"NCT00968214","Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27",[],"2018-09",[18],[5801],{"nctId":5835,"briefTitle":5836,"status":105,"phases":5897,"primaryCompletion":5838,"start":547,"enrollment":5839,"conditions":5898,"interventions":5899},[],[15],[5790,5818,5842,5767,5801],{"nctId":5901,"briefTitle":5902,"status":105,"phases":5903,"primaryCompletion":5904,"completion":5904,"start":5905,"enrollment":5906,"conditions":5907,"interventions":5908},"NCT01327794","Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer",[],"2014-08","2011-06",265,[171],[5801],{"intervention":5910,"totalTrials":430,"cells":5911},"cytogenetic analysis",{"EARLY_PHASE1":5912,"PHASE1":5914,"PHASE2":5916,"PHASE3":5918,"PHASE4":5920,"NA":5922},{"trials":5913,"activeCount":123},[],{"trials":5915,"activeCount":123},[],{"trials":5917,"activeCount":123},[],{"trials":5919,"activeCount":123},[],{"trials":5921,"activeCount":123},[],{"trials":5923,"activeCount":272,"soonestReadout":5796},[5924,5932,5942,5949,5960],{"nctId":5925,"briefTitle":5926,"status":925,"phases":5927,"primaryCompletion":1047,"start":5928,"enrollment":1783,"conditions":5929,"interventions":5930},"NCT01004640","Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial",[],"1998-12-15",[27],[5790,5931,5910,5791],"Southern blotting",{"nctId":5933,"briefTitle":5934,"status":105,"phases":5935,"primaryCompletion":1860,"completion":1860,"start":5936,"enrollment":5937,"conditions":5938,"interventions":5939},"NCT00003863","Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma",[],"1999-06",391,[21],[5940,5910,3148,5941],"comparative genomic hybridization","gene rearrangement analysis",{"nctId":5943,"briefTitle":5944,"status":105,"phases":5945,"primaryCompletion":1741,"completion":1741,"start":3511,"enrollment":5797,"conditions":5946,"interventions":5947},"NCT00055848","Genetic Study of Familial Factors in Patients With Colon Cancer",[],[24],[5910,5948,5809],"gene mapping",{"nctId":5950,"briefTitle":5951,"status":258,"phases":5952,"primaryCompletion":5796,"start":5953,"enrollment":5954,"conditions":5955,"interventions":5959},"NCT00048958","Cytogenetic Studies in Acute Leukemia and Multiple Myeloma",[],"1984-06",9000,[5956,5957,5958,2525],"Acute Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndrome",[5910],{"nctId":5961,"briefTitle":5962,"status":105,"phases":5963,"primaryCompletion":589,"completion":705,"start":159,"enrollment":5964,"conditions":5965,"interventions":5966},"NCT00049010","Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma",[94],314,[581],[5940,5910,3148],{"intervention":5800,"totalTrials":852,"cells":5968},{"EARLY_PHASE1":5969,"PHASE1":5971,"PHASE2":5973,"PHASE3":5975,"PHASE4":5977,"NA":5979},{"trials":5970,"activeCount":123},[],{"trials":5972,"activeCount":123},[],{"trials":5974,"activeCount":123},[],{"trials":5976,"activeCount":123},[],{"trials":5978,"activeCount":123},[],{"trials":5980,"activeCount":272,"soonestReadout":5796},[5981,5985],{"nctId":5793,"briefTitle":5794,"status":258,"phases":5982,"primaryCompletion":5796,"start":578,"enrollment":5797,"conditions":5983,"interventions":5984},[],[27],[5767,5800,5801,5802],{"nctId":5986,"briefTitle":5987,"status":925,"phases":5988,"primaryCompletion":299,"start":191,"enrollment":5989,"conditions":5990,"interventions":5991},"NCT00898092","Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia",[],735,[27],[5809,5800,5819,5791,5820],{"intervention":5802,"totalTrials":852,"cells":5993},{"EARLY_PHASE1":5994,"PHASE1":5996,"PHASE2":5998,"PHASE3":6000,"PHASE4":6002,"NA":6004},{"trials":5995,"activeCount":123},[],{"trials":5997,"activeCount":123},[],{"trials":5999,"activeCount":123},[],{"trials":6001,"activeCount":123},[],{"trials":6003,"activeCount":123},[],{"trials":6005,"activeCount":272,"soonestReadout":5796},[6006,6010],{"nctId":5793,"briefTitle":5794,"status":258,"phases":6007,"primaryCompletion":5796,"start":578,"enrollment":5797,"conditions":6008,"interventions":6009},[],[27],[5767,5800,5801,5802],{"nctId":5804,"briefTitle":5805,"status":105,"phases":6011,"primaryCompletion":2682,"completion":2682,"start":2533,"enrollment":798,"conditions":6012,"interventions":6013},[],[1022],[5767,5809,5802],{"intervention":428,"totalTrials":272,"cells":6015},{"EARLY_PHASE1":6016,"PHASE1":6018,"PHASE2":6020,"PHASE3":6022,"PHASE4":6024,"NA":6026},{"trials":6017,"activeCount":123},[],{"trials":6019,"activeCount":123},[],{"trials":6021,"activeCount":123},[],{"trials":6023,"activeCount":123},[],{"trials":6025,"activeCount":123},[],{"trials":6027,"activeCount":272,"soonestReadout":412},[6028],{"nctId":409,"briefTitle":410,"status":380,"phases":6029,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":6030,"interventions":6031},[94],[417,418,419,420,421,422,423,424,425,426],[226,428,228],{"intervention":593,"totalTrials":3220,"cells":6033},{"EARLY_PHASE1":6034,"PHASE1":6036,"PHASE2":6042,"PHASE3":6112,"PHASE4":6122,"NA":6124},{"trials":6035,"activeCount":123},[],{"trials":6037,"activeCount":123},[6038],{"nctId":1710,"briefTitle":1711,"status":105,"phases":6039,"primaryCompletion":1713,"completion":609,"start":754,"enrollment":1714,"conditions":6040,"interventions":6041},[90],[21],[1010,1717,1718,1719,1094],{"trials":6043,"activeCount":123},[6044,6048,6052,6056,6060,6064,6068,6072,6076,6080,6084,6088,6092,6096,6100,6104,6108],{"nctId":3022,"briefTitle":3023,"status":105,"phases":6045,"primaryCompletion":589,"completion":589,"start":2403,"enrollment":246,"conditions":6046,"interventions":6047},[91],[21],[593,1219,1162,594,1221,1222],{"nctId":2521,"briefTitle":2522,"status":105,"phases":6049,"primaryCompletion":648,"completion":755,"start":640,"enrollment":1783,"conditions":6050,"interventions":6051},[91],[2525,2526],[593,2528,1219,1830,2067,1220,1832],{"nctId":585,"briefTitle":586,"status":105,"phases":6053,"primaryCompletion":588,"completion":589,"start":211,"enrollment":590,"conditions":6054,"interventions":6055},[91],[15],[593,524,594,540,595],{"nctId":2050,"briefTitle":2051,"status":105,"phases":6057,"primaryCompletion":1601,"completion":813,"start":2053,"enrollment":569,"conditions":6058,"interventions":6059},[91],[27],[593,1829,1011,594,1220],{"nctId":2546,"briefTitle":2547,"status":105,"phases":6061,"primaryCompletion":648,"completion":648,"start":2450,"enrollment":1917,"conditions":6062,"interventions":6063},[91],[2550],[593,2552,1219,1830,1220,1832],{"nctId":3040,"briefTitle":3041,"status":105,"phases":6065,"primaryCompletion":1207,"completion":859,"start":3043,"enrollment":34,"conditions":6066,"interventions":6067},[91],[21],[593,1219],{"nctId":635,"briefTitle":636,"status":105,"phases":6069,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":6070,"interventions":6071},[91],[15],[593,524,595],{"nctId":1212,"briefTitle":1213,"status":105,"phases":6073,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":6074,"interventions":6075},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":645,"briefTitle":646,"status":105,"phases":6077,"primaryCompletion":372,"completion":648,"start":649,"enrollment":28,"conditions":6078,"interventions":6079},[91],[33],[593,524,43,652],{"nctId":1228,"briefTitle":1229,"status":105,"phases":6081,"primaryCompletion":236,"completion":1231,"start":290,"enrollment":1232,"conditions":6082,"interventions":6083},[91],[21],[593,1010,1011,594,140,1220,828],{"nctId":4586,"briefTitle":4587,"status":105,"phases":6085,"primaryCompletion":1526,"completion":1526,"start":840,"enrollment":841,"conditions":6086,"interventions":6087},[91],[15],[593,540,595],{"nctId":2578,"briefTitle":2579,"status":312,"phases":6089,"primaryCompletion":547,"completion":618,"start":776,"enrollment":2581,"conditions":6090,"interventions":6091},[91],[27,21,2583,2584,2535,2585],[2538,2587,593,2552,1829,1830,1220,2539,1832],{"nctId":1045,"briefTitle":762,"status":105,"phases":6093,"primaryCompletion":191,"completion":191,"start":1047,"enrollment":201,"conditions":6094,"interventions":6095},[90,91],[1031,15,1049],[593,1051,791,594,540,595],{"nctId":761,"briefTitle":762,"status":105,"phases":6097,"primaryCompletion":764,"completion":754,"start":765,"enrollment":600,"conditions":6098,"interventions":6099},[91],[15],[593,524,594,540,595],{"nctId":2601,"briefTitle":2602,"status":105,"phases":6101,"primaryCompletion":190,"completion":2604,"start":2175,"enrollment":2605,"conditions":6102,"interventions":6103},[91],[2607,2608],[593,2610,1829,1830,1220,1832],{"nctId":1295,"briefTitle":1296,"status":105,"phases":6105,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":6106,"interventions":6107},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"nctId":1846,"briefTitle":1847,"status":105,"phases":6109,"primaryCompletion":200,"completion":754,"start":1849,"enrollment":16,"conditions":6110,"interventions":6111},[91],[21],[593,1010,1219,1162,594,1221,1222],{"trials":6113,"activeCount":123},[6114,6118],{"nctId":1855,"briefTitle":1856,"status":105,"phases":6115,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":1861,"conditions":6116,"interventions":6117},[92],[1863],[1010,1219,1865,1866,1221,594,593,745],{"nctId":1156,"briefTitle":1157,"status":105,"phases":6119,"primaryCompletion":796,"completion":754,"start":134,"enrollment":525,"conditions":6120,"interventions":6121},[92],[1160],[593,791,1162,185],{"trials":6123,"activeCount":123},[],{"trials":6125,"activeCount":123},[],{"intervention":1830,"totalTrials":3366,"cells":6127},{"EARLY_PHASE1":6128,"PHASE1":6130,"PHASE2":6132,"PHASE3":6184,"PHASE4":6190,"NA":6192},{"trials":6129,"activeCount":123},[],{"trials":6131,"activeCount":123},[],{"trials":6133,"activeCount":123},[6134,6138,6144,6148,6152,6156,6160,6164,6168,6176,6180],{"nctId":2521,"briefTitle":2522,"status":105,"phases":6135,"primaryCompletion":648,"completion":755,"start":640,"enrollment":1783,"conditions":6136,"interventions":6137},[91],[2525,2526],[593,2528,1219,1830,2067,1220,1832],{"nctId":6139,"briefTitle":6140,"status":105,"phases":6141,"primaryCompletion":990,"completion":755,"start":568,"enrollment":4470,"conditions":6142,"interventions":6143},"NCT00004857","Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia",[91],[27],[3567,1830],{"nctId":2530,"briefTitle":2531,"status":105,"phases":6145,"primaryCompletion":2533,"completion":360,"start":1140,"enrollment":974,"conditions":6146,"interventions":6147},[91],[27,21,2525,2526,2535,2536],[2538,885,1829,1830,1220,2539,1832,2540],{"nctId":2546,"briefTitle":2547,"status":105,"phases":6149,"primaryCompletion":648,"completion":648,"start":2450,"enrollment":1917,"conditions":6150,"interventions":6151},[91],[2550],[593,2552,1219,1830,1220,1832],{"nctId":3059,"briefTitle":3060,"status":105,"phases":6153,"primaryCompletion":686,"completion":1665,"start":3062,"enrollment":31,"conditions":6154,"interventions":6155},[91],[27],[1219,1830],{"nctId":2578,"briefTitle":2579,"status":312,"phases":6157,"primaryCompletion":547,"completion":618,"start":776,"enrollment":2581,"conditions":6158,"interventions":6159},[91],[27,21,2583,2584,2535,2585],[2538,2587,593,2552,1829,1830,1220,2539,1832],{"nctId":1822,"briefTitle":1823,"status":105,"phases":6161,"primaryCompletion":1825,"completion":1826,"start":755,"enrollment":1805,"conditions":6162,"interventions":6163},[91],[27,21],[1010,1829,1219,1830,1220,1831,1832],{"nctId":1834,"briefTitle":1835,"status":105,"phases":6165,"primaryCompletion":243,"completion":281,"start":1837,"enrollment":1838,"conditions":6166,"interventions":6167},[91],[27],[1010,1830],{"nctId":6169,"briefTitle":6170,"status":105,"phases":6171,"primaryCompletion":1346,"completion":6172,"start":964,"enrollment":31,"conditions":6173,"interventions":6174},"NCT00002779","Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma",[91],"2015-06",[21],[1830,6175],"octreotide acetate",{"nctId":2601,"briefTitle":2602,"status":105,"phases":6177,"primaryCompletion":190,"completion":2604,"start":2175,"enrollment":2605,"conditions":6178,"interventions":6179},[91],[2607,2608],[593,2610,1829,1830,1220,1832],{"nctId":3562,"briefTitle":3563,"status":167,"phases":6181,"primaryCompletion":764,"completion":764,"start":191,"enrollment":123,"conditions":6182,"interventions":6183},[90,91],[27,21,2584,2535,2585],[3567,3568,1830,2067,2539],{"trials":6185,"activeCount":123},[6186],{"nctId":1882,"briefTitle":1883,"status":312,"phases":6187,"primaryCompletion":1885,"completion":1885,"start":535,"enrollment":1763,"conditions":6188,"interventions":6189},[92],[27],[1010,1830],{"trials":6191,"activeCount":123},[],{"trials":6193,"activeCount":123},[],{"intervention":710,"totalTrials":2003,"cells":6195},{"EARLY_PHASE1":6196,"PHASE1":6198,"PHASE2":6200,"PHASE3":6245,"PHASE4":6255,"NA":6257},{"trials":6197,"activeCount":123},[],{"trials":6199,"activeCount":123},[],{"trials":6201,"activeCount":123},[6202,6210,6214,6218,6222,6226,6233,6237,6241],{"nctId":6203,"briefTitle":6204,"status":105,"phases":6205,"primaryCompletion":6206,"completion":6207,"start":696,"enrollment":19,"conditions":6208,"interventions":6209},"NCT01085630","Pemetrexed Disodium\u002FObservation in Treating Patients W\u002F Malignant Pleural Mesothelioma w\u002FOut Progressive Disease After 1st Line Chemotherapy",[91],"2017-07","2021-04-01",[4729],[710],{"nctId":4907,"briefTitle":4908,"status":105,"phases":6211,"primaryCompletion":788,"completion":1665,"start":1018,"enrollment":4910,"conditions":6212,"interventions":6213},[91],[15],[185,710],{"nctId":4957,"briefTitle":4958,"status":105,"phases":6215,"primaryCompletion":134,"completion":675,"start":4960,"enrollment":246,"conditions":6216,"interventions":6217},[91],[18],[185,710],{"nctId":3264,"briefTitle":3265,"status":105,"phases":6219,"primaryCompletion":147,"completion":696,"start":191,"enrollment":160,"conditions":6220,"interventions":6221},[91],[15],[184,710],{"nctId":701,"briefTitle":702,"status":105,"phases":6223,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":6224,"interventions":6225},[91],[15],[524,710],{"nctId":6227,"briefTitle":6228,"status":105,"phases":6229,"primaryCompletion":823,"completion":806,"start":741,"enrollment":6230,"conditions":6231,"interventions":6232},"NCT00454194","Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],110,[15],[710,3234],{"nctId":4985,"briefTitle":4986,"status":105,"phases":6234,"primaryCompletion":674,"completion":133,"start":2175,"enrollment":1805,"conditions":6235,"interventions":6236},[90,91],[1275,1276,1277],[185,710],{"nctId":802,"briefTitle":803,"status":105,"phases":6238,"primaryCompletion":805,"completion":806,"start":576,"enrollment":600,"conditions":6239,"interventions":6240},[91],[15],[184,524,710],{"nctId":810,"briefTitle":811,"status":105,"phases":6242,"primaryCompletion":813,"completion":814,"start":815,"enrollment":816,"conditions":6243,"interventions":6244},[91],[15],[205,524,710],{"trials":6246,"activeCount":123},[6247,6251],{"nctId":1172,"briefTitle":1173,"status":312,"phases":6248,"primaryCompletion":999,"completion":824,"start":813,"enrollment":31,"conditions":6249,"interventions":6250},[92],[15],[791,43,185,710,1177],{"nctId":932,"briefTitle":933,"status":312,"phases":6252,"primaryCompletion":935,"completion":235,"start":755,"enrollment":936,"conditions":6253,"interventions":6254},[92],[15],[524,285,185,710],{"trials":6256,"activeCount":123},[],{"trials":6258,"activeCount":123},[],{"intervention":3825,"totalTrials":2581,"cells":6260},{"EARLY_PHASE1":6261,"PHASE1":6263,"PHASE2":6265,"PHASE3":6286,"PHASE4":6304,"NA":6306},{"trials":6262,"activeCount":123},[],{"trials":6264,"activeCount":123},[],{"trials":6266,"activeCount":123},[6267,6275,6279],{"nctId":6268,"briefTitle":6269,"status":105,"phases":6270,"primaryCompletion":618,"completion":6271,"start":1298,"enrollment":1974,"conditions":6272,"interventions":6273},"NCT01105312","Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer",[90,91],"2013-09-03",[18],[3825,6274,5842,5809,5820],"panobinostat",{"nctId":3622,"briefTitle":3623,"status":105,"phases":6276,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":1020,"conditions":6277,"interventions":6278},[91],[3629,3630,3631],[3633,3634,3635],{"nctId":6280,"briefTitle":6281,"status":105,"phases":6282,"primaryCompletion":6283,"completion":2682,"start":5786,"enrollment":12,"conditions":6284,"interventions":6285},"NCT01439711","Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ",[91],"2016-08",[18],[3825],{"trials":6287,"activeCount":123},[6288,6292,6300],{"nctId":3794,"briefTitle":3795,"status":2755,"phases":6289,"primaryCompletion":3797,"completion":3798,"start":3799,"enrollment":3800,"conditions":6290,"interventions":6291},[92],[3802,3803,3804,3805,3806],[3808,3634,3809,3810,3811],{"nctId":6293,"briefTitle":6294,"status":105,"phases":6295,"primaryCompletion":4749,"completion":169,"start":157,"enrollment":6296,"conditions":6297,"interventions":6299},"NCT00107263","Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer",[92],558,[18,6298],"Osteoporosis",[3825,2007],{"nctId":3817,"briefTitle":3818,"status":105,"phases":6301,"primaryCompletion":169,"completion":3820,"start":859,"enrollment":3821,"conditions":6302,"interventions":6303},[92],[18],[3659,3824,3825],{"trials":6305,"activeCount":123},[],{"trials":6307,"activeCount":123},[],{"intervention":285,"totalTrials":430,"cells":6309},{"EARLY_PHASE1":6310,"PHASE1":6312,"PHASE2":6314,"PHASE3":6331,"PHASE4":6341,"NA":6343},{"trials":6311,"activeCount":123},[],{"trials":6313,"activeCount":123},[],{"trials":6315,"activeCount":123},[6316,6320,6327],{"nctId":554,"briefTitle":555,"status":105,"phases":6317,"primaryCompletion":371,"completion":557,"start":372,"enrollment":558,"conditions":6318,"interventions":6319},[91],[15],[524,285,185,561],{"nctId":6321,"briefTitle":6322,"status":312,"phases":6323,"primaryCompletion":676,"completion":236,"start":1601,"enrollment":1727,"conditions":6324,"interventions":6325},"NCT00045591","Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer",[91],[18],[285,6326],"Celecoxib",{"nctId":4736,"briefTitle":4737,"status":312,"phases":6328,"primaryCompletion":706,"completion":179,"start":200,"enrollment":459,"conditions":6329,"interventions":6330},[91],[24],[121,285],{"trials":6332,"activeCount":123},[6333,6337],{"nctId":276,"briefTitle":277,"status":105,"phases":6334,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":6335,"interventions":6336},[92],[24],[285,120,97,119],{"nctId":932,"briefTitle":933,"status":312,"phases":6338,"primaryCompletion":935,"completion":235,"start":755,"enrollment":936,"conditions":6339,"interventions":6340},[92],[15],[524,285,185,710],{"trials":6342,"activeCount":123},[],{"trials":6344,"activeCount":123},[],{"intervention":1177,"totalTrials":430,"cells":6346},{"EARLY_PHASE1":6347,"PHASE1":6349,"PHASE2":6351,"PHASE3":6373,"PHASE4":6379,"NA":6381},{"trials":6348,"activeCount":123},[],{"trials":6350,"activeCount":123},[],{"trials":6352,"activeCount":123},[6353,6359,6363,6369],{"nctId":6354,"briefTitle":6355,"status":105,"phases":6356,"primaryCompletion":589,"completion":3240,"start":640,"enrollment":98,"conditions":6357,"interventions":6358},"NCT00022152","Vinorelbine in Treating Older Women With Stage IV Breast Cancer",[91],[18],[1177],{"nctId":3444,"briefTitle":3445,"status":105,"phases":6360,"primaryCompletion":576,"completion":806,"start":732,"enrollment":1232,"conditions":6361,"interventions":6362},[91],[18],[669,121,1177],{"nctId":6364,"briefTitle":6365,"status":105,"phases":6366,"primaryCompletion":134,"completion":685,"start":1283,"enrollment":246,"conditions":6367,"interventions":6368},"NCT00008333","Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",[91],[15],[1177],{"nctId":5037,"briefTitle":5038,"status":105,"phases":6370,"primaryCompletion":674,"completion":674,"start":1346,"enrollment":5040,"conditions":6371,"interventions":6372},[90,91],[21],[185,5043,1177],{"trials":6374,"activeCount":123},[6375],{"nctId":1172,"briefTitle":1173,"status":312,"phases":6376,"primaryCompletion":999,"completion":824,"start":813,"enrollment":31,"conditions":6377,"interventions":6378},[92],[15],[791,43,185,710,1177],{"trials":6380,"activeCount":123},[],{"trials":6382,"activeCount":123},[],{"intervention":1708,"totalTrials":430,"cells":6384},{"EARLY_PHASE1":6385,"PHASE1":6387,"PHASE2":6411,"PHASE3":6417,"PHASE4":6423,"NA":6425},{"trials":6386,"activeCount":123},[],{"trials":6388,"activeCount":123},[6389,6400,6404],{"nctId":6390,"briefTitle":6391,"status":105,"phases":6392,"primaryCompletion":6393,"completion":6394,"start":6395,"enrollment":1602,"conditions":6396,"interventions":6398},"NCT01838434","Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",[90],"2014-09-30","2017-05","2013-07",[6397],"Relapsed\u002FRefractory Mantle Cell Lymphoma",[1708,6399],"idelalisib",{"nctId":1699,"briefTitle":1700,"status":105,"phases":6401,"primaryCompletion":314,"completion":1702,"start":1703,"enrollment":953,"conditions":6402,"interventions":6403},[90],[1705],[1010,1707,1708],{"nctId":6405,"briefTitle":6406,"status":105,"phases":6407,"primaryCompletion":5904,"completion":6394,"start":6395,"enrollment":5224,"conditions":6408,"interventions":6410},"NCT01644799","Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma",[90],[6409],"Recurrent Follicular Lymphoma",[6399,1708],{"trials":6412,"activeCount":123},[6413],{"nctId":1771,"briefTitle":1772,"status":105,"phases":6414,"primaryCompletion":1063,"completion":1774,"start":589,"enrollment":1775,"conditions":6415,"interventions":6416},[91],[21],[1010,1708],{"trials":6418,"activeCount":123},[6419],{"nctId":1998,"briefTitle":1999,"status":925,"phases":6420,"primaryCompletion":2001,"start":2002,"enrollment":2003,"conditions":6421,"interventions":6422},[92],[2005],[1949,1708,1012,2007],{"trials":6424,"activeCount":123},[],{"trials":6426,"activeCount":123},[],{"intervention":2007,"totalTrials":430,"cells":6428},{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6433,"PHASE3":6435,"PHASE4":6475,"NA":6477},{"trials":6430,"activeCount":123},[],{"trials":6432,"activeCount":123},[],{"trials":6434,"activeCount":123},[],{"trials":6436,"activeCount":123},[6437,6444,6454,6458,6462],{"nctId":6438,"briefTitle":6439,"status":105,"phases":6440,"primaryCompletion":4749,"completion":778,"start":3511,"enrollment":6441,"conditions":6442,"interventions":6443},"NCT00022087","Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer",[92],439,[18,6298],[2007],{"nctId":6445,"briefTitle":6446,"status":105,"phases":6447,"primaryCompletion":6448,"completion":1299,"start":2175,"enrollment":6449,"conditions":6450,"interventions":6451},"NCT00079001","Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases",[92],"2012-07",645,[203,33],[2007,6452,6453],"androgen deprivation therapy","GnRH agonist",{"nctId":1998,"briefTitle":1999,"status":925,"phases":6455,"primaryCompletion":2001,"start":2002,"enrollment":2003,"conditions":6456,"interventions":6457},[92],[2005],[1949,1708,1012,2007],{"nctId":6293,"briefTitle":6294,"status":105,"phases":6459,"primaryCompletion":4749,"completion":169,"start":157,"enrollment":6296,"conditions":6460,"interventions":6461},[92],[18,6298],[3825,2007],{"nctId":6463,"briefTitle":6464,"status":105,"phases":6465,"primaryCompletion":3118,"completion":545,"start":813,"enrollment":6466,"conditions":6467,"interventions":6474},"NCT00869206","Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",[92],1822,[6468,6469,6470,6471,907,6472,6473],"Breast Adenocarcinoma","DS Stage I Plasma Cell Myeloma","DS Stage II Plasma Cell Myeloma","Metastatic Malignant Neoplasm to the Bone","Musculoskeletal Complication","Urinary Complications",[2007],{"trials":6476,"activeCount":123},[],{"trials":6478,"activeCount":123},[],{"intervention":119,"totalTrials":459,"cells":6480},{"EARLY_PHASE1":6481,"PHASE1":6487,"PHASE2":6489,"PHASE3":6491,"PHASE4":6501,"NA":6503},{"trials":6482,"activeCount":123},[6483],{"nctId":103,"briefTitle":104,"status":105,"phases":6484,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":6485,"interventions":6486},[89],[112,113,114,115,116],[97,118,119,120,121,122],{"trials":6488,"activeCount":123},[],{"trials":6490,"activeCount":123},[],{"trials":6492,"activeCount":123},[6493,6497],{"nctId":276,"briefTitle":277,"status":105,"phases":6494,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":6495,"interventions":6496},[92],[24],[285,120,97,119],{"nctId":368,"briefTitle":369,"status":312,"phases":6498,"primaryCompletion":371,"completion":281,"start":372,"enrollment":373,"conditions":6499,"interventions":6500},[92],[24],[205,376,118,119,97],{"trials":6502,"activeCount":123},[],{"trials":6504,"activeCount":123},[],{"intervention":6175,"totalTrials":459,"cells":6506},{"EARLY_PHASE1":6507,"PHASE1":6509,"PHASE2":6511,"PHASE3":6517,"PHASE4":6541,"NA":6543},{"trials":6508,"activeCount":123},[],{"trials":6510,"activeCount":123},[],{"trials":6512,"activeCount":123},[6513],{"nctId":6169,"briefTitle":6170,"status":105,"phases":6514,"primaryCompletion":1346,"completion":6172,"start":964,"enrollment":31,"conditions":6515,"interventions":6516},[91],[21],[1830,6175],{"trials":6518,"activeCount":123},[6519,6526],{"nctId":6520,"briefTitle":6521,"status":105,"phases":6522,"primaryCompletion":619,"completion":300,"start":6523,"enrollment":148,"conditions":6524,"interventions":6525},"NCT00182754","Octreotide in Treating Patients With Cancer-Related Malignant Ascites",[92],"2005-10",[203,30],[6175],{"nctId":6527,"briefTitle":6528,"status":105,"phases":6529,"primaryCompletion":1028,"completion":1028,"start":1345,"enrollment":6530,"conditions":6531,"interventions":6540},"NCT00033605","Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis",[92],130,[6532,24,6533,6534,6535,6536,33,6537,30,6538,6539],"Cervical Cancer","Diarrhea","Endometrial Cancer","Fallopian Tube Cancer","Ovarian Cancer","Sarcoma","Vaginal Cancer","Vulvar Cancer",[6175],{"trials":6542,"activeCount":123},[],{"trials":6544,"activeCount":123},[],{"intervention":3810,"totalTrials":459,"cells":6546},{"EARLY_PHASE1":6547,"PHASE1":6549,"PHASE2":6551,"PHASE3":6562,"PHASE4":6572,"NA":6574},{"trials":6548,"activeCount":123},[],{"trials":6550,"activeCount":123},[],{"trials":6552,"activeCount":123},[6553],{"nctId":6554,"briefTitle":6555,"status":105,"phases":6556,"primaryCompletion":567,"completion":6557,"start":849,"enrollment":6558,"conditions":6559,"interventions":6561},"NCT00031720","Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease",[91],"2013-11",112,[18,3500,6560],"Hot Flushes",[3810],{"trials":6563,"activeCount":123},[6564,6568],{"nctId":3794,"briefTitle":3795,"status":2755,"phases":6565,"primaryCompletion":3797,"completion":3798,"start":3799,"enrollment":3800,"conditions":6566,"interventions":6567},[92],[3802,3803,3804,3805,3806],[3808,3634,3809,3810,3811],{"nctId":3472,"briefTitle":3473,"status":167,"phases":6569,"enrollment":123,"conditions":6570,"interventions":6571},[92],[3476,3477],[3479,669],{"trials":6573,"activeCount":123},[],{"trials":6575,"activeCount":123},[],{"intervention":2654,"totalTrials":459,"cells":6577},{"EARLY_PHASE1":6578,"PHASE1":6580,"PHASE2":6582,"PHASE3":6598,"PHASE4":6610,"NA":6612},{"trials":6579,"activeCount":123},[],{"trials":6581,"activeCount":123},[],{"trials":6583,"activeCount":123},[6584,6588],{"nctId":2644,"briefTitle":2645,"status":105,"phases":6585,"primaryCompletion":2647,"completion":973,"start":2648,"enrollment":2649,"conditions":6586,"interventions":6587},[91],[36],[205,2652,2653,2654],{"nctId":6589,"briefTitle":6590,"status":925,"phases":6591,"primaryCompletion":6592,"start":1139,"enrollment":6593,"conditions":6594,"interventions":6596},"NCT02839343","Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer",[91],"2020-11-30",126,[1118,6595],"Borderline Resectable Adenocarcinoma of the Head of the Pancrease",[6597,2654],"mFOLFIRINOX",{"trials":6599,"activeCount":123},[6600],{"nctId":6601,"briefTitle":6602,"status":925,"phases":6603,"primaryCompletion":6604,"completion":6605,"start":6606,"enrollment":6607,"conditions":6608,"interventions":6609},"NCT01515787","PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery",[91,92],"2022-12-31","2024-06-30","2012-06-12",1194,[24],[2654],{"trials":6611,"activeCount":123},[],{"trials":6613,"activeCount":123},[],{"intervention":6615,"totalTrials":852,"cells":6616},"risedronate sodium",{"EARLY_PHASE1":6617,"PHASE1":6619,"PHASE2":6621,"PHASE3":6623,"PHASE4":6640,"NA":6642},{"trials":6618,"activeCount":123},[],{"trials":6620,"activeCount":123},[],{"trials":6622,"activeCount":123},[],{"trials":6624,"activeCount":123},[6625,6633],{"nctId":6626,"briefTitle":6627,"status":105,"phases":6628,"primaryCompletion":648,"completion":236,"start":1581,"enrollment":6629,"conditions":6630,"interventions":6631},"NCT00043069","Calcium With or Without Estrogen and\u002For Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer",[92],71,[6298,33],[6632,6615],"Estrogen Antagonists",{"nctId":6634,"briefTitle":6635,"status":105,"phases":6636,"primaryCompletion":1762,"completion":675,"start":990,"enrollment":6637,"conditions":6638,"interventions":6639},"NCT00054418","Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer",[92],216,[18,6298],[6615],{"trials":6641,"activeCount":123},[],{"trials":6643,"activeCount":123},[],{"intervention":6645,"totalTrials":852,"cells":6646},"epoetin alfa",{"EARLY_PHASE1":6647,"PHASE1":6649,"PHASE2":6651,"PHASE3":6653,"PHASE4":6673,"NA":6675},{"trials":6648,"activeCount":123},[],{"trials":6650,"activeCount":123},[],{"trials":6652,"activeCount":123},[],{"trials":6654,"activeCount":123},[6655,6663],{"nctId":6656,"briefTitle":6657,"status":105,"phases":6658,"primaryCompletion":191,"completion":191,"start":244,"enrollment":6659,"conditions":6660,"interventions":6662},"NCT00058331","Epoetin Alfa in Treating Anemia in Patients With Solid Tumors",[92],365,[1030,27,21,2583,2584,6661,30],"Precancerous Condition",[6645],{"nctId":6664,"briefTitle":6665,"status":105,"phases":6666,"primaryCompletion":3511,"completion":236,"start":6667,"enrollment":6668,"conditions":6669,"interventions":6672},"NCT00003600","Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy",[92],"1998-12",344,[1030,18,6670,1031,27,15,21,2584,6661,6671,30],"Chronic Myeloproliferative Disorders","Small Intestine Cancer",[6645],{"trials":6674,"activeCount":123},[],{"trials":6676,"activeCount":123},[],{"intervention":1144,"totalTrials":852,"cells":6678},{"EARLY_PHASE1":6679,"PHASE1":6681,"PHASE2":6683,"PHASE3":6689,"PHASE4":6695,"NA":6697},{"trials":6680,"activeCount":123},[],{"trials":6682,"activeCount":123},[],{"trials":6684,"activeCount":123},[6685],{"nctId":4897,"briefTitle":4898,"status":105,"phases":6686,"primaryCompletion":732,"completion":675,"start":1207,"enrollment":537,"conditions":6687,"interventions":6688},[91],[4729],[1144,185],{"trials":6690,"activeCount":123},[6691],{"nctId":1136,"briefTitle":1137,"status":105,"phases":6692,"primaryCompletion":1063,"completion":1139,"start":1140,"enrollment":1141,"conditions":6693,"interventions":6694},[92],[36,162],[791,1144,138,140],{"trials":6696,"activeCount":123},[],{"trials":6698,"activeCount":123},[],{"intervention":307,"totalTrials":852,"cells":6700},{"EARLY_PHASE1":6701,"PHASE1":6703,"PHASE2":6705,"PHASE3":6707,"PHASE4":6719,"NA":6721},{"trials":6702,"activeCount":123},[],{"trials":6704,"activeCount":123},[],{"trials":6706,"activeCount":123},[],{"trials":6708,"activeCount":123},[6709,6715],{"nctId":6710,"briefTitle":6711,"status":105,"phases":6712,"primaryCompletion":535,"completion":824,"start":859,"enrollment":1838,"conditions":6713,"interventions":6714},"NCT00316914","Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery",[92],[24,305],[307,308],{"nctId":296,"briefTitle":297,"status":105,"phases":6716,"primaryCompletion":299,"completion":300,"start":281,"enrollment":301,"conditions":6717,"interventions":6718},[92],[303,24,304,305],[307,308,97],{"trials":6720,"activeCount":123},[],{"trials":6722,"activeCount":123},[],{"intervention":308,"totalTrials":852,"cells":6724},{"EARLY_PHASE1":6725,"PHASE1":6727,"PHASE2":6729,"PHASE3":6731,"PHASE4":6741,"NA":6743},{"trials":6726,"activeCount":123},[],{"trials":6728,"activeCount":123},[],{"trials":6730,"activeCount":123},[],{"trials":6732,"activeCount":123},[6733,6737],{"nctId":6710,"briefTitle":6711,"status":105,"phases":6734,"primaryCompletion":535,"completion":824,"start":859,"enrollment":1838,"conditions":6735,"interventions":6736},[92],[24,305],[307,308],{"nctId":296,"briefTitle":297,"status":105,"phases":6738,"primaryCompletion":299,"completion":300,"start":281,"enrollment":301,"conditions":6739,"interventions":6740},[92],[303,24,304,305],[307,308,97],{"trials":6742,"activeCount":123},[],{"trials":6744,"activeCount":123},[],{"intervention":1154,"totalTrials":852,"cells":6746},{"EARLY_PHASE1":6747,"PHASE1":6749,"PHASE2":6751,"PHASE3":6757,"PHASE4":6763,"NA":6765},{"trials":6748,"activeCount":123},[],{"trials":6750,"activeCount":123},[],{"trials":6752,"activeCount":123},[6753],{"nctId":4964,"briefTitle":4965,"status":105,"phases":6754,"primaryCompletion":4749,"completion":557,"start":1617,"enrollment":1838,"conditions":6755,"interventions":6756},[91],[21],[1162,185,1154],{"trials":6758,"activeCount":123},[6759],{"nctId":1146,"briefTitle":1147,"status":312,"phases":6760,"primaryCompletion":132,"completion":132,"start":1149,"enrollment":272,"conditions":6761,"interventions":6762},[92],[1151,1152],[791,883,540,1154],{"trials":6764,"activeCount":123},[],{"trials":6766,"activeCount":123},[],{"intervention":3809,"totalTrials":852,"cells":6768},{"EARLY_PHASE1":6769,"PHASE1":6771,"PHASE2":6773,"PHASE3":6775,"PHASE4":6785,"NA":6787},{"trials":6770,"activeCount":123},[],{"trials":6772,"activeCount":123},[],{"trials":6774,"activeCount":123},[],{"trials":6776,"activeCount":123},[6777,6781],{"nctId":3794,"briefTitle":3795,"status":2755,"phases":6778,"primaryCompletion":3797,"completion":3798,"start":3799,"enrollment":3800,"conditions":6779,"interventions":6780},[92],[3802,3803,3804,3805,3806],[3808,3634,3809,3810,3811],{"nctId":3817,"briefTitle":3818,"status":105,"phases":6782,"primaryCompletion":169,"completion":3820,"start":859,"enrollment":3821,"conditions":6783,"interventions":6784},[92],[18],[3659,3824,3825],{"trials":6786,"activeCount":123},[],{"trials":6788,"activeCount":123},[],{"intervention":6790,"totalTrials":852,"cells":6791},"aspirin",{"EARLY_PHASE1":6792,"PHASE1":6794,"PHASE2":6796,"PHASE3":6798,"PHASE4":6820,"NA":6822},{"trials":6793,"activeCount":123},[],{"trials":6795,"activeCount":123},[],{"trials":6797,"activeCount":123},[],{"trials":6799,"activeCount":123},[6800,6808],{"nctId":6801,"briefTitle":6802,"status":105,"phases":6803,"primaryCompletion":990,"completion":859,"start":6804,"enrollment":6805,"conditions":6806,"interventions":6807},"NCT00002527","Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed",[92],"1993-05",635,[24],[6790],{"nctId":6809,"briefTitle":6810,"status":312,"phases":6811,"primaryCompletion":6812,"completion":6813,"start":6814,"enrollment":6815,"conditions":6816,"interventions":6818},"NCT02927249","Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and\u002For Radiation Therapy",[92],"2021-12-13","2023-02-15","2016-12-08",3021,[6817],"Node Positive HER2 Negative Breast Cancer",[6819],"Aspirin",{"trials":6821,"activeCount":123},[],{"trials":6823,"activeCount":123},[],{"intervention":1949,"totalTrials":852,"cells":6825},{"EARLY_PHASE1":6826,"PHASE1":6828,"PHASE2":6830,"PHASE3":6836,"PHASE4":6842,"NA":6844},{"trials":6827,"activeCount":123},[],{"trials":6829,"activeCount":123},[],{"trials":6831,"activeCount":123},[6832],{"nctId":1939,"briefTitle":1940,"status":925,"phases":6833,"primaryCompletion":1942,"start":1943,"enrollment":1944,"conditions":6834,"interventions":6835},[90,91],[1946],[1948,1949,1012],{"trials":6837,"activeCount":123},[6838],{"nctId":1998,"briefTitle":1999,"status":925,"phases":6839,"primaryCompletion":2001,"start":2002,"enrollment":2003,"conditions":6840,"interventions":6841},[92],[2005],[1949,1708,1012,2007],{"trials":6843,"activeCount":123},[],{"trials":6845,"activeCount":123},[],{"intervention":1244,"totalTrials":852,"cells":6847},{"EARLY_PHASE1":6848,"PHASE1":6850,"PHASE2":6852,"PHASE3":6858,"PHASE4":6869,"NA":6871},{"trials":6849,"activeCount":123},[],{"trials":6851,"activeCount":123},[],{"trials":6853,"activeCount":123},[6854],{"nctId":1236,"briefTitle":1237,"status":105,"phases":6855,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":6856,"interventions":6857},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"trials":6859,"activeCount":123},[6860],{"nctId":6861,"briefTitle":6862,"status":105,"phases":6863,"primaryCompletion":134,"completion":754,"start":6864,"enrollment":6865,"conditions":6866,"interventions":6867},"NCT00002760","Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer",[92],"1996-08",260,[33],[6868,1244],"ketoconazole",{"trials":6870,"activeCount":123},[],{"trials":6872,"activeCount":123},[],{"intervention":376,"totalTrials":852,"cells":6874},{"EARLY_PHASE1":6875,"PHASE1":6877,"PHASE2":6879,"PHASE3":6885,"PHASE4":6891,"NA":6893},{"trials":6876,"activeCount":123},[],{"trials":6878,"activeCount":123},[],{"trials":6880,"activeCount":123},[6881],{"nctId":1585,"briefTitle":1586,"status":312,"phases":6882,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":430,"conditions":6883,"interventions":6884},[91],[224,1591,162],[376,121,43,271],{"trials":6886,"activeCount":123},[6887],{"nctId":368,"briefTitle":369,"status":312,"phases":6888,"primaryCompletion":371,"completion":281,"start":372,"enrollment":373,"conditions":6889,"interventions":6890},[92],[24],[205,376,118,119,97],{"trials":6892,"activeCount":123},[],{"trials":6894,"activeCount":123},[],{"intervention":1336,"totalTrials":852,"cells":6896},{"EARLY_PHASE1":6897,"PHASE1":6899,"PHASE2":6901,"PHASE3":6907,"PHASE4":6913,"NA":6915},{"trials":6898,"activeCount":123},[],{"trials":6900,"activeCount":123},[],{"trials":6902,"activeCount":123},[6903],{"nctId":2474,"briefTitle":2475,"status":105,"phases":6904,"primaryCompletion":200,"completion":200,"start":2477,"enrollment":2478,"conditions":6905,"interventions":6906},[91],[24,203],[1336,139],{"trials":6908,"activeCount":123},[6909],{"nctId":1330,"briefTitle":208,"status":105,"phases":6910,"primaryCompletion":589,"completion":178,"start":1332,"enrollment":1333,"conditions":6911,"interventions":6912},[92],[24,203],[1012,1336,138,140],{"trials":6914,"activeCount":123},[],{"trials":6916,"activeCount":123},[],{"intervention":6918,"totalTrials":852,"cells":6919},"palonosetron hydrochloride",{"EARLY_PHASE1":6920,"PHASE1":6922,"PHASE2":6924,"PHASE3":6936,"PHASE4":6942,"NA":6944},{"trials":6921,"activeCount":123},[],{"trials":6923,"activeCount":123},[],{"trials":6925,"activeCount":123},[6926],{"nctId":6927,"briefTitle":6928,"status":312,"phases":6929,"primaryCompletion":315,"completion":806,"start":619,"enrollment":2221,"conditions":6930,"interventions":6935},"NCT00903396","Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer",[91],[6931,6932,24,1275,1276,162,6933,1277,1994,171,6934,6671],"Anal Cancer","Carcinoma of the Appendix","Gastrointestinal Carcinoid Tumor","Primary Peritoneal Cavity Cancer",[6918],{"trials":6937,"activeCount":123},[6938],{"nctId":2024,"briefTitle":2025,"status":105,"phases":6939,"primaryCompletion":2027,"completion":2028,"start":2029,"enrollment":2030,"conditions":6940,"interventions":6941},[92],[2020],[2033,2034,1812,2035,2036],{"trials":6943,"activeCount":123},[],{"trials":6945,"activeCount":123},[],{"intervention":2298,"totalTrials":272,"cells":6947},{"EARLY_PHASE1":6948,"PHASE1":6950,"PHASE2":6952,"PHASE3":6954,"PHASE4":6960,"NA":6962},{"trials":6949,"activeCount":123},[],{"trials":6951,"activeCount":123},[],{"trials":6953,"activeCount":123},[],{"trials":6955,"activeCount":123},[6956],{"nctId":2285,"briefTitle":2286,"status":925,"phases":6957,"primaryCompletion":2288,"completion":2289,"start":2290,"enrollment":2291,"conditions":6958,"interventions":6959},[92],[2293,2294,2295,2296],[48,2298,1221],{"trials":6961,"activeCount":123},[],{"trials":6963,"activeCount":123},[],{"intervention":6965,"totalTrials":272,"cells":6966},"prasterone",{"EARLY_PHASE1":6967,"PHASE1":6969,"PHASE2":6971,"PHASE3":6973,"PHASE4":6984,"NA":6986},{"trials":6968,"activeCount":123},[],{"trials":6970,"activeCount":123},[],{"trials":6972,"activeCount":123},[],{"trials":6974,"activeCount":123},[6975],{"nctId":6976,"briefTitle":6977,"status":105,"phases":6978,"primaryCompletion":618,"completion":6979,"start":221,"enrollment":6980,"conditions":6981,"interventions":6983},"NCT01376349","Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms",[92],"2017-11",464,[18,6982],"Gynecologic Cancer",[6965],{"trials":6985,"activeCount":123},[],{"trials":6987,"activeCount":123},[],{"intervention":6989,"totalTrials":272,"cells":6990},"citalopram hydrobromide",{"EARLY_PHASE1":6991,"PHASE1":6993,"PHASE2":6995,"PHASE3":6997,"PHASE4":7007,"NA":7009},{"trials":6992,"activeCount":123},[],{"trials":6994,"activeCount":123},[],{"trials":6996,"activeCount":123},[],{"trials":6998,"activeCount":123},[6999],{"nctId":7000,"briefTitle":7001,"status":105,"phases":7002,"primaryCompletion":756,"completion":776,"start":2533,"enrollment":7003,"conditions":7004,"interventions":7006},"NCT00363909","Citalopram in Treating Postmenopausal Women With Hot Flashes",[92],254,[18,3500,7005],"Psychosocial Effects of Cancer and Its Treatment",[6989],{"trials":7008,"activeCount":123},[],{"trials":7010,"activeCount":123},[],{"intervention":7012,"totalTrials":272,"cells":7013},"lidocaine",{"EARLY_PHASE1":7014,"PHASE1":7016,"PHASE2":7018,"PHASE3":7020,"PHASE4":7028,"NA":7030},{"trials":7015,"activeCount":123},[],{"trials":7017,"activeCount":123},[],{"trials":7019,"activeCount":123},[],{"trials":7021,"activeCount":123},[7022],{"nctId":7023,"briefTitle":7024,"status":105,"phases":7025,"primaryCompletion":1028,"completion":685,"start":1617,"enrollment":779,"conditions":7026,"interventions":7027},"NCT00058357","Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery",[92],[907,30],[7012],{"trials":7029,"activeCount":123},[],{"trials":7031,"activeCount":123},[],{"intervention":1638,"totalTrials":272,"cells":7033},{"EARLY_PHASE1":7034,"PHASE1":7036,"PHASE2":7038,"PHASE3":7040,"PHASE4":7046,"NA":7048},{"trials":7035,"activeCount":123},[],{"trials":7037,"activeCount":123},[],{"trials":7039,"activeCount":123},[],{"trials":7041,"activeCount":123},[7042],{"nctId":1629,"briefTitle":1630,"status":167,"phases":7043,"enrollment":123,"conditions":7044,"interventions":7045},[92],[1633,18,1537,1634,1635,1636],[1638,43],{"trials":7047,"activeCount":123},[],{"trials":7049,"activeCount":123},[],{"intervention":6632,"totalTrials":272,"cells":7051},{"EARLY_PHASE1":7052,"PHASE1":7054,"PHASE2":7056,"PHASE3":7058,"PHASE4":7064,"NA":7066},{"trials":7053,"activeCount":123},[],{"trials":7055,"activeCount":123},[],{"trials":7057,"activeCount":123},[],{"trials":7059,"activeCount":123},[7060],{"nctId":6626,"briefTitle":6627,"status":105,"phases":7061,"primaryCompletion":648,"completion":236,"start":1581,"enrollment":6629,"conditions":7062,"interventions":7063},[92],[6298,33],[6632,6615],{"trials":7065,"activeCount":123},[],{"trials":7067,"activeCount":123},[],{"intervention":3195,"totalTrials":272,"cells":7069},{"EARLY_PHASE1":7070,"PHASE1":7072,"PHASE2":7074,"PHASE3":7076,"PHASE4":7082,"NA":7084},{"trials":7071,"activeCount":123},[],{"trials":7073,"activeCount":123},[],{"trials":7075,"activeCount":123},[],{"trials":7077,"activeCount":123},[7078],{"nctId":3186,"briefTitle":3187,"status":105,"phases":7079,"primaryCompletion":3189,"completion":609,"start":3190,"enrollment":3191,"conditions":7080,"interventions":7081},[92],[3193,1994,30],[2036,3170,3195],{"trials":7083,"activeCount":123},[],{"trials":7085,"activeCount":123},[],{"intervention":3502,"totalTrials":272,"cells":7087},{"EARLY_PHASE1":7088,"PHASE1":7090,"PHASE2":7092,"PHASE3":7094,"PHASE4":7100,"NA":7102},{"trials":7089,"activeCount":123},[],{"trials":7091,"activeCount":123},[],{"trials":7093,"activeCount":123},[],{"trials":7095,"activeCount":123},[7096],{"nctId":3495,"briefTitle":3496,"status":105,"phases":7097,"primaryCompletion":1762,"completion":1762,"start":3498,"enrollment":1944,"conditions":7098,"interventions":7099},[92],[18,3500],[1996,3502],{"trials":7101,"activeCount":123},[],{"trials":7103,"activeCount":123},[],{"intervention":7105,"totalTrials":272,"cells":7106},"dalteparin",{"EARLY_PHASE1":7107,"PHASE1":7109,"PHASE2":7111,"PHASE3":7113,"PHASE4":7124,"NA":7126},{"trials":7108,"activeCount":123},[],{"trials":7110,"activeCount":123},[],{"trials":7112,"activeCount":123},[],{"trials":7114,"activeCount":123},[7115],{"nctId":7116,"briefTitle":7117,"status":105,"phases":7118,"primaryCompletion":1149,"completion":1149,"start":6667,"enrollment":7119,"conditions":7120,"interventions":7122},"NCT00003674","Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer",[92],141,[18,24,15,33,7121],"Veno-occlusive Disease",[7105,7123],"standard therapy",{"trials":7125,"activeCount":123},[],{"trials":7127,"activeCount":123},[],{"intervention":7123,"totalTrials":272,"cells":7129},{"EARLY_PHASE1":7130,"PHASE1":7132,"PHASE2":7134,"PHASE3":7136,"PHASE4":7142,"NA":7144},{"trials":7131,"activeCount":123},[],{"trials":7133,"activeCount":123},[],{"trials":7135,"activeCount":123},[],{"trials":7137,"activeCount":123},[7138],{"nctId":7116,"briefTitle":7117,"status":105,"phases":7139,"primaryCompletion":1149,"completion":1149,"start":6667,"enrollment":7119,"conditions":7140,"interventions":7141},[92],[18,24,15,33,7121],[7105,7123],{"trials":7143,"activeCount":123},[],{"trials":7145,"activeCount":123},[],{"intervention":7147,"totalTrials":272,"cells":7148},"hydroxyurea",{"EARLY_PHASE1":7149,"PHASE1":7151,"PHASE2":7153,"PHASE3":7155,"PHASE4":7164,"NA":7166},{"trials":7150,"activeCount":123},[],{"trials":7152,"activeCount":123},[],{"trials":7154,"activeCount":123},[],{"trials":7156,"activeCount":123},[7157],{"nctId":7158,"briefTitle":7159,"status":312,"phases":7160,"primaryCompletion":686,"completion":686,"start":568,"enrollment":430,"conditions":7161,"interventions":7162},"NCT00004933","Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",[92],[27],[7147,7163],"Homoharringtonine",{"trials":7165,"activeCount":123},[],{"trials":7167,"activeCount":123},[],{"intervention":7163,"totalTrials":272,"cells":7169},{"EARLY_PHASE1":7170,"PHASE1":7172,"PHASE2":7174,"PHASE3":7176,"PHASE4":7182,"NA":7184},{"trials":7171,"activeCount":123},[],{"trials":7173,"activeCount":123},[],{"trials":7175,"activeCount":123},[],{"trials":7177,"activeCount":123},[7178],{"nctId":7158,"briefTitle":7159,"status":312,"phases":7179,"primaryCompletion":686,"completion":686,"start":568,"enrollment":430,"conditions":7180,"interventions":7181},[92],[27],[7147,7163],{"trials":7183,"activeCount":123},[],{"trials":7185,"activeCount":123},[],{"intervention":7187,"totalTrials":272,"cells":7188},"doxepin hydrochloride oral solution",{"EARLY_PHASE1":7189,"PHASE1":7191,"PHASE2":7193,"PHASE3":7195,"PHASE4":7208,"NA":7210},{"trials":7190,"activeCount":123},[],{"trials":7192,"activeCount":123},[],{"trials":7194,"activeCount":123},[],{"trials":7196,"activeCount":123},[7197],{"nctId":7198,"briefTitle":7199,"status":105,"phases":7200,"primaryCompletion":7201,"completion":664,"start":7202,"enrollment":7203,"conditions":7204,"interventions":7206},"NCT02229539","Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy",[92],"2016-05-23","2014-11-18",275,[7205],"Acute Oral Mucositis Pain",[7187,7207],"DLA (diphenhydramine, lidocaine and antacids) rinse",{"trials":7209,"activeCount":123},[],{"trials":7211,"activeCount":123},[],{"intervention":7207,"totalTrials":272,"cells":7213},{"EARLY_PHASE1":7214,"PHASE1":7216,"PHASE2":7218,"PHASE3":7220,"PHASE4":7226,"NA":7228},{"trials":7215,"activeCount":123},[],{"trials":7217,"activeCount":123},[],{"trials":7219,"activeCount":123},[],{"trials":7221,"activeCount":123},[7222],{"nctId":7198,"briefTitle":7199,"status":105,"phases":7223,"primaryCompletion":7201,"completion":664,"start":7202,"enrollment":7203,"conditions":7224,"interventions":7225},[92],[7205],[7187,7207],{"trials":7227,"activeCount":123},[],{"trials":7229,"activeCount":123},[],{"intervention":7231,"totalTrials":272,"cells":7232},"ondansetron",{"EARLY_PHASE1":7233,"PHASE1":7235,"PHASE2":7237,"PHASE3":7239,"PHASE4":7248,"NA":7250},{"trials":7234,"activeCount":123},[],{"trials":7236,"activeCount":123},[],{"trials":7238,"activeCount":123},[],{"trials":7240,"activeCount":123},[7241],{"nctId":7242,"briefTitle":7243,"status":105,"phases":7244,"primaryCompletion":765,"completion":765,"start":1007,"enrollment":3538,"conditions":7245,"interventions":7247},"NCT00006348","Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment",[92],[6670,27,21,2584,2535,1994,6661,6671,30,7246],"Unspecified Childhood Solid Tumor, Protocol Specific",[7231],{"trials":7249,"activeCount":123},[],{"trials":7251,"activeCount":123},[],{"intervention":3122,"totalTrials":272,"cells":7253},{"EARLY_PHASE1":7254,"PHASE1":7256,"PHASE2":7258,"PHASE3":7260,"PHASE4":7266,"NA":7268},{"trials":7255,"activeCount":123},[],{"trials":7257,"activeCount":123},[],{"trials":7259,"activeCount":123},[],{"trials":7261,"activeCount":123},[7262],{"nctId":3115,"briefTitle":3116,"status":105,"phases":7263,"primaryCompletion":1713,"completion":3118,"start":536,"enrollment":3119,"conditions":7264,"interventions":7265},[92],[18],[3122,1219,1162,540],{"trials":7267,"activeCount":123},[],{"trials":7269,"activeCount":123},[],{"intervention":7271,"totalTrials":272,"cells":7272},"armodafinil 150 mg",{"EARLY_PHASE1":7273,"PHASE1":7275,"PHASE2":7277,"PHASE3":7279,"PHASE4":7292,"NA":7294},{"trials":7274,"activeCount":123},[],{"trials":7276,"activeCount":123},[],{"trials":7278,"activeCount":123},[],{"trials":7280,"activeCount":123},[7281],{"nctId":7282,"briefTitle":7283,"status":105,"phases":7284,"primaryCompletion":7285,"completion":7286,"start":7287,"enrollment":7288,"conditions":7289,"interventions":7290},"NCT01781468","Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma",[92],"2019-05","2019-12-15","2013-06-21",328,[1077],[7271,7291],"armodafinil 250 mg",{"trials":7293,"activeCount":123},[],{"trials":7295,"activeCount":123},[],{"intervention":7291,"totalTrials":272,"cells":7297},{"EARLY_PHASE1":7298,"PHASE1":7300,"PHASE2":7302,"PHASE3":7304,"PHASE4":7310,"NA":7312},{"trials":7299,"activeCount":123},[],{"trials":7301,"activeCount":123},[],{"trials":7303,"activeCount":123},[],{"trials":7305,"activeCount":123},[7306],{"nctId":7282,"briefTitle":7283,"status":105,"phases":7307,"primaryCompletion":7285,"completion":7286,"start":7287,"enrollment":7288,"conditions":7308,"interventions":7309},[92],[1077],[7271,7291],{"trials":7311,"activeCount":123},[],{"trials":7313,"activeCount":123},[],{"intervention":7315,"totalTrials":272,"cells":7316},"Ginkgo Biloba",{"EARLY_PHASE1":7317,"PHASE1":7319,"PHASE2":7321,"PHASE3":7323,"PHASE4":7332,"NA":7334},{"trials":7318,"activeCount":123},[],{"trials":7320,"activeCount":123},[],{"trials":7322,"activeCount":123},[],{"trials":7324,"activeCount":123},[7325],{"nctId":7326,"briefTitle":7327,"status":105,"phases":7328,"primaryCompletion":578,"completion":1749,"start":1140,"enrollment":7329,"conditions":7330,"interventions":7331},"NCT00046891","EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer",[92],226,[18,305],[7315],{"trials":7333,"activeCount":123},[],{"trials":7335,"activeCount":123},[],{"intervention":1671,"totalTrials":272,"cells":7337},{"EARLY_PHASE1":7338,"PHASE1":7340,"PHASE2":7342,"PHASE3":7344,"PHASE4":7350,"NA":7352},{"trials":7339,"activeCount":123},[],{"trials":7341,"activeCount":123},[],{"trials":7343,"activeCount":123},[],{"trials":7345,"activeCount":123},[7346],{"nctId":1662,"briefTitle":1663,"status":105,"phases":7347,"primaryCompletion":706,"completion":1665,"start":629,"enrollment":1666,"conditions":7348,"interventions":7349},[92],[1668,1669,1077,15],[1671,43],{"trials":7351,"activeCount":123},[],{"trials":7353,"activeCount":123},[],{"intervention":7355,"totalTrials":272,"cells":7356},"doxepin hydrochloride",{"EARLY_PHASE1":7357,"PHASE1":7359,"PHASE2":7361,"PHASE3":7363,"PHASE4":7375,"NA":7377},{"trials":7358,"activeCount":123},[],{"trials":7360,"activeCount":123},[],{"trials":7362,"activeCount":123},[],{"trials":7364,"activeCount":123},[7365],{"nctId":7366,"briefTitle":7367,"status":105,"phases":7368,"primaryCompletion":1703,"completion":7369,"start":776,"enrollment":7370,"conditions":7371,"interventions":7374},"NCT01156142","Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy",[92],"2015-03-02",155,[1537,7372,7373,907],"Mucositis","Oral Complications of Radiation Therapy",[7355],{"trials":7376,"activeCount":123},[],{"trials":7378,"activeCount":123},[],{"intervention":7380,"totalTrials":272,"cells":7381},"baclofen\u002Famitriptyline\u002Fketamine gel",{"EARLY_PHASE1":7382,"PHASE1":7384,"PHASE2":7386,"PHASE3":7388,"PHASE4":7397,"NA":7399},{"trials":7383,"activeCount":123},[],{"trials":7385,"activeCount":123},[],{"trials":7387,"activeCount":123},[],{"trials":7389,"activeCount":123},[7390],{"nctId":7391,"briefTitle":7392,"status":105,"phases":7393,"primaryCompletion":754,"completion":236,"start":133,"enrollment":7394,"conditions":7395,"interventions":7396},"NCT00516503","Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer",[92],208,[6670,27,21,2583,2584,2535,2585,305,907,30],[7380],{"trials":7398,"activeCount":123},[],{"trials":7400,"activeCount":123},[],{"intervention":7402,"totalTrials":272,"cells":7403},"sunscreen",{"EARLY_PHASE1":7404,"PHASE1":7406,"PHASE2":7408,"PHASE3":7410,"PHASE4":7420,"NA":7422},{"trials":7405,"activeCount":123},[],{"trials":7407,"activeCount":123},[],{"trials":7409,"activeCount":123},[],{"trials":7411,"activeCount":123},[7412],{"nctId":7413,"briefTitle":7414,"status":105,"phases":7415,"primaryCompletion":685,"completion":705,"start":578,"enrollment":7416,"conditions":7417,"interventions":7419},"NCT00362986","Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer",[92],116,[7418,30],"Dermatologic Complications",[7402],{"trials":7421,"activeCount":123},[],{"trials":7423,"activeCount":123},[],{"intervention":2686,"totalTrials":272,"cells":7425},{"EARLY_PHASE1":7426,"PHASE1":7428,"PHASE2":7430,"PHASE3":7432,"PHASE4":7438,"NA":7440},{"trials":7427,"activeCount":123},[],{"trials":7429,"activeCount":123},[],{"trials":7431,"activeCount":123},[],{"trials":7433,"activeCount":123},[7434],{"nctId":2679,"briefTitle":2680,"status":105,"phases":7435,"primaryCompletion":1694,"completion":2682,"start":638,"enrollment":2683,"conditions":7436,"interventions":7437},[92],[24],[184,205,2686,2687],{"trials":7439,"activeCount":123},[],{"trials":7441,"activeCount":123},[],{"intervention":2687,"totalTrials":272,"cells":7443},{"EARLY_PHASE1":7444,"PHASE1":7446,"PHASE2":7448,"PHASE3":7450,"PHASE4":7456,"NA":7458},{"trials":7445,"activeCount":123},[],{"trials":7447,"activeCount":123},[],{"trials":7449,"activeCount":123},[],{"trials":7451,"activeCount":123},[7452],{"nctId":2679,"briefTitle":2680,"status":105,"phases":7453,"primaryCompletion":1694,"completion":2682,"start":638,"enrollment":2683,"conditions":7454,"interventions":7455},[92],[24],[184,205,2686,2687],{"trials":7457,"activeCount":123},[],{"trials":7459,"activeCount":123},[],{"intervention":3811,"totalTrials":272,"cells":7461},{"EARLY_PHASE1":7462,"PHASE1":7464,"PHASE2":7466,"PHASE3":7468,"PHASE4":7474,"NA":7476},{"trials":7463,"activeCount":123},[],{"trials":7465,"activeCount":123},[],{"trials":7467,"activeCount":123},[],{"trials":7469,"activeCount":123},[7470],{"nctId":3794,"briefTitle":3795,"status":2755,"phases":7471,"primaryCompletion":3797,"completion":3798,"start":3799,"enrollment":3800,"conditions":7472,"interventions":7473},[92],[3802,3803,3804,3805,3806],[3808,3634,3809,3810,3811],{"trials":7475,"activeCount":123},[],{"trials":7477,"activeCount":123},[],{"intervention":7479,"totalTrials":272,"cells":7480},"testosterone",{"EARLY_PHASE1":7481,"PHASE1":7483,"PHASE2":7485,"PHASE3":7487,"PHASE4":7501,"NA":7503},{"trials":7482,"activeCount":123},[],{"trials":7484,"activeCount":123},[],{"trials":7486,"activeCount":123},[],{"trials":7488,"activeCount":123},[7489],{"nctId":7490,"briefTitle":7491,"status":105,"phases":7492,"primaryCompletion":7493,"completion":7494,"start":7495,"enrollment":3710,"conditions":7496,"interventions":7500},"NCT01573442","Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment",[92],"2018-02-28","2019-09-01","2013-09-10",[7497,18,3500,7498,7499],"Arthralgia","Musculoskeletal Complications","Sexual Dysfunction",[7479],{"trials":7502,"activeCount":123},[],{"trials":7504,"activeCount":123},[],{"intervention":921,"totalTrials":272,"cells":7506},{"EARLY_PHASE1":7507,"PHASE1":7509,"PHASE2":7511,"PHASE3":7513,"PHASE4":7519,"NA":7521},{"trials":7508,"activeCount":123},[],{"trials":7510,"activeCount":123},[],{"trials":7512,"activeCount":123},[],{"trials":7514,"activeCount":123},[7515],{"nctId":900,"briefTitle":901,"status":105,"phases":7516,"primaryCompletion":169,"completion":169,"start":903,"enrollment":904,"conditions":7517,"interventions":7518},[92],[303,304,906,907,908,909,910,911,912,913,914,915,916,917,918,919],[229,921,230],{"trials":7520,"activeCount":123},[],{"trials":7522,"activeCount":123},[],{"intervention":7524,"totalTrials":272,"cells":7525},"BenFin",{"EARLY_PHASE1":7526,"PHASE1":7528,"PHASE2":7530,"PHASE3":7532,"PHASE4":7540,"NA":7542},{"trials":7527,"activeCount":123},[],{"trials":7529,"activeCount":123},[],{"trials":7531,"activeCount":123},[],{"trials":7533,"activeCount":123},[7534],{"nctId":7535,"briefTitle":7536,"status":105,"phases":7537,"primaryCompletion":848,"completion":848,"start":1018,"enrollment":1931,"conditions":7538,"interventions":7539},"NCT00026117","Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer",[92],[18,24],[7524],{"trials":7541,"activeCount":123},[],{"trials":7543,"activeCount":123},[],{"intervention":7545,"totalTrials":272,"cells":7546},"lamotrigine",{"EARLY_PHASE1":7547,"PHASE1":7549,"PHASE2":7551,"PHASE3":7553,"PHASE4":7562,"NA":7564},{"trials":7548,"activeCount":123},[],{"trials":7550,"activeCount":123},[],{"trials":7552,"activeCount":123},[],{"trials":7554,"activeCount":123},[7555],{"nctId":7556,"briefTitle":7557,"status":105,"phases":7558,"primaryCompletion":191,"completion":6557,"start":1253,"enrollment":7559,"conditions":7560,"interventions":7561},"NCT00068445","Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer",[92],131,[305,907,30],[7545],{"trials":7563,"activeCount":123},[],{"trials":7565,"activeCount":123},[],{"intervention":6452,"totalTrials":272,"cells":7567},{"EARLY_PHASE1":7568,"PHASE1":7570,"PHASE2":7572,"PHASE3":7574,"PHASE4":7580,"NA":7582},{"trials":7569,"activeCount":123},[],{"trials":7571,"activeCount":123},[],{"trials":7573,"activeCount":123},[],{"trials":7575,"activeCount":123},[7576],{"nctId":6445,"briefTitle":6446,"status":105,"phases":7577,"primaryCompletion":6448,"completion":1299,"start":2175,"enrollment":6449,"conditions":7578,"interventions":7579},[92],[203,33],[2007,6452,6453],{"trials":7581,"activeCount":123},[],{"trials":7583,"activeCount":123},[],{"intervention":6453,"totalTrials":272,"cells":7585},{"EARLY_PHASE1":7586,"PHASE1":7588,"PHASE2":7590,"PHASE3":7592,"PHASE4":7598,"NA":7600},{"trials":7587,"activeCount":123},[],{"trials":7589,"activeCount":123},[],{"trials":7591,"activeCount":123},[],{"trials":7593,"activeCount":123},[7594],{"nctId":6445,"briefTitle":6446,"status":105,"phases":7595,"primaryCompletion":6448,"completion":1299,"start":2175,"enrollment":6449,"conditions":7596,"interventions":7597},[92],[203,33],[2007,6452,6453],{"trials":7599,"activeCount":123},[],{"trials":7601,"activeCount":123},[],{"intervention":7603,"totalTrials":272,"cells":7604},"sulfasalazine",{"EARLY_PHASE1":7605,"PHASE1":7607,"PHASE2":7609,"PHASE3":7611,"PHASE4":7623,"NA":7625},{"trials":7606,"activeCount":123},[],{"trials":7608,"activeCount":123},[],{"trials":7610,"activeCount":123},[],{"trials":7612,"activeCount":123},[7613],{"nctId":7614,"briefTitle":7615,"status":105,"phases":7616,"primaryCompletion":7617,"completion":7618,"start":2647,"enrollment":7619,"conditions":7620,"interventions":7622},"NCT01198145","Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy",[92],"2013-07-22","2017-07-15",87,[6533,7621,30],"Gastrointestinal Complications",[7603],{"trials":7624,"activeCount":123},[],{"trials":7626,"activeCount":123},[],{"intervention":7628,"totalTrials":272,"cells":7629},"bupropion hydrochloride",{"EARLY_PHASE1":7630,"PHASE1":7632,"PHASE2":7634,"PHASE3":7636,"PHASE4":7646,"NA":7648},{"trials":7631,"activeCount":123},[],{"trials":7633,"activeCount":123},[],{"trials":7635,"activeCount":123},[],{"trials":7637,"activeCount":123},[7638],{"nctId":7639,"briefTitle":7640,"status":105,"phases":7641,"primaryCompletion":1028,"completion":1028,"start":1849,"enrollment":7642,"conditions":7643,"interventions":7644},"NCT00033592","Comparison of Nicotine Inhaler and\u002For Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking",[92],1708,[15],[7628,7645],"nicotine",{"trials":7647,"activeCount":123},[],{"trials":7649,"activeCount":123},[],{"intervention":7645,"totalTrials":272,"cells":7651},{"EARLY_PHASE1":7652,"PHASE1":7654,"PHASE2":7656,"PHASE3":7658,"PHASE4":7664,"NA":7666},{"trials":7653,"activeCount":123},[],{"trials":7655,"activeCount":123},[],{"trials":7657,"activeCount":123},[],{"trials":7659,"activeCount":123},[7660],{"nctId":7639,"briefTitle":7640,"status":105,"phases":7661,"primaryCompletion":1028,"completion":1028,"start":1849,"enrollment":7642,"conditions":7662,"interventions":7663},[92],[15],[7628,7645],{"trials":7665,"activeCount":123},[],{"trials":7667,"activeCount":123},[],{"intervention":6868,"totalTrials":272,"cells":7669},{"EARLY_PHASE1":7670,"PHASE1":7672,"PHASE2":7674,"PHASE3":7676,"PHASE4":7682,"NA":7684},{"trials":7671,"activeCount":123},[],{"trials":7673,"activeCount":123},[],{"trials":7675,"activeCount":123},[],{"trials":7677,"activeCount":123},[7678],{"nctId":6861,"briefTitle":6862,"status":105,"phases":7679,"primaryCompletion":134,"completion":754,"start":6864,"enrollment":6865,"conditions":7680,"interventions":7681},[92],[33],[6868,1244],{"trials":7683,"activeCount":123},[],{"trials":7685,"activeCount":123},[],{"intervention":364,"totalTrials":272,"cells":7687},{"EARLY_PHASE1":7688,"PHASE1":7690,"PHASE2":7692,"PHASE3":7694,"PHASE4":7700,"NA":7702},{"trials":7689,"activeCount":123},[],{"trials":7691,"activeCount":123},[],{"trials":7693,"activeCount":123},[],{"trials":7695,"activeCount":123},[7696],{"nctId":356,"briefTitle":357,"status":312,"phases":7697,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":7698,"interventions":7699},[92],[24],[184,205,364,365,121,138,139,140,366,97],{"trials":7701,"activeCount":123},[],{"trials":7703,"activeCount":123},[],{"intervention":365,"totalTrials":272,"cells":7705},{"EARLY_PHASE1":7706,"PHASE1":7708,"PHASE2":7710,"PHASE3":7712,"PHASE4":7718,"NA":7720},{"trials":7707,"activeCount":123},[],{"trials":7709,"activeCount":123},[],{"trials":7711,"activeCount":123},[],{"trials":7713,"activeCount":123},[7714],{"nctId":356,"briefTitle":357,"status":312,"phases":7715,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":7716,"interventions":7717},[92],[24],[184,205,364,365,121,138,139,140,366,97],{"trials":7719,"activeCount":123},[],{"trials":7721,"activeCount":123},[],{"intervention":366,"totalTrials":272,"cells":7723},{"EARLY_PHASE1":7724,"PHASE1":7726,"PHASE2":7728,"PHASE3":7730,"PHASE4":7736,"NA":7738},{"trials":7725,"activeCount":123},[],{"trials":7727,"activeCount":123},[],{"trials":7729,"activeCount":123},[],{"trials":7731,"activeCount":123},[7732],{"nctId":356,"briefTitle":357,"status":312,"phases":7733,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":7734,"interventions":7735},[92],[24],[184,205,364,365,121,138,139,140,366,97],{"trials":7737,"activeCount":123},[],{"trials":7739,"activeCount":123},[],{"intervention":3360,"totalTrials":272,"cells":7741},{"EARLY_PHASE1":7742,"PHASE1":7744,"PHASE2":7746,"PHASE3":7748,"PHASE4":7754,"NA":7756},{"trials":7743,"activeCount":123},[],{"trials":7745,"activeCount":123},[],{"trials":7747,"activeCount":123},[],{"trials":7749,"activeCount":123},[7750],{"nctId":3353,"briefTitle":3354,"status":105,"phases":7751,"primaryCompletion":2175,"completion":824,"start":3356,"enrollment":3357,"conditions":7752,"interventions":7753},[92],[2550],[184,3360],{"trials":7755,"activeCount":123},[],{"trials":7757,"activeCount":123},[],{"intervention":7759,"totalTrials":272,"cells":7760},"donepezil hydrochloride",{"EARLY_PHASE1":7761,"PHASE1":7763,"PHASE2":7765,"PHASE3":7767,"PHASE4":7776,"NA":7778},{"trials":7762,"activeCount":123},[],{"trials":7764,"activeCount":123},[],{"trials":7766,"activeCount":123},[],{"trials":7768,"activeCount":123},[7769],{"nctId":7770,"briefTitle":7771,"status":105,"phases":7772,"primaryCompletion":157,"completion":764,"start":1047,"enrollment":2129,"conditions":7773,"interventions":7775},"NCT00006349","Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer",[92],[318,7774,1076,15,1049],"Delirium",[7759],{"trials":7777,"activeCount":123},[],{"trials":7779,"activeCount":123},[],{"intervention":7781,"totalTrials":272,"cells":7782},"urea\u002Flactic acid-based topical cream",{"EARLY_PHASE1":7783,"PHASE1":7785,"PHASE2":7787,"PHASE3":7789,"PHASE4":7798,"NA":7800},{"trials":7784,"activeCount":123},[],{"trials":7786,"activeCount":123},[],{"trials":7788,"activeCount":123},[],{"trials":7790,"activeCount":123},[7791],{"nctId":7792,"briefTitle":7793,"status":105,"phases":7794,"primaryCompletion":1103,"start":648,"enrollment":7795,"conditions":7796,"interventions":7797},"NCT00296036","Pyridoxine and Topical Urea\u002FLactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer",[92],137,[18,1031,30],[7781],{"trials":7799,"activeCount":123},[],{"trials":7801,"activeCount":123},[],{"intervention":7803,"totalTrials":272,"cells":7804},"talc",{"EARLY_PHASE1":7805,"PHASE1":7807,"PHASE2":7809,"PHASE3":7811,"PHASE4":7822,"NA":7824},{"trials":7806,"activeCount":123},[],{"trials":7808,"activeCount":123},[],{"trials":7810,"activeCount":123},[],{"trials":7812,"activeCount":123},[7813],{"nctId":7814,"briefTitle":7815,"status":105,"phases":7816,"primaryCompletion":2174,"completion":859,"start":7817,"enrollment":7818,"conditions":7819,"interventions":7820},"NCT00002622","Talc in Treating Patients With Malignant Pleural Effusion",[92],"1994-12",501,[203],[7803,7821],"Talc",{"trials":7823,"activeCount":123},[],{"trials":7825,"activeCount":123},[],{"intervention":7827,"totalTrials":272,"cells":7828},"pregabalin",{"EARLY_PHASE1":7829,"PHASE1":7831,"PHASE2":7833,"PHASE3":7835,"PHASE4":7844,"NA":7846},{"trials":7830,"activeCount":123},[],{"trials":7832,"activeCount":123},[],{"trials":7834,"activeCount":123},[],{"trials":7836,"activeCount":123},[7837],{"nctId":7838,"briefTitle":7839,"status":105,"phases":7840,"primaryCompletion":755,"completion":833,"start":5814,"enrollment":7841,"conditions":7842,"interventions":7843},"NCT00702949","Pregabalin in Treating Women With Hot Flashes",[92],207,[18,3500],[7827],{"trials":7845,"activeCount":123},[],{"trials":7847,"activeCount":123},[],{"intervention":7849,"totalTrials":272,"cells":7850},"pilocarpine hydrochloride",{"EARLY_PHASE1":7851,"PHASE1":7853,"PHASE2":7855,"PHASE3":7857,"PHASE4":7867,"NA":7869},{"trials":7852,"activeCount":123},[],{"trials":7854,"activeCount":123},[],{"trials":7856,"activeCount":123},[],{"trials":7858,"activeCount":123},[7859],{"nctId":7860,"briefTitle":7861,"status":105,"phases":7862,"primaryCompletion":1103,"completion":299,"start":371,"enrollment":7863,"conditions":7864,"interventions":7866},"NCT00343382","Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer",[92],201,[18,7865],"Vaginal Dryness",[7849],{"trials":7868,"activeCount":123},[],{"trials":7870,"activeCount":123},[],{"intervention":7872,"totalTrials":272,"cells":7873},"medroxyprogesterone",{"EARLY_PHASE1":7874,"PHASE1":7876,"PHASE2":7878,"PHASE3":7880,"PHASE4":7889,"NA":7891},{"trials":7875,"activeCount":123},[],{"trials":7877,"activeCount":123},[],{"trials":7879,"activeCount":123},[],{"trials":7881,"activeCount":123},[7882],{"nctId":7883,"briefTitle":7884,"status":105,"phases":7885,"primaryCompletion":706,"completion":848,"start":1345,"enrollment":3710,"conditions":7886,"interventions":7887},"NCT00030914","Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women",[92],[3500],[7872,7888],"venlafaxine",{"trials":7890,"activeCount":123},[],{"trials":7892,"activeCount":123},[],{"intervention":7888,"totalTrials":272,"cells":7894},{"EARLY_PHASE1":7895,"PHASE1":7897,"PHASE2":7899,"PHASE3":7901,"PHASE4":7907,"NA":7909},{"trials":7896,"activeCount":123},[],{"trials":7898,"activeCount":123},[],{"trials":7900,"activeCount":123},[],{"trials":7902,"activeCount":123},[7903],{"nctId":7883,"briefTitle":7884,"status":105,"phases":7904,"primaryCompletion":706,"completion":848,"start":1345,"enrollment":3710,"conditions":7905,"interventions":7906},[92],[3500],[7872,7888],{"trials":7908,"activeCount":123},[],{"trials":7910,"activeCount":123},[],{"intervention":7912,"totalTrials":272,"cells":7913},"Varenicline",{"EARLY_PHASE1":7914,"PHASE1":7916,"PHASE2":7918,"PHASE3":7920,"PHASE4":7932,"NA":7934},{"trials":7915,"activeCount":123},[],{"trials":7917,"activeCount":123},[],{"trials":7919,"activeCount":123},[],{"trials":7921,"activeCount":123},[7922],{"nctId":7923,"briefTitle":7924,"status":312,"phases":7925,"primaryCompletion":7926,"completion":7927,"start":7928,"enrollment":110,"conditions":7929,"interventions":7931},"NCT02856581","Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes",[92],"2021-05-28","2022-04-15","2017-09-29",[7930],"Lung Carcinoma",[7912],{"trials":7933,"activeCount":123},[],{"trials":7935,"activeCount":123},[],{"intervention":7937,"totalTrials":272,"cells":7938},"American ginseng",{"EARLY_PHASE1":7939,"PHASE1":7941,"PHASE2":7943,"PHASE3":7945,"PHASE4":7954,"NA":7956},{"trials":7940,"activeCount":123},[],{"trials":7942,"activeCount":123},[],{"trials":7944,"activeCount":123},[],{"trials":7946,"activeCount":123},[7947],{"nctId":7948,"briefTitle":7949,"status":105,"phases":7950,"primaryCompletion":7951,"completion":618,"start":1665,"enrollment":3180,"conditions":7952,"interventions":7953},"NCT00719563","American Ginseng in Treating Patients With Fatigue Caused by Cancer",[92],"2011-08",[6670,1077,27,21,2583,2584,2535,2585,6661,30],[7937],{"trials":7955,"activeCount":123},[],{"trials":7957,"activeCount":123},[],{"intervention":2121,"totalTrials":272,"cells":7959},{"EARLY_PHASE1":7960,"PHASE1":7962,"PHASE2":7964,"PHASE3":7966,"PHASE4":7972,"NA":7974},{"trials":7961,"activeCount":123},[],{"trials":7963,"activeCount":123},[],{"trials":7965,"activeCount":123},[],{"trials":7967,"activeCount":123},[7968],{"nctId":2114,"briefTitle":2115,"status":925,"phases":7969,"primaryCompletion":2117,"start":158,"enrollment":2118,"conditions":7970,"interventions":7971},[92],[27],[1011,2121,2122,2123],{"trials":7973,"activeCount":123},[],{"trials":7975,"activeCount":123},[],{"intervention":2122,"totalTrials":272,"cells":7977},{"EARLY_PHASE1":7978,"PHASE1":7980,"PHASE2":7982,"PHASE3":7984,"PHASE4":7990,"NA":7992},{"trials":7979,"activeCount":123},[],{"trials":7981,"activeCount":123},[],{"trials":7983,"activeCount":123},[],{"trials":7985,"activeCount":123},[7986],{"nctId":2114,"briefTitle":2115,"status":925,"phases":7987,"primaryCompletion":2117,"start":158,"enrollment":2118,"conditions":7988,"interventions":7989},[92],[27],[1011,2121,2122,2123],{"trials":7991,"activeCount":123},[],{"trials":7993,"activeCount":123},[],{"intervention":2123,"totalTrials":272,"cells":7995},{"EARLY_PHASE1":7996,"PHASE1":7998,"PHASE2":8000,"PHASE3":8002,"PHASE4":8008,"NA":8010},{"trials":7997,"activeCount":123},[],{"trials":7999,"activeCount":123},[],{"trials":8001,"activeCount":123},[],{"trials":8003,"activeCount":123},[8004],{"nctId":2114,"briefTitle":2115,"status":925,"phases":8005,"primaryCompletion":2117,"start":158,"enrollment":2118,"conditions":8006,"interventions":8007},[92],[27],[1011,2121,2122,2123],{"trials":8009,"activeCount":123},[],{"trials":8011,"activeCount":123},[],{"intervention":8013,"totalTrials":272,"cells":8014},"therapeutic testosterone",{"EARLY_PHASE1":8015,"PHASE1":8017,"PHASE2":8019,"PHASE3":8021,"PHASE4":8032,"NA":8034},{"trials":8016,"activeCount":123},[],{"trials":8018,"activeCount":123},[],{"trials":8020,"activeCount":123},[],{"trials":8022,"activeCount":123},[8023],{"nctId":8024,"briefTitle":8025,"status":105,"phases":8026,"primaryCompletion":147,"completion":199,"start":1149,"enrollment":8027,"conditions":8028,"interventions":8031},"NCT00075855","Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors",[92],150,[8029,7499,8030,30],"Cancer Survivor","Sexuality and Reproductive Issues",[8013],{"trials":8033,"activeCount":123},[],{"trials":8035,"activeCount":123},[],{"intervention":4813,"totalTrials":272,"cells":8037},{"EARLY_PHASE1":8038,"PHASE1":8040,"PHASE2":8042,"PHASE3":8044,"PHASE4":8050,"NA":8052},{"trials":8039,"activeCount":123},[],{"trials":8041,"activeCount":123},[],{"trials":8043,"activeCount":123},[],{"trials":8045,"activeCount":123},[8046],{"nctId":4807,"briefTitle":4808,"status":105,"phases":8047,"primaryCompletion":675,"completion":824,"start":765,"enrollment":4810,"conditions":8048,"interventions":8049},[92],[18],[4813,121],{"trials":8051,"activeCount":123},[],{"trials":8053,"activeCount":123},[],{"intervention":8055,"totalTrials":272,"cells":8056},"methylphenidate hydrochloride",{"EARLY_PHASE1":8057,"PHASE1":8059,"PHASE2":8061,"PHASE3":8063,"PHASE4":8072,"NA":8074},{"trials":8058,"activeCount":123},[],{"trials":8060,"activeCount":123},[],{"trials":8062,"activeCount":123},[],{"trials":8064,"activeCount":123},[8065],{"nctId":8066,"briefTitle":8067,"status":105,"phases":8068,"primaryCompletion":281,"completion":281,"start":133,"enrollment":8069,"conditions":8070,"interventions":8071},"NCT00376675","Methylphenidate in Treating Patients With Fatigue Caused by Cancer",[92],148,[1077,30],[8055],{"trials":8073,"activeCount":123},[],{"trials":8075,"activeCount":123},[],{"intervention":2034,"totalTrials":272,"cells":8077},{"EARLY_PHASE1":8078,"PHASE1":8080,"PHASE2":8082,"PHASE3":8084,"PHASE4":8090,"NA":8092},{"trials":8079,"activeCount":123},[],{"trials":8081,"activeCount":123},[],{"trials":8083,"activeCount":123},[],{"trials":8085,"activeCount":123},[8086],{"nctId":2024,"briefTitle":2025,"status":105,"phases":8087,"primaryCompletion":2027,"completion":2028,"start":2029,"enrollment":2030,"conditions":8088,"interventions":8089},[92],[2020],[2033,2034,1812,2035,2036],{"trials":8091,"activeCount":123},[],{"trials":8093,"activeCount":123},[],{"intervention":2035,"totalTrials":272,"cells":8095},{"EARLY_PHASE1":8096,"PHASE1":8098,"PHASE2":8100,"PHASE3":8102,"PHASE4":8108,"NA":8110},{"trials":8097,"activeCount":123},[],{"trials":8099,"activeCount":123},[],{"trials":8101,"activeCount":123},[],{"trials":8103,"activeCount":123},[8104],{"nctId":2024,"briefTitle":2025,"status":105,"phases":8105,"primaryCompletion":2027,"completion":2028,"start":2029,"enrollment":2030,"conditions":8106,"interventions":8107},[92],[2020],[2033,2034,1812,2035,2036],{"trials":8109,"activeCount":123},[],{"trials":8111,"activeCount":123},[],{"intervention":595,"totalTrials":2129,"cells":8113},{"EARLY_PHASE1":8114,"PHASE1":8116,"PHASE2":8118,"PHASE3":8160,"PHASE4":8162,"NA":8164},{"trials":8115,"activeCount":123},[],{"trials":8117,"activeCount":123},[],{"trials":8119,"activeCount":123},[8120,8126,8130,8136,8140,8144,8148,8152,8156],{"nctId":8121,"briefTitle":8122,"status":105,"phases":8123,"primaryCompletion":797,"completion":754,"start":211,"enrollment":3538,"conditions":8124,"interventions":8125},"NCT00003675","Topotecan in Treating Patients With Myelodysplastic Syndrome",[91],[27,2535],[595],{"nctId":585,"briefTitle":586,"status":105,"phases":8127,"primaryCompletion":588,"completion":589,"start":211,"enrollment":590,"conditions":8128,"interventions":8129},[91],[15],[593,524,594,540,595],{"nctId":8131,"briefTitle":8132,"status":105,"phases":8133,"primaryCompletion":178,"start":1346,"conditions":8134,"interventions":8135},"NCT00006125","Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma",[91],[21],[1162,595],{"nctId":635,"briefTitle":636,"status":105,"phases":8137,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":8138,"interventions":8139},[91],[15],[593,524,595],{"nctId":4586,"briefTitle":4587,"status":105,"phases":8141,"primaryCompletion":1526,"completion":1526,"start":840,"enrollment":841,"conditions":8142,"interventions":8143},[91],[15],[593,540,595],{"nctId":4603,"briefTitle":4604,"status":105,"phases":8145,"primaryCompletion":589,"completion":589,"start":1182,"enrollment":1763,"conditions":8146,"interventions":8147},[91],[15],[540,595],{"nctId":1045,"briefTitle":762,"status":105,"phases":8149,"primaryCompletion":191,"completion":191,"start":1047,"enrollment":201,"conditions":8150,"interventions":8151},[90,91],[1031,15,1049],[593,1051,791,594,540,595],{"nctId":761,"briefTitle":762,"status":105,"phases":8153,"primaryCompletion":764,"completion":754,"start":765,"enrollment":600,"conditions":8154,"interventions":8155},[91],[15],[593,524,594,540,595],{"nctId":837,"briefTitle":838,"status":105,"phases":8157,"primaryCompletion":371,"completion":371,"start":840,"enrollment":841,"conditions":8158,"interventions":8159},[91],[27],[524,595],{"trials":8161,"activeCount":123},[],{"trials":8163,"activeCount":123},[],{"trials":8165,"activeCount":123},[],{"intervention":1832,"totalTrials":2221,"cells":8167},{"EARLY_PHASE1":8168,"PHASE1":8170,"PHASE2":8172,"PHASE3":8202,"PHASE4":8204,"NA":8206},{"trials":8169,"activeCount":123},[],{"trials":8171,"activeCount":123},[],{"trials":8173,"activeCount":123},[8174,8178,8182,8186,8190,8194,8198],{"nctId":2521,"briefTitle":2522,"status":105,"phases":8175,"primaryCompletion":648,"completion":755,"start":640,"enrollment":1783,"conditions":8176,"interventions":8177},[91],[2525,2526],[593,2528,1219,1830,2067,1220,1832],{"nctId":2530,"briefTitle":2531,"status":105,"phases":8179,"primaryCompletion":2533,"completion":360,"start":1140,"enrollment":974,"conditions":8180,"interventions":8181},[91],[27,21,2525,2526,2535,2536],[2538,885,1829,1830,1220,2539,1832,2540],{"nctId":2546,"briefTitle":2547,"status":105,"phases":8183,"primaryCompletion":648,"completion":648,"start":2450,"enrollment":1917,"conditions":8184,"interventions":8185},[91],[2550],[593,2552,1219,1830,1220,1832],{"nctId":2061,"briefTitle":2062,"status":105,"phases":8187,"primaryCompletion":1601,"completion":1601,"start":631,"enrollment":403,"conditions":8188,"interventions":8189},[91],[2065,21],[53,2067,594,1011,1832,1220,1013],{"nctId":2578,"briefTitle":2579,"status":312,"phases":8191,"primaryCompletion":547,"completion":618,"start":776,"enrollment":2581,"conditions":8192,"interventions":8193},[91],[27,21,2583,2584,2535,2585],[2538,2587,593,2552,1829,1830,1220,2539,1832],{"nctId":1822,"briefTitle":1823,"status":105,"phases":8195,"primaryCompletion":1825,"completion":1826,"start":755,"enrollment":1805,"conditions":8196,"interventions":8197},[91],[27,21],[1010,1829,1219,1830,1220,1831,1832],{"nctId":2601,"briefTitle":2602,"status":105,"phases":8199,"primaryCompletion":190,"completion":2604,"start":2175,"enrollment":2605,"conditions":8200,"interventions":8201},[91],[2607,2608],[593,2610,1829,1830,1220,1832],{"trials":8203,"activeCount":123},[],{"trials":8205,"activeCount":123},[],{"trials":8207,"activeCount":123},[],{"intervention":1829,"totalTrials":430,"cells":8209},{"EARLY_PHASE1":8210,"PHASE1":8212,"PHASE2":8214,"PHASE3":8236,"PHASE4":8238,"NA":8240},{"trials":8211,"activeCount":123},[],{"trials":8213,"activeCount":123},[],{"trials":8215,"activeCount":123},[8216,8220,8224,8228,8232],{"nctId":2530,"briefTitle":2531,"status":105,"phases":8217,"primaryCompletion":2533,"completion":360,"start":1140,"enrollment":974,"conditions":8218,"interventions":8219},[91],[27,21,2525,2526,2535,2536],[2538,885,1829,1830,1220,2539,1832,2540],{"nctId":2050,"briefTitle":2051,"status":105,"phases":8221,"primaryCompletion":1601,"completion":813,"start":2053,"enrollment":569,"conditions":8222,"interventions":8223},[91],[27],[593,1829,1011,594,1220],{"nctId":2578,"briefTitle":2579,"status":312,"phases":8225,"primaryCompletion":547,"completion":618,"start":776,"enrollment":2581,"conditions":8226,"interventions":8227},[91],[27,21,2583,2584,2535,2585],[2538,2587,593,2552,1829,1830,1220,2539,1832],{"nctId":1822,"briefTitle":1823,"status":105,"phases":8229,"primaryCompletion":1825,"completion":1826,"start":755,"enrollment":1805,"conditions":8230,"interventions":8231},[91],[27,21],[1010,1829,1219,1830,1220,1831,1832],{"nctId":2601,"briefTitle":2602,"status":105,"phases":8233,"primaryCompletion":190,"completion":2604,"start":2175,"enrollment":2605,"conditions":8234,"interventions":8235},[91],[2607,2608],[593,2610,1829,1830,1220,1832],{"trials":8237,"activeCount":123},[],{"trials":8239,"activeCount":123},[],{"trials":8241,"activeCount":123},[],{"intervention":3234,"totalTrials":430,"cells":8243},{"EARLY_PHASE1":8244,"PHASE1":8246,"PHASE2":8256,"PHASE3":8274,"PHASE4":8276,"NA":8278},{"trials":8245,"activeCount":123},[],{"trials":8247,"activeCount":123},[8248],{"nctId":8249,"briefTitle":8250,"status":105,"phases":8251,"primaryCompletion":1825,"completion":8252,"start":1703,"enrollment":1191,"conditions":8253,"interventions":8254},"NCT01497444","Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery",[90],"2019-11-01",[2550,1277],[8255,3234],"hypoxia-activated prodrug TH-302",{"trials":8257,"activeCount":123},[8258,8262,8266,8270],{"nctId":3229,"briefTitle":3230,"status":105,"phases":8259,"primaryCompletion":1713,"completion":806,"start":754,"enrollment":1191,"conditions":8260,"interventions":8261},[90,91],[1277],[184,3234],{"nctId":3253,"briefTitle":3254,"status":105,"phases":8263,"primaryCompletion":236,"completion":1943,"start":619,"enrollment":3256,"conditions":8264,"interventions":8265},[91],[3258,3259,3260,3261],[3234,184],{"nctId":3282,"briefTitle":3283,"status":105,"phases":8267,"primaryCompletion":1741,"completion":3285,"start":3286,"enrollment":3287,"conditions":8268,"interventions":8269},[91],[1022],[184,3234],{"nctId":6227,"briefTitle":6228,"status":105,"phases":8271,"primaryCompletion":823,"completion":806,"start":741,"enrollment":6230,"conditions":8272,"interventions":8273},[91],[15],[710,3234],{"trials":8275,"activeCount":123},[],{"trials":8277,"activeCount":123},[],{"trials":8279,"activeCount":123},[],{"intervention":1013,"totalTrials":430,"cells":8281},{"EARLY_PHASE1":8282,"PHASE1":8284,"PHASE2":8292,"PHASE3":8314,"PHASE4":8316,"NA":8318},{"trials":8283,"activeCount":123},[],{"trials":8285,"activeCount":123},[8286],{"nctId":8287,"briefTitle":8288,"status":105,"phases":8289,"primaryCompletion":824,"completion":824,"start":536,"enrollment":28,"conditions":8290,"interventions":8291},"NCT00017121","Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung",[90],[581,203],[1013],{"trials":8293,"activeCount":123},[8294,8298,8302,8308],{"nctId":2061,"briefTitle":2062,"status":105,"phases":8295,"primaryCompletion":1601,"completion":1601,"start":631,"enrollment":403,"conditions":8296,"interventions":8297},[91],[2065,21],[53,2067,594,1011,1832,1220,1013],{"nctId":1004,"briefTitle":1005,"status":105,"phases":8299,"primaryCompletion":566,"completion":133,"start":1007,"enrollment":742,"conditions":8300,"interventions":8301},[91],[21],[1010,791,1011,1012,1013],{"nctId":8303,"briefTitle":8304,"status":105,"phases":8305,"primaryCompletion":648,"completion":648,"start":3868,"enrollment":1974,"conditions":8306,"interventions":8307},"NCT00005610","Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung",[91],[581,203],[1013],{"nctId":8309,"briefTitle":8310,"status":105,"phases":8311,"primaryCompletion":3386,"completion":787,"start":1007,"enrollment":641,"conditions":8312,"interventions":8313},"NCT00006483","Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung",[91],[2550,203],[1013],{"trials":8315,"activeCount":123},[],{"trials":8317,"activeCount":123},[],{"trials":8319,"activeCount":123},[],{"intervention":583,"totalTrials":403,"cells":8321},{"EARLY_PHASE1":8322,"PHASE1":8324,"PHASE2":8326,"PHASE3":8344,"PHASE4":8346,"NA":8348},{"trials":8323,"activeCount":123},[],{"trials":8325,"activeCount":123},[],{"trials":8327,"activeCount":123},[8328,8332,8336,8340],{"nctId":573,"briefTitle":574,"status":105,"phases":8329,"primaryCompletion":576,"completion":577,"start":578,"enrollment":579,"conditions":8330,"interventions":8331},[91],[581],[524,583],{"nctId":605,"briefTitle":606,"status":105,"phases":8333,"primaryCompletion":608,"completion":609,"start":610,"enrollment":16,"conditions":8334,"interventions":8335},[91],[15],[524,613,583],{"nctId":3291,"briefTitle":3292,"status":105,"phases":8337,"primaryCompletion":360,"completion":618,"start":3294,"enrollment":707,"conditions":8338,"interventions":8339},[91],[18],[184,185,583],{"nctId":820,"briefTitle":821,"status":105,"phases":8341,"primaryCompletion":823,"completion":824,"start":639,"enrollment":825,"conditions":8342,"interventions":8343},[91],[581],[184,524,583,828],{"trials":8345,"activeCount":123},[],{"trials":8347,"activeCount":123},[],{"trials":8349,"activeCount":123},[],{"intervention":613,"totalTrials":403,"cells":8351},{"EARLY_PHASE1":8352,"PHASE1":8354,"PHASE2":8356,"PHASE3":8374,"PHASE4":8376,"NA":8378},{"trials":8353,"activeCount":123},[],{"trials":8355,"activeCount":123},[],{"trials":8357,"activeCount":123},[8358,8362,8366,8370],{"nctId":605,"briefTitle":606,"status":105,"phases":8359,"primaryCompletion":608,"completion":609,"start":610,"enrollment":16,"conditions":8360,"interventions":8361},[91],[15],[524,613,583],{"nctId":4918,"briefTitle":4919,"status":105,"phases":8363,"primaryCompletion":178,"completion":630,"start":244,"enrollment":2306,"conditions":8364,"interventions":8365},[91],[18],[613,185],{"nctId":4928,"briefTitle":4929,"status":105,"phases":8367,"primaryCompletion":179,"completion":806,"start":813,"enrollment":1838,"conditions":8368,"interventions":8369},[91],[171],[1002,613,185],{"nctId":4934,"briefTitle":4935,"status":105,"phases":8371,"primaryCompletion":219,"completion":4937,"start":754,"enrollment":4938,"conditions":8372,"interventions":8373},[91],[171],[613,185],{"trials":8375,"activeCount":123},[],{"trials":8377,"activeCount":123},[],{"trials":8379,"activeCount":123},[],{"intervention":2067,"totalTrials":459,"cells":8381},{"EARLY_PHASE1":8382,"PHASE1":8384,"PHASE2":8386,"PHASE3":8400,"PHASE4":8402,"NA":8404},{"trials":8383,"activeCount":123},[],{"trials":8385,"activeCount":123},[],{"trials":8387,"activeCount":123},[8388,8392,8396],{"nctId":2521,"briefTitle":2522,"status":105,"phases":8389,"primaryCompletion":648,"completion":755,"start":640,"enrollment":1783,"conditions":8390,"interventions":8391},[91],[2525,2526],[593,2528,1219,1830,2067,1220,1832],{"nctId":2061,"briefTitle":2062,"status":105,"phases":8393,"primaryCompletion":1601,"completion":1601,"start":631,"enrollment":403,"conditions":8394,"interventions":8395},[91],[2065,21],[53,2067,594,1011,1832,1220,1013],{"nctId":3562,"briefTitle":3563,"status":167,"phases":8397,"primaryCompletion":764,"completion":764,"start":191,"enrollment":123,"conditions":8398,"interventions":8399},[90,91],[27,21,2584,2535,2585],[3567,3568,1830,2067,2539],{"trials":8401,"activeCount":123},[],{"trials":8403,"activeCount":123},[],{"trials":8405,"activeCount":123},[],{"intervention":1717,"totalTrials":459,"cells":8407},{"EARLY_PHASE1":8408,"PHASE1":8410,"PHASE2":8416,"PHASE3":8428,"PHASE4":8430,"NA":8432},{"trials":8409,"activeCount":123},[],{"trials":8411,"activeCount":123},[8412],{"nctId":1710,"briefTitle":1711,"status":105,"phases":8413,"primaryCompletion":1713,"completion":609,"start":754,"enrollment":1714,"conditions":8414,"interventions":8415},[90],[21],[1010,1717,1718,1719,1094],{"trials":8417,"activeCount":123},[8418,8422],{"nctId":1731,"briefTitle":1732,"status":105,"phases":8419,"primaryCompletion":859,"completion":1734,"start":1601,"enrollment":779,"conditions":8420,"interventions":8421},[91],[21],[1010,1717],{"nctId":8423,"briefTitle":8424,"status":105,"phases":8425,"primaryCompletion":132,"completion":576,"start":3770,"enrollment":569,"conditions":8426,"interventions":8427},"NCT00002879","Cladribine in Patients With Mantle Cell Lymphoma",[91],[21],[1717],{"trials":8429,"activeCount":123},[],{"trials":8431,"activeCount":123},[],{"trials":8433,"activeCount":123},[],{"intervention":2538,"totalTrials":459,"cells":8435},{"EARLY_PHASE1":8436,"PHASE1":8438,"PHASE2":8440,"PHASE3":8454,"PHASE4":8456,"NA":8458},{"trials":8437,"activeCount":123},[],{"trials":8439,"activeCount":123},[],{"trials":8441,"activeCount":123},[8442,8446,8450],{"nctId":2530,"briefTitle":2531,"status":105,"phases":8443,"primaryCompletion":2533,"completion":360,"start":1140,"enrollment":974,"conditions":8444,"interventions":8445},[91],[27,21,2525,2526,2535,2536],[2538,885,1829,1830,1220,2539,1832,2540],{"nctId":2578,"briefTitle":2579,"status":312,"phases":8447,"primaryCompletion":547,"completion":618,"start":776,"enrollment":2581,"conditions":8448,"interventions":8449},[91],[27,21,2583,2584,2535,2585],[2538,2587,593,2552,1829,1830,1220,2539,1832],{"nctId":2601,"briefTitle":2602,"status":105,"phases":8451,"primaryCompletion":190,"completion":2604,"start":2175,"enrollment":2605,"conditions":8452,"interventions":8453},[91],[2607,2608],[593,2610,1829,1830,1220,1832],{"trials":8455,"activeCount":123},[],{"trials":8457,"activeCount":123},[],{"trials":8459,"activeCount":123},[],{"intervention":3921,"totalTrials":459,"cells":8461},{"EARLY_PHASE1":8462,"PHASE1":8464,"PHASE2":8466,"PHASE3":8487,"PHASE4":8489,"NA":8491},{"trials":8463,"activeCount":123},[],{"trials":8465,"activeCount":123},[],{"trials":8467,"activeCount":123},[8468,8476,8480],{"nctId":8469,"briefTitle":8470,"status":105,"phases":8471,"primaryCompletion":536,"completion":577,"start":891,"enrollment":442,"conditions":8472,"interventions":8474},"NCT00003323","Hormone Therapy in Treating Patients With Prostate Cancer",[91],[33,8473],"Sexual Dysfunction and Infertility",[8475,3921],"finasteride",{"nctId":3914,"briefTitle":3915,"status":105,"phases":8477,"primaryCompletion":2175,"completion":1446,"start":3917,"enrollment":3918,"conditions":8478,"interventions":8479},[91],[33],[3921,3922,3923],{"nctId":8481,"briefTitle":8482,"status":105,"phases":8483,"primaryCompletion":1028,"completion":1028,"start":8484,"enrollment":3869,"conditions":8485,"interventions":8486},"NCT00006214","Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate",[91],"2000-08",[33],[3921],{"trials":8488,"activeCount":123},[],{"trials":8490,"activeCount":123},[],{"trials":8492,"activeCount":123},[],{"intervention":1002,"totalTrials":459,"cells":8494},{"EARLY_PHASE1":8495,"PHASE1":8497,"PHASE2":8499,"PHASE3":8513,"PHASE4":8515,"NA":8517},{"trials":8496,"activeCount":123},[],{"trials":8498,"activeCount":123},[],{"trials":8500,"activeCount":123},[8501,8505,8509],{"nctId":996,"briefTitle":997,"status":105,"phases":8502,"primaryCompletion":999,"completion":145,"start":630,"enrollment":8,"conditions":8503,"interventions":8504},[91],[224,36],[1002,791,43],{"nctId":4928,"briefTitle":4929,"status":105,"phases":8506,"primaryCompletion":179,"completion":806,"start":813,"enrollment":1838,"conditions":8507,"interventions":8508},[91],[171],[1002,613,185],{"nctId":1443,"briefTitle":1444,"status":105,"phases":8510,"primaryCompletion":221,"completion":806,"start":1446,"enrollment":1447,"conditions":8511,"interventions":8512},[91],[171],[1002,121,138,185],{"trials":8514,"activeCount":123},[],{"trials":8516,"activeCount":123},[],{"trials":8518,"activeCount":123},[],{"intervention":2185,"totalTrials":459,"cells":8520},{"EARLY_PHASE1":8521,"PHASE1":8523,"PHASE2":8525,"PHASE3":8541,"PHASE4":8543,"NA":8545},{"trials":8522,"activeCount":123},[],{"trials":8524,"activeCount":123},[],{"trials":8526,"activeCount":123},[8527,8531,8535],{"nctId":3270,"briefTitle":3271,"status":105,"phases":8528,"primaryCompletion":314,"completion":1702,"start":705,"enrollment":3273,"conditions":8529,"interventions":8530},[91],[3275],[184,2185],{"nctId":2179,"briefTitle":2180,"status":105,"phases":8532,"primaryCompletion":1299,"completion":2155,"start":1446,"enrollment":2182,"conditions":8533,"interventions":8534},[90,91],[1022],[2185,828],{"nctId":8536,"briefTitle":8537,"status":105,"phases":8538,"primaryCompletion":755,"completion":299,"start":3240,"enrollment":620,"conditions":8539,"interventions":8540},"NCT00509041","Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma",[91],[4729],[2185],{"trials":8542,"activeCount":123},[],{"trials":8544,"activeCount":123},[],{"trials":8546,"activeCount":123},[],{"intervention":3567,"totalTrials":852,"cells":8548},{"EARLY_PHASE1":8549,"PHASE1":8551,"PHASE2":8553,"PHASE3":8563,"PHASE4":8565,"NA":8567},{"trials":8550,"activeCount":123},[],{"trials":8552,"activeCount":123},[],{"trials":8554,"activeCount":123},[8555,8559],{"nctId":6139,"briefTitle":6140,"status":105,"phases":8556,"primaryCompletion":990,"completion":755,"start":568,"enrollment":4470,"conditions":8557,"interventions":8558},[91],[27],[3567,1830],{"nctId":3562,"briefTitle":3563,"status":167,"phases":8560,"primaryCompletion":764,"completion":764,"start":191,"enrollment":123,"conditions":8561,"interventions":8562},[90,91],[27,21,2584,2535,2585],[3567,3568,1830,2067,2539],{"trials":8564,"activeCount":123},[],{"trials":8566,"activeCount":123},[],{"trials":8568,"activeCount":123},[],{"intervention":3568,"totalTrials":852,"cells":8570},{"EARLY_PHASE1":8571,"PHASE1":8573,"PHASE2":8575,"PHASE3":8588,"PHASE4":8590,"NA":8592},{"trials":8572,"activeCount":123},[],{"trials":8574,"activeCount":123},[],{"trials":8576,"activeCount":123},[8577,8584],{"nctId":8578,"briefTitle":8579,"status":105,"phases":8580,"primaryCompletion":1860,"completion":1860,"start":849,"enrollment":779,"conditions":8581,"interventions":8583},"NCT00031980","Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer",[91],[1030,27,1032,8582],"Thrombocytopenia",[3568],{"nctId":3562,"briefTitle":3563,"status":167,"phases":8585,"primaryCompletion":764,"completion":764,"start":191,"enrollment":123,"conditions":8586,"interventions":8587},[90,91],[27,21,2584,2535,2585],[3567,3568,1830,2067,2539],{"trials":8589,"activeCount":123},[],{"trials":8591,"activeCount":123},[],{"trials":8593,"activeCount":123},[],{"intervention":759,"totalTrials":852,"cells":8595},{"EARLY_PHASE1":8596,"PHASE1":8598,"PHASE2":8600,"PHASE3":8610,"PHASE4":8612,"NA":8614},{"trials":8597,"activeCount":123},[],{"trials":8599,"activeCount":123},[],{"trials":8601,"activeCount":123},[8602,8606],{"nctId":2385,"briefTitle":2386,"status":312,"phases":8603,"primaryCompletion":2388,"completion":999,"start":610,"enrollment":430,"conditions":8604,"interventions":8605},[91],[24],[759,139],{"nctId":751,"briefTitle":752,"status":105,"phases":8607,"primaryCompletion":754,"completion":755,"start":756,"enrollment":442,"conditions":8608,"interventions":8609},[91],[15],[524,759,185],{"trials":8611,"activeCount":123},[],{"trials":8613,"activeCount":123},[],{"trials":8615,"activeCount":123},[],{"intervention":603,"totalTrials":852,"cells":8617},{"EARLY_PHASE1":8618,"PHASE1":8620,"PHASE2":8622,"PHASE3":8634,"PHASE4":8636,"NA":8638},{"trials":8619,"activeCount":123},[],{"trials":8621,"activeCount":123},[],{"trials":8623,"activeCount":123},[8624,8630],{"nctId":8625,"briefTitle":8626,"status":105,"phases":8627,"primaryCompletion":3240,"completion":705,"start":796,"enrollment":8,"conditions":8628,"interventions":8629},"NCT00100945","Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer",[91],[36],[603],{"nctId":597,"briefTitle":598,"status":105,"phases":8631,"primaryCompletion":178,"completion":179,"start":290,"enrollment":600,"conditions":8632,"interventions":8633},[91],[15],[524,603,540],{"trials":8635,"activeCount":123},[],{"trials":8637,"activeCount":123},[],{"trials":8639,"activeCount":123},[],{"intervention":2552,"totalTrials":852,"cells":8641},{"EARLY_PHASE1":8642,"PHASE1":8644,"PHASE2":8646,"PHASE3":8656,"PHASE4":8658,"NA":8660},{"trials":8643,"activeCount":123},[],{"trials":8645,"activeCount":123},[],{"trials":8647,"activeCount":123},[8648,8652],{"nctId":2546,"briefTitle":2547,"status":105,"phases":8649,"primaryCompletion":648,"completion":648,"start":2450,"enrollment":1917,"conditions":8650,"interventions":8651},[91],[2550],[593,2552,1219,1830,1220,1832],{"nctId":2578,"briefTitle":2579,"status":312,"phases":8653,"primaryCompletion":547,"completion":618,"start":776,"enrollment":2581,"conditions":8654,"interventions":8655},[91],[27,21,2583,2584,2535,2585],[2538,2587,593,2552,1829,1830,1220,2539,1832],{"trials":8657,"activeCount":123},[],{"trials":8659,"activeCount":123},[],{"trials":8661,"activeCount":123},[],{"intervention":1793,"totalTrials":852,"cells":8663},{"EARLY_PHASE1":8664,"PHASE1":8666,"PHASE2":8668,"PHASE3":8681,"PHASE4":8683,"NA":8685},{"trials":8665,"activeCount":123},[],{"trials":8667,"activeCount":123},[],{"trials":8669,"activeCount":123},[8670,8677],{"nctId":8671,"briefTitle":8672,"status":105,"phases":8673,"primaryCompletion":8674,"completion":1694,"start":5814,"enrollment":779,"conditions":8675,"interventions":8676},"NCT00516217","Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma",[91],"2011-09",[21],[1793],{"nctId":1787,"briefTitle":1788,"status":105,"phases":8678,"primaryCompletion":756,"completion":618,"start":180,"enrollment":1790,"conditions":8679,"interventions":8680},[91],[21],[1793,1010],{"trials":8682,"activeCount":123},[],{"trials":8684,"activeCount":123},[],{"trials":8686,"activeCount":123},[],{"intervention":680,"totalTrials":852,"cells":8688},{"EARLY_PHASE1":8689,"PHASE1":8691,"PHASE2":8693,"PHASE3":8707,"PHASE4":8709,"NA":8711},{"trials":8690,"activeCount":123},[],{"trials":8692,"activeCount":123},[],{"trials":8694,"activeCount":123},[8695,8703],{"nctId":8696,"briefTitle":8697,"status":105,"phases":8698,"primaryCompletion":190,"completion":8699,"start":648,"enrollment":8700,"conditions":8701,"interventions":8702},"NCT00310037","Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma",[91],"2022-06",151,[1896],[680],{"nctId":671,"briefTitle":672,"status":105,"phases":8704,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":8705,"interventions":8706},[91],[36],[680,524,540],{"trials":8708,"activeCount":123},[],{"trials":8710,"activeCount":123},[],{"trials":8712,"activeCount":123},[],{"intervention":3392,"totalTrials":852,"cells":8714},{"EARLY_PHASE1":8715,"PHASE1":8717,"PHASE2":8719,"PHASE3":8729,"PHASE4":8731,"NA":8733},{"trials":8716,"activeCount":123},[],{"trials":8718,"activeCount":123},[],{"trials":8720,"activeCount":123},[8721,8725],{"nctId":3383,"briefTitle":3384,"status":105,"phases":8722,"primaryCompletion":3386,"completion":1526,"start":3387,"enrollment":3388,"conditions":8723,"interventions":8724},[91],[1022],[3391,3392,1222],{"nctId":3074,"briefTitle":3075,"status":105,"phases":8726,"primaryCompletion":3077,"completion":2682,"start":2388,"enrollment":3078,"conditions":8727,"interventions":8728},[91],[21],[3081,3082,3083,3084,3085,1810,3086,1221,3087],{"trials":8730,"activeCount":123},[],{"trials":8732,"activeCount":123},[],{"trials":8734,"activeCount":123},[],{"intervention":4580,"totalTrials":852,"cells":8736},{"EARLY_PHASE1":8737,"PHASE1":8739,"PHASE2":8741,"PHASE3":8756,"PHASE4":8758,"NA":8760},{"trials":8738,"activeCount":123},[],{"trials":8740,"activeCount":123},[],{"trials":8742,"activeCount":123},[8743,8752],{"nctId":8744,"briefTitle":8745,"status":105,"phases":8746,"primaryCompletion":8747,"completion":2028,"start":8748,"enrollment":1904,"conditions":8749,"interventions":8751},"NCT02249949","Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery",[91],"2018-10-04","2015-02-11",[8750],"Liposarcoma",[4580],{"nctId":4570,"briefTitle":4571,"status":105,"phases":8753,"primaryCompletion":4573,"completion":4574,"start":4575,"enrollment":37,"conditions":8754,"interventions":8755},[91],[4577,4578],[4580,540],{"trials":8757,"activeCount":123},[],{"trials":8759,"activeCount":123},[],{"trials":8761,"activeCount":123},[],{"intervention":1753,"totalTrials":852,"cells":8763},{"EARLY_PHASE1":8764,"PHASE1":8766,"PHASE2":8768,"PHASE3":8778,"PHASE4":8780,"NA":8782},{"trials":8765,"activeCount":123},[],{"trials":8767,"activeCount":123},[],{"trials":8769,"activeCount":123},[8770,8774],{"nctId":1746,"briefTitle":1747,"status":105,"phases":8771,"primaryCompletion":1665,"completion":1749,"start":859,"enrollment":1750,"conditions":8772,"interventions":8773},[91],[21],[1753,1010,1219,1162,1221,1222],{"nctId":1779,"briefTitle":1780,"status":105,"phases":8775,"primaryCompletion":823,"completion":1782,"start":610,"enrollment":1783,"conditions":8776,"interventions":8777},[91],[21],[1753,1010],{"trials":8779,"activeCount":123},[],{"trials":8781,"activeCount":123},[],{"trials":8783,"activeCount":123},[],{"intervention":652,"totalTrials":852,"cells":8785},{"EARLY_PHASE1":8786,"PHASE1":8788,"PHASE2":8790,"PHASE3":8800,"PHASE4":8802,"NA":8804},{"trials":8787,"activeCount":123},[],{"trials":8789,"activeCount":123},[],{"trials":8791,"activeCount":123},[8792,8796],{"nctId":645,"briefTitle":646,"status":105,"phases":8793,"primaryCompletion":372,"completion":648,"start":649,"enrollment":28,"conditions":8794,"interventions":8795},[91],[33],[593,524,43,652],{"nctId":1578,"briefTitle":1579,"status":105,"phases":8797,"primaryCompletion":859,"completion":754,"start":1581,"enrollment":1528,"conditions":8798,"interventions":8799},[91],[33],[43,652,736],{"trials":8801,"activeCount":123},[],{"trials":8803,"activeCount":123},[],{"trials":8805,"activeCount":123},[],{"intervention":736,"totalTrials":852,"cells":8807},{"EARLY_PHASE1":8808,"PHASE1":8810,"PHASE2":8812,"PHASE3":8822,"PHASE4":8824,"NA":8826},{"trials":8809,"activeCount":123},[],{"trials":8811,"activeCount":123},[],{"trials":8813,"activeCount":123},[8814,8818],{"nctId":1578,"briefTitle":1579,"status":105,"phases":8815,"primaryCompletion":859,"completion":754,"start":1581,"enrollment":1528,"conditions":8816,"interventions":8817},[91],[33],[43,652,736],{"nctId":729,"briefTitle":730,"status":105,"phases":8819,"primaryCompletion":732,"completion":133,"start":733,"enrollment":25,"conditions":8820,"interventions":8821},[91],[15],[524,594,736],{"trials":8823,"activeCount":123},[],{"trials":8825,"activeCount":123},[],{"trials":8827,"activeCount":123},[],{"intervention":561,"totalTrials":272,"cells":8829},{"EARLY_PHASE1":8830,"PHASE1":8832,"PHASE2":8834,"PHASE3":8840,"PHASE4":8842,"NA":8844},{"trials":8831,"activeCount":123},[],{"trials":8833,"activeCount":123},[],{"trials":8835,"activeCount":123},[8836],{"nctId":554,"briefTitle":555,"status":105,"phases":8837,"primaryCompletion":371,"completion":557,"start":372,"enrollment":558,"conditions":8838,"interventions":8839},[91],[15],[524,285,185,561],{"trials":8841,"activeCount":123},[],{"trials":8843,"activeCount":123},[],{"trials":8845,"activeCount":123},[],{"intervention":2528,"totalTrials":272,"cells":8847},{"EARLY_PHASE1":8848,"PHASE1":8850,"PHASE2":8852,"PHASE3":8858,"PHASE4":8860,"NA":8862},{"trials":8849,"activeCount":123},[],{"trials":8851,"activeCount":123},[],{"trials":8853,"activeCount":123},[8854],{"nctId":2521,"briefTitle":2522,"status":105,"phases":8855,"primaryCompletion":648,"completion":755,"start":640,"enrollment":1783,"conditions":8856,"interventions":8857},[91],[2525,2526],[593,2528,1219,1830,2067,1220,1832],{"trials":8859,"activeCount":123},[],{"trials":8861,"activeCount":123},[],{"trials":8863,"activeCount":123},[],{"intervention":8865,"totalTrials":272,"cells":8866},"Seneca Valley virus-001",{"EARLY_PHASE1":8867,"PHASE1":8869,"PHASE2":8871,"PHASE3":8880,"PHASE4":8882,"NA":8884},{"trials":8868,"activeCount":123},[],{"trials":8870,"activeCount":123},[],{"trials":8872,"activeCount":123},[8873],{"nctId":8874,"briefTitle":8875,"status":312,"phases":8876,"primaryCompletion":787,"completion":8877,"start":236,"enrollment":246,"conditions":8878,"interventions":8879},"NCT01017601","Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[91],"2014-11-15",[15],[8865],{"trials":8881,"activeCount":123},[],{"trials":8883,"activeCount":123},[],{"trials":8885,"activeCount":123},[],{"intervention":2770,"totalTrials":272,"cells":8887},{"EARLY_PHASE1":8888,"PHASE1":8890,"PHASE2":8892,"PHASE3":8898,"PHASE4":8900,"NA":8902},{"trials":8889,"activeCount":123},[],{"trials":8891,"activeCount":123},[],{"trials":8893,"activeCount":123},[8894],{"nctId":2753,"briefTitle":2754,"status":2755,"phases":8895,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":8896,"interventions":8897},[91],[2761,2762,2763,2764,2765,2766,2767],[1810,1820,1811,1818,2769,2770,2771],{"trials":8899,"activeCount":123},[],{"trials":8901,"activeCount":123},[],{"trials":8903,"activeCount":123},[],{"intervention":2771,"totalTrials":272,"cells":8905},{"EARLY_PHASE1":8906,"PHASE1":8908,"PHASE2":8910,"PHASE3":8916,"PHASE4":8918,"NA":8920},{"trials":8907,"activeCount":123},[],{"trials":8909,"activeCount":123},[],{"trials":8911,"activeCount":123},[8912],{"nctId":2753,"briefTitle":2754,"status":2755,"phases":8913,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":8914,"interventions":8915},[91],[2761,2762,2763,2764,2765,2766,2767],[1810,1820,1811,1818,2769,2770,2771],{"trials":8917,"activeCount":123},[],{"trials":8919,"activeCount":123},[],{"trials":8921,"activeCount":123},[],{"intervention":8475,"totalTrials":272,"cells":8923},{"EARLY_PHASE1":8924,"PHASE1":8926,"PHASE2":8928,"PHASE3":8934,"PHASE4":8936,"NA":8938},{"trials":8925,"activeCount":123},[],{"trials":8927,"activeCount":123},[],{"trials":8929,"activeCount":123},[8930],{"nctId":8469,"briefTitle":8470,"status":105,"phases":8931,"primaryCompletion":536,"completion":577,"start":891,"enrollment":442,"conditions":8932,"interventions":8933},[91],[33,8473],[8475,3921],{"trials":8935,"activeCount":123},[],{"trials":8937,"activeCount":123},[],{"trials":8939,"activeCount":123},[],{"intervention":994,"totalTrials":272,"cells":8941},{"EARLY_PHASE1":8942,"PHASE1":8944,"PHASE2":8946,"PHASE3":8952,"PHASE4":8954,"NA":8956},{"trials":8943,"activeCount":123},[],{"trials":8945,"activeCount":123},[],{"trials":8947,"activeCount":123},[8948],{"nctId":986,"briefTitle":987,"status":105,"phases":8949,"primaryCompletion":685,"completion":989,"start":990,"enrollment":991,"conditions":8950,"interventions":8951},[91],[171],[994,791,120],{"trials":8953,"activeCount":123},[],{"trials":8955,"activeCount":123},[],{"trials":8957,"activeCount":123},[],{"intervention":8959,"totalTrials":272,"cells":8960},"pentostatin",{"EARLY_PHASE1":8961,"PHASE1":8963,"PHASE2":8965,"PHASE3":8973,"PHASE4":8975,"NA":8977},{"trials":8962,"activeCount":123},[],{"trials":8964,"activeCount":123},[],{"trials":8966,"activeCount":123},[8967],{"nctId":8968,"briefTitle":8969,"status":105,"phases":8970,"primaryCompletion":639,"completion":107,"start":372,"enrollment":1727,"conditions":8971,"interventions":8972},"NCT00074035","Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease",[91],[2065],[8959],{"trials":8974,"activeCount":123},[],{"trials":8976,"activeCount":123},[],{"trials":8978,"activeCount":123},[],{"intervention":1744,"totalTrials":272,"cells":8980},{"EARLY_PHASE1":8981,"PHASE1":8983,"PHASE2":8985,"PHASE3":8991,"PHASE4":8993,"NA":8995},{"trials":8982,"activeCount":123},[],{"trials":8984,"activeCount":123},[],{"trials":8986,"activeCount":123},[8987],{"nctId":1738,"briefTitle":1739,"status":105,"phases":8988,"primaryCompletion":1741,"completion":805,"start":158,"enrollment":1191,"conditions":8989,"interventions":8990},[91],[21],[1744,1010],{"trials":8992,"activeCount":123},[],{"trials":8994,"activeCount":123},[],{"trials":8996,"activeCount":123},[],{"intervention":8998,"totalTrials":272,"cells":8999},"pixantrone dimaleate",{"EARLY_PHASE1":9000,"PHASE1":9002,"PHASE2":9004,"PHASE3":9012,"PHASE4":9014,"NA":9016},{"trials":9001,"activeCount":123},[],{"trials":9003,"activeCount":123},[],{"trials":9005,"activeCount":123},[9006],{"nctId":9007,"briefTitle":9008,"status":105,"phases":9009,"primaryCompletion":359,"completion":8877,"start":2388,"enrollment":620,"conditions":9010,"interventions":9011},"NCT01086605","Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer",[91],[18],[8998],{"trials":9013,"activeCount":123},[],{"trials":9015,"activeCount":123},[],{"trials":9017,"activeCount":123},[],{"intervention":9019,"totalTrials":272,"cells":9020},"PTK787\u002FZK 222584",{"EARLY_PHASE1":9021,"PHASE1":9023,"PHASE2":9025,"PHASE3":9033,"PHASE4":9035,"NA":9037},{"trials":9022,"activeCount":123},[],{"trials":9024,"activeCount":123},[],{"trials":9026,"activeCount":123},[9027],{"nctId":9028,"briefTitle":9029,"status":105,"phases":9030,"primaryCompletion":796,"completion":648,"start":566,"enrollment":1232,"conditions":9031,"interventions":9032},"NCT00053885","PTK787\u002FZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma",[91],[4729],[9019],{"trials":9034,"activeCount":123},[],{"trials":9036,"activeCount":123},[],{"trials":9038,"activeCount":123},[],{"intervention":3391,"totalTrials":272,"cells":9040},{"EARLY_PHASE1":9041,"PHASE1":9043,"PHASE2":9045,"PHASE3":9051,"PHASE4":9053,"NA":9055},{"trials":9042,"activeCount":123},[],{"trials":9044,"activeCount":123},[],{"trials":9046,"activeCount":123},[9047],{"nctId":3383,"briefTitle":3384,"status":105,"phases":9048,"primaryCompletion":3386,"completion":1526,"start":3387,"enrollment":3388,"conditions":9049,"interventions":9050},[91],[1022],[3391,3392,1222],{"trials":9052,"activeCount":123},[],{"trials":9054,"activeCount":123},[],{"trials":9056,"activeCount":123},[],{"intervention":9058,"totalTrials":272,"cells":9059},"vatalanib",{"EARLY_PHASE1":9060,"PHASE1":9062,"PHASE2":9064,"PHASE3":9072,"PHASE4":9074,"NA":9076},{"trials":9061,"activeCount":123},[],{"trials":9063,"activeCount":123},[],{"trials":9065,"activeCount":123},[9066],{"nctId":9067,"briefTitle":9068,"status":105,"phases":9069,"primaryCompletion":3294,"completion":3118,"start":372,"enrollment":7370,"conditions":9070,"interventions":9071},"NCT00072475","Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes",[91],[27,2535,2585],[9058],{"trials":9073,"activeCount":123},[],{"trials":9075,"activeCount":123},[],{"trials":9077,"activeCount":123},[],{"intervention":4752,"totalTrials":272,"cells":9079},{"EARLY_PHASE1":9080,"PHASE1":9082,"PHASE2":9084,"PHASE3":9090,"PHASE4":9092,"NA":9094},{"trials":9081,"activeCount":123},[],{"trials":9083,"activeCount":123},[],{"trials":9085,"activeCount":123},[9086],{"nctId":4746,"briefTitle":4747,"status":167,"phases":9087,"primaryCompletion":630,"completion":630,"start":4749,"enrollment":123,"conditions":9088,"interventions":9089},[91],[18],[121,4752],{"trials":9091,"activeCount":123},[],{"trials":9093,"activeCount":123},[],{"trials":9095,"activeCount":123},[],{"intervention":4760,"totalTrials":272,"cells":9097},{"EARLY_PHASE1":9098,"PHASE1":9100,"PHASE2":9102,"PHASE3":9108,"PHASE4":9110,"NA":9112},{"trials":9099,"activeCount":123},[],{"trials":9101,"activeCount":123},[],{"trials":9103,"activeCount":123},[9104],{"nctId":4754,"briefTitle":4755,"status":105,"phases":9105,"primaryCompletion":787,"completion":787,"start":4757,"enrollment":3366,"conditions":9106,"interventions":9107},[91],[224,36],[121,4760],{"trials":9109,"activeCount":123},[],{"trials":9111,"activeCount":123},[],{"trials":9113,"activeCount":123},[],{"intervention":1034,"totalTrials":272,"cells":9115},{"EARLY_PHASE1":9116,"PHASE1":9118,"PHASE2":9120,"PHASE3":9126,"PHASE4":9128,"NA":9130},{"trials":9117,"activeCount":123},[],{"trials":9119,"activeCount":123},[],{"trials":9121,"activeCount":123},[9122],{"nctId":1025,"briefTitle":1026,"status":105,"phases":9123,"primaryCompletion":1028,"completion":754,"start":732,"enrollment":9,"conditions":9124,"interventions":9125},[91],[1030,1031,15,1032],[1034,745,791,43,1035],{"trials":9127,"activeCount":123},[],{"trials":9129,"activeCount":123},[],{"trials":9131,"activeCount":123},[],{"intervention":1035,"totalTrials":272,"cells":9133},{"EARLY_PHASE1":9134,"PHASE1":9136,"PHASE2":9138,"PHASE3":9144,"PHASE4":9146,"NA":9148},{"trials":9135,"activeCount":123},[],{"trials":9137,"activeCount":123},[],{"trials":9139,"activeCount":123},[9140],{"nctId":1025,"briefTitle":1026,"status":105,"phases":9141,"primaryCompletion":1028,"completion":754,"start":732,"enrollment":9,"conditions":9142,"interventions":9143},[91],[1030,1031,15,1032],[1034,745,791,43,1035],{"trials":9145,"activeCount":123},[],{"trials":9147,"activeCount":123},[],{"trials":9149,"activeCount":123},[],{"intervention":3922,"totalTrials":272,"cells":9151},{"EARLY_PHASE1":9152,"PHASE1":9154,"PHASE2":9156,"PHASE3":9162,"PHASE4":9164,"NA":9166},{"trials":9153,"activeCount":123},[],{"trials":9155,"activeCount":123},[],{"trials":9157,"activeCount":123},[9158],{"nctId":3914,"briefTitle":3915,"status":105,"phases":9159,"primaryCompletion":2175,"completion":1446,"start":3917,"enrollment":3918,"conditions":9160,"interventions":9161},[91],[33],[3921,3922,3923],{"trials":9163,"activeCount":123},[],{"trials":9165,"activeCount":123},[],{"trials":9167,"activeCount":123},[],{"intervention":3872,"totalTrials":272,"cells":9169},{"EARLY_PHASE1":9170,"PHASE1":9172,"PHASE2":9174,"PHASE3":9180,"PHASE4":9182,"NA":9184},{"trials":9171,"activeCount":123},[],{"trials":9173,"activeCount":123},[],{"trials":9175,"activeCount":123},[9176],{"nctId":3865,"briefTitle":3866,"status":105,"phases":9177,"primaryCompletion":199,"completion":547,"start":3868,"enrollment":3869,"conditions":9178,"interventions":9179},[91],[33],[1660,3872],{"trials":9181,"activeCount":123},[],{"trials":9183,"activeCount":123},[],{"trials":9185,"activeCount":123},[],{"intervention":173,"totalTrials":272,"cells":9187},{"EARLY_PHASE1":9188,"PHASE1":9190,"PHASE2":9192,"PHASE3":9198,"PHASE4":9200,"NA":9202},{"trials":9189,"activeCount":123},[],{"trials":9191,"activeCount":123},[],{"trials":9193,"activeCount":123},[9194],{"nctId":165,"briefTitle":166,"status":167,"phases":9195,"primaryCompletion":169,"start":169,"enrollment":123,"conditions":9196,"interventions":9197},[90,91],[171],[173,138,139,140,97],{"trials":9199,"activeCount":123},[],{"trials":9201,"activeCount":123},[],{"trials":9203,"activeCount":123},[],{"intervention":659,"totalTrials":272,"cells":9205},{"EARLY_PHASE1":9206,"PHASE1":9208,"PHASE2":9210,"PHASE3":9216,"PHASE4":9218,"NA":9220},{"trials":9207,"activeCount":123},[],{"trials":9209,"activeCount":123},[],{"trials":9211,"activeCount":123},[9212],{"nctId":654,"briefTitle":655,"status":167,"phases":9213,"enrollment":123,"conditions":9214,"interventions":9215},[91],[15],[659,524,185],{"trials":9217,"activeCount":123},[],{"trials":9219,"activeCount":123},[],{"trials":9221,"activeCount":123},[],{"intervention":6274,"totalTrials":272,"cells":9223},{"EARLY_PHASE1":9224,"PHASE1":9226,"PHASE2":9228,"PHASE3":9234,"PHASE4":9236,"NA":9238},{"trials":9225,"activeCount":123},[],{"trials":9227,"activeCount":123},[],{"trials":9229,"activeCount":123},[9230],{"nctId":6268,"briefTitle":6269,"status":105,"phases":9231,"primaryCompletion":618,"completion":6271,"start":1298,"enrollment":1974,"conditions":9232,"interventions":9233},[90,91],[18],[3825,6274,5842,5809,5820],{"trials":9235,"activeCount":123},[],{"trials":9237,"activeCount":123},[],{"trials":9239,"activeCount":123},[],{"intervention":9241,"totalTrials":272,"cells":9242},"liposomal SN-38",{"EARLY_PHASE1":9243,"PHASE1":9245,"PHASE2":9247,"PHASE3":9255,"PHASE4":9257,"NA":9259},{"trials":9244,"activeCount":123},[],{"trials":9246,"activeCount":123},[],{"trials":9248,"activeCount":123},[9249],{"nctId":9250,"briefTitle":9251,"status":167,"phases":9252,"enrollment":123,"conditions":9253,"interventions":9254},"NCT00104754","Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer",[91],[15],[9241],{"trials":9256,"activeCount":123},[],{"trials":9258,"activeCount":123},[],{"trials":9260,"activeCount":123},[],{"intervention":9262,"totalTrials":272,"cells":9263},"Naloxegol",{"EARLY_PHASE1":9264,"PHASE1":9266,"PHASE2":9268,"PHASE3":9280,"PHASE4":9282,"NA":9284},{"trials":9265,"activeCount":123},[],{"trials":9267,"activeCount":123},[],{"trials":9269,"activeCount":123},[9270],{"nctId":9271,"briefTitle":9272,"status":312,"phases":9273,"primaryCompletion":9274,"completion":220,"start":9275,"enrollment":707,"conditions":9276,"interventions":9279},"NCT03087708","Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer",[91],"2021-01-04","2018-03-23",[9277,9278],"Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer",[9262],{"trials":9281,"activeCount":123},[],{"trials":9283,"activeCount":123},[],{"trials":9285,"activeCount":123},[],{"intervention":9287,"totalTrials":272,"cells":9288},"ceramide",{"EARLY_PHASE1":9289,"PHASE1":9291,"PHASE2":9293,"PHASE3":9301,"PHASE4":9303,"NA":9305},{"trials":9290,"activeCount":123},[],{"trials":9292,"activeCount":123},[],{"trials":9294,"activeCount":123},[9295],{"nctId":9296,"briefTitle":9297,"status":105,"phases":9298,"primaryCompletion":1345,"completion":705,"start":981,"enrollment":953,"conditions":9299,"interventions":9300},"NCT00008320","Ceramide Cream in Treating Women With Cutaneous Breast Cancer",[91],[18],[9287],{"trials":9302,"activeCount":123},[],{"trials":9304,"activeCount":123},[],{"trials":9306,"activeCount":123},[],{"intervention":9308,"totalTrials":272,"cells":9309},"nitrocamptothecin",{"EARLY_PHASE1":9310,"PHASE1":9312,"PHASE2":9314,"PHASE3":9323,"PHASE4":9325,"NA":9327},{"trials":9311,"activeCount":123},[],{"trials":9313,"activeCount":123},[],{"trials":9315,"activeCount":123},[9316],{"nctId":9317,"briefTitle":9318,"status":105,"phases":9319,"primaryCompletion":9320,"completion":848,"start":2403,"enrollment":5240,"conditions":9321,"interventions":9322},"NCT00005820","Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy",[91],"2004-09",[33],[9308],{"trials":9324,"activeCount":123},[],{"trials":9326,"activeCount":123},[],{"trials":9328,"activeCount":123},[],{"intervention":689,"totalTrials":272,"cells":9330},{"EARLY_PHASE1":9331,"PHASE1":9333,"PHASE2":9335,"PHASE3":9341,"PHASE4":9343,"NA":9345},{"trials":9332,"activeCount":123},[],{"trials":9334,"activeCount":123},[],{"trials":9336,"activeCount":123},[9337],{"nctId":682,"briefTitle":683,"status":105,"phases":9338,"primaryCompletion":685,"completion":675,"start":686,"enrollment":31,"conditions":9339,"interventions":9340},[91],[33],[524,689,540,690],{"trials":9342,"activeCount":123},[],{"trials":9344,"activeCount":123},[],{"trials":9346,"activeCount":123},[],{"intervention":690,"totalTrials":272,"cells":9348},{"EARLY_PHASE1":9349,"PHASE1":9351,"PHASE2":9353,"PHASE3":9359,"PHASE4":9361,"NA":9363},{"trials":9350,"activeCount":123},[],{"trials":9352,"activeCount":123},[],{"trials":9354,"activeCount":123},[9355],{"nctId":682,"briefTitle":683,"status":105,"phases":9356,"primaryCompletion":685,"completion":675,"start":686,"enrollment":31,"conditions":9357,"interventions":9358},[91],[33],[524,689,540,690],{"trials":9360,"activeCount":123},[],{"trials":9362,"activeCount":123},[],{"trials":9364,"activeCount":123},[],{"intervention":9366,"totalTrials":272,"cells":9367},"mitoxantrone hydrochloride",{"EARLY_PHASE1":9368,"PHASE1":9370,"PHASE2":9372,"PHASE3":9380,"PHASE4":9382,"NA":9384},{"trials":9369,"activeCount":123},[],{"trials":9371,"activeCount":123},[],{"trials":9373,"activeCount":123},[9374],{"nctId":9375,"briefTitle":9376,"status":167,"phases":9377,"enrollment":123,"conditions":9378,"interventions":9379},"NCT00003858","Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence",[91],[33],[9366],{"trials":9381,"activeCount":123},[],{"trials":9383,"activeCount":123},[],{"trials":9385,"activeCount":123},[],{"intervention":9387,"totalTrials":272,"cells":9388},"BRD4 Inhibitor PLX2853",{"EARLY_PHASE1":9389,"PHASE1":9391,"PHASE2":9393,"PHASE3":9407,"PHASE4":9409,"NA":9411},{"trials":9390,"activeCount":123},[],{"trials":9392,"activeCount":123},[],{"trials":9394,"activeCount":123},[9395],{"nctId":9396,"briefTitle":9397,"status":167,"phases":9398,"primaryCompletion":9399,"completion":9399,"start":9400,"enrollment":123,"conditions":9401,"interventions":9405},"NCT05677373","Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma",[90,91],"2025-07-31","2023-01-13",[9402,9403,9404],"Advanced Uveal Melanoma","Metastatic Uveal Melanoma","Unresectable Uveal Melanoma",[9387,9406],"Trametinib",{"trials":9408,"activeCount":123},[],{"trials":9410,"activeCount":123},[],{"trials":9412,"activeCount":123},[],{"intervention":9406,"totalTrials":272,"cells":9414},{"EARLY_PHASE1":9415,"PHASE1":9417,"PHASE2":9419,"PHASE3":9425,"PHASE4":9427,"NA":9429},{"trials":9416,"activeCount":123},[],{"trials":9418,"activeCount":123},[],{"trials":9420,"activeCount":123},[9421],{"nctId":9396,"briefTitle":9397,"status":167,"phases":9422,"primaryCompletion":9399,"completion":9399,"start":9400,"enrollment":123,"conditions":9423,"interventions":9424},[90,91],[9402,9403,9404],[9387,9406],{"trials":9426,"activeCount":123},[],{"trials":9428,"activeCount":123},[],{"trials":9430,"activeCount":123},[],{"intervention":9432,"totalTrials":272,"cells":9433},"karenitecin",{"EARLY_PHASE1":9434,"PHASE1":9436,"PHASE2":9438,"PHASE3":9447,"PHASE4":9449,"NA":9451},{"trials":9435,"activeCount":123},[],{"trials":9437,"activeCount":123},[],{"trials":9439,"activeCount":123},[9440],{"nctId":9441,"briefTitle":9442,"status":105,"phases":9443,"primaryCompletion":243,"completion":859,"start":1283,"enrollment":9444,"conditions":9445,"interventions":9446},"NCT00010218","Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer",[91],55,[15],[9432],{"trials":9448,"activeCount":123},[],{"trials":9450,"activeCount":123},[],{"trials":9452,"activeCount":123},[],{"intervention":1948,"totalTrials":272,"cells":9454},{"EARLY_PHASE1":9455,"PHASE1":9457,"PHASE2":9459,"PHASE3":9465,"PHASE4":9467,"NA":9469},{"trials":9456,"activeCount":123},[],{"trials":9458,"activeCount":123},[],{"trials":9460,"activeCount":123},[9461],{"nctId":1939,"briefTitle":1940,"status":925,"phases":9462,"primaryCompletion":1942,"start":1943,"enrollment":1944,"conditions":9463,"interventions":9464},[90,91],[1946],[1948,1949,1012],{"trials":9466,"activeCount":123},[],{"trials":9468,"activeCount":123},[],{"trials":9470,"activeCount":123},[],{"intervention":1243,"totalTrials":272,"cells":9472},{"EARLY_PHASE1":9473,"PHASE1":9475,"PHASE2":9477,"PHASE3":9483,"PHASE4":9485,"NA":9487},{"trials":9474,"activeCount":123},[],{"trials":9476,"activeCount":123},[],{"trials":9478,"activeCount":123},[9479],{"nctId":1236,"briefTitle":1237,"status":105,"phases":9480,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":9481,"interventions":9482},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"trials":9484,"activeCount":123},[],{"trials":9486,"activeCount":123},[],{"trials":9488,"activeCount":123},[],{"intervention":2652,"totalTrials":272,"cells":9490},{"EARLY_PHASE1":9491,"PHASE1":9493,"PHASE2":9495,"PHASE3":9501,"PHASE4":9503,"NA":9505},{"trials":9492,"activeCount":123},[],{"trials":9494,"activeCount":123},[],{"trials":9496,"activeCount":123},[9497],{"nctId":2644,"briefTitle":2645,"status":105,"phases":9498,"primaryCompletion":2647,"completion":973,"start":2648,"enrollment":2649,"conditions":9499,"interventions":9500},[91],[36],[205,2652,2653,2654],{"trials":9502,"activeCount":123},[],{"trials":9504,"activeCount":123},[],{"trials":9506,"activeCount":123},[],{"intervention":2653,"totalTrials":272,"cells":9508},{"EARLY_PHASE1":9509,"PHASE1":9511,"PHASE2":9513,"PHASE3":9519,"PHASE4":9521,"NA":9523},{"trials":9510,"activeCount":123},[],{"trials":9512,"activeCount":123},[],{"trials":9514,"activeCount":123},[9515],{"nctId":2644,"briefTitle":2645,"status":105,"phases":9516,"primaryCompletion":2647,"completion":973,"start":2648,"enrollment":2649,"conditions":9517,"interventions":9518},[91],[36],[205,2652,2653,2654],{"trials":9520,"activeCount":123},[],{"trials":9522,"activeCount":123},[],{"trials":9524,"activeCount":123},[],{"intervention":9526,"totalTrials":272,"cells":9527},"systemic chemotherapy",{"EARLY_PHASE1":9528,"PHASE1":9530,"PHASE2":9532,"PHASE3":9541,"PHASE4":9543,"NA":9545},{"trials":9529,"activeCount":123},[],{"trials":9531,"activeCount":123},[],{"trials":9533,"activeCount":123},[9534],{"nctId":9535,"briefTitle":9536,"status":105,"phases":9537,"primaryCompletion":824,"completion":4574,"start":1103,"enrollment":9538,"conditions":9539,"interventions":9540},"NCT00881361","Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer",[91],756,[18],[9526],{"trials":9542,"activeCount":123},[],{"trials":9544,"activeCount":123},[],{"trials":9546,"activeCount":123},[],{"intervention":1258,"totalTrials":272,"cells":9548},{"EARLY_PHASE1":9549,"PHASE1":9551,"PHASE2":9553,"PHASE3":9559,"PHASE4":9561,"NA":9563},{"trials":9550,"activeCount":123},[],{"trials":9552,"activeCount":123},[],{"trials":9554,"activeCount":123},[9555],{"nctId":1250,"briefTitle":1251,"status":105,"phases":9556,"primaryCompletion":1253,"completion":236,"start":1254,"enrollment":1255,"conditions":9557,"interventions":9558},[91],[27],[885,1258,1219,1011,1259,140,1260,1220,1221,1222,1261],{"trials":9560,"activeCount":123},[],{"trials":9562,"activeCount":123},[],{"trials":9564,"activeCount":123},[],{"intervention":9566,"totalTrials":272,"cells":9567},"ABVD",{"EARLY_PHASE1":9568,"PHASE1":9570,"PHASE2":9572,"PHASE3":9583,"PHASE4":9585,"NA":9587},{"trials":9569,"activeCount":123},[],{"trials":9571,"activeCount":123},[],{"trials":9573,"activeCount":123},[9574],{"nctId":9575,"briefTitle":9576,"status":105,"phases":9577,"primaryCompletion":9578,"completion":9579,"start":1298,"enrollment":442,"conditions":9580,"interventions":9581},"NCT01118026","Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma",[91],"2020-09-30","2021-09-29",[21],[9566,9582],"BEACOPP",{"trials":9584,"activeCount":123},[],{"trials":9586,"activeCount":123},[],{"trials":9588,"activeCount":123},[],{"intervention":9582,"totalTrials":272,"cells":9590},{"EARLY_PHASE1":9591,"PHASE1":9593,"PHASE2":9595,"PHASE3":9601,"PHASE4":9603,"NA":9605},{"trials":9592,"activeCount":123},[],{"trials":9594,"activeCount":123},[],{"trials":9596,"activeCount":123},[9597],{"nctId":9575,"briefTitle":9576,"status":105,"phases":9598,"primaryCompletion":9578,"completion":9579,"start":1298,"enrollment":442,"conditions":9599,"interventions":9600},[91],[21],[9566,9582],{"trials":9602,"activeCount":123},[],{"trials":9604,"activeCount":123},[],{"trials":9606,"activeCount":123},[],{"intervention":6597,"totalTrials":272,"cells":9608},{"EARLY_PHASE1":9609,"PHASE1":9611,"PHASE2":9613,"PHASE3":9619,"PHASE4":9621,"NA":9623},{"trials":9610,"activeCount":123},[],{"trials":9612,"activeCount":123},[],{"trials":9614,"activeCount":123},[9615],{"nctId":6589,"briefTitle":6590,"status":925,"phases":9616,"primaryCompletion":6592,"start":1139,"enrollment":6593,"conditions":9617,"interventions":9618},[91],[1118,6595],[6597,2654],{"trials":9620,"activeCount":123},[],{"trials":9622,"activeCount":123},[],{"trials":9624,"activeCount":123},[],{"intervention":3081,"totalTrials":272,"cells":9626},{"EARLY_PHASE1":9627,"PHASE1":9629,"PHASE2":9631,"PHASE3":9637,"PHASE4":9639,"NA":9641},{"trials":9628,"activeCount":123},[],{"trials":9630,"activeCount":123},[],{"trials":9632,"activeCount":123},[9633],{"nctId":3074,"briefTitle":3075,"status":105,"phases":9634,"primaryCompletion":3077,"completion":2682,"start":2388,"enrollment":3078,"conditions":9635,"interventions":9636},[91],[21],[3081,3082,3083,3084,3085,1810,3086,1221,3087],{"trials":9638,"activeCount":123},[],{"trials":9640,"activeCount":123},[],{"trials":9642,"activeCount":123},[],{"intervention":3084,"totalTrials":272,"cells":9644},{"EARLY_PHASE1":9645,"PHASE1":9647,"PHASE2":9649,"PHASE3":9655,"PHASE4":9657,"NA":9659},{"trials":9646,"activeCount":123},[],{"trials":9648,"activeCount":123},[],{"trials":9650,"activeCount":123},[9651],{"nctId":3074,"briefTitle":3075,"status":105,"phases":9652,"primaryCompletion":3077,"completion":2682,"start":2388,"enrollment":3078,"conditions":9653,"interventions":9654},[91],[21],[3081,3082,3083,3084,3085,1810,3086,1221,3087],{"trials":9656,"activeCount":123},[],{"trials":9658,"activeCount":123},[],{"trials":9660,"activeCount":123},[],{"intervention":3085,"totalTrials":272,"cells":9662},{"EARLY_PHASE1":9663,"PHASE1":9665,"PHASE2":9667,"PHASE3":9673,"PHASE4":9675,"NA":9677},{"trials":9664,"activeCount":123},[],{"trials":9666,"activeCount":123},[],{"trials":9668,"activeCount":123},[9669],{"nctId":3074,"briefTitle":3075,"status":105,"phases":9670,"primaryCompletion":3077,"completion":2682,"start":2388,"enrollment":3078,"conditions":9671,"interventions":9672},[91],[21],[3081,3082,3083,3084,3085,1810,3086,1221,3087],{"trials":9674,"activeCount":123},[],{"trials":9676,"activeCount":123},[],{"trials":9678,"activeCount":123},[],{"intervention":3087,"totalTrials":272,"cells":9680},{"EARLY_PHASE1":9681,"PHASE1":9683,"PHASE2":9685,"PHASE3":9691,"PHASE4":9693,"NA":9695},{"trials":9682,"activeCount":123},[],{"trials":9684,"activeCount":123},[],{"trials":9686,"activeCount":123},[9687],{"nctId":3074,"briefTitle":3075,"status":105,"phases":9688,"primaryCompletion":3077,"completion":2682,"start":2388,"enrollment":3078,"conditions":9689,"interventions":9690},[91],[21],[3081,3082,3083,3084,3085,1810,3086,1221,3087],{"trials":9692,"activeCount":123},[],{"trials":9694,"activeCount":123},[],{"trials":9696,"activeCount":123},[],{"intervention":9698,"totalTrials":272,"cells":9699},"Oxybutynin Chloride",{"EARLY_PHASE1":9700,"PHASE1":9702,"PHASE2":9704,"PHASE3":9716,"PHASE4":9718,"NA":9720},{"trials":9701,"activeCount":123},[],{"trials":9703,"activeCount":123},[],{"trials":9705,"activeCount":123},[9706],{"nctId":9707,"briefTitle":9708,"status":105,"phases":9709,"primaryCompletion":9710,"completion":9711,"start":9712,"enrollment":1931,"conditions":9713,"interventions":9715},"NCT04600336","Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer",[91],"2024-02-05","2024-03-11","2021-10-28",[9714],"Prostate Carcinoma",[9698],{"trials":9717,"activeCount":123},[],{"trials":9719,"activeCount":123},[],{"trials":9721,"activeCount":123},[],{"intervention":9723,"totalTrials":272,"cells":9724},"6-hydroxymethylacylfulvene",{"EARLY_PHASE1":9725,"PHASE1":9727,"PHASE2":9729,"PHASE3":9738,"PHASE4":9740,"NA":9742},{"trials":9726,"activeCount":123},[],{"trials":9728,"activeCount":123},[],{"trials":9730,"activeCount":123},[9731],{"nctId":9732,"briefTitle":9733,"status":105,"phases":9734,"primaryCompletion":9320,"completion":859,"start":9735,"enrollment":1917,"conditions":9736,"interventions":9737},"NCT00003666","Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer",[91],"1998-11",[15],[9723],{"trials":9739,"activeCount":123},[],{"trials":9741,"activeCount":123},[],{"trials":9743,"activeCount":123},[],{"intervention":2587,"totalTrials":272,"cells":9745},{"EARLY_PHASE1":9746,"PHASE1":9748,"PHASE2":9750,"PHASE3":9756,"PHASE4":9758,"NA":9760},{"trials":9747,"activeCount":123},[],{"trials":9749,"activeCount":123},[],{"trials":9751,"activeCount":123},[9752],{"nctId":2578,"briefTitle":2579,"status":312,"phases":9753,"primaryCompletion":547,"completion":618,"start":776,"enrollment":2581,"conditions":9754,"interventions":9755},[91],[27,21,2583,2584,2535,2585],[2538,2587,593,2552,1829,1830,1220,2539,1832],{"trials":9757,"activeCount":123},[],{"trials":9759,"activeCount":123},[],{"trials":9761,"activeCount":123},[],{"intervention":4975,"totalTrials":272,"cells":9763},{"EARLY_PHASE1":9764,"PHASE1":9766,"PHASE2":9768,"PHASE3":9774,"PHASE4":9776,"NA":9778},{"trials":9765,"activeCount":123},[],{"trials":9767,"activeCount":123},[],{"trials":9769,"activeCount":123},[9770],{"nctId":4970,"briefTitle":4971,"status":105,"phases":9771,"primaryCompletion":2175,"completion":2175,"start":1047,"enrollment":160,"conditions":9772,"interventions":9773},[91],[171],[4975,185],{"trials":9775,"activeCount":123},[],{"trials":9777,"activeCount":123},[],{"trials":9779,"activeCount":123},[],{"intervention":9781,"totalTrials":272,"cells":9782},"magnesium oxide",{"EARLY_PHASE1":9783,"PHASE1":9785,"PHASE2":9787,"PHASE3":9796,"PHASE4":9798,"NA":9800},{"trials":9784,"activeCount":123},[],{"trials":9786,"activeCount":123},[],{"trials":9788,"activeCount":123},[9789],{"nctId":9790,"briefTitle":9791,"status":105,"phases":9792,"primaryCompletion":618,"completion":618,"start":8674,"enrollment":9793,"conditions":9794,"interventions":9795},"NCT01439945","Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer",[91],289,[18,8029,3500],[9781],{"trials":9797,"activeCount":123},[],{"trials":9799,"activeCount":123},[],{"trials":9801,"activeCount":123},[],{"intervention":1831,"totalTrials":272,"cells":9803},{"EARLY_PHASE1":9804,"PHASE1":9806,"PHASE2":9808,"PHASE3":9814,"PHASE4":9816,"NA":9818},{"trials":9805,"activeCount":123},[],{"trials":9807,"activeCount":123},[],{"trials":9809,"activeCount":123},[9810],{"nctId":1822,"briefTitle":1823,"status":105,"phases":9811,"primaryCompletion":1825,"completion":1826,"start":755,"enrollment":1805,"conditions":9812,"interventions":9813},[91],[27,21],[1010,1829,1219,1830,1220,1831,1832],{"trials":9815,"activeCount":123},[],{"trials":9817,"activeCount":123},[],{"trials":9819,"activeCount":123},[],{"intervention":9821,"totalTrials":272,"cells":9822},"ara-C",{"EARLY_PHASE1":9823,"PHASE1":9825,"PHASE2":9827,"PHASE3":9836,"PHASE4":9838,"NA":9840},{"trials":9824,"activeCount":123},[],{"trials":9826,"activeCount":123},[],{"trials":9828,"activeCount":123},[9829],{"nctId":9830,"briefTitle":9831,"status":105,"phases":9832,"primaryCompletion":200,"completion":1860,"start":2459,"enrollment":1783,"conditions":9833,"interventions":9834},"NCT00006265","Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[91],[27],[9821,9835],"gemtuzumab ozogamicin",{"trials":9837,"activeCount":123},[],{"trials":9839,"activeCount":123},[],{"trials":9841,"activeCount":123},[],{"intervention":9835,"totalTrials":272,"cells":9843},{"EARLY_PHASE1":9844,"PHASE1":9846,"PHASE2":9848,"PHASE3":9854,"PHASE4":9856,"NA":9858},{"trials":9845,"activeCount":123},[],{"trials":9847,"activeCount":123},[],{"trials":9849,"activeCount":123},[9850],{"nctId":9830,"briefTitle":9831,"status":105,"phases":9851,"primaryCompletion":200,"completion":1860,"start":2459,"enrollment":1783,"conditions":9852,"interventions":9853},[91],[27],[9821,9835],{"trials":9855,"activeCount":123},[],{"trials":9857,"activeCount":123},[],{"trials":9859,"activeCount":123},[],{"intervention":9861,"totalTrials":272,"cells":9862},"recombinant interleukin-12",{"EARLY_PHASE1":9863,"PHASE1":9865,"PHASE2":9867,"PHASE3":9876,"PHASE4":9878,"NA":9880},{"trials":9864,"activeCount":123},[],{"trials":9866,"activeCount":123},[],{"trials":9868,"activeCount":123},[9869],{"nctId":9870,"briefTitle":9871,"status":105,"phases":9872,"primaryCompletion":1849,"completion":1849,"start":9873,"enrollment":430,"conditions":9874,"interventions":9875},"NCT00004893","Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer",[91],"1999-12",[18],[9861],{"trials":9877,"activeCount":123},[],{"trials":9879,"activeCount":123},[],{"trials":9881,"activeCount":123},[],{"intervention":9883,"totalTrials":272,"cells":9884},"Imatinib Mesylate",{"EARLY_PHASE1":9885,"PHASE1":9887,"PHASE2":9889,"PHASE3":9901,"PHASE4":9903,"NA":9905},{"trials":9886,"activeCount":123},[],{"trials":9888,"activeCount":123},[],{"trials":9890,"activeCount":123},[9891],{"nctId":9892,"briefTitle":9893,"status":105,"phases":9894,"primaryCompletion":7951,"completion":7494,"start":244,"enrollment":2452,"conditions":9895,"interventions":9900},"NCT00049127","Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor",[90,91],[9896,9897,9898,9899],"Adult Anaplastic Oligodendroglioma","Adult Mixed Glioma","Adult Oligodendroglioma","Recurrent Adult Brain Neoplasm",[9883],{"trials":9902,"activeCount":123},[],{"trials":9904,"activeCount":123},[],{"trials":9906,"activeCount":123},[],{"intervention":1051,"totalTrials":272,"cells":9908},{"EARLY_PHASE1":9909,"PHASE1":9911,"PHASE2":9913,"PHASE3":9919,"PHASE4":9921,"NA":9923},{"trials":9910,"activeCount":123},[],{"trials":9912,"activeCount":123},[],{"trials":9914,"activeCount":123},[9915],{"nctId":1045,"briefTitle":762,"status":105,"phases":9916,"primaryCompletion":191,"completion":191,"start":1047,"enrollment":201,"conditions":9917,"interventions":9918},[90,91],[1031,15,1049],[593,1051,791,594,540,595],{"trials":9920,"activeCount":123},[],{"trials":9922,"activeCount":123},[],{"trials":9924,"activeCount":123},[],{"intervention":4783,"totalTrials":272,"cells":9926},{"EARLY_PHASE1":9927,"PHASE1":9929,"PHASE2":9931,"PHASE3":9937,"PHASE4":9939,"NA":9941},{"trials":9928,"activeCount":123},[],{"trials":9930,"activeCount":123},[],{"trials":9932,"activeCount":123},[9933],{"nctId":4778,"briefTitle":4779,"status":105,"phases":9934,"primaryCompletion":3240,"completion":806,"start":706,"enrollment":160,"conditions":9935,"interventions":9936},[91],[18],[121,4783],{"trials":9938,"activeCount":123},[],{"trials":9940,"activeCount":123},[],{"trials":9942,"activeCount":123},[],{"intervention":1968,"totalTrials":272,"cells":9944},{"EARLY_PHASE1":9945,"PHASE1":9947,"PHASE2":9949,"PHASE3":9955,"PHASE4":9957,"NA":9959},{"trials":9946,"activeCount":123},[],{"trials":9948,"activeCount":123},[],{"trials":9950,"activeCount":123},[9951],{"nctId":1959,"briefTitle":1960,"status":105,"phases":9952,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":9953,"interventions":9954},[91],[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],{"trials":9956,"activeCount":123},[],{"trials":9958,"activeCount":123},[],{"trials":9960,"activeCount":123},[],{"intervention":9962,"totalTrials":272,"cells":9963},"ofatumumab",{"EARLY_PHASE1":9964,"PHASE1":9966,"PHASE2":9968,"PHASE3":9977,"PHASE4":9979,"NA":9981},{"trials":9965,"activeCount":123},[],{"trials":9967,"activeCount":123},[],{"trials":9969,"activeCount":123},[9970],{"nctId":9971,"briefTitle":9972,"status":105,"phases":9973,"primaryCompletion":833,"completion":9974,"start":7951,"enrollment":569,"conditions":9975,"interventions":9976},"NCT01190449","Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma",[91],"2020-10-15",[21],[9962],{"trials":9978,"activeCount":123},[],{"trials":9980,"activeCount":123},[],{"trials":9982,"activeCount":123},[],{"intervention":4625,"totalTrials":272,"cells":9984},{"EARLY_PHASE1":9985,"PHASE1":9987,"PHASE2":9989,"PHASE3":9995,"PHASE4":9997,"NA":9999},{"trials":9986,"activeCount":123},[],{"trials":9988,"activeCount":123},[],{"trials":9990,"activeCount":123},[9991],{"nctId":4613,"briefTitle":4614,"status":2755,"phases":9992,"primaryCompletion":4616,"completion":4617,"start":4618,"enrollment":4619,"conditions":9993,"interventions":9994},[91],[4621,4622,4623],[230,4625],{"trials":9996,"activeCount":123},[],{"trials":9998,"activeCount":123},[],{"trials":10000,"activeCount":123},[],{"intervention":10002,"totalTrials":272,"cells":10003},"imiquimod",{"EARLY_PHASE1":10004,"PHASE1":10006,"PHASE2":10008,"PHASE3":10017,"PHASE4":10019,"NA":10021},{"trials":10005,"activeCount":123},[],{"trials":10007,"activeCount":123},[],{"trials":10009,"activeCount":123},[10010],{"nctId":10011,"briefTitle":10012,"status":105,"phases":10013,"primaryCompletion":1526,"completion":755,"start":5936,"enrollment":10014,"conditions":10015,"interventions":10016},"NCT00031759","Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia",[91],57,[6532,6661],[10002],{"trials":10018,"activeCount":123},[],{"trials":10020,"activeCount":123},[],{"trials":10022,"activeCount":123},[],{"intervention":1067,"totalTrials":272,"cells":10024},{"EARLY_PHASE1":10025,"PHASE1":10027,"PHASE2":10029,"PHASE3":10035,"PHASE4":10037,"NA":10039},{"trials":10026,"activeCount":123},[],{"trials":10028,"activeCount":123},[],{"trials":10030,"activeCount":123},[10031],{"nctId":1060,"briefTitle":1061,"status":105,"phases":10032,"primaryCompletion":1063,"completion":107,"start":281,"enrollment":160,"conditions":10033,"interventions":10034},[91],[1065],[1067,791],{"trials":10036,"activeCount":123},[],{"trials":10038,"activeCount":123},[],{"trials":10040,"activeCount":123},[],{"intervention":1079,"totalTrials":272,"cells":10042},{"EARLY_PHASE1":10043,"PHASE1":10045,"PHASE2":10047,"PHASE3":10053,"PHASE4":10055,"NA":10057},{"trials":10044,"activeCount":123},[],{"trials":10046,"activeCount":123},[],{"trials":10048,"activeCount":123},[10049],{"nctId":1069,"briefTitle":1070,"status":105,"phases":10050,"primaryCompletion":1072,"completion":1072,"start":1018,"enrollment":1073,"conditions":10051,"interventions":10052},[91],[1075,1076,1077,15],[791,1079,185],{"trials":10054,"activeCount":123},[],{"trials":10056,"activeCount":123},[],{"trials":10058,"activeCount":123},[],{"intervention":782,"totalTrials":272,"cells":10060},{"EARLY_PHASE1":10061,"PHASE1":10063,"PHASE2":10065,"PHASE3":10071,"PHASE4":10073,"NA":10075},{"trials":10062,"activeCount":123},[],{"trials":10064,"activeCount":123},[],{"trials":10066,"activeCount":123},[10067],{"nctId":773,"briefTitle":774,"status":105,"phases":10068,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":10069,"interventions":10070},[91],[18],[669,524,43,782],{"trials":10072,"activeCount":123},[],{"trials":10074,"activeCount":123},[],{"trials":10076,"activeCount":123},[],{"intervention":10078,"totalTrials":272,"cells":10079},"SN-38 liposome",{"EARLY_PHASE1":10080,"PHASE1":10082,"PHASE2":10084,"PHASE3":10092,"PHASE4":10094,"NA":10096},{"trials":10081,"activeCount":123},[],{"trials":10083,"activeCount":123},[],{"trials":10085,"activeCount":123},[10086],{"nctId":10087,"briefTitle":10088,"status":105,"phases":10089,"primaryCompletion":764,"completion":281,"start":859,"enrollment":779,"conditions":10090,"interventions":10091},"NCT00311610","Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer",[91],[24],[10078],{"trials":10093,"activeCount":123},[],{"trials":10095,"activeCount":123},[],{"trials":10097,"activeCount":123},[],{"intervention":3321,"totalTrials":272,"cells":10099},{"EARLY_PHASE1":10100,"PHASE1":10102,"PHASE2":10104,"PHASE3":10110,"PHASE4":10112,"NA":10114},{"trials":10101,"activeCount":123},[],{"trials":10103,"activeCount":123},[],{"trials":10105,"activeCount":123},[10106],{"nctId":3310,"briefTitle":3311,"status":312,"phases":10107,"primaryCompletion":3313,"completion":3314,"start":3315,"enrollment":192,"conditions":10108,"interventions":10109},[91],[3317,3318,3319],[3321,184],{"trials":10111,"activeCount":123},[],{"trials":10113,"activeCount":123},[],{"trials":10115,"activeCount":123},[],{"intervention":3333,"totalTrials":272,"cells":10117},{"EARLY_PHASE1":10118,"PHASE1":10120,"PHASE2":10122,"PHASE3":10128,"PHASE4":10130,"NA":10132},{"trials":10119,"activeCount":123},[],{"trials":10121,"activeCount":123},[],{"trials":10123,"activeCount":123},[10124],{"nctId":3323,"briefTitle":3324,"status":312,"phases":10125,"primaryCompletion":3326,"completion":3327,"start":3328,"enrollment":37,"conditions":10126,"interventions":10127},[91],[3330,3331],[184,3333],{"trials":10129,"activeCount":123},[],{"trials":10131,"activeCount":123},[],{"trials":10133,"activeCount":123},[],{"intervention":10135,"totalTrials":272,"cells":10136},"monoclonal antibody 11D10 anti-idiotype",{"EARLY_PHASE1":10137,"PHASE1":10139,"PHASE2":10141,"PHASE3":10150,"PHASE4":10152,"NA":10154},{"trials":10138,"activeCount":123},[],{"trials":10140,"activeCount":123},[],{"trials":10142,"activeCount":123},[10143],{"nctId":10144,"briefTitle":10145,"status":105,"phases":10146,"primaryCompletion":4749,"completion":281,"start":3511,"enrollment":798,"conditions":10147,"interventions":10148},"NCT00033748","Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver",[91],[24,203],[10135,10149],"monoclonal antibody 3H1 Alu Gel",{"trials":10151,"activeCount":123},[],{"trials":10153,"activeCount":123},[],{"trials":10155,"activeCount":123},[],{"intervention":10149,"totalTrials":272,"cells":10157},{"EARLY_PHASE1":10158,"PHASE1":10160,"PHASE2":10162,"PHASE3":10168,"PHASE4":10170,"NA":10172},{"trials":10159,"activeCount":123},[],{"trials":10161,"activeCount":123},[],{"trials":10163,"activeCount":123},[10164],{"nctId":10144,"briefTitle":10145,"status":105,"phases":10165,"primaryCompletion":4749,"completion":281,"start":3511,"enrollment":798,"conditions":10166,"interventions":10167},[91],[24,203],[10135,10149],{"trials":10169,"activeCount":123},[],{"trials":10171,"activeCount":123},[],{"trials":10173,"activeCount":123},[],{"intervention":5043,"totalTrials":272,"cells":10175},{"EARLY_PHASE1":10176,"PHASE1":10178,"PHASE2":10180,"PHASE3":10186,"PHASE4":10188,"NA":10190},{"trials":10177,"activeCount":123},[],{"trials":10179,"activeCount":123},[],{"trials":10181,"activeCount":123},[10182],{"nctId":5037,"briefTitle":5038,"status":105,"phases":10183,"primaryCompletion":674,"completion":674,"start":1346,"enrollment":5040,"conditions":10184,"interventions":10185},[90,91],[21],[185,5043,1177],{"trials":10187,"activeCount":123},[],{"trials":10189,"activeCount":123},[],{"trials":10191,"activeCount":123},[],{"intervention":6399,"totalTrials":852,"cells":10193},{"EARLY_PHASE1":10194,"PHASE1":10196,"PHASE2":10206,"PHASE3":10208,"PHASE4":10210,"NA":10212},{"trials":10195,"activeCount":123},[],{"trials":10197,"activeCount":123},[10198,10202],{"nctId":6390,"briefTitle":6391,"status":105,"phases":10199,"primaryCompletion":6393,"completion":6394,"start":6395,"enrollment":1602,"conditions":10200,"interventions":10201},[90],[6397],[1708,6399],{"nctId":6405,"briefTitle":6406,"status":105,"phases":10203,"primaryCompletion":5904,"completion":6394,"start":6395,"enrollment":5224,"conditions":10204,"interventions":10205},[90],[6409],[6399,1708],{"trials":10207,"activeCount":123},[],{"trials":10209,"activeCount":123},[],{"trials":10211,"activeCount":123},[],{"trials":10213,"activeCount":123},[],{"intervention":10215,"totalTrials":272,"cells":10216},"interleukin 2",{"EARLY_PHASE1":10217,"PHASE1":10219,"PHASE2":10230,"PHASE3":10232,"PHASE4":10234,"NA":10236},{"trials":10218,"activeCount":123},[],{"trials":10220,"activeCount":123},[10221],{"nctId":10222,"briefTitle":10223,"status":105,"phases":10224,"primaryCompletion":649,"completion":1345,"start":10225,"enrollment":10226,"conditions":10227,"interventions":10228},"NCT00002994","Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors",[90],"1997-07",355,[30],[10215,10229],"rhuMAb",{"trials":10231,"activeCount":123},[],{"trials":10233,"activeCount":123},[],{"trials":10235,"activeCount":123},[],{"trials":10237,"activeCount":123},[],{"intervention":10229,"totalTrials":272,"cells":10239},{"EARLY_PHASE1":10240,"PHASE1":10242,"PHASE2":10248,"PHASE3":10250,"PHASE4":10252,"NA":10254},{"trials":10241,"activeCount":123},[],{"trials":10243,"activeCount":123},[10244],{"nctId":10222,"briefTitle":10223,"status":105,"phases":10245,"primaryCompletion":649,"completion":1345,"start":10225,"enrollment":10226,"conditions":10246,"interventions":10247},[90],[30],[10215,10229],{"trials":10249,"activeCount":123},[],{"trials":10251,"activeCount":123},[],{"trials":10253,"activeCount":123},[],{"trials":10255,"activeCount":123},[],{"intervention":1707,"totalTrials":272,"cells":10257},{"EARLY_PHASE1":10258,"PHASE1":10260,"PHASE2":10266,"PHASE3":10268,"PHASE4":10270,"NA":10272},{"trials":10259,"activeCount":123},[],{"trials":10261,"activeCount":123},[10262],{"nctId":1699,"briefTitle":1700,"status":105,"phases":10263,"primaryCompletion":314,"completion":1702,"start":1703,"enrollment":953,"conditions":10264,"interventions":10265},[90],[1705],[1010,1707,1708],{"trials":10267,"activeCount":123},[],{"trials":10269,"activeCount":123},[],{"trials":10271,"activeCount":123},[],{"trials":10273,"activeCount":123},[],{"intervention":8255,"totalTrials":272,"cells":10275},{"EARLY_PHASE1":10276,"PHASE1":10278,"PHASE2":10284,"PHASE3":10286,"PHASE4":10288,"NA":10290},{"trials":10277,"activeCount":123},[],{"trials":10279,"activeCount":123},[10280],{"nctId":8249,"briefTitle":8250,"status":105,"phases":10281,"primaryCompletion":1825,"completion":8252,"start":1703,"enrollment":1191,"conditions":10282,"interventions":10283},[90],[2550,1277],[8255,3234],{"trials":10285,"activeCount":123},[],{"trials":10287,"activeCount":123},[],{"trials":10289,"activeCount":123},[],{"trials":10291,"activeCount":123},[],{"intervention":1718,"totalTrials":272,"cells":10293},{"EARLY_PHASE1":10294,"PHASE1":10296,"PHASE2":10302,"PHASE3":10304,"PHASE4":10306,"NA":10308},{"trials":10295,"activeCount":123},[],{"trials":10297,"activeCount":123},[10298],{"nctId":1710,"briefTitle":1711,"status":105,"phases":10299,"primaryCompletion":1713,"completion":609,"start":754,"enrollment":1714,"conditions":10300,"interventions":10301},[90],[21],[1010,1717,1718,1719,1094],{"trials":10303,"activeCount":123},[],{"trials":10305,"activeCount":123},[],{"trials":10307,"activeCount":123},[],{"trials":10309,"activeCount":123},[],{"intervention":10311,"totalTrials":272,"cells":10312},"Compound 506U78",{"EARLY_PHASE1":10313,"PHASE1":10315,"PHASE2":10323,"PHASE3":10325,"PHASE4":10327,"NA":10329},{"trials":10314,"activeCount":123},[],{"trials":10316,"activeCount":123},[10317],{"nctId":10318,"briefTitle":10319,"status":312,"phases":10320,"primaryCompletion":797,"completion":797,"start":9873,"enrollment":1115,"conditions":10321,"interventions":10322},"NCT00004239","506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment",[90],[6670,27,21,2584,2535],[10311],{"trials":10324,"activeCount":123},[],{"trials":10326,"activeCount":123},[],{"trials":10328,"activeCount":123},[],{"trials":10330,"activeCount":123},[],{"intervention":1162,"totalTrials":10332,"cells":10333},16,{"EARLY_PHASE1":10334,"PHASE1":10336,"PHASE2":10342,"PHASE3":10388,"PHASE4":10402,"NA":10404},{"trials":10335,"activeCount":123},[],{"trials":10337,"activeCount":123},[10338],{"nctId":1691,"briefTitle":1692,"status":105,"phases":10339,"primaryCompletion":1694,"completion":1695,"start":547,"enrollment":953,"conditions":10340,"interventions":10341},[90],[21],[1010,1219,1162,624,1221,1222],{"trials":10343,"activeCount":123},[10344,10348,10352,10356,10360,10364,10368,10372,10376,10380,10384],{"nctId":3022,"briefTitle":3023,"status":105,"phases":10345,"primaryCompletion":589,"completion":589,"start":2403,"enrollment":246,"conditions":10346,"interventions":10347},[91],[21],[593,1219,1162,594,1221,1222],{"nctId":8131,"briefTitle":8132,"status":105,"phases":10349,"primaryCompletion":178,"start":1346,"conditions":10350,"interventions":10351},[91],[21],[1162,595],{"nctId":1913,"briefTitle":1914,"status":105,"phases":10353,"primaryCompletion":578,"completion":578,"start":1916,"enrollment":1917,"conditions":10354,"interventions":10355},[91],[21],[53,1219,1011,1012,1162,1220,1222],{"nctId":1746,"briefTitle":1747,"status":105,"phases":10357,"primaryCompletion":1665,"completion":1749,"start":859,"enrollment":1750,"conditions":10358,"interventions":10359},[91],[21],[1753,1010,1219,1162,1221,1222],{"nctId":1212,"briefTitle":1213,"status":105,"phases":10361,"primaryCompletion":371,"completion":619,"start":1215,"enrollment":1216,"conditions":10362,"interventions":10363},[91],[21],[593,1010,53,1219,1011,1162,594,140,1220,1221,1222],{"nctId":4964,"briefTitle":4965,"status":105,"phases":10365,"primaryCompletion":4749,"completion":557,"start":1617,"enrollment":1838,"conditions":10366,"interventions":10367},[91],[21],[1162,185,1154],{"nctId":1236,"briefTitle":1237,"status":105,"phases":10369,"primaryCompletion":134,"completion":859,"start":1239,"enrollment":1240,"conditions":10370,"interventions":10371},[91],[27,21],[1219,1011,1012,1162,594,883,140,1243,1220,1221,1244,1222],{"nctId":3074,"briefTitle":3075,"status":105,"phases":10373,"primaryCompletion":3077,"completion":2682,"start":2388,"enrollment":3078,"conditions":10374,"interventions":10375},[91],[21],[3081,3082,3083,3084,3085,1810,3086,1221,3087],{"nctId":1959,"briefTitle":1960,"status":105,"phases":10377,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":10378,"interventions":10379},[91],[27],[1219,1011,1259,1012,1162,1260,1220,1968,1969,1222],{"nctId":1295,"briefTitle":1296,"status":105,"phases":10381,"primaryCompletion":1298,"completion":1299,"start":536,"enrollment":1300,"conditions":10382,"interventions":10383},[91],[27,21],[593,1010,1219,1011,1012,1162,594,883,140,1220,1221,1222,1261],{"nctId":1846,"briefTitle":1847,"status":105,"phases":10385,"primaryCompletion":200,"completion":754,"start":1849,"enrollment":16,"conditions":10386,"interventions":10387},[91],[21],[593,1010,1219,1162,594,1221,1222],{"trials":10389,"activeCount":123},[10390,10394,10398],{"nctId":3115,"briefTitle":3116,"status":105,"phases":10391,"primaryCompletion":1713,"completion":3118,"start":536,"enrollment":3119,"conditions":10392,"interventions":10393},[92],[18],[3122,1219,1162,540],{"nctId":1156,"briefTitle":1157,"status":105,"phases":10395,"primaryCompletion":796,"completion":754,"start":134,"enrollment":525,"conditions":10396,"interventions":10397},[92],[1160],[593,791,1162,185],{"nctId":3128,"briefTitle":3129,"status":105,"phases":10399,"primaryCompletion":243,"completion":244,"start":3131,"enrollment":3132,"conditions":10400,"interventions":10401},[92],[18],[1219,1162,540],{"trials":10403,"activeCount":123},[],{"trials":10405,"activeCount":123},[10406],{"nctId":3140,"briefTitle":3141,"status":105,"phases":10407,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":3145,"conditions":10408,"interventions":10409},[],[18],[1219,1162,540,3148],{"intervention":5791,"totalTrials":1115,"cells":10411},{"EARLY_PHASE1":10412,"PHASE1":10414,"PHASE2":10416,"PHASE3":10418,"PHASE4":10420,"NA":10422},{"trials":10413,"activeCount":123},[],{"trials":10415,"activeCount":123},[],{"trials":10417,"activeCount":123},[],{"trials":10419,"activeCount":123},[],{"trials":10421,"activeCount":123},[],{"trials":10423,"activeCount":123},[10424,10428,10432,10436,10443,10447,10451,10459,10463,10471],{"nctId":5782,"briefTitle":5783,"status":105,"phases":10425,"primaryCompletion":5785,"completion":5785,"start":5786,"enrollment":5787,"conditions":10426,"interventions":10427},[],[18],[5790,5767,5791],{"nctId":5986,"briefTitle":5987,"status":925,"phases":10429,"primaryCompletion":299,"start":191,"enrollment":5989,"conditions":10430,"interventions":10431},[],[27],[5809,5800,5819,5791,5820],{"nctId":5925,"briefTitle":5926,"status":925,"phases":10433,"primaryCompletion":1047,"start":5928,"enrollment":1783,"conditions":10434,"interventions":10435},[],[27],[5790,5931,5910,5791],{"nctId":10437,"briefTitle":10438,"status":105,"phases":10439,"primaryCompletion":608,"completion":608,"start":823,"enrollment":10440,"conditions":10441,"interventions":10442},"NCT01139944","Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer",[],99,[15],[5818,5791],{"nctId":5811,"briefTitle":5812,"status":925,"phases":10444,"primaryCompletion":2002,"start":5814,"enrollment":5815,"conditions":10445,"interventions":10446},[],[27],[5790,5818,5767,5819,5791,5820],{"nctId":5822,"briefTitle":5823,"status":105,"phases":10448,"primaryCompletion":2388,"completion":5786,"start":754,"enrollment":5825,"conditions":10449,"interventions":10450},[],[18],[5767,5791],{"nctId":10452,"briefTitle":10453,"status":105,"phases":10454,"primaryCompletion":10455,"completion":10455,"start":675,"enrollment":10456,"conditions":10457,"interventions":10458},"NCT00897182","Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia",[],"2014-03",96,[27],[5809,5791],{"nctId":5844,"briefTitle":5845,"status":105,"phases":10460,"primaryCompletion":1231,"completion":1231,"start":989,"enrollment":5847,"conditions":10461,"interventions":10462},[],[27],[5790,3148,5767,5809,5819,5791],{"nctId":10464,"briefTitle":10465,"status":105,"phases":10466,"primaryCompletion":300,"completion":300,"start":10467,"enrollment":1333,"conditions":10468,"interventions":10469},"NCT01004523","Study of Tissue and Blood Samples From Patients With Low-Grade Glioma",[],"1995-12",[1022],[3148,10470,5791],"loss of heterozygosity analysis",{"nctId":10472,"briefTitle":10473,"status":105,"phases":10474,"primaryCompletion":10475,"completion":10475,"start":705,"enrollment":5797,"conditions":10476,"interventions":10477},"NCT01005368","Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia",[],"2022-04-01",[27],[3148,5819,10478,5791,10479],"nucleic acid sequencing","western blotting",{"intervention":5819,"totalTrials":1115,"cells":10481},{"EARLY_PHASE1":10482,"PHASE1":10484,"PHASE2":10486,"PHASE3":10488,"PHASE4":10490,"NA":10492},{"trials":10483,"activeCount":123},[],{"trials":10485,"activeCount":123},[],{"trials":10487,"activeCount":123},[],{"trials":10489,"activeCount":123},[],{"trials":10491,"activeCount":123},[],{"trials":10493,"activeCount":123},[10494,10498,10502,10509,10513,10517,10524,10528,10536,10543],{"nctId":5986,"briefTitle":5987,"status":925,"phases":10495,"primaryCompletion":299,"start":191,"enrollment":5989,"conditions":10496,"interventions":10497},[],[27],[5809,5800,5819,5791,5820],{"nctId":5869,"briefTitle":5870,"status":105,"phases":10499,"primaryCompletion":1741,"completion":5872,"start":1665,"enrollment":8,"conditions":10500,"interventions":10501},[],[15],[5790,5842,5809,5819,5801],{"nctId":10503,"briefTitle":10504,"status":105,"phases":10505,"primaryCompletion":2682,"completion":2682,"start":1734,"enrollment":10506,"conditions":10507,"interventions":10508},"NCT01243372","Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer",[],1142,[24],[5819],{"nctId":5882,"briefTitle":5883,"status":105,"phases":10510,"primaryCompletion":5885,"completion":5885,"start":576,"enrollment":272,"conditions":10511,"interventions":10512},[],[5887],[5819,5801],{"nctId":5811,"briefTitle":5812,"status":925,"phases":10514,"primaryCompletion":2002,"start":5814,"enrollment":5815,"conditions":10515,"interventions":10516},[],[27],[5790,5818,5767,5819,5791,5820],{"nctId":10518,"briefTitle":10519,"status":105,"phases":10520,"primaryCompletion":859,"completion":859,"start":2436,"enrollment":3997,"conditions":10521,"interventions":10522},"NCT00003571","Gene Testing in Patients With Colon Cancer",[],[24],[5819,10523],"tumor replication error analysis",{"nctId":5844,"briefTitle":5845,"status":105,"phases":10525,"primaryCompletion":1231,"completion":1231,"start":989,"enrollment":5847,"conditions":10526,"interventions":10527},[],[27],[5790,3148,5767,5809,5819,5791],{"nctId":10529,"briefTitle":10530,"status":105,"phases":10531,"primaryCompletion":2533,"completion":2533,"start":1345,"enrollment":10532,"conditions":10533,"interventions":10534},"NCT00048971","Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy",[],308,[24,6533,1032],[5819,10535],"polymorphic microsatellite marker analysis",{"nctId":10537,"briefTitle":10538,"status":105,"phases":10539,"primaryCompletion":589,"completion":823,"start":638,"enrollment":1783,"conditions":10540,"interventions":10541},"NCT00898924","Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer",[],[15],[10542,5819],"molecular diagnostic method",{"nctId":10472,"briefTitle":10473,"status":105,"phases":10544,"primaryCompletion":10475,"completion":10475,"start":705,"enrollment":5797,"conditions":10545,"interventions":10546},[],[27],[3148,5819,10478,5791,10479],{"intervention":5809,"totalTrials":2129,"cells":10548},{"EARLY_PHASE1":10549,"PHASE1":10551,"PHASE2":10553,"PHASE3":10559,"PHASE4":10561,"NA":10563},{"trials":10550,"activeCount":123},[],{"trials":10552,"activeCount":123},[],{"trials":10554,"activeCount":123},[10555],{"nctId":6268,"briefTitle":6269,"status":105,"phases":10556,"primaryCompletion":618,"completion":6271,"start":1298,"enrollment":1974,"conditions":10557,"interventions":10558},[90,91],[18],[3825,6274,5842,5809,5820],{"trials":10560,"activeCount":123},[],{"trials":10562,"activeCount":123},[],{"trials":10564,"activeCount":123},[10565,10572,10576,10580,10584,10588,10592,10596],{"nctId":10566,"briefTitle":10567,"status":167,"phases":10568,"primaryCompletion":610,"completion":610,"start":610,"enrollment":123,"conditions":10569,"interventions":10570},"NCT00899704","Biomarkers in Tissue Samples From Patients Who Have Undergone Neck Dissection for Oral Cancer",[],[1537],[5809,10571],"allele-specific oligonucleotide real-time quantitative polymerase chain reaction",{"nctId":5986,"briefTitle":5987,"status":925,"phases":10573,"primaryCompletion":299,"start":191,"enrollment":5989,"conditions":10574,"interventions":10575},[],[27],[5809,5800,5819,5791,5820],{"nctId":5869,"briefTitle":5870,"status":105,"phases":10577,"primaryCompletion":1741,"completion":5872,"start":1665,"enrollment":8,"conditions":10578,"interventions":10579},[],[15],[5790,5842,5809,5819,5801],{"nctId":5804,"briefTitle":5805,"status":105,"phases":10581,"primaryCompletion":2682,"completion":2682,"start":2533,"enrollment":798,"conditions":10582,"interventions":10583},[],[1022],[5767,5809,5802],{"nctId":5943,"briefTitle":5944,"status":105,"phases":10585,"primaryCompletion":1741,"completion":1741,"start":3511,"enrollment":5797,"conditions":10586,"interventions":10587},[],[24],[5910,5948,5809],{"nctId":5829,"briefTitle":5830,"status":105,"phases":10589,"primaryCompletion":314,"completion":314,"start":1103,"enrollment":3538,"conditions":10590,"interventions":10591},[],[15],[5767,5809,5820],{"nctId":10452,"briefTitle":10453,"status":105,"phases":10593,"primaryCompletion":10455,"completion":10455,"start":675,"enrollment":10456,"conditions":10594,"interventions":10595},[],[27],[5809,5791],{"nctId":5844,"briefTitle":5845,"status":105,"phases":10597,"primaryCompletion":1231,"completion":1231,"start":989,"enrollment":5847,"conditions":10598,"interventions":10599},[],[27],[5790,3148,5767,5809,5819,5791],{"intervention":5790,"totalTrials":2581,"cells":10601},{"EARLY_PHASE1":10602,"PHASE1":10604,"PHASE2":10606,"PHASE3":10608,"PHASE4":10610,"NA":10612},{"trials":10603,"activeCount":123},[],{"trials":10605,"activeCount":123},[],{"trials":10607,"activeCount":123},[],{"trials":10609,"activeCount":123},[],{"trials":10611,"activeCount":123},[],{"trials":10613,"activeCount":123},[10614,10618,10622,10626,10630,10634],{"nctId":5782,"briefTitle":5783,"status":105,"phases":10615,"primaryCompletion":5785,"completion":5785,"start":5786,"enrollment":5787,"conditions":10616,"interventions":10617},[],[18],[5790,5767,5791],{"nctId":5869,"briefTitle":5870,"status":105,"phases":10619,"primaryCompletion":1741,"completion":5872,"start":1665,"enrollment":8,"conditions":10620,"interventions":10621},[],[15],[5790,5842,5809,5819,5801],{"nctId":5925,"briefTitle":5926,"status":925,"phases":10623,"primaryCompletion":1047,"start":5928,"enrollment":1783,"conditions":10624,"interventions":10625},[],[27],[5790,5931,5910,5791],{"nctId":5811,"briefTitle":5812,"status":925,"phases":10627,"primaryCompletion":2002,"start":5814,"enrollment":5815,"conditions":10628,"interventions":10629},[],[27],[5790,5818,5767,5819,5791,5820],{"nctId":5835,"briefTitle":5836,"status":105,"phases":10631,"primaryCompletion":5838,"start":547,"enrollment":5839,"conditions":10632,"interventions":10633},[],[15],[5790,5818,5842,5767,5801],{"nctId":5844,"briefTitle":5845,"status":105,"phases":10635,"primaryCompletion":1231,"completion":1231,"start":989,"enrollment":5847,"conditions":10636,"interventions":10637},[],[27],[5790,3148,5767,5809,5819,5791],{"intervention":5820,"totalTrials":2581,"cells":10639},{"EARLY_PHASE1":10640,"PHASE1":10642,"PHASE2":10644,"PHASE3":10650,"PHASE4":10652,"NA":10654},{"trials":10641,"activeCount":123},[],{"trials":10643,"activeCount":123},[],{"trials":10645,"activeCount":123},[10646],{"nctId":6268,"briefTitle":6269,"status":105,"phases":10647,"primaryCompletion":618,"completion":6271,"start":1298,"enrollment":1974,"conditions":10648,"interventions":10649},[90,91],[18],[3825,6274,5842,5809,5820],{"trials":10651,"activeCount":123},[],{"trials":10653,"activeCount":123},[],{"trials":10655,"activeCount":123},[10656,10660,10666,10670,10674],{"nctId":5986,"briefTitle":5987,"status":925,"phases":10657,"primaryCompletion":299,"start":191,"enrollment":5989,"conditions":10658,"interventions":10659},[],[27],[5809,5800,5819,5791,5820],{"nctId":10661,"briefTitle":10662,"status":105,"phases":10663,"primaryCompletion":849,"completion":281,"start":3917,"enrollment":7818,"conditions":10664,"interventions":10665},"NCT00003006","Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer",[],[15],[5820],{"nctId":5811,"briefTitle":5812,"status":925,"phases":10667,"primaryCompletion":2002,"start":5814,"enrollment":5815,"conditions":10668,"interventions":10669},[],[27],[5790,5818,5767,5819,5791,5820],{"nctId":5829,"briefTitle":5830,"status":105,"phases":10671,"primaryCompletion":314,"completion":314,"start":1103,"enrollment":3538,"conditions":10672,"interventions":10673},[],[15],[5767,5809,5820],{"nctId":10675,"briefTitle":10676,"status":105,"phases":10677,"primaryCompletion":648,"completion":648,"start":1041,"enrollment":10678,"conditions":10679,"interventions":10680},"NCT00003931","Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia",[],9769,[27],[5820],{"intervention":3148,"totalTrials":2581,"cells":10682},{"EARLY_PHASE1":10683,"PHASE1":10685,"PHASE2":10687,"PHASE3":10689,"PHASE4":10691,"NA":10693},{"trials":10684,"activeCount":123},[],{"trials":10686,"activeCount":123},[],{"trials":10688,"activeCount":123},[],{"trials":10690,"activeCount":123},[],{"trials":10692,"activeCount":123},[],{"trials":10694,"activeCount":123},[10695,10699,10703,10707,10711,10715],{"nctId":5933,"briefTitle":5934,"status":105,"phases":10696,"primaryCompletion":1860,"completion":1860,"start":5936,"enrollment":5937,"conditions":10697,"interventions":10698},[],[21],[5940,5910,3148,5941],{"nctId":5961,"briefTitle":5962,"status":105,"phases":10700,"primaryCompletion":589,"completion":705,"start":159,"enrollment":5964,"conditions":10701,"interventions":10702},[94],[581],[5940,5910,3148],{"nctId":5844,"briefTitle":5845,"status":105,"phases":10704,"primaryCompletion":1231,"completion":1231,"start":989,"enrollment":5847,"conditions":10705,"interventions":10706},[],[27],[5790,3148,5767,5809,5819,5791],{"nctId":3140,"briefTitle":3141,"status":105,"phases":10708,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":3145,"conditions":10709,"interventions":10710},[],[18],[1219,1162,540,3148],{"nctId":10464,"briefTitle":10465,"status":105,"phases":10712,"primaryCompletion":300,"completion":300,"start":10467,"enrollment":1333,"conditions":10713,"interventions":10714},[],[1022],[3148,10470,5791],{"nctId":10472,"briefTitle":10473,"status":105,"phases":10716,"primaryCompletion":10475,"completion":10475,"start":705,"enrollment":5797,"conditions":10717,"interventions":10718},[],[27],[3148,5819,10478,5791,10479],{"intervention":5842,"totalTrials":459,"cells":10720},{"EARLY_PHASE1":10721,"PHASE1":10723,"PHASE2":10725,"PHASE3":10731,"PHASE4":10733,"NA":10735},{"trials":10722,"activeCount":123},[],{"trials":10724,"activeCount":123},[],{"trials":10726,"activeCount":123},[10727],{"nctId":6268,"briefTitle":6269,"status":105,"phases":10728,"primaryCompletion":618,"completion":6271,"start":1298,"enrollment":1974,"conditions":10729,"interventions":10730},[90,91],[18],[3825,6274,5842,5809,5820],{"trials":10732,"activeCount":123},[],{"trials":10734,"activeCount":123},[],{"trials":10736,"activeCount":123},[10737,10741],{"nctId":5869,"briefTitle":5870,"status":105,"phases":10738,"primaryCompletion":1741,"completion":5872,"start":1665,"enrollment":8,"conditions":10739,"interventions":10740},[],[15],[5790,5842,5809,5819,5801],{"nctId":5835,"briefTitle":5836,"status":105,"phases":10742,"primaryCompletion":5838,"start":547,"enrollment":5839,"conditions":10743,"interventions":10744},[],[15],[5790,5818,5842,5767,5801],{"intervention":10746,"totalTrials":459,"cells":10747},"DNA stability analysis",{"EARLY_PHASE1":10748,"PHASE1":10750,"PHASE2":10752,"PHASE3":10754,"PHASE4":10756,"NA":10758},{"trials":10749,"activeCount":123},[],{"trials":10751,"activeCount":123},[],{"trials":10753,"activeCount":123},[],{"trials":10755,"activeCount":123},[],{"trials":10757,"activeCount":123},[],{"trials":10759,"activeCount":123},[10760,10767,10775],{"nctId":10761,"briefTitle":10762,"status":105,"phases":10763,"primaryCompletion":178,"completion":178,"start":1041,"enrollment":10764,"conditions":10765,"interventions":10766},"NCT00003833","Genetic Study in Patients With Stage II or Stage III Colon Cancer",[],598,[24],[10746,5948],{"nctId":10768,"briefTitle":10769,"status":105,"phases":10770,"primaryCompletion":566,"completion":1860,"start":3131,"enrollment":10771,"conditions":10772,"interventions":10773},"NCT00014079","Genetic Markers in Patients With Colorectal Cancer",[],675,[24],[10746,10470,10774],"microsatellite instability analysis",{"nctId":10776,"briefTitle":10777,"status":105,"phases":10778,"primaryCompletion":191,"completion":191,"start":943,"enrollment":10779,"conditions":10780,"interventions":10781},"NCT00003648","Genetic Study of Patients and Families With a History of Colorectal Cancer",[],1500,[24],[10746,5941],{"intervention":5818,"totalTrials":459,"cells":10783},{"EARLY_PHASE1":10784,"PHASE1":10786,"PHASE2":10788,"PHASE3":10790,"PHASE4":10792,"NA":10794},{"trials":10785,"activeCount":123},[],{"trials":10787,"activeCount":123},[],{"trials":10789,"activeCount":123},[],{"trials":10791,"activeCount":123},[],{"trials":10793,"activeCount":123},[],{"trials":10795,"activeCount":123},[10796,10800,10804],{"nctId":10437,"briefTitle":10438,"status":105,"phases":10797,"primaryCompletion":608,"completion":608,"start":823,"enrollment":10440,"conditions":10798,"interventions":10799},[],[15],[5818,5791],{"nctId":5811,"briefTitle":5812,"status":925,"phases":10801,"primaryCompletion":2002,"start":5814,"enrollment":5815,"conditions":10802,"interventions":10803},[],[27],[5790,5818,5767,5819,5791,5820],{"nctId":5835,"briefTitle":5836,"status":105,"phases":10805,"primaryCompletion":5838,"start":547,"enrollment":5839,"conditions":10806,"interventions":10807},[],[15],[5790,5818,5842,5767,5801],{"intervention":10774,"totalTrials":852,"cells":10809},{"EARLY_PHASE1":10810,"PHASE1":10812,"PHASE2":10814,"PHASE3":10816,"PHASE4":10818,"NA":10820},{"trials":10811,"activeCount":123},[],{"trials":10813,"activeCount":123},[],{"trials":10815,"activeCount":123},[],{"trials":10817,"activeCount":123},[],{"trials":10819,"activeCount":123},[],{"trials":10821,"activeCount":123},[10822,10829],{"nctId":10823,"briefTitle":10824,"status":105,"phases":10825,"primaryCompletion":200,"completion":200,"start":536,"enrollment":10826,"conditions":10827,"interventions":10828},"NCT00044967","Genetic Study of Young Patients With Colorectal Cancer",[],651,[24],[10774],{"nctId":10768,"briefTitle":10769,"status":105,"phases":10830,"primaryCompletion":566,"completion":1860,"start":3131,"enrollment":10771,"conditions":10831,"interventions":10832},[],[24],[10746,10470,10774],{"intervention":5948,"totalTrials":852,"cells":10834},{"EARLY_PHASE1":10835,"PHASE1":10837,"PHASE2":10839,"PHASE3":10841,"PHASE4":10843,"NA":10845},{"trials":10836,"activeCount":123},[],{"trials":10838,"activeCount":123},[],{"trials":10840,"activeCount":123},[],{"trials":10842,"activeCount":123},[],{"trials":10844,"activeCount":123},[],{"trials":10846,"activeCount":123},[10847,10851],{"nctId":10761,"briefTitle":10762,"status":105,"phases":10848,"primaryCompletion":178,"completion":178,"start":1041,"enrollment":10764,"conditions":10849,"interventions":10850},[],[24],[10746,5948],{"nctId":5943,"briefTitle":5944,"status":105,"phases":10852,"primaryCompletion":1741,"completion":1741,"start":3511,"enrollment":5797,"conditions":10853,"interventions":10854},[],[24],[5910,5948,5809],{"intervention":5940,"totalTrials":852,"cells":10856},{"EARLY_PHASE1":10857,"PHASE1":10859,"PHASE2":10861,"PHASE3":10863,"PHASE4":10865,"NA":10867},{"trials":10858,"activeCount":123},[],{"trials":10860,"activeCount":123},[],{"trials":10862,"activeCount":123},[],{"trials":10864,"activeCount":123},[],{"trials":10866,"activeCount":123},[],{"trials":10868,"activeCount":123},[10869,10873],{"nctId":5933,"briefTitle":5934,"status":105,"phases":10870,"primaryCompletion":1860,"completion":1860,"start":5936,"enrollment":5937,"conditions":10871,"interventions":10872},[],[21],[5940,5910,3148,5941],{"nctId":5961,"briefTitle":5962,"status":105,"phases":10874,"primaryCompletion":589,"completion":705,"start":159,"enrollment":5964,"conditions":10875,"interventions":10876},[94],[581],[5940,5910,3148],{"intervention":5941,"totalTrials":852,"cells":10878},{"EARLY_PHASE1":10879,"PHASE1":10881,"PHASE2":10883,"PHASE3":10885,"PHASE4":10887,"NA":10889},{"trials":10880,"activeCount":123},[],{"trials":10882,"activeCount":123},[],{"trials":10884,"activeCount":123},[],{"trials":10886,"activeCount":123},[],{"trials":10888,"activeCount":123},[],{"trials":10890,"activeCount":123},[10891,10895],{"nctId":5933,"briefTitle":5934,"status":105,"phases":10892,"primaryCompletion":1860,"completion":1860,"start":5936,"enrollment":5937,"conditions":10893,"interventions":10894},[],[21],[5940,5910,3148,5941],{"nctId":10776,"briefTitle":10777,"status":105,"phases":10896,"primaryCompletion":191,"completion":191,"start":943,"enrollment":10779,"conditions":10897,"interventions":10898},[],[24],[10746,5941],{"intervention":10470,"totalTrials":852,"cells":10900},{"EARLY_PHASE1":10901,"PHASE1":10903,"PHASE2":10905,"PHASE3":10907,"PHASE4":10909,"NA":10911},{"trials":10902,"activeCount":123},[],{"trials":10904,"activeCount":123},[],{"trials":10906,"activeCount":123},[],{"trials":10908,"activeCount":123},[],{"trials":10910,"activeCount":123},[],{"trials":10912,"activeCount":123},[10913,10917],{"nctId":10768,"briefTitle":10769,"status":105,"phases":10914,"primaryCompletion":566,"completion":1860,"start":3131,"enrollment":10771,"conditions":10915,"interventions":10916},[],[24],[10746,10470,10774],{"nctId":10464,"briefTitle":10465,"status":105,"phases":10918,"primaryCompletion":300,"completion":300,"start":10467,"enrollment":1333,"conditions":10919,"interventions":10920},[],[1022],[3148,10470,5791],{"intervention":10571,"totalTrials":272,"cells":10922},{"EARLY_PHASE1":10923,"PHASE1":10925,"PHASE2":10927,"PHASE3":10929,"PHASE4":10931,"NA":10933},{"trials":10924,"activeCount":123},[],{"trials":10926,"activeCount":123},[],{"trials":10928,"activeCount":123},[],{"trials":10930,"activeCount":123},[],{"trials":10932,"activeCount":123},[],{"trials":10934,"activeCount":123},[10935],{"nctId":10566,"briefTitle":10567,"status":167,"phases":10936,"primaryCompletion":610,"completion":610,"start":610,"enrollment":123,"conditions":10937,"interventions":10938},[],[1537],[5809,10571],{"intervention":5931,"totalTrials":272,"cells":10940},{"EARLY_PHASE1":10941,"PHASE1":10943,"PHASE2":10945,"PHASE3":10947,"PHASE4":10949,"NA":10951},{"trials":10942,"activeCount":123},[],{"trials":10944,"activeCount":123},[],{"trials":10946,"activeCount":123},[],{"trials":10948,"activeCount":123},[],{"trials":10950,"activeCount":123},[],{"trials":10952,"activeCount":123},[10953],{"nctId":5925,"briefTitle":5926,"status":925,"phases":10954,"primaryCompletion":1047,"start":5928,"enrollment":1783,"conditions":10955,"interventions":10956},[],[27],[5790,5931,5910,5791],{"intervention":10958,"totalTrials":272,"cells":10959},"tetracycline hydrochloride",{"EARLY_PHASE1":10960,"PHASE1":10962,"PHASE2":10964,"PHASE3":10966,"PHASE4":10968,"NA":10970},{"trials":10961,"activeCount":123},[],{"trials":10963,"activeCount":123},[],{"trials":10965,"activeCount":123},[],{"trials":10967,"activeCount":123},[],{"trials":10969,"activeCount":123},[],{"trials":10971,"activeCount":123},[10972],{"nctId":10973,"briefTitle":10974,"status":105,"phases":10975,"primaryCompletion":676,"completion":1103,"start":200,"enrollment":6530,"conditions":10976,"interventions":10977},"NCT00091247","Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer",[94],[30],[10958],{"intervention":10979,"totalTrials":272,"cells":10980},"acitretin",{"EARLY_PHASE1":10981,"PHASE1":10983,"PHASE2":10985,"PHASE3":10987,"PHASE4":10989,"NA":10991},{"trials":10982,"activeCount":123},[],{"trials":10984,"activeCount":123},[],{"trials":10986,"activeCount":123},[],{"trials":10988,"activeCount":123},[],{"trials":10990,"activeCount":123},[],{"trials":10992,"activeCount":123},[10993],{"nctId":10994,"briefTitle":10995,"status":105,"phases":10996,"primaryCompletion":1601,"completion":244,"start":2403,"enrollment":10997,"conditions":10998,"interventions":11000},"NCT00003611","Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation",[94],129,[10999],"Non-melanomatous Skin Cancer",[10979],{"intervention":10523,"totalTrials":272,"cells":11002},{"EARLY_PHASE1":11003,"PHASE1":11005,"PHASE2":11007,"PHASE3":11009,"PHASE4":11011,"NA":11013},{"trials":11004,"activeCount":123},[],{"trials":11006,"activeCount":123},[],{"trials":11008,"activeCount":123},[],{"trials":11010,"activeCount":123},[],{"trials":11012,"activeCount":123},[],{"trials":11014,"activeCount":123},[11015],{"nctId":10518,"briefTitle":10519,"status":105,"phases":11016,"primaryCompletion":859,"completion":859,"start":2436,"enrollment":3997,"conditions":11017,"interventions":11018},[],[24],[5819,10523],{"intervention":11020,"totalTrials":272,"cells":11021},"proteomic profiling",{"EARLY_PHASE1":11022,"PHASE1":11024,"PHASE2":11026,"PHASE3":11028,"PHASE4":11030,"NA":11032},{"trials":11023,"activeCount":123},[],{"trials":11025,"activeCount":123},[],{"trials":11027,"activeCount":123},[],{"trials":11029,"activeCount":123},[],{"trials":11031,"activeCount":123},[],{"trials":11033,"activeCount":123},[11034],{"nctId":11035,"briefTitle":11036,"status":105,"phases":11037,"primaryCompletion":999,"completion":999,"start":1253,"enrollment":11038,"conditions":11039,"interventions":11040},"NCT00077324","Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions",[],1000,[15],[11020],{"intervention":10535,"totalTrials":272,"cells":11042},{"EARLY_PHASE1":11043,"PHASE1":11045,"PHASE2":11047,"PHASE3":11049,"PHASE4":11051,"NA":11053},{"trials":11044,"activeCount":123},[],{"trials":11046,"activeCount":123},[],{"trials":11048,"activeCount":123},[],{"trials":11050,"activeCount":123},[],{"trials":11052,"activeCount":123},[],{"trials":11054,"activeCount":123},[11055],{"nctId":10529,"briefTitle":10530,"status":105,"phases":11056,"primaryCompletion":2533,"completion":2533,"start":1345,"enrollment":10532,"conditions":11057,"interventions":11058},[],[24,6533,1032],[5819,10535],{"intervention":10542,"totalTrials":272,"cells":11060},{"EARLY_PHASE1":11061,"PHASE1":11063,"PHASE2":11065,"PHASE3":11067,"PHASE4":11069,"NA":11071},{"trials":11062,"activeCount":123},[],{"trials":11064,"activeCount":123},[],{"trials":11066,"activeCount":123},[],{"trials":11068,"activeCount":123},[],{"trials":11070,"activeCount":123},[],{"trials":11072,"activeCount":123},[11073],{"nctId":10537,"briefTitle":10538,"status":105,"phases":11074,"primaryCompletion":589,"completion":823,"start":638,"enrollment":1783,"conditions":11075,"interventions":11076},[],[15],[10542,5819],{"intervention":10478,"totalTrials":272,"cells":11078},{"EARLY_PHASE1":11079,"PHASE1":11081,"PHASE2":11083,"PHASE3":11085,"PHASE4":11087,"NA":11089},{"trials":11080,"activeCount":123},[],{"trials":11082,"activeCount":123},[],{"trials":11084,"activeCount":123},[],{"trials":11086,"activeCount":123},[],{"trials":11088,"activeCount":123},[],{"trials":11090,"activeCount":123},[11091],{"nctId":10472,"briefTitle":10473,"status":105,"phases":11092,"primaryCompletion":10475,"completion":10475,"start":705,"enrollment":5797,"conditions":11093,"interventions":11094},[],[27],[3148,5819,10478,5791,10479],{"intervention":10479,"totalTrials":272,"cells":11096},{"EARLY_PHASE1":11097,"PHASE1":11099,"PHASE2":11101,"PHASE3":11103,"PHASE4":11105,"NA":11107},{"trials":11098,"activeCount":123},[],{"trials":11100,"activeCount":123},[],{"trials":11102,"activeCount":123},[],{"trials":11104,"activeCount":123},[],{"trials":11106,"activeCount":123},[],{"trials":11108,"activeCount":123},[11109],{"nctId":10472,"briefTitle":10473,"status":105,"phases":11110,"primaryCompletion":10475,"completion":10475,"start":705,"enrollment":5797,"conditions":11111,"interventions":11112},[],[27],[3148,5819,10478,5791,10479]]